<SEC-DOCUMENT>0001047469-18-003259.txt : 20180427
<SEC-HEADER>0001047469-18-003259.hdr.sgml : 20180427
<ACCEPTANCE-DATETIME>20180427060831
ACCESSION NUMBER:		0001047469-18-003259
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20180607
FILED AS OF DATE:		20180427
DATE AS OF CHANGE:		20180427
EFFECTIVENESS DATE:		20180427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		18780867

	BUSINESS ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		(609) 662-2000

	MAIL ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2235408zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#18ZAG13701_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Amicus Therapeutics,&nbsp;Inc.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=93504,FOLIO='blank',FILE='DISK109:[18ZAG1.18ZAG13701]BA13701A.;6',USER='CHE109870',CD='20-APR-2018;12:24' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g429299.jpg" ALT="LOGO" WIDTH="291" HEIGHT="97">
  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>April&nbsp;27,
2018 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Dear
Stockholder: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are pleased to invite you to attend our 2018 Annual Meeting of Stockholders to be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury,
New Jersey 08512 on Thursday, June&nbsp;7, 2018, at 9:00&nbsp;a.m. Eastern Daylight Time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enclosed
are the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Our Notice of Annual Meeting of Stockholders and Proxy Statement for 2018; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Our Annual Report on Form&nbsp;10-K for 2017; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> A proxy card with a return envelope to record your vote. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
accompanying notice of the 2018 Annual Meeting and Proxy Statement describe the business we will conduct at the meeting and provide information about Amicus Therapeutics,&nbsp;Inc.
that you should consider when you vote your shares. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
vote is important. When you have finished reading the Proxy Statement, please promptly vote your shares by marking, signing, dating and returning the proxy card in the enclosed
envelope or vote via telephone or Internet according to the instructions in the Proxy Statement. If you attend the Annual Meeting, you may vote your shares in person even though you have previously
voted by proxy if you follow the instructions in the Proxy Statement. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting, whether or not you can attend
in person. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Sincerely,
</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>
<IMG SRC="g650180.jpg" ALT="GRAPHIC" WIDTH="237" HEIGHT="96">
  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR>
John F. Crowley<BR></FONT> <FONT SIZE=2><I>Chairman and Chief Executive Officer</I></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=233483,FOLIO='blank',FILE='DISK109:[18ZAG1.18ZAG13701]BC13701A.;9',USER='CHE109870',CD='20-APR-2018;12:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g429299.jpg" ALT="LOGO" WIDTH="291" HEIGHT="97">
  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>April&nbsp;27,
2018 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="be13701_notice_of_2018_annual_meeting_of_stockholders"> </A>
<A NAME="toc_be13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  NOTICE OF&nbsp;2018 ANNUAL MEETING OF STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>To
our Stockholders: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2018 Annual Meeting of Stockholders of Amicus Therapeutics,&nbsp;Inc. will be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury, New
Jersey 08512 on Thursday, June&nbsp;7, 2018 at 9:00&nbsp;a.m. Eastern Daylight Time. The purpose of this meeting is to vote on the following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Elect
two Class&nbsp;II directors as nominated by the Board of Directors each to serve a three</FONT><FONT SIZE=2><B>-</B></FONT><FONT SIZE=2>year term expiring at
the 2021 Annual Meeting or until their respective successors have been elected;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Approve
an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01 per share, that we are authorized
to issue from 250,000,000 shares to 500,000,000 shares
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Approve
the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Ratify
the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as the Company's independent registered public accounting firm for the fiscal year ending
December&nbsp;31, 2018;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Approve,
on an advisory basis, the Company's executive compensation; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>6.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consider
and act upon any other business that is properly presented at the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
items of business are more fully described in the Proxy Statement accompanying this Notice. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
record date for the 2018 Annual Meeting is April&nbsp;16, 2018. Only stockholders of record at the close of business on that date are entitled to notice of and to vote at the
meeting or any adjournment thereof. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>BY ORDER OF THE BOARD OF DIRECTORS:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g245976.jpg" ALT="GRAPHIC" WIDTH="211" HEIGHT="72">
 </B></FONT><FONT SIZE=2><BR>
<BR>
Ellen Rosenberg<BR></FONT> <FONT SIZE=2><I>General Counsel and Corporate Secretary</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>Cranbury,
New Jersey<BR>
April&nbsp;27, 2018 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cordially invited to attend the meeting in person. Whether or not you expect to attend the meeting, please complete, date, sign and return the proxy card or vote by telephone or
the Internet as instructed in the accompanying materials as promptly as possible in order to ensure your representation at the meeting. You can revoke a proxy at any time prior to its exercise by
following the instructions in the Proxy Statement. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must provide
a valid proxy issued in your name from that record holder. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=306293,FOLIO='blank',FILE='DISK109:[18ZAG1.18ZAG13701]BE13701A.;9',USER='CHE109870',CD='20-APR-2018;12:30' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dc13701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>AMICUS THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>1 Cedar Brook Drive, Cranbury, New Jersey 08512<BR>
(609)&nbsp;662-2000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT FOR THE AMICUS THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>2018 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON<BR>
JUNE 7, 2018  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> GENERAL INFORMATION ABOUT THE ANNUAL MEETING  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Why Did You Send Me this Proxy Statement?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We sent you this Proxy Statement and the enclosed proxy card because the Board of Directors (the "Board") of Amicus Therapeutics,&nbsp;Inc.
(sometimes referred to as "we," "us," "our," "Amicus" or the "Company") is soliciting your proxy to vote at the 2018 Annual Meeting of
Stockholders (the "Annual Meeting") and any adjournments of the meeting to be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury, New Jersey 08512 on
Thursday, June&nbsp;7, 2018 at 9:00&nbsp;a.m. Eastern Daylight Time. This Proxy Statement, along with the accompanying Notice of Annual Meeting of Stockholders, summarizes the purposes of the
meeting and the information you need to know to vote at the Annual Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this Proxy Statement. You do not need to
attend the Annual Meeting to vote your shares. Instead you may simply complete, date, sign and return the enclosed proxy card, or follow the instructions on the enclosed proxy card to submit your
proxy by telephone or on the Internet. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to mail this Proxy Statement, our 2017 Annual Report on Form&nbsp;10-K, the attached Notice of Annual Meeting and the enclosed proxy card to all stockholders entitled to vote
at the Annual Meeting on or about April&nbsp;27, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc13701_important_notice_regarding_the__imp04167"> </A>
<A NAME="toc_dc13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS<BR>  FOR THE ANNUAL MEETING TO BE HELD ON JUNE 7, 2018.    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc13701_the_proxy_statement_and_form_o__the00927"> </A>
<A NAME="toc_dc13701_2"> </A></FONT> <FONT SIZE=2><B>  THE PROXY STATEMENT AND FORM OF PROXY FOR OUR 2018 ANNUAL MEETING<BR>  OF STOCKHOLDERS AND OUR ANNUAL REPORT ON FORM 10-K FOR THE<BR>  YEAR ENDED DECEMBER 31, 2017 ARE AVAILABLE AT:<BR>
</B></FONT><FONT SIZE=2><I>www.sec.gov</I></FONT><FONT SIZE=2>, through the Investor Relations section of our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> or at<BR>  http://www.astproxyportal.com/ast/15417/
<BR></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Can Vote?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on April&nbsp;16, 2018 are entitled to vote at the Annual Meeting. On this record date,
there were [187,995,994] shares of our common stock ("Common Stock")
outstanding and entitled to vote. Each share of Common Stock is entitled to one vote. The Common Stock is our only outstanding class of voting stock. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder of Record: Shares Registered in Your Name  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, on April&nbsp;16, 2018, your shares were registered directly in your name with our transfer agent, American Stock Transfer&nbsp;&amp; Trust
Company, then you are a stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy. Whether or not you attend the Annual Meeting, we urge you to
fill out and return the enclosed proxy card or follow the instructions on the proxy card to submit your vote by telephone or Internet to ensure your vote is counted. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=762504,FOLIO='1',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;11',USER='CHE109865',CD='23-APR-2018;11:31' -->
<A NAME="page_dc13701_1_2"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Beneficial Owner: Shares Registered in the Name of a Broker or Bank  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, on April&nbsp;16, 2018, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer, or other
similar organization, then you are the beneficial owner of shares held in "street name" and these proxy materials are being forwarded to you by that organization. The organization holding your account
is considered the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent on how to vote the shares in your
account. A number of brokers and banks enable beneficial owners to give voting instructions&nbsp;via telephone or the Internet. Please refer to the voting instructions provided by your bank or
broker. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are also invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you provide a valid
proxy from your broker, bank or other custodian. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What am I voting on?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are five matters scheduled for a vote:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Elect two Class&nbsp;II directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Approve an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01 per share,
that we are authorized to issue from 250,000,000 shares to 500,000,000 shares </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Approve the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Ratify the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for our fiscal year ending
December&nbsp;31, 2018; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Approval, on an advisory basis, of the Company's executive compensation. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Do I Vote?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether you plan to attend the Annual Meeting or not, we urge you to vote by proxy. Voting by proxy will not affect your right to attend the
Annual Meeting. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If your shares are registered directly in your name, you may vote: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> By mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Complete and mail the enclosed proxy card in the enclosed postage
prepaid envelope. Your proxy will be voted in accordance with your instructions. If you sign the proxy card but do not specify how you want your shares voted, they will be voted as recommended by our
Board.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> In person at the meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you attend the meeting, you may deliver your
completed proxy card in person or you may vote by completing a ballot, which will be available at the meeting.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> By telephone.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may vote over the telephone by calling toll-free
1-800-PROXIES (1-800-776-9437) in the United States or 1-718-921-8500 from outside the United States and follow the recorded instructions. Please have your proxy card available when you call. Your
vote must be received by 11:59&nbsp;p.m. Eastern Daylight Time on June&nbsp;6, 2018 to be counted.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may vote via the Internet by going to </FONT> <FONT SIZE=2><I>www.voteproxy.com</I></FONT><FONT SIZE=2> and follow the
on-screen instructions. Please have your proxy card available when you access the web page. Your vote must be received
by 11:59&nbsp;p.m. Eastern Daylight Time on June&nbsp;6, 2018 to be counted. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=854201,FOLIO='2',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;11',USER='CHE109865',CD='23-APR-2018;11:31' -->
<A NAME="page_dc13701_1_3"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held in "street name" (held in the name of a bank, broker or other nominee), you must provide the
bank, broker
or other nominee with instructions on how to vote your shares and can do so as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> By mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions from your broker or other nominee
explaining how to vote your shares.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> In person at the meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Contact the broker or other nominee who holds
your shares to obtain a broker's proxy card and bring it with you to the meeting. You will not be able to vote at the meeting unless you have a proxy card from your broker. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Many Votes do I have?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of Common Stock that you own as of April&nbsp;16, 2018, entitles you to one vote on each matter to be voted on at the Annual
Meeting. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Will My Shares be Voted if I Do Not Return My Proxy Card?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your shares are registered in your name, they will not be voted if you do not return your proxy card by mail or vote at the meeting as
described above under "How Do I Vote?" If your shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above
under "How Do I Vote?," the bank, broker or other nominee has the authority to vote your unvoted shares only for Proposal 4. The broker, bank or other nominee will not be permitted to vote on the
other Proposals without your voting instructions. We encourage you to provide voting instructions. This ensures your shares will be voted at the meeting in the manner you desire. If your broker cannot
vote your shares on a particular matter because it has not received instructions from you and does not have discretionary voting authority on that matter or because your broker chooses not to vote on
a matter for which it does have discretionary voting authority, this is referred to as a "broker non-vote". </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


May I Revoke My Proxy?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you give a proxy, you may revoke it at any time before the Annual Meeting. You may revoke your proxy in any one of the following
ways:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> signing a new proxy card and submitting it as instructed above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> notifying the Company's Secretary in writing before the Annual Meeting that you have revoked your proxy; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> attending the meeting in person and voting in person if you are a stockholder of record. Attending the meeting in person will not in and of
itself revoke a previously submitted proxy unless you specifically request it. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What if I Receive More Than One Proxy Card?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may receive more than one proxy card or voting instruction form if you hold shares of our Common Stock in more than one account, which may
be in registered form or held in street name. Please vote in the manner described under "How Do I Vote?" for each account to ensure that all of your shares are voted. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Does the Board of Directors Recommend That I Vote on the Proposals?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board recommends that you vote as follows: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>"FOR"</B></FONT><FONT SIZE=2> the election of the nominees for director; </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=19300,FOLIO='3',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;11',USER='CHE109865',CD='23-APR-2018;11:31' -->
<A NAME="page_dc13701_1_4"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>"FOR"</B></FONT><FONT SIZE=2> the approval of an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par
value $0.01 per share, that we are authorized to issue from 250,000,000 shares to 500,000,000 shares; </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><B>FOR</B></FONT><FONT SIZE=2>" the approval of the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool; </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>"FOR"</B></FONT><FONT SIZE=2> ratification of the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for our fiscal
year ending December&nbsp;31, 2018; and </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>"FOR"</B></FONT><FONT SIZE=2> the approval of the compensation of our named executive officers. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any other matter is properly presented, the proxy card provides that your shares will be voted by the proxy holder listed on the proxy card in accordance with his best judgment. At
the time this Proxy Statement was printed, we knew of no matters that needed to be acted on at the Annual Meeting other than those discussed in this Proxy Statement. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What Vote is Required to Approve Each Proposal and How are Votes Counted?  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 1: Elect Directors</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The nominees for director who receive the most votes (also known as a "plurality" of the votes) will be elected. Abstentions are not counted as voting on the matter for purposes of electing directors. You may vote FOR all of the nominees, WITHHOLD
 your vote from all of the nominees or WITHHOLD your vote from any one or more of the nominees. Votes that are withheld will not be included in the vote tally for the election of directors. Brokerage firms do not have authority to vote customers'
 unvoted shares held by the firms in street name for the election of directors. These broker non-votes will have no effect on the results of this vote.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 2: Approve the Amendment to our Restated Certificate of Incorporation</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to approve the amendment to our Restated Certificate of Incorporation. Abstentions will
 have the effect of a vote against this proposal. Brokerage firms do not have the authority to vote customers' unvoted shares held by the firms in street name on this proposal. These broker non-votes will have no effect on the results of this vote.
 Our Board has approved the amendment to our Restated Certificate of Incorporation and believes it is in the best interest of the stockholders to approve it.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=432353,FOLIO='4',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;11',USER='CHE109865',CD='23-APR-2018;11:31' -->
<A NAME="page_dc13701_1_5"> </A>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 3: Approve the Amended and Restated 2007 Equity Incentive Plan</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to approve the Amended and Restated 2007 Equity Incentive Plan. Abstentions will have
 the effect of a vote against this proposal. Brokerage firms do not have the authority to vote customers' unvoted shares held by the firms in street name on this proposal. These broker non-votes will have no effect on the results of this vote. Our
 Board has approved the Amended and Restated 2007 Equity Incentive Plan and believes it is in the best interest of the stockholders to approve it.</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 4: Ratify Selection of Independent Registered Public Accounting Firm</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to ratify the selection of our independent registered public accounting firm.
 Abstentions will have the effect of a vote against this proposal. Brokerage firms have authority to vote customers' unvoted shares held by the firms in street name on this proposal. We are not required to obtain the approval of our stockholders to
 select our independent registered public accounting firm. However, our Board believes it is advisable to give stockholders the opportunity to ratify this selection. If our stockholders do not ratify the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as
 our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2018, the Audit and Compliance Committee of our Board will reconsider its selection.</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Proposal 5: Approval, on an Advisory Basis, of Executive Compensation</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to adopt this resolution. Abstentions will have the effect of a vote against this
 proposal. Brokerage firms do not have authority to vote customers' unvoted shares held by the firms in street name for this proposal. If a broker does not exercise this authority, such broker non-votes will have no effect on the results of this vote.
 This advisory vote on executive compensation is not binding on our Board. However, the Board will take into account the result of the vote when determining future executive compensation arrangements.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How are votes counted?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes will be counted by the inspector of election appointed for the Annual Meeting, who will separately count "For" and "Withhold" and (with
respect to proposals other than the election of directors) "Against" votes, abstentions and broker non-votes. Shares represented by
abstentions and broker non-votes will be counted in determining whether there is a quorum for the Annual Meeting. Abstentions </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=492292,FOLIO='5',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;11',USER='CHE109865',CD='23-APR-2018;11:31' -->
<A NAME="page_dc13701_1_6"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>will
have no effect on Proposal 1 but will have the effect of a vote against Proposal 2, 3, 4 and 5. Broker non-votes will not be counted towards the vote total for any proposal. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Will Pay the Costs of Soliciting these Proxies and How Are They Being Solicited?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by telephone, fax or
email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy
materials to their principals and to obtain authority to execute proxies. We will then reimburse them for their expenses. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What Constitutes a Quorum for the Meeting?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The presence, in person or by proxy, of the holders of a majority of the issued and outstanding shares of our Common Stock is necessary to
constitute a quorum at the meeting. Votes of stockholders of record who are present at the meeting in person or by proxy, abstentions and broker non-votes are counted for purposes of determining
whether a quorum exists. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How can I find out the results of the voting at the Annual Meeting?  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary voting results will be announced at the Annual Meeting. Final voting results will be published in a Current Report on
Form&nbsp;8-K within four business days after the Annual Meeting. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


When are stockholder proposals due for next year's Annual Meeting?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you wish to submit a proposal to be considered for inclusion in next year's proxy materials or nominate a director, your proposal must be in
proper form according to Securities and Exchange Commission ("SEC") Regulation&nbsp;14A, Rule&nbsp;14a8 and received by the Secretary of the Company no later than December&nbsp;28, 2018.
Proposals received after that date will not be included in the proxy materials we send out in connection with the 2019 Annual Meeting of Stockholders. If a proposal is received before that date, the
proxies that management solicits for the meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. To be timely in
accordance with our Restated By-laws, stockholder notice of any such proposal must be received by us not earlier than November&nbsp;28, 2018 and not later than December&nbsp;28, 2018; provided,
however, that in the event that the date of the 2019 Annual Meeting of Stockholders is more than 30&nbsp;days before or more than 60&nbsp;days after the anniversary date of the 2018 Annual Meeting
of Stockholders, notice by the stockholder to be timely must be delivered not earlier than the close of business on the 90th&nbsp;day prior to the 2019 Annual Meeting of Stockholders and not later
than the close of business on the later of the 60th&nbsp;day prior to the 2019 Annual Meeting of Stockholders or the 10th&nbsp;day following the day on which we make a public announcement of the
2019 Annual Meeting of Stockholders. All stockholder proposals should be marked for the attention of General Counsel and Corporate Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive,
Cranbury, New Jersey 08512. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Attending the Annual Meeting  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Annual Meeting will be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury, New Jersey 08512
on Thursday, June&nbsp;7, 2018 at 9:00&nbsp;a.m. Eastern Daylight Time. When you arrive at Amicus, signs will direct you to the appropriate meeting rooms. You are not required to attend the Annual
Meeting in order to vote. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=9,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=506561,FOLIO='6',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;11',USER='CHE109865',CD='23-APR-2018;11:31' -->
<A NAME="page_dc13701_1_7"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc13701_proposal_no._1_#151;election_of_directors"> </A>
<A NAME="toc_dc13701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 1&#151;ELECTION OF DIRECTORS    <BR>    </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation</I></B></FONT><FONT SIZE=2><B>:  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>The Board recommends the vote "FOR" the election of each of </B></FONT><FONT SIZE=2><B><I>Donald Hayden, Jr.  </I></B></FONT><FONT SIZE=2>and </FONT><FONT
SIZE=2><B><I>Craig Wheeler</I></B></FONT><FONT SIZE=2><B> as a director, and proxies solicited by the Board will be voted in favor thereof unless a stockholder has
indicated otherwise on the proxy.</B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board has voted to nominate Donald Hayden, Jr. and Craig Wheeler for election at the Annual Meeting for a term of three years to serve as Class&nbsp;II directors until the 2021
Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified. The Class&nbsp;I directors&#151;Dr.&nbsp;Ted Love and Robert Essner&#151;and the
Class&nbsp;III directors&#151;John F. Crowley, Margaret McGlynn, Michael Raab, and Glenn Sblendorio&#151;will serve until the Annual Meetings of Stockholders to be held in 2020 and
2019, respectively, and until their respective successors have been elected and qualified. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
authority to vote for any of these nominees is withheld, the shares represented by the signed and dated proxy cards will be voted </FONT> <FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the election as directors of Donald Hayden, Jr. and Craig Wheeler.
In the event that any nominee becomes unable or unwilling to serve, the shares
represented by the enclosed proxy will be voted at the discretion of the individuals designated as proxies on the proxy cards. We have no reason to believe that any nominee will be unable or unwilling
to serve as a director. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
plurality of the shares voted at the Annual Meeting is required to elect each nominee as a director. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Board of Directors  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Restated Certificate of Incorporation and Restated By-laws provide that our business is to be managed by or under the direction of our
Board. Our Board is divided into three classes and one class is elected at each Annual Meeting of Stockholders to serve for a three-year term. Our Board consisted of eight members. Our Board is
divided amongst three classes as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Class&nbsp;I directors are Dr.&nbsp;Love and Mr.&nbsp;Essner and their term will expire at the 2020 Annual Meeting of Stockholders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Class&nbsp;II directors are Mr.&nbsp;Hayden and Mr.&nbsp;Wheeler and their term will expire at the 2018 Annual Meeting of
Stockholders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Class&nbsp;III directors are Messrs.&nbsp;Crowley, Raab, and Sblendorio and Ms.&nbsp;McGlynn, and their term will expire at the 2019
Annual Meeting of Stockholders. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Restated Certificate of Incorporation and Restated By-laws provide that the authorized number of directors may be changed only by resolution of the Board. Our Board has authorized
that the size of the Board be set at ten members. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February&nbsp;23, 2018, our Board, upon the recommendation of the Nominating and Corporate Governance Committee, voted to nominate Mr.&nbsp;Hayden and Mr.&nbsp;Wheeler for
re-election as Class&nbsp;II directors at the 2018 Annual Meeting for a term of three years to serve until the 2021 Annual Meeting of stockholders until their respective successors have been duly
elected and qualified. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board has determined that each of the director nominees possesses the requisite skills, personal integrity, business judgment, industry experience and willingness to devote adequate
time and effort necessary to serve as an effective member of the Board. A description of the background of each, along with other specific experiences, qualifications, attributes or skills that
contributed to the Board's
decision to nominate the nominees, is set forth below, followed immediately by like disclosure for our existing directors whose terms of office extend beyond the Annual Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=10,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=172649,FOLIO='7',FILE='DISK109:[18ZAG1.18ZAG13701]DC13701A.;11',USER='CHE109865',CD='23-APR-2018;11:31' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_de13701_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->



<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominees for Election at the Annual Meeting  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald Hayden(1)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler(3)(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chair
of Nominating/Corporate Governance Committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Lead
Independent Director
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Compensation Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Science and Technology Committee  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Donald J. Hayden, Jr.</I></FONT><FONT SIZE=2> has served as a member of our Board since March 2006 and as Lead Independent Director since February 2010.
Mr.&nbsp;Hayden served as Chairman from March 2006 until February 2010 and from September 2006 until March 2007 as Interim President and Chief Executive Officer. From 1981 to 2006, he held several
executive positions with Bristol-Myers Squibb Company, most recently serving as Executive Vice President and President, Americas. Mr.&nbsp;Hayden is Chair of the Boards of Directors of Insmed
Incorporated (NASDAQ: INSM) and REGENXBIO&nbsp;Inc. (NASDAQ: RGNX). Mr.&nbsp;Hayden holds a B.A. from Harvard University and an M.B.A. from Indiana University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Hayden has more than 30&nbsp;years of experience in the pharmaceutical industry, including
leadership roles
in commercialization, drug launch, executive management, financial and strategic planning and business development. He also has significant Board experience through his service on the Board of
Directors of other publicly-held biopharmaceutical companies and his service as our Interim Chief Executive Officer all of which contribute to our conclusion that he should continue to serve as a
director of the Company and is particularly well suited to serve as Lead Independent Director and Chair of the Nominating and Corporate Governance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Craig Wheeler</I></FONT><FONT SIZE=2> has served as a member of our Board since June 2016. Since September 2006, Mr.&nbsp;Wheeler has served as President and
Chief Executive Officer of Momenta Pharmaceuticals,&nbsp;Inc. (NASDAQ: MNTA). At Momenta, Mr.&nbsp;Wheeler led the company through the launch of its first complex drug products. He has overseen
the company's growth into the diversified business it is today. In 2011, he was an E&amp;Y Entrepreneur of the Year Regional Award winner. In May 2012, the Boston Globe named Momenta the number one
company in their annual Globe 100 survey of top performing companies. Prior to joining Momenta, Mr.&nbsp;Wheeler was President of Chiron Biopharmaceuticals where, during his five-year tenure, he led
US and European commercial organizations and the pharmaceutical division's global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group's health care practice and
worked extensively in the health care sector with focus on pharma and biotech, particularly in regard to corporate and R&amp;D strategy. He began his career at Merck&nbsp;&amp; Company,&nbsp;Inc.'s (NYSE:
MRK) MSDRL research unit. He also previously served as the Chairman of the Board of Avanir Pharmaceuticals,&nbsp;Inc. where he helped oversee the transition of the company from a research-based
platform to a fully integrated CNS pharmaceutical company until 2015 when it was acquired by Otsuka Pharmaceuticals for $3.5&nbsp;billion. Mr.&nbsp;Wheeler received his BS and MS in chemical
engineering from Cornell University and his MBA from the Wharton School of the University of Pennsylvania. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Wheeler has extensive pharmaceutical industry knowledge and leadership experience, including his
demonstrated
expertise in drug development, manufacturing and the technical issues facing growing biopharmaceutical companies. Mr.&nbsp;Wheeler's deep understanding of the management and growth of pharmaceutical
companies contribute to our conclusion that he should continue to serve as a director of the Company and as a member of the Science and Technology and Compensation Committees. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=11,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=672953,FOLIO='8',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;12',USER='CHE107309',CD='23-APR-2018;11:34' -->
<A NAME="page_de13701_1_9"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors Whose Terms Do Not Expire This Year  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chairman</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret McGlynn(3)(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Raab(1)(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn Sblendorio(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted Love, MD(3)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Compensation Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chair,
Science and Technology Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Nominating/Corporate Governance Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Audit and Compliance Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Lead
Independent Director
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chair,
Compensation Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chair,
Audit and Compliance Committee  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>John F. Crowley</I></FONT><FONT SIZE=2> has served as a Director, Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since
January 2005, except for the period from April 2011 through August 2011 during which time he served as Executive Chairman. Mr.&nbsp;Crowley has also served as a director of Amicus since August 2004,
with the exception of the period from September 2006 to March 2007 when he was in active duty service in the United States Navy (Reserve). Mr.&nbsp;Crowley was President and Chief Executive Officer
of Orexigen Therapeutics,&nbsp;Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals,&nbsp;Inc., from March 2000 until that company
was acquired by Genzyme Corporation ("Genzyme") in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Mr.&nbsp;Crowley received a B.S.
degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Crowley possesses strong leadership qualities, demonstrated through his service as an executive in
the
pharmaceutical industry, including his prior roles as Chief Executive Officer of development stage biopharmaceutical companies, and has extensive and intimate knowledge of the rare disease community
and the needs of people living with rare diseases. He also provides our Board with in-depth knowledge of our company through the day-to-day leadership of our executives, all of which contributed to
our conclusion that he should continue to serve as a Director and Chairman of the Company. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Ted W. Love</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>M.D.</I></FONT><FONT SIZE=2>, has served as a member of the Board since June 2012. Dr.&nbsp;Love is
currently the CEO of Global Blood Therapeutics,&nbsp;Inc. (NASDAQ: GBT). From February 2010 to August 2012, Dr.&nbsp;Love served as Executive Vice President and Head of Research and Development of
Onyx Pharmaceuticals,&nbsp;Inc. From 2001 to 2009, Dr.&nbsp;Love was the President, Chief Executive Officer and Chairman of the Board of Directors of Nuvelo&nbsp;Inc. Before joining Nuvelo in
2001, he served as Senior Vice President of Development at Theravance,&nbsp;Inc. Prior to that, Dr.&nbsp;Love spent six years at Genentech,&nbsp;Inc. in a number of senior management positions
in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, Dr.&nbsp;Love oversaw all drugs in development including Herceptin, Rituxan,
and TNKase. He also served as chairman of Genentech's Product Development Committee. In addition to Amicus, Dr.&nbsp;Love currently serves on the Board of Directors of Global Blood </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=12,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=935206,FOLIO='9',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;12',USER='CHE107309',CD='23-APR-2018;11:34' -->
<A NAME="page_de13701_1_10"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>and
was previously a board member of Cascadian Therapeutics. Dr.&nbsp;Love holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Love's significant medical, scientific and drug development experience, in addition to his executive
leadership
experience in the pharmaceutical industry, experience as Chief Executive Officer and Chairman of a biopharmaceutical company and service on the Boards of Directors of other publicly-held
biopharmaceutical companies, contributed to our conclusion that he should be re-elected to serve as a director of the Company and lead the Science and Technology Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Robert Essner</I></FONT><FONT SIZE=2> has served as a member of the Board since June 2012. Mr.&nbsp;Essner is Senior Advisor to the global healthcare group at
The Carlyle Group, a global private equity firm. Mr.&nbsp;Essner retired as Chairman and Chief Executive Officer of Wyeth Pharmaceuticals,&nbsp;Inc., now part of Pfizer&nbsp;Inc., in 2008.
During his 32-year career in the pharmaceutical industry, he held several prominent leadership positions, including Chairman of the Pharmaceutical Research and Manufacturers Association. Prior to
Wyeth, Mr.&nbsp;Essner spent more than a decade in various management positions at Sandoz Pharmaceuticals Corporation and as President of Sandoz Consumer Healthcare Group. Mr.&nbsp;Essner is
currently a Director at MassMutual Financial Group. He received a Bachelor's degree from Miami University and a Master's degree from the University of Chicago. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Essner's significant executive leadership experience in the pharmaceutical industry, including
building and
leading pharmaceutical businesses, launching products and managing corporate risks, including as Chairman and Chief Executive Officer of a pharmaceutical company, as well as his service on the Board
of Directors of another publicly-held company in the pharmaceutical industry, contributed to our conclusion that he should be re-elected to serve as a director of the Company and continue to serve on
the Audit and Compliance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Margaret G. McGlynn</I></FONT><FONT SIZE=2> has served as a member of our Board since October 2009. Following a 26&nbsp;year career at Merck, Ms.&nbsp;McGlynn
served as CEO and President of The International AIDS Vaccine Initiative from July 2011 through September 2015. She previously served as President, Vaccines and Infectious Diseases of Merck from 2005
until her retirement in 2009, where she led a global organization of 2000&nbsp;employees with over $7B in sales. Ms.&nbsp;McGlynn joined Merck in 1983, and served in a variety of executive
leadership roles in marketing, sales and managed care. Currently, Ms.&nbsp;McGlynn serves as a member of the Boards of Directors of Air Products and Chemicals,&nbsp;Inc. (NYSE: APD) and Vertex
Pharmaceuticals,&nbsp;Inc. (NASDAQ: VRTX). She is also Chair of the Board of HCU Network America, a non-profit which provides advocacy and support for patients affected by the rare disease
homocystinuria. Ms.&nbsp;McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State University of New York at Buffalo. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;McGlynn has significant leadership experience in the pharmaceutical industry, including her service
as a senior
executive of Merck where she led commercialization across several therapeutic areas and geographies and managed large organizations. This experience, combined with her service on biopharmaceutical
company boards and a rare disease patient advocacy organization, which gives her important insights into Amicus's business and a comprehensive understanding of compensation management and the
relationship of compensation practices to the organization and its development, contributed to our conclusion that she should continue to serve as a director of the Company, Chair of the Compensation
Committee and member of the Nominating and Corporate Governance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Michael G. Raab</I></FONT><FONT SIZE=2> has served as a member of our Board of Directors since its founding. Mr.&nbsp;Raab has served as President and Chief
Executive Officer of Ardelyx,&nbsp;Inc. (NASDAQ: ARDX) since March 2009.
Mr.&nbsp;Raab previously served as a partner of New Enterprise Associates ("NEA") from June 2002 until December 2008, with a focus on healthcare investing. From 1999 to 2002, he was Senior Vice
President, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=13,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=838365,FOLIO='10',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;12',USER='CHE107309',CD='23-APR-2018;11:34' -->
<A NAME="page_de13701_1_11"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Therapeutics
and General Manager, Renagel&reg; at Genzyme Corporation. Mr.&nbsp;Raab currently serves as a member of the Board of Directors of Ardelyx,&nbsp;Inc. Mr.&nbsp;Raab holds a
B.A. from DePauw University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Raab has significant experience in drug development and commercialization of products in the rare
diseases,
cardio renal and GI diseases. He also has extensive management experience in the biopharmaceutical industry serving as Chief Executive Officer of a late-stage biopharmaceutical company and from his
prior time overseeing NEA investments in pharmaceuticals and biotechnology, all of which contributed to our conclusion that he should continue to serve as a director of the Company and a member of the
Audit and Compensation Committees. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Glenn P. Sblendorio</I></FONT><FONT SIZE=2> has served as a member of our Board since June 2006. Mr.&nbsp;Sblendorio is currently Chief Executive Officer of
Ophthotech Corporation (NASDAQ: OPHT) and is a Director on the Board of Directors of Ophthotech. Prior to Ophthotech, Mr.&nbsp;Sblendorio was President and Chief Financial Officer of The Medicines
Company (NASDAQ: MDCO) from March, 2006 through March, 2016 and was a member of the Board of Directors of the Medicines Company from July 2011 through December&nbsp;31, 2015. Before joining The
Medicines Company, Mr.&nbsp;Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals,&nbsp;Inc. from February 2002 until it was acquired by OSI
Pharmaceuticals,&nbsp;Inc. in November 2005. Mr.&nbsp;Sblendorio also serves as a member of the Boards of Directors of Intercept Pharmaceuticals,&nbsp;Inc. (NASDAQ: ICPT) (Chair, Audit).
Mr.&nbsp;Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Sblendorio has significant corporate leadership experience, industry knowledge and demonstrated
knowledge of
financial and financing matters through his prior experience in leading pharmaceutical companies. He brings substantial expertise in the management of financial and compliance risks associated with
global pharmaceutical operations and financial management strategies. Mr.&nbsp;Sblendorio's specific expertise includes his service on other boards and he devotes significant time to Amicus matters.
He is the "audit committee financial expert" as defined in the SEC regulations, with particular expertise in the matters faced by the audit committee of a company with its commercial revenue guidance,
geographic expansion and related expenses, all of which contributed to our conclusion that he should continue to serve as a director of the Company and Chair of the Audit and Compliance Committee. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de13701_amicus_corporate_govenance"> </A>
<A NAME="toc_de13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  AMICUS CORPORATE GOVENANCE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes key corporate governance policies and practices that we believe ensure that Amicus is managed for the long term benefit
of all our stakeholders. We continuously review these policies and practices and compare them to those of our peer group and those suggested by various authorities in corporate governance to ensure we
adopt best industry practices. Policies and practices that we have adopted include criteria for selecting director nominees, board leadership structure, and responsibilities of the Board of Directors
and its committees, among others. Complete copies of our Corporate Governance Guidelines, Board Committee charters, and Code of Conduct are available on the "Investors&#151;Corporate
Governance" section of our website, www.amicusrx.com. You may also request a copy of these documents in writing to: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amicus
Therapeutics&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, N.J. 08512, Attn: Ellen Rosenberg, Secretary </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Governance Guidelines  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has adopted corporate governance guidelines to assist our directors in the exercise of their duties and responsibilities
and to serve the best interests of Amicus and its stakeholders. These guidelines provide, among other things, that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The responsibility of the Board is to oversee the business and operations of Amicus; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=14,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1046964,FOLIO='11',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;12',USER='CHE107309',CD='23-APR-2018;11:34' -->
<A NAME="page_de13701_1_12"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The majority of the Board must be independent directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The directors have full access to management and to outside independent consultants as needed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Board conducts an annual self-evaluation; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Board establishes appropriate limitations for service as directors on other company boards. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board has reviewed the materiality of any relationship that each of our directors has with Amicus, either directly or indirectly as well as
other factors that may impact the independence determination for each of our directors. Based on this review, our Board has determined that the following directors are "independent directors" as
defined by the rules and regulations of The Nasdaq Stock Market&nbsp;LLC ("NASDAQ"): Messrs.&nbsp;Essner, Hayden, Raab, Sblendorio and Wheeler, Dr.&nbsp;Love, and Ms.&nbsp;McGlynn. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2010, the Board elected Mr.&nbsp;Crowley as chairman of the Board in addition to his role as chief executive officer to succeed
Donald J. Hayden, Jr. Simultaneous with Mr.&nbsp;Crowley's election to chairman, the Board appointed Mr.&nbsp;Hayden as Lead Independent Director. As Lead Independent Director, Mr.&nbsp;Hayden
is responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> leading executive sessions of the Board's independent directors, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> advising the independent Board Committee chairs in fulfilling their responsibilities to the Board, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> assisting the Board and the Company's officers in complying with the Company's governance guidelines, and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing the process of evaluating, developing and compensating the chief executive officer. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company combines the chairman and chief executive officer positions because it believes that, at this critical juncture in the Company's development, Mr.&nbsp;Crowley is best
suited to oversee the development and implementation of the Company's strategic vision including our ongoing transition from a development stage entity into a commercial biotechnology company.
Mr.&nbsp;Crowley's tenure as chairman also reflects the Board's confidence in his leadership and vision for the Company and recognizes his accomplishments since joining the Company. However, the
Company wished to maintain the strong independent leadership provided by Mr.&nbsp;Hayden during his tenure as chairman. The Company believes that by creating a Lead Independent Director position
held by Mr.&nbsp;Hayden, it has designed a governance structure that best advances the objectives of the Company while maintaining proper checks and balances on senior management, and providing the
independent members of the Board with open and transparent communication regarding the Company's strategic planning activities. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risk Oversight Management  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board provides risk oversight for the Company primarily through the Audit and Compliance Committee. Under our Risk Management Action Plan,
the Company identifies risks utilizing various methodologies, including interviews with senior employees and members of the Board. We then evaluate the identified risks and implement procedures and
activities, as necessary, which are designed to manage and mitigate such risks. We present reports on this risk identification, management and mitigation process along with regular updates on
compliance issues generally to the Audit and Compliance Committee, who provides guidance and feedback to senior management. The Audit and Compliance Committee apprises the Board of any developments
under this plan throughout the year. The Chief Compliance Officer has a dotted line reporting to the Audit and Compliance Committee and provides quarterly updates on the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=15,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=242802,FOLIO='12',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;12',USER='CHE107309',CD='23-APR-2018;11:34' -->
<A NAME="page_de13701_1_13"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>development
of the Compliance Program and any reports of violations of the Code of Conduct or other policies. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CODE OF CONDUCT AND ETHICS  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a code of conduct and ethics that applies to all of our employees, including our principal executive officer and principal
financial and accounting officer, and our directors. The text of the code of conduct and ethics is posted on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> and will
be made available to stockholders without charge, upon request, in writing to Secretary, c/o Amicus Therapeutics,&nbsp;Inc. at 1&nbsp;Cedar Brook Drive, Cranbury, New Jersey 08512. Disclosure
regarding any amendments to, or waivers from, provisions of the code of conduct and ethics that apply to our directors, principal executive and financial and accounting officers will be included in a
Current Report on Form&nbsp;8-K within four business days following the date of the amendment or waiver, unless web site posting of such amendments or waivers is then permitted by the rules of
NASDAQ. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Attendance  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the year ended December&nbsp;31, 2017, there were thirteen meetings of our Board, and the various committees of the Board met a total
of twenty times. No director attended fewer than 86% of the total number of meetings of the Board and of Committees of the Board on which he or she served during 2017. The Board has adopted a policy
under which each member of the Board is strongly encouraged to attend each Annual Meeting of our Stockholders. All of the directors, with the exception of Mr.&nbsp;Essner, attended our 2017 Annual
Meeting of Stockholders. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committees of the Board and Meetings  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board has an Audit and Compliance Committee, a Compensation Committee, a Nominating and Corporate Governance Committee and a Science and
Technology Committee, each of which has the composition and responsibilities described below. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit and Compliance Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Audit and Compliance Committee ("ACC") met six times during 2017. The current members of our ACC are
Messrs.&nbsp;Sblendorio, Essner and Raab. Mr.&nbsp;Sblendorio is the Chair of the ACC. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that Mr.&nbsp;Sblendorio is an Audit and Compliance Committee financial expert within the meaning of Item&nbsp;407(d)(5) of Regulation&nbsp;S-K and has
"accounting or related financial management expertise" within the meaning of the rules and regulations of NASDAQ. Our Audit and Compliance Committee was established in accordance with
Section&nbsp;3(a)(58) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Our ACC assists our Board in its oversight of the integrity of our financial statements, our
independent registered public accounting firm's qualifications and independence and the performance of our independent registered public accounting firm. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ACC's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of certain reports
from our independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements
and related disclosures; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=16,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=711724,FOLIO='13',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;12',USER='CHE107309',CD='23-APR-2018;11:34' -->
<A NAME="page_de13701_1_14"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> monitoring our Compliance Program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for the receipt and
retention of accounting related complaints and concerns; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> meeting independently with our independent registered public accounting firm and management; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> meeting independently with our Chief Compliance Officer; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> preparing the Audit Committee report required by SEC rules. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
audit and non-audit services to be provided to us by our independent registered public accounting firm must be approved in advance by our Audit and Compliance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NASDAQ
rules require that all members of the Audit and Compliance Committee be independent directors, as defined by the rules of NASDAQ and the SEC. Our Board has determined that all the
members of the Audit and Compliance Committee satisfy the independence requirements for service on the Audit and Compliance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the ACC written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee met five times during 2017. Ms.&nbsp;McGlynn, Mr.&nbsp;Raab and Mr.&nbsp;Wheeler are
the
members of our Compensation Committee. Ms.&nbsp;McGlynn is the chair of the Compensation Committee. Our Compensation Committee assists our Board in the discharge of its responsibilities relating to
the compensation of our executive officers. The Compensation Committee has retained Pay Governance,&nbsp;LLC ("Pay Governance") as its independent executive compensation consultant. Pay Governance
reports directly to the Compensation Committee and provides guidance on matters including trends in executive and non-employee director compensation, the development of certain executive compensation
programs, determination of the Company peer group and other matters as directed by the Compensation Committee. Pay Governance does not provide any other services to the Company. Based on the
consideration of the various factors as set forth in the rules of the SEC, the Compensation Committee has determined that its relationship with Pay Governance and the work of Pay Governance on behalf
of the Compensation Committee has not raised any conflict of interest. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and approving executive officer compensation including the compensation of our Chief Executive Officer; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing the evaluation of performance of our senior executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing and administering, and making recommendations to our Board with respect to our cash and equity incentive plans; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and approving potential executive and senior management succession plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and approving non-routine employment agreements, severance agreements and change in control agreements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and recommending to the Board for approval the annual corporate goals and objectives; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing the Company's performance against the annual corporate goals and objectives and recommending to the Board a corporate multiplier
which represents the percentage of achievement against the corporate goals and objectives. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that the members of our Compensation Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=17,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=983284,FOLIO='14',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;12',USER='CHE107309',CD='23-APR-2018;11:34' -->
<A NAME="page_de13701_1_15"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the Compensation Committee's written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further
discussion of the process and procedures for considering and determining executive compensation, including the role that our executive officers play in determining compensation
for other executive officers, is included below in the section entitled "Compensation Discussion and Analysis." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
also see the report of the Compensation Committee set forth elsewhere in this Proxy Statement. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nominating and Corporate Governance Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Nominating and Corporate Governance Committee met five times during 2017.
Mr.&nbsp;Hayden,
Dr.&nbsp;Love and Ms.&nbsp;McGlynn are the members of our Nominating and Corporate Governance Committee. Mr.&nbsp;Hayden chairs the Nominating and Corporate Governance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Nominating and Corporate Governance Committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> recommending to our Board the persons to be nominated for election as directors and to each of the Board's Committees; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> conducting searches for appropriate directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing the size, composition and structure of our Board; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> developing and recommending to our Board corporate governance principles; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing a periodic self-evaluation of our Board and any Board Committees; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing compensation and benefits for directors and Board Committee members. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that the members of our Nominating and Corporate Governance Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the Nominating and Corporate Governance Committee's written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Science and Technology Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Science and Technology Committee met four times in 2017. Dr.&nbsp;Love and Mr.&nbsp;Wheeler are
currently
members of our Science and Technology Committee. Dr.&nbsp;Love serves as Chair of the committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Science and Technology Committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> identifying and discussing new and emerging trends in pharmaceutical science, technology and regulation to ensure that the Company makes well
informed choices in the investment of its Research and Development resources; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing, evaluating and advising the Board regarding the quality, direction and competitiveness of the Company's Research and Development
programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing, evaluating and advising the Board regarding the Company's overall manufacturing strategy to ensure that the Company makes well
informed choices in the investment in manufacturing capabilities and secures appropriate levels of drug supply and drug product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing, evaluating and advising the Board regarding the Company's clinical and regulatory strategy, goals and objectives, and progress in
achieving the clinical and regulatory strategy, goals and objectives; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and making recommendations to the Board on the Company's internal and external investments in science and technology. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=18,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=2155,FOLIO='15',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;12',USER='CHE107309',CD='23-APR-2018;11:34' -->
<A NAME="page_de13701_1_16"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that the members of the Science and Technology Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC. A copy of the
Science and Technology Committee's written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policies Governing Director Nominations  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director Qualifications.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Nominating and Corporate Governance Committee is responsible for reviewing with the directors from time to
time the
appropriate qualities, skills and characteristics desired of members of the Board in the context of the needs of the business and the composition of the Board. This assessment includes consideration
of the following minimum qualifications that the Nominating and Corporate Governance Committee believes must be met by all directors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a reputation for integrity, honesty and adherence to high ethical standards; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability to exercise sound business judgment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> substantial business or professional experience and the ability to offer meaningful advice and guidance to the Company's management based on
that experience; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability to devote the time and effort necessary to fulfill their responsibilities to the Company. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Nominating and Corporate Governance Committee also considers numerous other qualities, skills and characteristics when evaluating director nominees, including whether the nominee has
specific strengths that would augment existing skills and experience of the Board, such as an understanding of and experience in technology, drug development, accounting, governance, finance or
commercialization and whether the nominee has leadership experience with public companies or other sophisticated and complex organizations. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Process for Identifying and Evaluating Director Nominees.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Nominating and Corporate Governance
Committee has established a process for identifying and evaluating nominees for director. Although the Nominating and Corporate Governance Committee will consider nominees recommended by stockholders,
it believes that the process it uses to identify and evaluate nominees for director is designed to produce nominees that possess the educational, professional, business and personal attributes that
are best suited to further the Company's mission. Our Nominating and Governance Committee may identify nominees through the use of professional search firms that may utilize proprietary screening
techniques to match candidates to the Nominating and Governance Committee's specified qualifications. The Nominating and Governance Committee may also receive recommendations from existing directors,
executive officers, key business partners, and trade or industry affiliations. Our Nominating and Corporate Governance Committee will evaluate nominations at regular or special meetings, and in
evaluating nominations, will seek to achieve a balance of knowledge, experience and capability on the Board and to address the membership criteria set forth above under "Director Qualifications." The
Board itself is ultimately responsible for recommending candidates for election to the stockholders or for appointing individuals to fulfill a vacancy. Although the Board does not have a policy with
regard to the consideration of diversity in identifying director nominees, among the various factors the Nominating and Corporate Governance Committee considers in selecting candidates for nomination
to the Board are the benefits to the Company of national origin, gender, race, scientific and pharmaceutical experience and cultural diversity in board composition. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Procedures for Recommendation of Director Nominees by Stockholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Nominating and Corporate Governance Committee will consider
director
candidates recommended by our stockholders. In evaluating candidates recommended by our stockholders, the Nominating and Corporate Governance Committee applies the same criteria set forth above under
"Director Qualifications." Any stockholder recommendations of director nominees proposed for consideration by the Nominating and Corporate Governance Committee should include the nominee's name and
qualifications for Board membership and should be addressed in writing to the Nominating and Corporate Governance Committee, care of: Amicus </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=19,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=234760,FOLIO='16',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;12',USER='CHE107309',CD='23-APR-2018;11:34' -->
<A NAME="page_de13701_1_17"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Therapeutics&nbsp;Inc.,
1 Cedar Brook Drive, Cranbury, New Jersey 08512, Attention: Secretary. In addition, our Restated By-laws permit stockholders to nominate directors for consideration at an
annual stockholder meeting in accordance with certain procedures described in this Proxy Statement under the heading "Stockholder Proposals and Nominations for Director." </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation Committee Interlocks and Insider Participation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;McGlynn, Mr.&nbsp;Raab and Mr.&nbsp;Wheeler are the members of our
Compensation Committee. None of the members of our Compensation Committee has ever been an officer or employee of the Company. None of our executive officers serves as a member of the Board of
Directors or Compensation Committee, or other committee serving an
equivalent function, of any entity that has one or more of its executive officers serving as a member of our Board or our Compensation Committee. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Communications to the Board  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board provides a process for stockholders to send communications to the Board. Any stockholders who wish to address questions regarding our
business directly with our Board, or any individual director, should direct his or her questions in writing to the Chairman of the Board or the Secretary of the Board, c/o Amicus
Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512. Communications will be distributed to the Board, or to any individual director or directors as appropriate, depending on the
facts and circumstances outlined in the communications. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a brief summary of the background of each of our executive officers: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>John F. Crowley, 50,</I></FONT><FONT SIZE=2> has served as Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January
2005, except for the period during April 2011 through August 2011 during which time he served as Executive Chairman. Mr.&nbsp;Crowley has also served as a director of Amicus since August 2004, with
the exception of the period from September 2006 to March 2007 when he was not an officer or director of Amicus while he was in active duty service in the United States Navy (Reserve).
Mr.&nbsp;Crowley was President and Chief Executive Officer of Orexigen Therapeutics,&nbsp;Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme
Pharmaceuticals,&nbsp;Inc., from March 2000 until that company was acquired by Genzyme Corporation in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until
December 2002. Mr.&nbsp;Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A.
from Harvard Business School. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Bradley L. Campbell, 42,</I></FONT><FONT SIZE=2> has served as President and Chief Operating Officer since January 2015. Mr.&nbsp;Campbell served as Chief
Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012, Mr.&nbsp;Campbell served as Senior Vice President,
Business Operations; from May 2007 to January 2010, as Vice President, Business Planning and from April 2006 until May 2007, as Senior Director, Business Development. Mr.&nbsp;Campbell served as
Senior Product Manager of Myozyme&copy; for Pompe Disease and
later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr.&nbsp;Campbell has also worked in sales&nbsp;&amp; marketing for Bristol-Myers Squibb and as a business
strategy consultant for Marakon Associates. Mr.&nbsp;Campbell is also a director for Progenics (NASDAQ: PGNX) and a board member of BioNJ. Mr.&nbsp;Campbell received his B.A. from Duke University
and his M.B.A. from Harvard Business School. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>William D. "Chip" Baird III, 46,</I></FONT><FONT SIZE=2> has served as Chief Financial Officer since April 2012. Prior to joining Amicus, Mr.&nbsp;Baird served
as Chief Financial Officer of PTC Therapeutics,&nbsp;Inc. ("PTC") from April 2005 until April 2012. Before that, Mr.&nbsp;Baird held various positions of increasing responsibility with PTC from
2002 to 2005. Mr.&nbsp;Baird previously worked at L.E.K. Consulting, a strategy consulting firm, from 1999 to 2002 and at First Union National Bank as a corporate underwriter from 1994 to 1997.
Mr.&nbsp;Baird received a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=20,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=13096,FOLIO='17',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;12',USER='CHE107309',CD='23-APR-2018;11:34' -->
<A NAME="page_de13701_1_18"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>B.S.
from Georgetown University's Edmund A. Walsh School of Foreign Service and an M.B.A. from The Wharton School of the University of Pennsylvania. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Jay Barth, M.D., 54,</I></FONT><FONT SIZE=2> has served as Chief Medical Officer since March 2014. Prior to joining Amicus, Dr.&nbsp;Barth held roles of
increasing responsibility at PTC from 2009 to 2014. He most recently served as PTC's Senior Vice President, Clinical Development. Previously Dr.&nbsp;Barth served as Executive Director of Clinical
Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US,&nbsp;Inc.; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical
Research&nbsp;Inc. Dr.&nbsp;Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School Of Medicine. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Hung Do, Ph.D., 50</I></FONT><FONT SIZE=2>, has served as Chief Science Officer since July 2015. Previously, he served as Senior Vice President, Discovery Biology
since December 2013. Prior to joining Amicus, Dr.&nbsp;Do was a co-founder and Chief Scientific Officer of Callidus Biopharma,&nbsp;Inc. ("Callidus") a privately held biologics company that was
acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to
demonstrate proof of concept for ERTs, and served as the project leader for a second generation Pompe ERT at Genzyme. Dr.&nbsp;Do also led molecular biology, cell culture and purification work and
helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme Pharmaceuticals,&nbsp;Inc., which was acquired by Genzyme. Dr.&nbsp;Do
holds a Ph.D. in medical biochemistry and genetics from Texas A&amp;M University and was a post-doctoral fellow in Hematology/Oncology at Emory University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Ellen S. Rosenberg, 55</I></FONT><FONT SIZE=2>, has served as our General Counsel and Corporate Secretary since February 2016. Prior to joining Amicus, she served
as Senior Vice President, Associate General Counsel of Shire
Pharmaceuticals. Prior to Shire, Ms.&nbsp;Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono&nbsp;Inc., the U.S. affiliate of Merck KGaA.
Ms.&nbsp;Rosenberg brings extensive and broad ranging legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions, licensing, corporate governance,
product launches, risk management, and compliance matters. Ms.&nbsp;Rosenberg also has significant experience building and developing legal teams and the in-house legal function.
Ms.&nbsp;Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Daphne Quimi, 52</I></FONT><FONT SIZE=2>, currently serves as our Senior Vice President, Finance and has been employed with Amicus since September 2007. Prior to
Amicus, Ms.&nbsp;Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at
Johnson&nbsp;&amp; Johnson. Ms.&nbsp;Quimi brings extensive experience in public accounting and financial reporting. Ms.&nbsp;Quimi received a B.S. in Accountancy from Monmouth University and an
M.B.A. from the Stern School of Business of New York University. She is a certified public accountant in New Jersey. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Kurt J.W. Andrews, 48,</I></FONT><FONT SIZE=2> has served as our Senior Vice President, Human Resources since February 2016. Prior to joining Amicus,
Mr.&nbsp;Andrews served as Vice President, Human Resources at Valeritas,&nbsp;Inc. Previously Mr.&nbsp;Andrews was Vice President, Human Resources and Administration at PTC
Therapeutics,&nbsp;Inc. Mr.&nbsp;Andrews brings experience working in leadership roles at biotechnology and technology companies including business and commercial strategy, implementation of
organization-wide goals and strategies, performance management, and compensation planning. Mr.&nbsp;Andrews earned a B.A. and M.A. from The University of Illinois at Urbana-Champaign. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=21,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=305117,FOLIO='18',FILE='DISK109:[18ZAG1.18ZAG13701]DE13701A.;12',USER='CHE107309',CD='23-APR-2018;11:34' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dg13701_1_19"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg13701_compensation_discussion_and_analysis_#151;2017"> </A>
<A NAME="toc_dg13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION DISCUSSION AND ANALYSIS&#151;2017    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Summary  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee, in consultation with the Board, is responsible for establishing, implementing and overseeing our overall
compensation strategy and policies, including our executive compensation program, in a manner that supports our business objectives. Based on the events described below, our Compensation Committee
determined that in 2017, the Company made significant progress towards the goal of becoming a leading orphan and rare disease company with global commercial operations and a diversified product
pipeline. Specific milestones achieved in 2017 in support of the Company's business strategy include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> In 2017, we made significant progress in the advancement of the International commercial launch of Galafold (migalastat) for the treatment of
Fabry patients with amenable mutations. We exceeded the corporate goal of 300 patients and achieved more than 310 patients taking reimbursed Galafold at year end. We secured access and reimbursement
for Galafold in 15&nbsp;countries and recognized $36.9&nbsp;million of net product revenue in 2017. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> In July 2017, we announced that, based on feedback from the U.S&nbsp;Food and Drug Administration ("FDA"), data from completed studies were
deemed sufficient to support a New Drug Application ("NDA") for migalastat under the accelerated approval pathway. This reversed prior FDA guidance received in the fourth quarter of 2016 which stated
that the Company would need to conduct a new Phase&nbsp;3 study focused on collecting gastrointestinal symptoms data prior to submitting an NDA. The updated FDA guidance announced in July 2017
accelerated the potential approval of migalastat by several years. In December 2017, the Company completed the submission of the NDA for migalastat. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> During 2017, we provided several updates from our ongoing Phase&nbsp;1/2 study of our novel Enzyme Replacement Therapy ("ERT") combined with
chaperone, ATB200/AT2221, in patients with Pompe disease. The final update was presented at the World Muscle Society meeting in October 2017. The data showed that both previously-treated patients and
na&iuml;ve patients experienced meaningful improvements in their six-minute walk tests, an accepted measure of clinical benefit in Pompe disease. Patients showed consistent and durable
improvements in other measures of muscle function, as well as improvements in key biomarkers of disease. Patients experienced very low rates (&#60;1%) of infusion associated reactions,
which are a common side effect of existing ERTs. Taken together, these results exceeded our expectations and suggest that the effect of ATB200/AT2221 may be very clinically meaningful for people
living with Pompe disease. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> We substantially strengthened our financial position in 2017. In July 2017, we completed a $258.8&nbsp;million follow on equity offering.
Through careful expense management, our net cash spend for 2017 was $216.5&nbsp;million, which was within the full-year guidance range of $200&nbsp;million to $225&nbsp;million. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee adheres to a long-standing pay-for-performance philosophy. The Compensation Committee continually evaluates our compensation program, taking into consideration
best practices and emerging trends, stockholder input as well as data and feedback provided by our independent executive compensation consultant, Pay Governance. In the past year, we have continued
to take measures to align our compensation program with stockholder interests including the following actions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Base salaries comprise approximately 18% of our named executive officers' total compensation on an aggregate basis, with Mr.&nbsp;Crowley's
2017 salary representing approximately 11% of his total compensation and, for our other named executive officers, representing between 20% and 28% of their total compensation. For 2017, the
Compensation Committee determined that Mr.&nbsp;Crowley would receive an increase in his base salary of 3.0%. Approximately 16% of Mr.&nbsp;Crowley's total </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=22,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=128343,FOLIO='19',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;11',USER='CHE109576',CD='20-APR-2018;12:25' -->
<A NAME="page_dg13701_1_20"> </A>
<UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>compensation
in 2017 was represented by payments we make to him for medical expenses and associated tax liabilities incurred for the treatment of a rare medical condition afflicting two members of
Mr.&nbsp;Crowley's immediate family. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> A large portion of our named executive officers compensation was represented by long-term incentives, including the grant date fair value of
equity awards, which are inherently performance based. Approximately 61% of Mr.&nbsp;Crowley's total compensation was in the form of long-term incentives. For our named executive officers other than
Mr.&nbsp;Crowley, 54% to 60% of their total compensation for 2017 was represented by long-term incentives. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> For 2017, the Compensation Committee determined that Mr.&nbsp;Crowley, along with the Senior Leadership team, including all of our named
executive officers, would receive one-third of the value of their equity grant in Performance Restricted Stock Units ("PRSUs"). This was part of an overall strategic shift which encompassed using 1/3
the value of annual grants in Stock Options, 1/3 of the value in Restricted Stock Units and 1/3 in PRSUs. The PRSUs utilized performance measures of relative total shareholder return and strategic
pipeline metrics. Utilizing PRSUs aligns the management team with shareholders and strengthens our pay-for-performance philosophy because these awards only deliver value to our named executive
officers if the Company achieves the performance goals selected. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Consistent with our pay-for-performance philosophy, and in recognition of our strong performance against stated corporate objectives, with most
corporate objectives fully accomplished or exceeded and additional achievements beyond the stated objectives, the Compensation Committee determined that the corporate multiplier used in determining
cash bonuses for our named executive officers for 2017 should be set at 158.5%, resulting in bonuses above target levels. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results of our compensation program in 2017 show a clear heavy weighting on Performance Based Compensation for not only the CEO, but all named executive officers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g677153.jpg" ALT="GRAPHIC" WIDTH="523" HEIGHT="285">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=23,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1044525,FOLIO='20',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;11',USER='CHE109576',CD='20-APR-2018;12:25' -->
<A NAME="page_dg13701_1_21"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g144310.jpg" ALT="GRAPHIC" WIDTH="523" HEIGHT="285">
  </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Ownership Guidelines  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of January&nbsp;1, 2018, we implemented a stock ownership and retention guidelines for our directors and executive officers to ensure that
each of them has a long term equity stake in Amicus, in order to both closely align the interests of directors and executive officers to those of our shareholders and to further our commitment to
corporate governance. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the stock ownership guidelines, directors and executive officers must maintain a multiple of their annual retainer or salary, as applicable, as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="39%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="39%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Retention Amount </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CEO</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>4 times executive's base salary</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>President</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2 times executive's base salary</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Executive Officers</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>1 time executive's base salary</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Directors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>3 times director's annual retainer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
executive officer or director has five years to attain the required stock ownership. Stock ownership includes shares of common stock, vested restricted stock units ("RSUs") and
vested PRSUs in a deferred equity plan. All executive officers and directors have met or are on track to meet the stock ownership guidelines. . The Compensation Committee of the Board monitors
compliance with this policy and will take any actions necessary to ensure compliance. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clawback Policy  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also have established a policy for recoupment of performance based compensation in the event of a financial restatement. Our policy provides
that in the event of a financial restatement, the Board will seek to recover any incentive based compensation and equity awards made to an executive officer during the three-year period preceding a
restatement. In determining whether a recoupment is necessary, the Board may consider (1)&nbsp;the executive officer's intentional misconduct or gross negligence that was a contributing factor to
the restatement; (2)&nbsp;the amount of incentive compensation or equity award predicated on achieving financial results that were part of the restatement and (3)&nbsp;the difference in the amount
of incentive compensation or equity award that would have been awarded based upon the restatement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=24,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=150896,FOLIO='21',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;11',USER='CHE109576',CD='20-APR-2018;12:25' -->
<A NAME="page_dg13701_1_22"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
factors that the Board can consider include (1)&nbsp;whether the recoupment would violate law or prejudice a claim; (2)&nbsp;other penalties or repercussions, instead of
recoupment; and/or; (3)&nbsp;the nature of events leading to a restatement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board retains the discretion to amend the policy as appropriate. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We describe our executive compensation program below and provide an analysis of the compensation paid and earned in 2017 by our "named executive
officers"&#151;our chief executive officer, chief financial officer, and three other most highly compensated executive officers. In 2017, our named executive officers
were:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Chairman and Chief Executive Officer, John F. Crowley; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Chief Financial Officer, William D. Baird, III; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> President and Chief Operating Officer, Bradley L. Campbell; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Chief Medical Officer, Jay Barth, M.D.; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> General Counsel and Corporate Secretary, Ellen S. Rosenberg. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation Good Governance Practices  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below we summarize certain executive compensation-related good governance practices that we follow and that we believe serve our stockholders'
long-term interests. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What
We Do:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Maintain an Executive Compensation Program Designed to Align Pay with Performance </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Conduct an Annual Say-on-Pay Vote </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Seek Input from, Listen to and Respond to Stockholders </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Have Double-Trigger on Executive Severance Arrangements and Executive Stock Option Grants </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Prohibit Hedging and Pledging of Company Stock </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Retain an Independent Compensation Consultant </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Maintain Stock Ownership Guidelines </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Maintain a Claw-Back Policy </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What
We Do Not Do:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provide Executives with Tax Gross-ups other than for Company required relocations </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provide Guaranteed Bonuses </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


"Say-on-Pay" Consideration  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At our 2017 annual meeting of stockholders, approximately 99% of the shares voted at the meeting approved, on an advisory basis, the
compensation of the named executive officers. In addition to the voting at the annual meeting, we proactively engaged with major stockholders representing approximately 78% of shares outstanding on
the Company's pay practices. The great majority of the shares voted approved the 'say-on-pay' advisory proposal and the Compensation Committee continues to focus on pay practices that align
compensation with performance. The Compensation Committee placed a continued emphasis on performance-based pay, in tying one third of the targeted equity compensation value to the performance of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=25,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=209073,FOLIO='22',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;11',USER='CHE109576',CD='20-APR-2018;12:25' -->
<A NAME="page_dg13701_1_23"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Amicus
in Total Shareholder Return and pipeline goals over three years. The Compensation Committee monitors and considers the results of the annual advisory 'say-on-pay' proposal and feedback received
from stockholders. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Objectives and Philosophy of Executive Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a global, commercial stage, patient-focused biotechnology company engaged in the discovery and development of a diverse set of novel
treatments for patients living with devastating rare and orphan diseases. We operate in an extremely competitive, rapidly changing and heavily regulated industry, and the long-term success of our
business requires a high degree of innovation and adaptability. We believe that the skill, talent and dedication of our executive officers are critical factors affecting our long-term success,
especially at this critical time in our history as we execute our business strategy. Therefore, our compensation program for our executive officers, including our named executive officers, is designed
to attract, retain and motivate the best possible executive talent. Utilizing a pay-for-performance compensation philosophy, we have designed a program that provides the ability to differentiate the
total compensation mix of our named executive officers based on their demonstrated performance and their potential to contribute to our long-term success. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
compensation philosophy is to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> provide our executives a competitive total compensation opportunity relative to the organizations with which we compete for executive talent; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> attract and retain individuals of superior ability and managerial talent who can successfully perform and succeed in our environment; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> increase the incentive to achieve key strategic and financial performance measures by linking compensation opportunities and actual
compensation earned through our pay for performance compensation program to the achievement of corporate goals; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> deliver pay in a cost efficient manner that aligns employees' compensation with stockholders' long-term interests. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
compensation program is designed to reward the accomplishment of our corporate goals in a manner consistent with the Company's values, which stresses not only results but also how
those results are attained. In order to meet the objectives of our compensation philosophy, we maintain a robust goal setting and performance management program. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
chief executive officer established general individual goals for the named executive officers other than himself at the beginning of 2017 that were specific to such executive
officer's area of expertise and supported our corporate goals for the year. For 2017, annual cash incentive bonuses for our named executive officers other than Mr.&nbsp;Crowley were determined by
the combination of both the corporate and an individual multiplier. For Messrs.&nbsp;Baird, Campbell, Dr.&nbsp;Barth and Ms.&nbsp;Rosenberg the attainment of individual goals was assessed with a
0-150% multiplier for each individual; this multiplier was applied to the final corporate multiplier to determine final annual incentive bonus payouts. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee believes that the corporate multiplier should continue to be the dominant factor in determining bonus payouts because it closely aligns our named executive
officers' compensation with the interests of our stockholders, and that some portion of an executive's compensation should be linked to individual performance, which we believe is consistent with our
peers. The Compensation Committee believes that including the individual multiplier as a component of named executive officers' bonus payouts is important to incentivize our officers during this
crucial time in Amicus' history as we continue our transformation into a global commercial biotechnology company. However, because of Mr.&nbsp;Crowley's influence on the overall performance of
Amicus, the Compensation Committee believes it is appropriate and in the best interests of our stockholders to continue to base Mr.&nbsp;Crowley's </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=26,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=523458,FOLIO='23',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;11',USER='CHE109576',CD='20-APR-2018;12:25' -->
<A NAME="page_dg13701_1_24"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>cash
bonus solely on the Compensation Committee's determination regarding the achievement of corporate objectives. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risk Analysis of Compensation Policies and Practices  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee is aware that compensation arrangements, if not properly designed, could encourage inappropriate or excessive risk
taking. We believe that our overall compensation program encourages our named executive officers and other employees to focus on both short-term and long-term objectives and does not encourage
excessive risk taking. While the value of stock options is inherently tied to the performance of the Company, and an important part of our current and future performance based compensation, our stock
options vest over multiple years and the value is not directly linked to the achievement of short term defined metrics. To enhance this posture, the Committee made the decision in 2017 to award
performance-based restricted stock grants in addition to market priced options and restricted stock units. In addition, cash incentive bonuses tied to the achievement of Company and individual goals
have historically made up a small percentage of our executive officers' total compensation package. For example, in 2017, payouts under our cash incentive bonus plan represented approximately 14% of
the total compensation, or 16% of direct compensation awarded to our named executive officers. Further, we operate as a single business unit and therefore are not exposed to the risks that may be
associated with operating through several segments, such as one business unit being significantly more profitable than another or having a compensation structure that is significantly different than
that of other units. The Compensation Committee will continue to review risk as one of the elements it considers in the planning process for executive compensation in the future. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Program Elements and Pay Level Determination  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each year, the Compensation Committee reviews and determines base salaries, annual cash incentive and long-term incentive awards for all
executive officers. In setting our executive compensation programs, the Compensation Committee reviews market data at the 25<SUP>th</SUP>, 50<SUP>th</SUP>, and
75<SUP>th</SUP>&nbsp;percentile and generally targets aggregate total direct compensation for the named executive officers as a group to approximately the 50<SUP>th</SUP>&nbsp;percentile of
our peer group (as discussed below). Actual compensation levels for each named executive officer depend on factors such as individual performance, Company performance, skills/capabilities, overall
impact/contribution, experience in
position, criticality of position and internal equity. For 2016, the base salaries, annual cash incentives and long-term incentive awards determination for all named executive officers, including our
chief executive officer, were approved by our Compensation Committee, which is comprised solely of independent directors. The Compensation Committee considered all the information presented (including
external competitiveness, the individual's performance, Company performance and internal equity) and applied its collective knowledge and discretion to determine the compensation for each named
executive officer. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of the compensation evaluation process, the chief executive officer presents to the Compensation Committee an individual assessment of each named executive officer's performance,
excluding the chief executive officer's performance, over the prior year, as well as the recommended compensation action for each such named executive officer. Based on corporate and individual
performance, the chief executive officer makes a compensation recommendation for each such named executive officer which includes actions on base salary, bonus and long-term incentive grant target
value. Individual goals and objectives are established at the beginning of each year and are designed to support the achievement of the corporate goals. All employees, including the named executive
officers, participate in annual individual goal setting as well as mid-year and year-end performance reviews. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results of the named executive officer's performance (other than the performance of the chief executive officer) are a determination by each such named executive officer's
supervisor, the chief executive officer, with input from other peers, and direct reports, as appropriate, but the final determination is made by the Compensation Committee. The chief executive
officer's performance is </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=27,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=284607,FOLIO='24',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;11',USER='CHE109576',CD='20-APR-2018;12:25' -->
<A NAME="page_dg13701_1_25"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>assessed
by all independent directors under the leadership of our Lead Independent Director while the chief executive officer compensation recommendation to the Board is made by the Compensation
Committee based upon this assessment. Long-term incentive grants are based on an executive's level within the organization, and in the case of our named executive officers, several other factors which
are more fully described below under "Long-Term Incentive Programs". Long-term incentive grants are designed to motivate the executive team to best achieve the Company's goals and implement our
business strategy, thereby increasing stockholder value. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Developments in Company Leadership in 2017  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We had no material changes to our leadership structure in 2017. In August 2017, Bradley Campbell, President and COO, completed the one year
assignment working from the
Company's United Kingdom office to oversee and ensure the successful commercialization of Galafold and returned to continue his duties in the United States. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Role of Independent Compensation Consultant  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee has engaged Pay Governance to assist the Compensation Committee by providing ongoing executive compensation
consulting. The Compensation Committee has concluded that Pay Governance's work does not raise any conflict of interest. The Compensation Committee has also considered the independence of Pay
Governance. Because of policies and procedures that Pay Governance and the Compensation Committee have in place, the Compensation Committee is confident that the advice it receives from executive
compensation consultants at Pay Governance is objective and not influenced by Pay Governance's or its affiliates' relationships with the Company or its officers. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Peer Group  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee, with the help of its independent executive compensation consultant, Pay Governance, established the peer group set
forth below as a reference point for assessing named executive officer target compensation against market competitive data. The Compensation Committee, upon advice of Pay Governance, selected the
companies that comprise our peer group through a robust screening process that considered publicly traded U.S. biopharmaceutical companies that were similar to Amicus in size, market capitalization
and business operating model and operate in geographic locations that generally have similar pay levels. Four companies (CellDex Therapeutics, Raptor Pharmaceuticals, Rigel Pharmaceuticals and Sangamo
Biosciences) were removed from the peer group established last year due primarily to acquisition or changes in structure or size, including market capitalization. The Compensation Committee replaced
these entities with four companies (</FONT><FONT SIZE=2><I>Intercept Pharmaceuticals, Ionis Pharmaceuticals, Spark Therapeutics and Theravance Biopharma</I></FONT><FONT SIZE=2>) upon the
recommendation of Pay Governance due to each company's similarity based on the criteria set forth above. The Compensation Committee intends to continue reviewing and revising the peer group
periodically to ensure that it continues to reflect publicly traded companies of similar size and business model. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="153pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="147pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>ACADIA Pharmaceuticals</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Insmed</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Sarepta Therapeutics</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Acceleron Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Intercept Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Spark Therapeutics</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Agios Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ionis Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Theravance Biopharma</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Bluebird Bio</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>PTC Therapeutics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ultragenyx Pharmaceutical</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Cytokinetics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sage Therapeutics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ziopharm Oncology</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Elements of Compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive compensation consists of base salary, annual cash incentive plan, and long-term incentive program, each of which plays an
important role in our pay-for-performance philosophy and in achieving our compensation program objectives. For each element of compensation, we target an overall executive compensation program that is
competitive with market data. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=28,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=769514,FOLIO='25',FILE='DISK109:[18ZAG1.18ZAG13701]DG13701A.;11',USER='CHE109576',CD='20-APR-2018;12:25' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_di13701_1_26"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Base Salaries  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base salaries are paid to our named executive officers to provide a level of compensation that is both competitive with the external market and
is commensurate with each executive officer's scope of responsibilities, past performance, experience and skills. The base salary for each of our named executive officers was as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Base salary at<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>601,037</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>619,068</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>396,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>408,447</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>427,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>450,105</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>431,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>444,548</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>400,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>412,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2017, Messrs.&nbsp;Crowley, Baird and Campbell, Dr.&nbsp;Barth and Ms.&nbsp;Rosenberg each received a base salary market increase of 3%. Mr.&nbsp;Campbell received an
additional base salary increase of 2.3%, reflecting additional global operational responsibilities. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Cash Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain an annual cash incentive program to motivate and reward the attainment of annual strategic, operational, financial and individual
goals. For all program participants, annual target cash incentive opportunities are expressed as a percentage of base salary, which we believe is consistent with market practice. The target bonus
percentages of base salary were generally determined by level in the organization in accordance with market-based considerations and contractual entitlements. The target bonus percentages for 2017 are
as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 Target<BR>
Bonus % of<BR>
Base Salary </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief executive officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>President</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other chief officers</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Senior vice presidents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vice presidents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2017, bonuses awarded under the plan to our named executive officers, other than Mr.&nbsp;Crowley, were determined based on both the corporate multiplier and an individual
multiplier. The corporate multiplier generally ranges from 50% to 150%, with the Compensation Committee having final discretion to adjust the upper or lower limits as appropriate. For bonuses related
to 2017 performance, the corporate multiplier was determined to be 158.5% based on the Company's performance for the reasons discussed below. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to determine bonus calculations under the plan, the target bonus for each eligible named executive officer, other than Mr.&nbsp;Crowley, was determined by first multiplying
the officer's target bonus by the 158.5% corporate multiplier and then applying his or her individual multiplier. Mr.&nbsp;Crowley's bonus was determined by multiplying the 158.5% corporate
multiplier by his target bonus percentage of 60% of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=29,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=290095,FOLIO='26',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;18',USER='CHE107309',CD='23-APR-2018;11:33' -->
<A NAME="page_di13701_1_27"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>base
salary, which results in a 2017 bonus of approximately 95% of Mr.&nbsp;Crowley's base salary. The table below titled "Calculation of Annual Cash Incentive Bonuses" illustrates further how 2017
awards under the plan were calculated for our named executive officers. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2><U>The Corporate Multiplier</U> </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
an annual basis, the Board works with management to set Company goals and objectives that are challenging and reflect an ambitious timetable for the execution of the
Company's strategies commensurate with our short and long-term business plan. The Company's internal goals and objectives reflect complex assumptions based on internal analyses and projections, and
are intended to encourage the Company to pursue its business plan in an expedited, aggressive manner. Once the Company's goals and objectives have been developed, they are reviewed by the Compensation
Committee and finally approved by the full Board. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the time the goals and objectives are set, the Compensation Committee believes that their full attainment will be appropriately challenging and may not be reached, despite great
effort, due in part to internal and external factors, many of which may be out of the Company's control. However, while total achievement of all goals and objectives set at the beginning of the year
may not be expected, the Compensation Committee considers the achievement of the corporate objectives in its sole discretion in setting the corporate multiplier and holds management accountable to
significantly advance the Company's business objectives throughout the year in order to achieve a 100% corporate multiplier. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2017, our corporate objectives were as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Complete
successful launch of Galafold in additional International geographies and finish 2017 with at least 300 Fabry patients on reimbursed Galafold
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Advance
registration-directed activities for migalastat in key geographies
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Complete
successful Phase&nbsp;3 study of our development candidate SD-101
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Complete
successful Phase 1/2 study and define clinical development strategy for ATB200 for the treatment of Pompe
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Evaluate
research opportunities to develop clinical candidates for 2019 and beyond
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>6.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Finish
2017 with 18&nbsp;months of cash necessary to operate our business </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee then reviews corporate performance against each of the pre-established targets and weighting to determine the extent to which such goals were attained. The
Compensation Committee's rationale behind its determination of both the attainment of corporate goals and the percentage completed for each such goal is described below. In reaching its determination
on the corporate multiplier for 2017, the Compensation Committee applied the percentage that the Compensation Committee determined was completed against the pre-established weighting of the corporate
objectives as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Objective


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighting </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
Completed </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Score </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Complete successful launch of Galafold in additional International geographies and finish 2017 with at least 300 Fabry patients on reimbursed
Galafold</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Advance registration-directed activies for migalastat in key geographies</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Complete successful Phase&nbsp;3 study of our development candidate SD 101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Complete successful Phase <SUP>1</SUP>/<SMALL>2</SMALL> study and define clinical development strategy for ATB200 for the treatment of Pompe</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Evaluate research opportunities to develop clinical candidates for 2019 and beyond</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>95</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Finish 2017 with a minimum of 18&nbsp;months of cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Plus: Overall Performance Adjustment for exceptional results</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>TOTAL SCORE</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=30,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=667184,FOLIO='27',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;18',USER='CHE107309',CD='23-APR-2018;11:33' -->
<A NAME="page_di13701_1_28"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2><U>2017 Corporate Objectives Measurement</U> </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
establishing the 2017 corporate objectives at the end of 2016, the Company and the Compensation Committee believed that the three most important goals for Amicus in
2017 were related to the International Galafold commercial launch, advancing migalastat regulatory approvals in other geographies, and achieving definitive proof-of-concept for ATB200/AT2221 and
finding the best and fastest path to approval. Collectively, these three goals accounting for 70% of the overall weightings. The commercial objective for Galafold was focused on the successful launch
of Galafold in European and select other countries. "Target 300"&#151;the goal of having 300 patients on reimbursed commercial product by the end of the year was communicated externally in
January 2017. With more than 310 patients on reimbursed product at the end of the year and with $36.9&nbsp;million of revenue for 2017, the Compensation Committee determined that this objective was
105% completed and determined a score of 21.0% by multiplying the 20% weighting of this goal by the 105% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
regions where Galafold (migalastat) was not yet approved, the goal was to advance registration-directed activities towards eventual regulatory approval. In Japan, the goal was to
complete a J-NDA submission for regulatory approval. The J-NDA was successfully submitted in June 2017. In the U.S., we began 2017 with guidance from FDA which required the Company to successfully
complete a third Phase&nbsp;3 study prior to submitting an NDA which would have delayed an NDA submission by three or more years. Through a series of meetings and correspondences with the FDA, we
were successful in gaining agreement with the FDA that existing data were sufficient to support an NDA submission. We completed the successful submission of the migalastat NDA in December 2017. Given
the progress in Japan and the unexpected and extremely positive developments with the FDA, the Compensation Committee determined that this objective was 200% completed and determined a score of 50.0%
by multiplying the 25% weighting of this goal by the 200% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company began 2017 with the SD-101 program for Epidermolysis Bullosa close to completion of Phase&nbsp;3 enrollment. The Company and the Compensation Committee established the goal
for 2017 to successfully complete the Phase&nbsp;3 trial for SD-101. Through diligent efforts, the Company overenrolled the study and made favorable changes to the statistical analysis plan which
were approved by the FDA and the EMA. Unfortunately, in September 2017 the Company announced that the Phase&nbsp;3 study did not meet its two primary endpoints. Given the study results, we made the
difficult decision to discontinue future investment in the program. Given the Phase&nbsp;3 outcome, the Compensation Committee determined a score of 4% by multiplying the 10% weighting by a 40%
achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the significant level of unmet need in Pompe disease and our belief that we have a differentiated product candidate (ATB200 plus chaperone AT2221) that could offer meaningful
improvements over the current standard of care, we have identified Pompe disease as an area of long-term strategic importance to the Company. The Pompe goal for 2017 was to successfully complete our
Phase <SUP>1</SUP>/<SMALL>2</SMALL> study and define the clinical development strategy. In 2017, we provided several updates from our ongoing Phase <SUP>1</SUP>/<SMALL>2</SMALL> study which showed that both
previously-treated patients as well as na&iuml;ve patients experienced meaningful improvements in their six-minute walk tests, an accepted measure of clinical benefit in Pompe disease.
Patients showed consistent and durable improvements in other measures of muscle function as well as improvements in key biomarkers of disease. Patients experienced very low rates (&#60;1%)
of infusion associated reactions, which are a common side effect of existing ERTs. Taken together, these results exceeded our expectations and suggest that the effect of ATB200/AT2221 may be very
clinically meaningful for people living with Pompe disease. The Compensation Committee weighed these factors and determined that this objective was 200% completed and determined a score of 50.0% by
multiplying the 25% weighting by a 200% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the Company's stated objective of being at the forefront of rare and orphan disease, we believe that development of the earlier-stage pipeline is an important objective. In setting
pipeline development goals for 2017, the Compensation Committee felt the goal of evaluating research opportunities to develop </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=31,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=730094,FOLIO='28',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;18',USER='CHE107309',CD='23-APR-2018;11:33' -->
<A NAME="page_di13701_1_29"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>clinical
candidates for 2019 and beyond balanced the Company's strategic needs with its financial resources. Based upon the progress achieved with the CDKL5 program and the Fabry ERT program, but in
also taking into account the status of a comprehensive pipeline development strategy, the Compensation Committee subjectively determined that 95% of the goal was complete and determined a score of
4.8% by multiplying the 5% weighting by a 95% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
cash position directly affects our ability to establish commercial infrastructure, conduct our clinical and preclinical activities, hire and retain qualified and talented employees
and pursue business development opportunities. Even though we have commercial sales, careful management of our cash is critical to our operations. Due to our careful expense management and a
successful $258&nbsp;million equity financing in July 2017, we achieved our goal of ending the year with enough cash to fund our operations for a period of 18&nbsp;months. Given the achievement of
the cash goal and the strength and quality execution of the equity financing, the Compensation Committee determined a score of 18.8% by multiplying the 15% weighting by a 125% subjectively determined
completion percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
in evaluating the overall corporate performance for 2017, the Compensation Committee felt that the Company had significantly outperformed its peers and industry benchmarks as
evidenced by the 190% increase in the share price during 2017, had demonstrated high quality execution across the
business, and had positioned the Company for continued success in 2018 and beyond , particularly with the commercial and regulatory progress of migalastat and the strong momentum established in the
clinical program for ATB200/AT2221 for Pompe Disease. As such, the Compensation Committee awarded an additional 10% performance adjustment to the overall corporate modifier to arrive at a 158.5%
corporate modifier for 2018. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2><U>The Individual Multiplier</U> </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Design  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we believe that the corporate multiplier should remain the dominant factor in the bonus calculation, the Compensation Committee believes
it is important to recognize and incentivize individual performance of our non-CEO Executive Officers as we advance towards our goal of becoming a fully integrated pharmaceutical company. We therefore
determined that the individual multiplier for Messrs.&nbsp;Baird and Campbell, Dr.&nbsp;Barth, and Ms.&nbsp;Rosenberg would range from 0-150% based on performance described below. As noted
above, the Compensation Committee continues to believe that Mr.&nbsp;Crowley's bonus should be determined solely by reference to the corporate multiplier. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
individual multiplier for each executive is determined after considering several factors including achievement of individual objectives, departmental or organizational performance,
and other significant accomplishments. Individual objectives are necessarily tied to the particular area of expertise of the executive and are designed to support the Company's achievement of its
corporate goals. Individual goals are evaluated based on leadership and performance on specific functional goals that are tied to the corporate goals. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
objectives are set with the belief that full achievement will be difficult and challenging, but attainable, so long as the officer is fully committed to the accomplishment of such
objectives through significant effort and dedication to the Company's strategies, and an ability to quickly adapt to a constantly evolving business environment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Individual
performance objectives of our named executive officers, other than Mr.&nbsp;Crowley, are set by the executive officer to whom each such named executive officer reports,
which for 2017 was Mr.&nbsp;Crowley for all of our named executive officers. These objectives are neither reviewed nor approved by the Compensation Committee. Rather, these objectives serve as a
measuring tool for our chief
executive officer in formulating his recommendation to the Compensation Committee as to the appropriate individual multiplier for each named executive officer. During the annual review process, the
Company's </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=32,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1005490,FOLIO='29',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;18',USER='CHE107309',CD='23-APR-2018;11:33' -->
<A NAME="page_di13701_1_30"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>chief
executive officer discusses with the Compensation Committee his overall evaluation for each executive which includes each such executive's performance and accomplishments as they relate to the
Company's corporate goals, departmental performance, and other significant accomplishments. While the Compensation Committee relies in part on the chief executive officer's evaluation of the other
named executive officers, it also considers the degree of difficulty in attaining the Company's goals and such executive's accomplishments. In considering the degree of difficulty, the Compensation
Committee considers factors such as the influence of external events, including unanticipated clinical events and regulatory timelines, and the effort expanded by executives. The Compensation
Committee reviews and discusses their evaluation of the Company's chief executive officer's performance and accomplishments in executive session along with the Lead Independent Director of the Board
and without the presence of the chief executive officer. Upon the completion of such process the Compensation Committee subjectively determines the individual multiplier for each named executive
officer, other than the chief executive officer, based on the Compensation Committee's subjective determination of such officer's satisfaction of the applicable goals. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Determinations  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In determining the individual multiplier for our named executive officers, the Compensation Committee noted each executive officer's individual
and departmental performance throughout the year, and how those performances supported the Company's achievement of its corporate goals. The specific individual factors that the Compensation Committee
noted in subjectively determining each named executive officer's individual multiplier were as follows: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Bradley L. Campbell, President and Chief Operating Officer (120% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provided overall leadership of the continued build out of the international commercial organization and successful launch of Galafold Ex-US,
with high level of patient uptake in areas with reimbursement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Oversaw the program management function including the successful integration of development activities across migalastat, SD 101, and ATB200
programs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Oversaw the successful manufacturing scale up efforts for ATB200, including successful engineering batches at 1,000 liter commercial scale. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


William D. Baird, III, Chief Financial Officer (95% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Significantly strengthened the balance sheet through the leadership and execution of a $258&nbsp;million equity financing; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Led company-wide project to redesign decision making and governance to support future growth, increased entrepreneurship throughout the
company, and empowered functional leaders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provided strategic and financial leadership to the Board, the Senior Leadership Team, Business Development, and the program steering teams
throughout the year. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Jay Barth, Chief Medical Officer (95% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Oversaw regulatory discussions with FDA to obtain agreement that existing clinical results were sufficient to support NDA submission for
migalastat and that a third Phase&nbsp;3 study would no longer be required; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Led efforts among the clinical and regulatory teams to obtain regulatory approval for migalastat in Canada, Israel, and Switzerland and oversaw
successful regulatory submissions for migalastat in Japan and the U.S.; and; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=33,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=57002,FOLIO='30',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;18',USER='CHE107309',CD='23-APR-2018;11:33' -->
<A NAME="page_di13701_1_31"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Designed and oversaw implementation of clinical strategy for ATB200/AT2221 for Pompe disease, including the communication of ongoing Phase
<SUP>1</SUP>/<SMALL>2</SMALL> results and the discussions with regulators on the best and fastest path to approval for ATB200/AT2221. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ellen S. Rosenberg, General Counsel and Corporate Secretary (110% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Led due diligence and legal negotiations for successful $258&nbsp;million equity financing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Streamlined global legal operations to support rapid global commercial expansion, clinical development and manufacturing activities; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provided strategic legal counsel, corporate governance and risk mitigation advice to the Board and Board Committees, the CEO and Executive
Officers. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2><U>Calculation of Annual Cash Incentive Bonuses</U> </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
calculation of the named executive officers' individual cash incentive payments for service in 2017 is summarized in the table below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Corporate<BR>
Multiplier<BR>
(%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Individual<BR>
Multiplier<BR>
(%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target<BR>
Bonus<BR>
(%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Base<BR>
Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Payout<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>619,068</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>588,734</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>408,447</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>246,007</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>450,105</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>428,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>444,548</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>267,751</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>158.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>412,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>287,329</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Long Term Incentive Programs  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that long-term performance will be achieved through an ownership culture that rewards our executives for maximizing stockholder value
over time and that aligns the interests of our employees and management with those of stockholders. Our Amended and Restated 2007 Equity Incentive Plan, or the 2007 Plan, authorizes us to grant stock
options, restricted stock, RSUs and other equity-based awards. We have historically elected to use stock options as the primary long-term equity incentive vehicle. We typically grant an initial stock
option award to new employees and annual long-term incentive awards as part of our overall compensation program as well as option grants to reflect promotions, as necessary. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
continued our strategy for equity compensation that was implemented in 2016 of using a mix of non-qualified stock options and time based RSUs, however in 2017, we added PRSUs to
executive equity compensation. We utilize a value based approach to allocate equity, with one third of the assigned value to each named executive officers assigned to each type of equity vehicle.
Under our current equity plan, for the named executive officers, our non-qualified stock option awards vest over a four year period with 25% vesting one year after the vesting commencement date and
the remainder vesting ratably each month thereafter in equal installments over a three year period subject to continued employment or service with us. The non-qualified stock options expire ten years
after the date of grant. RSU awards vest over a four year period with 25% vesting each year upon the anniversary of the grant. PRSU awards vest over a three year period based on the attainment of the
applicable goals at the end of such period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=34,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=507426,FOLIO='31',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;18',USER='CHE107309',CD='23-APR-2018;11:33' -->
<A NAME="page_di13701_1_32"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
use a mix of stock options, RSUs, and PRSUs as long-term incentive vehicles because we believe that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Committee believes that stock options, RSUs, and PRSUs, along with their vesting periods, provide a balanced mix to attract, motivate and
retain executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Stock options are inherently performance based. Because all of the value received by the recipient of a stock option is based on the growth of
the stock price, stock options enhance the executives' incentive to increase our stock price and maximize stockholder value; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> RSUs help enhance executive actual stock ownership while helping to retain executives. Final value depends on the change in stock price over
the vesting period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> PRSUs align executives with the goals of the company and its shareholders, while still assisting in the retention of our executives. Final
value depends on company performance over the vesting period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Stock options, RSUs and PRSUs help to provide a balance to the overall executive compensation program as base salary and our annual performance
bonus program focus on short-term compensation, while stock options and RSUs reward executives for increases in stockholder value over the longer term. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Initial Equity Grants  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executives who join us are typically awarded initial equity grants. Amicus is utilizing a mix of Stock Options and RSUs to all employees,
including executives, as part of new hire grants. The options portion of the grants have an exercise price equal to the closing price of our Common Stock on the date of grant. Our goal is to create a
total compensation package for new employees that is competitive with other biotechnology companies and that will enable us to attract high quality people. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Option, Restricted Stock Unit Awards, Performance Restricted Stock Unit Awards  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee believes that providing annual equity awards beyond the initial equity awards provides management with a strong link
to long-term corporate performance and the creation of stockholder value, as well as providing continued retention via long-term vesting. Starting in 2017, the Compensation Committee decided that
Amicus should move to an annual grant cycle along with the new mix of equity vehicles consisting of fair market value stock options, RSUs and PRSUs as part of a performance share program. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee determines the value and corresponding number of shares subject to options or RSUs that are granted to our named executive officers in its sole discretion. In
applying that discretion, the Compensation Committee takes into account a number of factors including the current price of our Common Stock, peer group data, each individual's role and performance and
recent Company developments. All of the stock option and RSU awards are subject to four-year vesting schedules. The 2017 stock option and RSU grants are described in the section entitled "Grants of
Plan-Based Awards." With the introduction of RSUs, the committee moved to approving 2017 and future LTI grants based on a fixed dollar value instead of its historical approach of granting on a fixed
number of shares basis. The Compensation Committee determined that this methodology provides a greater level of sophistication in ensuring the value of LT1 grants is aligned to market. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
value of the PRSU grants in 2017 consisted of 33% of the total assigned equity compensation value to each executive officer. The goals associated with these PRSUs were established by
management and the Compensation Committee as total shareholder return ("TSR") versus NASDAQ Biotechnology lndex and a strategic pipeline goal. 50% of the PRSUs granted were assigned to the TSR goal
with 0-200% achievement of the number of target PRSU's and the remaining 50% of the PRSUs granted were based on the Company achieving certain clinical milestones. Both the TSR and strategic pipeline
PRSUs have 3-year cliff vesting period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=35,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=984792,FOLIO='32',FILE='DISK109:[18ZAG1.18ZAG13701]DI13701A.;18',USER='CHE107309',CD='23-APR-2018;11:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dk13701_1_33"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>The
Compensation Committee believes that these goal are difficult and challenging to attain and appropriately align incentives with performance. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have typically awarded the largest equity grant in each grant cycle to our chief executive officer in recognition of his role as our principal executive officer, Chairman of the Board
and primary decision maker for the Company. For these reasons, and the factors noted below for other executive officers, the Compensation Committee awarded Mr.&nbsp;Crowley options to purchase
282,485 shares of Common Stock, 203,252 Restricted Stock Units and 203,252 Performance Restricted Stock Units in our company-wide grant award in January 2017. The 2017 equity grants for all other NEOs
are described in the section entitled "Grants of Plan-Based Awards." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Factors
that the Compensation Committee and our chief executive officer considered in making these stock option grants for other Executive Officers included (i)&nbsp;relative
contribution toward achievement of current year corporate objectives, (ii)&nbsp;breadth of internal and external responsibilities, (iii)&nbsp;management responsibilities including managing direct
reports, (iv)&nbsp;external benchmarking and (v)&nbsp;tenure with Amicus. The specific individual factors that the Compensation Committee relied on for granting each award are substantially
similar to those factors that contributed to a determination of the individual multiplier for each named executive officer discussed above under "2017 Determinations." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Qualified Deferred Compensation Plans  </I></B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amicus Therapeutics,&nbsp;Inc. Restricted Stock Unit Deferral Plan  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains the Amicus Therapeutics,&nbsp;Inc. Restricted Stock Unit Deferral Plan as amended (the "Stock Deferral Plan"). The Stock
Deferral Plan provides eligible non-employee directors and executives, including each of the named executive officers, with the voluntary opportunity to defer the receipt of RSUs otherwise payable to
such eligible executives. The Stock Deferral Plan was updated in fiscal year 2017 to allow directors to participate. After a deferral election is made, an individual's account is credited with the
deferred RSUs. All RSUs deferred under the Stock Deferral Plan are fully vested. The Company does not otherwise contribute to the Stock Deferral Plan and the amount a participant receives at the end
of a deferral period is based solely on the value of the Company's stock at the end of the deferral period. Generally a participant may voluntarily elect to re-defer any previously deferred RSUs for
an additional period of not less than five years if, as required under the Code, such an election is made at least 12&nbsp;months before the year in which the RSUs would otherwise be delivered. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
only does the Stock Deferral Plan allow our participants, including the named executive officers to defer the Federal income taxes otherwise payable upon the delivery of RSUs, but
the Compensation Committee believes that with respect to non-employee directors and executives who avail themselves of the deferral features of the Stock Deferral Plan, such person will necessarily
hold Company stock for a longer period of time. Accordingly, any RSUs deferred under the Stock Deferral Plan will continue to align such portion of our non-employee directors and named executive
officers' compensation with the interests of our stockholders for a longer period of time than would be provided by typical vesting periods. Regardless of a participant's election, any deferred RSUs
will be distributed following the non-employee director or executive's death, disability or separation of service from the Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
amounts deferred under the Stock Deferral Plan will continue for all purposes to be a part of the general funds of the Company and the non-employee director's or executive's deferral
will be subject to the general creditors of the Company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amicus Therapeutics,&nbsp;Inc. Cash Deferral Plan  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains the Amicus Therapeutics,&nbsp;Inc. Cash Deferral Plan, as amended (the "Cash Deferral Plan"). The Cash Deferral Plan
provides eligible executives, including each of the named executive officers and non-employee directors, with the voluntary opportunity to defer receipt of such </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=36,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=730133,FOLIO='33',FILE='DISK109:[18ZAG1.18ZAG13701]DK13701A.;23',USER='CHE108068',CD='20-APR-2018;12:30' -->
<A NAME="page_dk13701_1_34"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>participant's
base salary, bonus and/or director's fees, as applicable. Any such deferrals are credited to a bookkeeping account maintained for the participant. The participant may make periodic
hypothetical investments of the account and gains and losses on such hypothetical investments will be credited to the participant's account. A participant is fully vested in all amounts, including
earnings deferred under the Cash Deferral Plan. Distribution of the deferred amounts will generally be made on the distribution date elected by the participant. Generally, a participant may
voluntarily elect to re-defer any previously deferred amount for an additional period of not less than five years if, as required under the Code, such an election is made at least 12&nbsp;months
before the year in which the amount would otherwise be delivered. Regardless of a participant's election, any deferred amount will be distributed following a change in control of the Company or upon
the participant's death, disability or separation of service from the Company. The Company does not match when a participant defers any amounts in the Cash Deferral Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
amounts deferred under the Cash Deferral Plan will continue for all purposes to be a part of the general funds of the Company and the amounts deferred by the participants, including
all deemed gains and losses attributable thereto, and will be subject to the general creditors of the Company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Compensation  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with our compensation philosophy, we intend to continue to maintain our current benefits for our named executive officers, including
medical, dental, vision and life insurance coverage. All employees receive Company paid term life insurance equal to two times annual base salary, up to a maximum benefit of $1,000,000. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we provide a Company match for our 401(k) Plan, subject to Federal guidelines and plan maximums. We match $1 for each $1 a participant, including each named executive
officer, defers into the plan up to 5% of each participant's salary and bonus paid during the year. The match vests 100% on the participant's one-year anniversary of employment at Amicus. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Additional Chief Executive Officer Benefits  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Company is engaged in a highly competitive industry developing medicines for unique and complicated genetic disorders. As chief executive
officer, Mr.&nbsp;Crowley has significant responsibility for leading our Company and managing its progress toward achieving our corporate goals. Mr.&nbsp;Crowley's compensation reflects this
responsibility and takes into account his unique circumstances. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of his overall compensation, Mr.&nbsp;Crowley receives significant payments and benefits from the Company related to the healthcare and other associated costs incurred by his
family. These amounts reflect substantial costs incurred for the treatment of a rare medical condition afflicting two members of Mr.&nbsp;Crowley's immediate family. We continued to make monthly
compensation payments of $66,667 to Mr.&nbsp;Crowley to help defray the substantial out-of-pocket medical expenses incurred by Mr.&nbsp;Crowley and his family which we refer to as the Monthly
Medical Payments. We agreed to make the Monthly Medical Payments to Mr.&nbsp;Crowley when we amended his employment agreement in December 2010 in order to compensate him for the loss of certain
medical benefits previously afforded to Mr.&nbsp;Crowley resulting from the passing of federal legislation in 2010, as well as to limit the Company's exposure to Mr.&nbsp;Crowley's expected growth
in future medical expenses. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Secondment Agreement with Mr.&nbsp;Campbell  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2016, the Company requested that Mr.&nbsp;Campbell temporarily relocate himself and his family to the United Kingdom to oversee and
ensure the successful launch of Galafold in the pivotal first year of its international launch. Accordingly, on August&nbsp;22, 2016, the Company entered into a secondment letter with Bradley
Campbell outlining the relocation and tax equalization benefits for such assignment over the expected twelve month term of the agreement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=37,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=909100,FOLIO='34',FILE='DISK109:[18ZAG1.18ZAG13701]DK13701A.;23',USER='CHE108068',CD='20-APR-2018;12:30' -->
<A NAME="page_dk13701_1_35"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to such agreement, the Company paid Mr.&nbsp;Campbell a lump sum relocation payment of $15,000 to assist with miscellaneous transition expenses, as well as providing him with
tuition reimbursement for his children and a per diem as a cost of living adjustment. In addition, the Company has reimbursed Mr.&nbsp;Campbell for, or directly paid, certain other expenses incurred
in connection with such relocation. Pursuant to the Agreement, Mr.&nbsp;Campbell was also entitled to certain tax equalization payments, including a gross-up, and other payments and/or
reimbursements upon his relocation back to the United States, which were intended to defray the costs he would otherwise incur in connection with this Company-requested relocation. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2017, Mr.&nbsp;Campbell completed the one year assignment working from the Company's United Kingdom office to oversee and ensure the successful commercialization of Galafold.
Upon his relocation to the United States, as stated above, he received a lump sum relocation payment of $15,936. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Termination-Based Compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon termination of employment under certain circumstances, our named executive officers are entitled to receive varying types of compensation.
Elements of this compensation may include payments based upon a number of months of base salary, bonus amounts, acceleration of vesting of equity, health care coverage and other similar benefits. We
believe that our termination-based compensation and acceleration of vesting of equity arrangements are in line with severance packages offered to named executive officers of other similar companies
based upon market information, and are otherwise appropriate given the executive's role and service to the Company. We also have granted severance and acceleration of vesting of equity benefits to our
named executive officers in the event of a change of control if the executive is terminated within a certain period of time following the change of control. We believe that change of control-related
benefits are necessary in order for our named executive officers to direct their full attention to the successful consummation of a transaction without distraction, and that this "double trigger"
requirement maximizes stockholder value because it prevents an unintended windfall to management in the event of a friendly or non-hostile change of control. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=38,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=697443,FOLIO='35',FILE='DISK109:[18ZAG1.18ZAG13701]DK13701A.;23',USER='CHE108068',CD='20-APR-2018;12:30' -->
<A NAME="page_dk13701_1_36"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk13701_summary_compensation_table"> </A>
<A NAME="toc_dk13701_1"> </A></FONT> <FONT SIZE=2><B>  Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information regarding the compensation that we paid to each person serving as our principal chief executive
officer, our principal financial officer and each of our other three most highly compensated executive officers during the years indicated below (collectively, the "named executive officers"). </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fiscal<BR>
Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus(1)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards(2)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards(2)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change in<BR>
Pension<BR>
Value&nbsp;&amp; Non-<BR>
Qualified<BR>
Deferred<BR>
Compensation<BR>
Earnings </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>619,068</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>588,734</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,385,162</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,044,082</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>94,189</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>881,845</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,613,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>601,037</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>299,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>254,169</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,198,129</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>31,539</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>815,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,199,368</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>582,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>314,496</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,013,039</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>815,166</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,725,101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>William D. Baird III</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>408,447</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>246,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>715,535</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>313,253</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,310</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,698,552</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>396,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>131,655</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>91,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>832,036</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,467,056</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>385,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>141,680</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,264,576</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,805,906</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>450,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>428,050</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>874,544</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>382,867</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>71,816</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,207,382</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>427,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>177,392</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>152,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>960,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>53,146</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,770,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Operating Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>415,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>152,720</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,346,302</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,166</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,929,188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Jay Barth, M.D.,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>444,548</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>267,751</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>596,284</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>261,045</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,584,188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Medical Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>431,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>336,127</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>91,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>832,036</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,505,828</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>415,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>154,380</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,205,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,789,823</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>412,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>287,329</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>596,284</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>261,045</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,571,218</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
2017 amount represents bonuses earned in 2017 and paid in 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
grant date fair value of time based restricted stock unit awards ("RSUs"), performance based restricted stock unit awards ("PRSUs") and option awards granted to
our named executive officers was computed in accordance with FASB ASC Topic 718, Compensation&#151;Stock Compensation. Assumptions made in this valuation are discussed in our annual report for
the year ended December&nbsp;31, 2017, filed with the SEC on Form&nbsp;10-K on March&nbsp;1, 2018 at Item&nbsp;7&#151;Management's Discussion and Analysis of Financial Condition and
Results of Operations&#151;Equity Compensation. These amounts reflect the stock price at the time of the grant. In accordance with SEC rules, the amounts reported in the Stock Awards column for
2017 include the grant date fair value of the RSUs and PRSUs granted during 2017. The grant date fair value for this purpose is required to be shown even where the PRSUs were not ultimately earned.
The following table provides information regarding the 2017 PRSUs based on the expected performance outcomes (and is the grant date fair value of the award, as reflected in the Summary Compensation
Table) and maximum performance outcomes:
<BR></FONT></DD></DL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 </DIV>
<DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant Date<BR>
Fair<BR>
Value for<BR>
2017 PRSUs<BR>
(i.e.,&nbsp;Based<BR>
on Expected<BR>
Performance)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value at<BR>
Grant Date<BR>
Assuming<BR>
Maximum<BR>
Performance<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual<BR>
Realizable<BR>
Value at<BR>
Grant<BR>
Date<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,342,479</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2,684,958</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>William D. Baird III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>402,733</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>805,466</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>492,231</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>984,462</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Jay Barth, M.D.,</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>335,613</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>671,226</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>335,613</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>671,226</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Consists
of gains on investments in Mr.&nbsp;Crowley's deferred compensation plan account; please see the "Nonqualified Deferred Compensation" table below.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $866,667 of Monthly Medical Payments pursuant to Mr.&nbsp;Crowley's current employment agreement (see page&nbsp;30),
$750 for health care savings account and $1,428 in life insurance premiums.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $1,500 for health care savings account and $810 in life insurance premiums.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $750 for health care savings account and $1,428 in life insurance premiums. In addition, the following items were related
to Mr.&nbsp;Campbell's secondment agreement: $15,936 for relocation, $17,746 for tuition reimbursement for his children and $23,324 for per diem payments for cost of living adjustment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $750 for health care savings account and $810 in life insurance premiums.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>As
described more fully below, Mr.&nbsp;Crowley participates in our Non-Qualified Cash Deferral Plan and for 2017, the deferral amounts were: $309,534 of salary
and $441,550 of bonus. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=39,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=500522,FOLIO='36',FILE='DISK109:[18ZAG1.18ZAG13701]DK13701A.;23',USER='CHE108068',CD='20-APR-2018;12:30' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dm13701_1_37"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Grants of Plan-Based Awards  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents information concerning grants of equity awards to each of the named executive officers during 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Stock<BR>
Awards:<BR>
Number of<BR>
Shares of<BR>
RSUs<BR>
Units(1)<BR>
(#) </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Option<BR>
Awards:<BR>
Number of<BR>
Securities<BR>
Underlying<BR>
Options(2)<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated Future Payouts<BR>
Under Equity Incentive<BR>
PRSU Awards </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercise or<BR>
Base<BR>
Price of<BR>
Option<BR>
Awards<BR>
($/Sh)(3) </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
Date Fair<BR>
Value of<BR>
Stock and<BR>
Option<BR>
Awards(4)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Threshold<BR>
# </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target<BR>
# </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum<BR>
# </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>282,485</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,044,182</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>203,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,042,683</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101,626</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>203,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>521,341</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101,626</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>203,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>821,138</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
84,745</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
313,253</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>312,802</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,243</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,487</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,974</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>156,398</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,243</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,487</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,974</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>246,335</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
103,578</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
382,867</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>382,313</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,631</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37,262</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74,524</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>191,154</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,631</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37,262</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74,524</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>301,077</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
261,045</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>260,671</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>205,280</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
261,045</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>260,671</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Corporate Secretary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/3/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>205,280</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Amounts
represent PRSUs granted to NEOs during the 2017 fiscal year. The criteria used to determine the number of PRSUs earned by each NEO are described above under
"Performance-Based Restricted Stock Units" The service-vesting schedule associated with the annual PRSUs granted to all NEOs on January&nbsp;3, 2017 is three-year graded vesting.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Vesting
of the RSU is subject to the participant's continuous service with the Company through the applicable vesting date with the following schedule: 25% of the
total number of shares vest on the first anniversary of the Grant Date, with 25% on each successive Grant Date anniversary.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Each
option has a term of ten years and vests in accordance with the following schedule: 25% of the total number of shares vest on the first anniversary of the Grant
Date and 1/48<SUP>th</SUP>&nbsp;of the total number of shares vest on the first day of the following 36&nbsp;months.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Amounts
represent the grant date fair value calculated in accordance with FASB ASC 718, as stated in footnote&nbsp;#2 to the Summary Compensation Table. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=107288,FOLIO='37',FILE='DISK109:[18ZAG1.18ZAG13701]DM13701A.;15',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dm13701_1_38"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at Year-End  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents the outstanding equity awards held by each of the named executive officers as of December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Units of<BR>
Stock That<BR>
Have Not<BR>
Vested<BR>
(#)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Units of<BR>
Stock That<BR>
Have Not<BR>
Vested<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Unearned<BR>
Units of<BR>
Stock That<BR>
Have Not<BR>
Vested<BR>
(#)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Unearned<BR>
Units of<BR>
Stock That<BR>
Have Not<BR>
Vested<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>103,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>41,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>207,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>103,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/19/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>203,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2,924,796</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>131,024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/15/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>101,626</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,462,398</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>136,378</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/4/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>203,252</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2,924,796</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,538</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/28/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11,686</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4,791</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>201,230</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>28,770</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>167,693</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>62,307</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>143,738</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>86,262</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>15.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>119,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>130,212</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11.74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>31,249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>52,084</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>31,249</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>52,084</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>7.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>282,245</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>William D. Baird III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>175,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4.66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4/16/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>161,888</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/4/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>60,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>877,430</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>38,259</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/28/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>30,487</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>438,708</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6,224</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/18/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>60,974</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>877,416</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>62,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>78,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>65,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>24,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>8.61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>56,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>33,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>43,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>46,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>37,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>84,745</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>32,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/5/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>18,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>269,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>36,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>74,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,072,415</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>30,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/19/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>37,262</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>536,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.06</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/16/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>74,524</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,072,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>70,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/15/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>80,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/4/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>78,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/28/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>85,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/18/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>88,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>78,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>65,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>24,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>8.61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>62,494</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>37,506</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>47,913</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>52,087</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>28,122</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>46,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>103,578</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>124,035</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10,965</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3/7/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>161,888</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>43,730</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6,270</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>731,199</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>58,318</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>21,682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>8.61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>365,592</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>56,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>33,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>731,185</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>43,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>46,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>22,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>37,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>57,290</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>67,710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/8/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4,687</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>67,446</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9,370</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>15,630</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,813</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>731,199</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-0pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Corporate Secretary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>25,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>365,592</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,812</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>731,185</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>25%
of the total number of shares subject to the option vest on the first anniversary of the date of grant; the remainder vest 1/36<SUP>th</SUP>&nbsp;per month
thereafter. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=382550,FOLIO='38',FILE='DISK109:[18ZAG1.18ZAG13701]DM13701A.;15',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dm13701_1_39"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Vesting
of the RSU is subject to the participant's continuous service with the Company through the applicable vesting date with the following schedule: 25% of the
total number of shares vest on the first anniversary of the grant date, with 25% on each successive grant date anniversary for the next three years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Vesting
of PRSUs are based on the goals were established by management and the Compensation Committee; the units noted for the total shareholder return goal and the
strategic pipeline goal related to the Pompe program are at target and maximum payout, respectively.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
market value is based on the closing stock price of $14.39 on December&nbsp;31, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was January&nbsp;3, 2014.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was March&nbsp;7, 2014.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was June&nbsp;26, 2014.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was January&nbsp;2, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was June&nbsp;1, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(10)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was January&nbsp;4, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(11)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was February&nbsp;8, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(12)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was June&nbsp;15, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(13)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was January&nbsp;3, 2017. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Option Exercises and Stock Vested at Year End  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive officers must use pre-established trading plans to sell shares of Amicus Therapeutics,&nbsp;Inc. stock. Trading plans may only
be entered into when the executive is not in possession of material non-public information about the Company, and we require a waiting period following the establishment of a trading plan before any
trades may be executed. Our policy is designed to provide safeguards that will allow our executives an opportunity to realize the value intended by the Company in granting equity-based awards. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows information regarding option exercises and stock vested for each named executive officer during the year ended December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Acquired on<BR>
Exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value<BR>
Realized<BR>
upon<BR>
Exercise(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Acquired on<BR>
Vesting </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value<BR>
Realized<BR>
upon<BR>
Vesting(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>666,395</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,505,043</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,417</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>91,565</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird III</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>469,332</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,963</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>106,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>567,938</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>347,605</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,963</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,563</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,739</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
value realized is the difference between the fair market value of a share of our common stock at the time of exercise and the option exercise price, multiplied
by the number of shares acquired on each exercise.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
value realized on vesting on stock awards is based on the closing price on the date of vesting.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=986565,FOLIO='39',FILE='DISK109:[18ZAG1.18ZAG13701]DM13701A.;15',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_do13701_1_40"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Qualified Deferred Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As described more fully above, our Non-Qualified Cash Deferral Plan (and Stock Deferral Plan (collectively, the "Deferral Plans") covers our
executive officers and our non-employee directors. Earnings are determined solely by an executive's hypothetical investment of any amount deferred in any pre-selected investment permitted under the
Cash Deferral Plan or in the value of our stock, with respect to the Stock Deferral Plan. All amounts in the Deferral Plans are fully vested at all times. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Executive<BR>
Contributions in<BR>
Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Earnings in<BR>
Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Distributions in<BR>
Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Balance at<BR>
Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>751,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,188</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,041,030</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>513,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>$309,534
of this amount is included in the salary column and $441,550 of this amount is included in the bonus column, respectively, in the summary compensation
table.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
investments gains determined by the hypothetical investments elected by Mr.&nbsp;Crowley in the last fiscal year as permitted under the Deferral Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
column includes $1,195,757 compensation earned and deferred in prior years, which was disclosed in prior year Proxy statements.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
amount in this column represents the value of the vested RSUs that Mr.&nbsp;Campbell deferred and distributed on January&nbsp;3, 2017.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Severance Benefits and Change of Control Arrangements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have agreed to provide severance benefits and change of control arrangements to our current executives as described below. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John F. Crowley.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We employ Mr.&nbsp;Crowley as our Chief Executive Officer pursuant to an employment agreement. The agreement will
continue for
successive one-year terms until either Mr.&nbsp;Crowley or the company provide written notice of termination to the other in accordance with the terms of the agreement. Upon the termination of his
employment by the company other than for cause, or if the company decides not to extend Mr.&nbsp;Crowley's agreement at the end of any term, or if Mr.&nbsp;Crowley resigns for good reason,
Mr.&nbsp;Crowley has the right to receive (i)&nbsp;a severance payment in an amount equal to his then current base salary payable over 18&nbsp;months in accordance with the company's regular
payroll practices, (ii)&nbsp;an additional payment equal to 150% of the target bonus for the year in which the
termination occurs, (iii)&nbsp;continued Monthly Medical Payments for a period of 18&nbsp;months, and (iv)&nbsp;continuation of health care coverage under COBRA with premiums to be paid by the
Company for up to 29&nbsp;months. Further, the vesting of all options then held by Mr.&nbsp;Crowley shall accelerate by one year. Mr.&nbsp;Crowley is not entitled to severance payments if the
company terminates him for cause or if he resigns without good reason. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
if upon the termination of Mr.&nbsp;Crowley's employment by the company other than for cause, or if the company decides not to extend his employment agreement at the end of
any term, or if Mr.&nbsp;Crowley resigns for good reason, in each case within twelve months following a change of control in the Company, then Mr.&nbsp;Crowley has the right to receive
(i)&nbsp;a severance payment in an amount equal to two times his then current base salary payable over 24&nbsp;months in accordance with our regular payroll practices, (ii)&nbsp;an additional
payment equal to 200% of the target bonus for the year in which the termination occurs, (iii)&nbsp;continued Monthly Medical Payments for a period of 24&nbsp;months, and (iv)&nbsp;continuation
of health care coverage under COBRA with premiums to be paid by the Company for up to 29&nbsp;months. Further, the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=43,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=695907,FOLIO='40',FILE='DISK109:[18ZAG1.18ZAG13701]DO13701A.;12',USER='CHE109873',CD='23-APR-2018;11:33' -->
<A NAME="page_do13701_1_41"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>vesting
of all remaining unvested options and restricted stock grants then held by Mr.&nbsp;Crowley would accelerate in full. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
if Mr.&nbsp;Crowley's employment ceases due to his death or disability, he (or his estate, as applicable) will be entitled to (i)&nbsp;continuation of the Monthly Medical
Payments for 12&nbsp;months, and (ii)&nbsp;continuation of health care coverage under COBRA with premiums to be subsidized by the Company for up to 12&nbsp;months. We believe that the severance
package for our chief executive officer is appropriate considering his role, responsibilities and his excellent historical service to the Company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Named Executive Officers.  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Messrs.&nbsp;Baird and Campbell, Dr.&nbsp;Barth and Ms.&nbsp;Rosenberg.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We employ Mr.&nbsp;Baird as our Chief Financial Officer,
Mr.&nbsp;Campbell as our President and Chief Operating Officer, Dr.&nbsp;Barth as our Chief Medical Officer, and Ms.&nbsp;Rosenberg as our General Counsel and Corporate Secretary, pursuant to
their
respective employment agreements. If any of these executive officers is terminated without cause, then the executive officer has the right to receive:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of such executive's base salary for 12&nbsp;months; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an amount equal to the target bonus for such executive officer pro-rated for the number of months actually worked in the year of termination; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> vesting of option awards then held by them will automatically accelerate by twelve months; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of health care coverage under COBRA with premiums to be paid by the Company for a period of 12&nbsp;months. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if any of these executive officers is terminated other than for cause within 12&nbsp;months following change of control or, if following those changes, the executive
officer resigns for good reason, then the executive officer has the right to receive:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of such executive's base salary for 18&nbsp;months; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an amount equal to such executive officer's target annual bonus; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any outstanding unvested stock options and restricted stock grants held by the executive officer will fully vest; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of health care coverage under COBRA with premiums to be paid by the Company for a period of 18&nbsp;months. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
if the executive's employment ceases due to death or disability, such executive will be entitled to continuation of health care coverage under COBRA with premiums to be
subsidized by the Company for up to 12&nbsp;months. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a condition to the payment of the foregoing severance benefits, a departing executive officer is required to execute a general release of claims against the Company and its
affiliates. Each named executive officer is bound by non-disclosure, inventions transfer, non-solicitation and non-competition covenants that prohibit the executive officer from competing with the
Company during the term of his or her employment and for twelve months after termination of employment. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments upon Termination without Cause or Resignation for Good Reason  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For each named executive officer the following table sets forth quantitative estimates of the benefits that would have accrued if such
executive's employment had been terminated without cause or, in the case of Mr.&nbsp;Crowley, he resigned for good reason, on December&nbsp;31, 2017 other than in connection with a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=44,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=707709,FOLIO='41',FILE='DISK109:[18ZAG1.18ZAG13701]DO13701A.;12',USER='CHE109873',CD='23-APR-2018;11:33' -->
<A NAME="page_do13701_1_42"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>change
of control. Amounts below reflect potential payments pursuant to the severance agreements for such named executive officers. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="15pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="15pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
Continuation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefit<BR>
Continuation<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
RSU<BR>
Vesting<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Stock<BR>
Option<BR>
Vesting<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>928,602</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>557,161</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,204,263</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>881,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,264,700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,835,826</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>408,447</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>246,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,747</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>273,309</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>949,640</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,905,150</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>450,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>428,050</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,820</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>358,038</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,082,848</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,343,861</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>444,548</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>267,751</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>26,997</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>236,759</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>925,768</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,901,823</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>412,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>287,329</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21,508</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>205,288</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>653,470</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,579,595</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Bonus
component paid in lump sum.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Other
than with respect to Mr.&nbsp;Crowley, benefits to be continued consist of COBRA premiums paid by the Company for 12&nbsp;months.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Value
of the options that would accelerate upon such event is calculated using the closing stock price of $14.39 on December&nbsp;31, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over an 18&nbsp;month period following such termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Benefits
to be continued consist of estimated healthcare costs and health insurance premiums for Mr.&nbsp;Crowley's family, which primarily consists of the Monthly
Medical Payments paid over 18&nbsp;months and up to 29&nbsp;months of COBRA coverage.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over a 6&nbsp;month period following such termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over a 12&nbsp;month period following such termination of employment. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments upon Termination Due to Change of Control  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth quantitative estimates of the benefits that would have accrued to each of our named executive officers, if his or
her employment had been terminated due to a termination without cause or a resignation with good reason on December&nbsp;31, 2017, assuming that such termination occurs </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=45,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=671373,FOLIO='42',FILE='DISK109:[18ZAG1.18ZAG13701]DO13701A.;12',USER='CHE109873',CD='23-APR-2018;11:33' -->
<A NAME="page_do13701_1_43"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>within
twelve months following a change of control or, in the case of Mr.&nbsp;Crowley, within three months prior to or twelve months following the date on which the change of control occurs. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="15pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="46pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="15pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
Continuation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefit<BR>
Continuation<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
RSU<BR>
Vesting<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Stock<BR>
Option<BR>
Vesting<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,238,137</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>742,882</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,604,265</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,299,280</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,282,937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,167,501</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>612,670</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>246,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,621</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,916,734</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,710,164</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,527,196</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>675,158</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>428,050</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>37,230</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,414,628</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,998,162</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,553,228</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>666,822</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>267,751</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,496</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,624,271</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,617,078</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,216,418</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>618,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>287,329</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,262</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,529,830</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,408,486</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,975,907</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Bonus
component paid in lump sum.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Other
than with respect to Mr.&nbsp;Crowley, benefits to be continued consist of COBRA premiums paid by the Company for 18&nbsp;months.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Value
of the options that would accelerate upon such event is calculated using the closing stock price of $14.39 on December&nbsp;31, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over a 24&nbsp;month period following such termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Benefits
to be continued consist of estimated healthcare costs and health insurance premiums for Mr.&nbsp;Crowley's family, which primarily consists of the Monthly
Medical Payments paid over 24&nbsp;months and up to 29&nbsp;months of COBRA coverage.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over an 18&nbsp;month period following such termination of employment. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=46,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=436800,FOLIO='43',FILE='DISK109:[18ZAG1.18ZAG13701]DO13701A.;12',USER='CHE109873',CD='23-APR-2018;11:33' -->
<A NAME="page_do13701_1_44"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments upon Termination Due to Death or Disability  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following sets forth quantitative estimates of the benefits that would have accrued to each of our named executive officers, if his or her
employment had been terminated due to death or disability on December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefit<BR>
Continuation<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>801,766</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>801,766</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,747</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,747</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,820</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,820</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26,997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,508</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,508</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Benefits
to be continued consist of COBRA and HSA premiums paid by the Company for 12&nbsp;months following such termination. For Mr.&nbsp;Crowley, this also
includes the Monthly Medical Payments.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


CEO Pay Ratio  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under Section&nbsp;953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item&nbsp;402(u) of Regulation&nbsp;S-K, we
are required to provide the following disclosure regarding the ratio of the annual total compensation of our Chief Executive Officer to the annual total compensation of our median employee (the "Pay
Ratio"). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the Pay Ratio calculation, we identified our median employee by determining the 2017 total annualized target cash compensation for all of our global employees (excluding
our Chief Executive Officer), whether employed on a full-time, part-time or seasonal basis, who were employed by us on October&nbsp;1, 2017 as our consistently applied compensation measure. Total
annualized target cash compensation for these purposes consists of annualized base salary and annual target bonus. Once we identified our median employee, we calculated such employee's annual total
compensation for 2017 in the same manner that we determined the total compensation of our Chief Executive Officer for purposes of the Summary Compensation Table disclosed above. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the year ended December&nbsp;31, 2017, (i)&nbsp;the annual total compensation of our Chief Executive Officer was $5,613,080; (ii)&nbsp;the annual total compensation of our
median employee was $184,514; and (iii)&nbsp;based
on this information, we reasonably estimate our Pay Ratio to be 30:1. Because the SEC rules for identifying the median employee and calculating the Pay Ratio allow companies to use different
methodologies, to apply certain exemptions, and to make reasonable estimates and assumptions, the Pay Ratio calculation presented above is a reasonable estimate and may not be comparable to the pay
ratio reported by other companies. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to our Director Compensation Policy, each non-employee member of our Board received the following cash compensation for Board services
during 2017, as applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $30,000 per year for service as lead independent director; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=47,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=665302,FOLIO='44',FILE='DISK109:[18ZAG1.18ZAG13701]DO13701A.;12',USER='CHE109873',CD='23-APR-2018;11:33' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dq13701_1_45"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $40,000 per year for service as a Board member; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $30,000 per year for service as chairperson of the Audit and Compliance Committee (inclusive of committee membership fees described below); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $20,000 per year for service as chairperson of the Compensation Committee (inclusive of committee membership fees described below); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $12,500 per year for service as chairperson of the Nominating/Corporate Governance Committee or the Science and Technology Committee (inclusive
of committee membership fees described below); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $10,000 per year for service as a member of the Audit and Compliance Committee and $7,500 per year for service as a member of the Compensation
Committee, the Nominating and Corporate Governance Committee or the Science and Technology Committee. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2017, after a market study completed by Pay Governance, the Board of Directors approved a new methodology to determine equity grants to members of the Board of Directors, using a
value based approach benchmarked vs peers to be aligned with executives. As of June 2017, each director received an annual grant of non-qualified options and RSUs worth $150,000, with 2/3 of the value
assigned to the non-qualified stock options, and 1/3 of the value assigned to RSUs. The grant date is the date of our Annual Meeting of Stockholders and each grant will vest in full at the following
Annual Meeting of Stockholders. The exercise price of each option granted to a non-employee director will be equal to 100% of the fair market value of a share on the date of grant. Options will have a
maximum term of 10&nbsp;years measured from the grant date, subject to termination in the event of the director's cessation of Board service. All of our directors are also eligible to participate in
our 2007 Equity Incentive Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of the new methodology, each of our new, independent Board members will receive non-qualified options and RSUs with the value of $225,000 in connection with their election to the
Board. The exercise price of each option granted will be equal to 100% of the fair market value of a share on the date of the grant. Unlike the annual grant to our directors, but consistent with our
grants to our named executive officers, these initial grant awards vest over a four year period with 25% vesting one year after the vesting commencement date and the remainder vesting ratably each
month thereafter in equal installments over a three year period subject to continued service as a director. We expect to make additional initial grants of stock options and RSUs to any new Board
members in the future. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of Non-Employee Director Compensation Table  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information regarding the compensation that each of our non-employee directors earned during the year ended
December&nbsp;31, 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees<BR>
Earned<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>RSU<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>218,763</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>198,763</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael G. Raab</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>55,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>205,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted W. Love, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>210,638</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald J. Hayden, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>232,513</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret G. McGlynn.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>216,263</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>201,263</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
fees earned by non-employee director pursuant to Director Compensation Policy. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=48,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=219602,FOLIO='45',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;14',USER='CHE108068',CD='20-APR-2018;12:26' -->
<A NAME="page_dq13701_1_46"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
the aggregate grant date fair value computed in accordance with FASB ASC Topic 718, Compensation&#151;Stock Compensation. Assumptions made in this
valuation are discussed in our annual report for the year ended December&nbsp;31, 2017, filed with the SEC on Form&nbsp;10-K on March&nbsp;1, 2018, at Item&nbsp;7&#151;Management's
Discussion and Analysis of Financial Condition and Results of Operations&#151;Equity Compensation. Subject generally to continued service, annual director grant options vest one year from date
of grant while the initial director grant options vest over four years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>As
described more fully below, Mr.&nbsp;Sblendorio participates in our Non-Qualified Cash Deferral Plan and for 2017, the fees deferred were $40,500. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, our non-employee directors had the following number of stock options outstanding: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="83pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Options<BR>
Outstanding </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Vested/Unvested </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael G. Raab</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>141,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>85,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald J. Hayden, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>156,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>140,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret G. McGlynn</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>151,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted W. Love, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>116,246</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>116,246</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000/16,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250/34,986</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-employee
directors are also eligible to defer board fees pursuant to the terms of the Cash Deferral Plan, described more fully above. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, our non-employee directors had the following number of restricted stock units outstanding: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Restricted<BR>
Stock Units<BR>
Outstanding </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael G. Raab</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald J. Hayden, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret G. McGlynn</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted W. Love, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,814</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Qualified Deferred Compensation for Non-Employee Directors  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Deferral Plans cover our executive officers and members of our Board. The Company does not match participants' voluntary contributions to
the deferral plan. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Director<BR>
Contributions<BR>
in Last Fiscal<BR>
Year(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Earnings<BR>
in Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Distributions<BR>
in Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Balance at<BR>
Last Fiscal<BR>
Year(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,844</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>37,051</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,895</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Amount
deferred is reflected in the "Fees Earned" column above in the Summary Director Compensation Table.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
column includes director fees earned and deferred in prior years.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=49,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=417955,FOLIO='46',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;14',USER='CHE108068',CD='20-APR-2018;12:26' -->
<A NAME="page_dq13701_1_47"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq13701_compensation_committee_report"> </A>
<A NAME="toc_dq13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION COMMITTEE REPORT    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee is comprised entirely of independent directors. The Compensation Committee of our Board has reviewed and discussed
the Compensation Discussion and Analysis required by Item&nbsp;402(b) of Regulation&nbsp;S-K, which appears in this Proxy Statement, with our management. Based on this review and discussion, the
Compensation Committee has recommended to the Board that the Compensation Discussion and Analysis be included in this Proxy Statement and our 2017 Annual Report on Form&nbsp;10-K. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Members
of the Amicus Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Compensation
Committee: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Margaret
G. McGlynn, Chair<BR>
Michael G. Raab<BR>
Craig Wheeler </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended (the "Securities Act") or the Exchange
Act that might incorporate this proxy statement or future filings with the SEC, in whole or in part, the above report shall not be deemed to
be "soliciting material" or "filed" with the SEC and shall not be deemed to be incorporated by reference into any such filing.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=50,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=686765,FOLIO='47',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;14',USER='CHE108068',CD='20-APR-2018;12:26' -->
<A NAME="page_dq13701_1_48"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq13701_section_16(a)_benefici__dq102032"> </A>
<A NAME="toc_dq13701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Exchange Act requires our directors, executive officers and persons who own more than 10% of a registered class of
our equity securities to file reports of holdings and transactions in our Common Stock with the SEC. To our knowledge, based solely on our review of copies of the reports received by us and written
representations by these individuals that no other reports were required, all such Section&nbsp;16(a) filing requirements were met. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq13701_security_ownership_of_certain___sec02525"> </A>
<A NAME="toc_dq13701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information with respect to the beneficial ownership of our Common Stock as of March&nbsp;31, 2018 for
(a)&nbsp;the executive officers named in the Summary Compensation Table contained in this Proxy Statement, (b)&nbsp;each of our directors and director nominees, (c)&nbsp;all of our current
directors and executive officers as a group and (d)&nbsp;each stockholder known by us to own beneficially more than 5% of our Common Stock. Beneficial ownership is determined in accordance with the
rules of the SEC and includes voting or investment power with respect to the securities. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
deem shares of Common Stock that may be acquired by an individual or group within 60&nbsp;days of March&nbsp;31, 2018 pursuant to the exercise of options or warrants to be
outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other
person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of
Common Stock shown to be beneficially owned by them based on information provided to us by these stockholders. Percentage of ownership is based on 187,972,218 shares of Common Stock outstanding on
March&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated below, the address of each of the individuals named below is: c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, NJ 08512. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Address of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
Of Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>5% Stockholders</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Perceptive Advisors&nbsp;LLC(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,424,424</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>499 Park Avenue, 25<SUP>th</SUP>&nbsp;Floor</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New York, NY 10022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Entities affiliated with FMR&nbsp;LLC(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,983,566</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 245 Summer Street</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Boston, MA 02210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Black Rock&nbsp;Inc.(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,712,097</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>55 East 52nd&nbsp;Street</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New York, NY 10055</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Entities affiliated with Vanguard Group(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,634,785</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 100 Vanguard Blvd.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Malvern, PA 19355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Redmile Group,&nbsp;LLC(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,085,770</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>One Letterman Drive, Bldg. D, Suite D3-700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>San Francisco, CA 94129</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Entities affiliated with Prudential Financial,&nbsp;Inc.(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,301,723</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 466 Lexington Avenue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 New York, NY 10017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=51,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=677004,FOLIO='48',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;14',USER='CHE108068',CD='20-APR-2018;12:26' -->
<A NAME="page_dq13701_1_49"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
Of Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Named Executive Officers and Directors</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John F. Crowley(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,610,967</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird III(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>692,566</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bradley L. Campbell(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>934,299</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>399,660</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ellen S. Rosenberg(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130,536</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald J. Hayden, Jr.(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,933</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael G. Raab(14)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>105,634</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret G. McGlynn(15)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>145,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted W. Love, M.D.(16)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>242,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner(17)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler(18)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All directors and executive officers as a group (15 persons)(19)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,530,678</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
beneficial ownership of less than one percent of our outstanding Common Stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G/A filed with the SEC on February&nbsp;14, 2018 by Perceptive
Advisors&nbsp;LLC ("Perceptive"), and supplemented by a Form&nbsp;4 filed with the SEC on March&nbsp;7, 2018. As of December&nbsp;31, 2017, Perceptive reported shared voting and investment
power of 17,888,597 shares of common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G/A filed with the SEC on February&nbsp;13, 2018 by FMR&nbsp;LLC
("FMR"). As of December&nbsp;31, 2017, FRM reported sole voting power of 2,807,665 shares of common stock and sole investment power of 17,983,566 shares of common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G/A filed with the SEC on February&nbsp;8, 2018 by
Blackrock&nbsp;Inc. ("Blackrock"). As of December&nbsp;31, 2017, Blackrock reported sole voting power of 13,343,785 shares of common stock and sole investment power of 13,712,097 shares of common
stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G filed with the SEC on February&nbsp;12, 2018 by Vanguard Group
("Vanguard"). As of December&nbsp;31, 2017, Vanguard reported sole voting power of 322,380 shares of common stock, shared voting power of 22,462 shares of common stock, sole investment power of
13,301,881 shares of common stock and shared investment power of 332,904 shares of common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G filed with the SEC on February&nbsp;14, 2018 by Redmile
Group&nbsp;LLC ("Redmile"). As of December&nbsp;31, 2017, Redmile reported shared voting and investment power of 12,085,770 shares of common stock. The numbers reported in this line include
2,060,000 warrants to purchase common stock, which may be exchanged for ordinary shares at a 1:1 ratio.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided solely in reliance upon information included in a Schedule&nbsp;13G filed with the SEC on January&nbsp;26, 2018 by Prudential
Financial,&nbsp;Inc. ("Prudential"). As of December&nbsp;31, 2017, Prudential reported sole voting power of 52,347 shares of common stock, shared voting power of 10,249,376 shares of common stock,
sole investment power of 52,347 shares of common stock and shared investment power of 10,249,376 shares of common stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 1,401,760 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018, 144,312 shares held directly by
Mr.&nbsp;Crowley and 64,895 shares held by a trust f/b/o Mr.&nbsp;Crowley. Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and
unvested restricted stock units as of May&nbsp;30, 2018. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=52,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=757695,FOLIO='49',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;14',USER='CHE108068',CD='20-APR-2018;12:26' -->
<A NAME="page_dq13701_1_50"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 661,729 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 30,837 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 893,816 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 40,483 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 390,997 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018, 8,538 shares held directly by
Dr.&nbsp;Barth and 125 shares held by his daughter. Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock
units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 105,819 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 9,717 shares held directly by
Ms.&nbsp;Rosenberg and 15,000 shares held by her spouse. Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted
stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 120,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 85,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 11,933 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 105,634 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(15)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 135,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 10,000 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(16)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 100,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 142,000 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(17)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 100,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(18)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 14,375 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(19)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 4,602,188 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2018 and 928,490 total shares held of
record. Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2018 and unvested restricted stock units as of May&nbsp;30, 2018. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=53,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=596430,FOLIO='50',FILE='DISK109:[18ZAG1.18ZAG13701]DQ13701A.;14',USER='CHE108068',CD='20-APR-2018;12:26' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_ds13701_1_51"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds13701_policies_and_procedure__ds102278"> </A>
<A NAME="toc_ds13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  POLICIES AND PROCEDURES FOR RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board maintains a formal written policy for the review of any transaction, arrangement or relationship in which Amicus is a participant and
one of our executive officers, directors, director nominees, 5% stockholders (or their immediate family members), each of whom we refer to as a "related party," has a direct or indirect interest. If a
related party proposes to enter into such a transaction, arrangement or relationship, which we refer to as a "related party transaction," the related party must report the proposed transaction to our
Chief Financial Officer or Senior Vice President, Finance. The proposed related party transaction must be reviewed and, if deemed appropriate, approved by the Board's Audit and Compliance Committee
prior to entry into such transaction, or ratified as soon as reasonably practicable after discovery that approval is required. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit and Compliance Committee may approve or ratify the transaction only if the Audit and Compliance Committee determines that, under all of the circumstances, the transaction is
not inconsistent with the Company's best interests and does not violate its Code of Business Conduct and Ethics. Any related party transactions that are ongoing in nature will be reviewed annually.
The Audit and Compliance Committee will review and consider such information regarding the related party transaction as it deems appropriate under the circumstances. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds13701_proposal_no._2_#151;approve_an__pro03198"> </A>
<A NAME="toc_ds13701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 2&#151;APPROVE AND ADOPT<BR>  AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION    <BR>    </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Description of the Amendment  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board has adopted a resolution to amend our Restated Certificate of Incorporation, as amended, to increase the number of shares of common
stock, par value $0.01 per share that we are authorized to issue from 250,000,000 to 500,000,000 shares and has directed that the proposed amendment be submitted to our stockholders for their approval
and adoption. The amendment will not change the number of shares of preferred stock that are authorized (10,000,000 shares), and the total authorized shares will be increased from 260,000,000 to
510,000,000. The amendment will replace the first sentence of Section&nbsp;4 of our current Restated Certificate of Incorporation with the following language: </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOURTH:
The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is Five Hundred Ten Million (510,000,000) shares, consisting solely
of: Five Hundred Million (500,000,000) shares of common stock, par value $0.01 per share ("Common Stock"); and Ten Million (10,000,000) shares of preferred stock, par value $0.01 per share ("Preferred
Stock"). </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation  </I></B></FONT></P>

</UL>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>The Board recommends the vote "FOR" the proposal to approve and adopt an amendment to our Restated Certificate of
Incorporation to increase the authorized shares of common stock to Five Hundred Million shares.</B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Background  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue shares of capital stock to the extent such shares have been authorized under our Restated Certificate of Incorporation. Currently,
we are authorized to issue up to 250,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of March&nbsp;31, 2018, the total shares of common stock issued and outstanding and reserved for issuance pursuant to outstanding warrants, options, and preferred stock equaled
215,825,718 as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 187,972,218 shares of common stock issued and outstanding; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 16,176,047 shares of common stock reserved for issuance pursuant to options to purchase common stock outstanding; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=54,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=985596,FOLIO='51',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;12',USER='CHE109572',CD='20-APR-2018;12:24' -->
<A NAME="page_ds13701_1_52"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 3,110,000 shares of common stock reserved for issuance pursuant to warrants to purchase common stock outstanding; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 3,540,679 shares of common stock reserved for issuance pursuant to unvested RSUs and PRSUs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 25,000 shares of common stock reserved for issuance pursuant to deferred vested RSUs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 5,001,774 shares of common stock available for issuance under our 2007 Equity Incentive and Director Plans. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result, we have only 34,174,282 unreserved shares of common stock available for issuance. There are no shares of preferred stock outstanding. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reason for the Proposal  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have only limited revenue as we are in the initial launch phase of our first marketed product and expect to continue to generate losses over
the next couple of years as we continue to support our geographic expansion, our late stage development of biologics, biologics manufacturing and pre-clinical and early clinical development of our
pipeline. These activities are expected to expand over time and will require further resources if we are to be successful. Because we have not generated significant commercial sales revenue to date
and we expect our losses will continue in the near future, we will need to raise additional capital through a range of activities including equity offerings or other business development
opportunities. Our Board believes that the current amount of unreserved shares of common stock is insufficient for our future financing needs because it is likely that the sale of shares of common
stock will be one of the principal means by which we will raise additional capital until such time as we are able to generate earnings sufficient to finance our operations. For similar reasons, our
Board may also consider using common stock to acquire, or invest in, complementary businesses, technologies, manufacturing, products or assets. Although our Board has no current plan, arrangement or
commitment to issue additional shares of common stock for the purposes described above, the Board believes that it is in the best interest of the Company and our stockholders to have a sufficient
number of authorized but unissued shares of common stock available for issuance in the future for such purposes. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
this proposal is approved, all or any of the authorized shares may be issued without further stockholder action (unless such approval is required by applicable law or regulatory
authorities) and without first offering those shares to the stockholders for subscription. The issuance of Common Stock in any manner other than on a pro-rata basis to all stockholders would reduce
the proportionate interest in the Company of each stockholder. Our stockholders have no preemptive rights to subscribe for additional shares of Common Stock when issued. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Possible Anti-Takeover Effects of the Amendment  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The proposed amendment to our Restated Certificate of Incorporation is not being recommended in response to any specific effort of which our
Board is aware to obtain control of the Corporation, and our Board does not intend or view the proposed increase in authorized common stock as an anti-takeover measure. However, the ability of our
Board to authorize the issuance of the additional shares of common stock that would be available if the proposed amendment is approved and adopted could have the effect of discouraging or preventing a
hostile takeover. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=55,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=717031,FOLIO='52',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;12',USER='CHE109572',CD='20-APR-2018;12:24' -->
<A NAME="page_ds13701_1_53"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ds13701_proposal_no._3_#151;approve_th__pro02590"> </A>
<A NAME="toc_ds13701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 3&#151;APPROVE THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In this proposal, we are requesting stockholders approve the amendment and restatement of the Amicus Amended and Restated 2007 Equity Incentive
Plan (the "2007 Plan") to increase the number of shares of common stock available for issuance under the 2007 Plan by 5,000,000 shares. The board of directors approved the amendment and restatement of
the 2007 Plan on April&nbsp;11, 2018 subject to and effective upon stockholder approval. The 2007 Plan, as amended and restated if this proposal is approved, is described in more detail below. If
this proposal is not approved by our stockholders, the amendment and restatement of the 2007 Plan will not become effective, but the 2007 Plan will remain in effect in accordance with its present
terms. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation:  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>The Board of Directors recommends the vote "FOR" the approval of the Amended and Restated 2007 Equity Incentive
Plan.</B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are asking our stockholders to approve our Amended and Restated 2007 Equity Incentive Plan (the "2007 Plan"). The Compensation Committee approved the 2007 Plan, subject to approval of
the Board and the stockholders, and the Board approved the 2007 Plan, subject to approval of the stockholders. If our stockholders do not approve the 2007 Plan, the existing version of the Amended and
Restated 2007 Equity Incentive Plan (the "Existing Plan") will remain in effect. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2007 Plan is substantially similar to the Existing Plan. The only change is an increase of 5,000,000 shares of Common Stock available for issuance as equity incentive awards. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Background and Reason for the Proposal  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity compensation has historically been a key element of our compensation program. The ability to grant stock options and restricted stock has
enabled us to attract and retain highly talented employees. Additionally, equity awards have also allowed us to link incentive rewards to Company performance, to encourage employee ownership in our
stock and to align the interests of employees with those of our stockholders. Equity based compensation is a common form of compensation in our industry. Without the ability to grant stock options and
restricted stock, we would be at a disadvantage against our competitors for recruiting and retaining key talent. We expect that we will be required to grow our employee population over the coming
years to meet the requirements of a global commercial enterprise. If we did not expand the pool of shares available, we would also be unable to offer competitive total compensation packages necessary
to attract, retain and motivate individuals critical to our future success. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
purpose of the 2007 Plan is to encourage ownership of our Common Stock by employees and directors of the Company and to provide additional incentive for them to promote the success
of the Company's business through the grant of awards of shares of the Company's Common Stock. As of March&nbsp;31, 2018, there are 4,894,629 shares remaining for issuance under the Existing Plan.
We are therefore seeking approval of the 2007 Plan in order to make an additional 5,000,000 shares of our Common Stock available for issuance as Awards under the 2007 Plan. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board believes that the 2007 Plan will serve a critical role in attracting and retaining officers and employees and in motivating these individuals to strive to meet our goals and
that, without the additional shares which may be offered under the 2007 Plan, we would be at a competitive disadvantage to our peers. The Board further believes that the increased number of shares
that would be available for issuance under the 2007 Plan would provide the Compensation Committee with the flexibility to make the types and amounts of awards it believes are necessary to attract and
retain qualified individuals. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=56,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=42199,FOLIO='53',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;12',USER='CHE109572',CD='20-APR-2018;12:24' -->
<A NAME="page_ds13701_1_54"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Considerations Relating to the Additional Shares Under the 2007 Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In recommending the 2007 Plan to the board of directors for approval, the Compensation Committee reviewed analyses prepared by Pay Governance,
the committee's independent compensation consultant. Considerations taken into account by the compensation committee included the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Competitiveness</I></FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
market for high caliber, experienced talent in our industry and in our geographic location is extremely competitive. We compete not only with other similar sized and larger
biotechnology companies, but we also compete for talent directly with much larger pharmaceutical companies that have significantly greater resources and generous compensation practices. Our ability to
grant equity awards is critical to our ability to be competitive and to attract, retain and motivate the talent we need to best position our Company for success. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Limited duration of current shares available</I></FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we do not increase the shares available for issuance under the 2007 Plan, we expect the number of available shares under the 2007 Plan to be substantially depleted by the midpoint of
2019 and that we would then be unable to continue to grant broad-based equity awards. If our stockholders approve the amendment and restatement, we estimate that the shares reserved for issuance under
the 2007 Plan, as amended and restated, would be sufficient for up to 18-24&nbsp;months of awards based on projected increase in overall number of employees, projected employee turnover and
historical grant practices. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Employee growth/turnover</I></FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
had a 23% increase in the number of employees in 2017. We are projecting a 40% increase in 2018 and a 30% increase in 2019. In addition, we are projecting employee turnover that is
consistent with the turnover rate of the biotechnology industry generally. In 2017, we had a total of 3 new hires and promotions involving positions at the vice president level or higher. We expect to
increase our hiring at all levels, including senior management, in 2018 and 2019. Accordingly, we anticipate an increase in new hire equity grants in 2018 and 2019, which are traditionally 50% to 100%
greater in value than annual grants, and as the overall number of employees continues to increase, we are planning for a resulting increase in annual equity grants as well. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Broad-based equity programs</I></FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe broad-based equity programs are important to our ability to attract, retain and motivate employees throughout the Company and align employee interests with those of our
stockholders. Historically, less than 30% of the total equity awards granted under the 2007 Plan have gone to our Named Executives. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Eligible Participants/Administration  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2007 Plan provides for the grant of incentive stock options, within the meaning of Section&nbsp;422 of the Code, to employees, and
non-qualified stock options and restricted stock, other stock awards and Performance Awards to our employees and directors. As of April&nbsp;1, 2018, approximately 360 employees and seven directors
are eligible to participate in the 2007 Plan. The 2007
Plan will be administered by the Compensation Committee of our Board, provided that the Board may itself exercise any of the powers and responsibilities assigned to the Committee under the 2007 Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the provisions of the 2007 Plan, the Compensation Committee has been granted the discretion to determine when awards are made, which employees receive awards, the form of an
award, the number of shares subject to each award, and all other relevant terms of the award, including vesting and acceleration of vesting, if any. The Compensation Committee also has been granted
broad discretion to construe and interpret the 2007 Plan and adopt rules and regulations thereunder. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=57,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=490706,FOLIO='54',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;12',USER='CHE109572',CD='20-APR-2018;12:24' -->
<A NAME="page_ds13701_1_55"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Number of Shares Authorized Under the 2007 Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares of our Common Stock that would be available for issuance after the effective date under the 2007 Plan is 20,058,703 shares,
subject to adjustment to avoid dilution or enlargement of intended benefits in the event of certain significant corporate events. No more than 10,058,703 of the shares of Common Stock available for
issuance under the 2007 Plan after the effective date under the 2007 Plan (upon approval of the requested share increase) as awards of restricted stock, performance restricted stock units, stock
grants and any other similar awards whose intrinsic value is not solely dependent on appreciation in the price of our Common Stock after the date of grant. Each of the above numbers is exclusive of
any grants made under the 2007 Plan prior to the effective date of the approval of the amendment by the Board. If any shares of Common Stock covered by an award granted under the 2007 Plan, or to
which such an award relates, are forfeited, or if an award has expired, terminated or has been canceled for any reason whatsoever (other than by reason of exercise or vesting), then the shares covered
by such award shall again be, or shall become, shares with respect to which awards may be granted under the 2007 Plan. Shares of Common Stock underlying awards under the 2007 Plan that have been used
to satisfy withholding obligations or pay an exercise price will not again be available for a future award. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to such adjustments as provided below, no employee will, in a single calendar year, be granted awards under the 2007 Plan with respect to more than 5,000,000 shares of Common
Stock. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of the 2007 Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section summarizes certain key features of the 2007 Plan, all of which remain unchanged. The only change is the increase in the number of
authorized shares of common stock, subject to stockholder approval. The summary is qualified in its entirety by reference to the complete text of the 2007 Plan. Stockholders are urged to read the
actual text of the stated 2007 Plan in its entirety which is set forth in </FONT><FONT SIZE=2><B>Exhibit&nbsp;A</B></FONT><FONT SIZE=2> to this proxy statement. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Term of the 2007 Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No award may be granted under the 2007 Plan after April 2026 which is the 10th&nbsp;anniversary of the date on which the 2007 Plan was
approved by the Board. Awards granted prior to the expiration of the 2007 Plan shall not expire solely by reason of the termination of the plan. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
closing price of a share of our Common Stock on April&nbsp;2, 2018 was $14.16. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms and Conditions of Options  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Options granted under the 2007 Plan shall be, as determined by the Compensation Committee, non-qualified or incentive stock options for federal
income tax purposes, and shall be subject to the foregoing and the following terms and conditions and to such other terms and conditions, not inconsistent therewith, as determined by the Compensation
Committee: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Option Exercise Price.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The price at which shares of Common Stock may be acquired under each incentive stock option shall not be less
than 100% of the
fair market value of a share on the date an option is granted; provided, however, that the exercise price of any incentive stock option granted to any participant who, at the time of grant, owns more
than 10% of the total combined voting power of all classes of the Company's stock (a "Ten Percent Holder") shall be at least 110% of the fair market value of the stock on the date of such grant. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercisability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Options granted under the 2007 Plan shall be exercisable at such time and upon such terms and conditions as may be
determined by the
Committee; provided, however, that in no event shall an option be exercisable more than ten years after its grant date or five years after the date it is granted to a Ten Percent Holder. An option may
be exercised by a participant providing written notice specifying the number of shares of Common Stock with respect to which the option is then being exercised. The purchase </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=58,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=501646,FOLIO='55',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;12',USER='CHE109572',CD='20-APR-2018;12:24' -->
<A NAME="page_ds13701_1_56"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>price
for the shares as to which an option is exercised shall be paid to the Company pursuant to one or more of the following methods: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(i)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>cash
or check payable to the Company;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(ii)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>shares
of Common Stock having a fair market value equal to the aggregate option exercise price for the shares being purchased, and only with the Compensation
Committee's approval; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(iii)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>if
there is a public market for the shares at such time, through and under the terms and conditions of any formal cashless exercise program authorized by the
Company entailing the sale of Common Stock subject to any option in a brokered transaction (other than to the Company). </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
participant shall be deemed for any purpose to be a stockholder of the Company with respect to any shares of Common Stock issuable pursuant to an option until the participant has
given written notice of exercise of the option and has paid in full for such shares. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms and Conditions of Restricted Stock  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of restricted stock may be issued under the 2007 Plan for such consideration, in cash, other property or services, or any combination
thereof, as determined by the Compensation Committee. During the period of time in which the shares of restricted stock are subject to a risk of forfeiture (the "Restriction Period"), such shares
shall be subject to limitations on transferability and a risk of forfeiture arising on the basis of such conditions related to the performance of services, Company performance or otherwise as the
Compensation Committee may determine and set forth in an award agreement. Any such risk of forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Compensation
Committee on such basis as it deems appropriate. Except as otherwise provided in the 2007 Plan or an applicable award agreement, at all times prior to the lapse of the Restriction Period, the
participant shall have all of the rights of a stockholder of the Company, including the right to vote the shares of restricted stock. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms and Conditions of Restricted Stock Units  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each restricted stock unit shall entitle the recipient to a share of Common Stock at the close of a Restriction Period as established by the
Compensation Committee and subject to a risk of forfeiture arising on the basis of such conditions related to the performance of services, Company performance or otherwise as the Compensation
Committee may determine and set forth in an award agreement. Any such risk of forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Compensation Committee on
such basis as it deems appropriate. A participant holding restricted stock units shall not be deemed for any purpose to be a stockholder of the Company with respect to any of the shares of Common
Stock subject to such restricted stock units except to the extent that the Restriction Period with respect to such restricted stock units shall have closed and a certificate shall have been issued for
such shares of Common Stock. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms and Conditions of Stock Grants  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock grants may be issued under the 2007 Plan for such consideration, in cash or other property or services, or any combination thereof, as
determined by the Compensation Committee. Stock grants may be awarded in such circumstances as the Compensation Committee deems appropriate, including in recognition of significant contributions to
the success of the Company or in lieu of compensation otherwise already due. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms and Conditions of Performance Awards</I></B></FONT><FONT SIZE=2><I>.  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee may grant Performance Awards ("PRSUs") under the 2007 Plan, which may be denominated as a number of shares of Common
Stock or a specified number of other awards (or a combination of both). Generally, Performance Awards require satisfaction of pre-established Performance Goals (as defined in the following sentence).
The potential performance metrics include: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=59,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=844214,FOLIO='56',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;12',USER='CHE109572',CD='20-APR-2018;12:24' -->
<A NAME="page_ds13701_1_57"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>cash
flow; earnings (including gross margin, earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation, amortization and charges for stock-based
compensation, earnings before interest, taxes, depreciation and amortization, and net earnings); earnings per share; growth in earnings or earnings per share; stock price; return on equity or average
stockholder equity; total stockholder return or growth in total stockholder return either directly or in relation to a comparative group; return on capital; return on assets or net assets; revenue,
growth in revenue or return on sales; income or net income; operating income, net operating income or net operating income after tax; operating profit or net operating profit; operating margin; return
on operating revenue or return on operating profit; regulatory filings; regulatory approvals, litigation and regulatory resolution goals; other operational, regulatory or departmental objectives;
budget comparisons; growth in stockholder value relative to established indexes, or another peer group or peer group index; development and implementation of strategic plans and/or organizational
restructuring goals; development and implementation of risk and crisis management programs; improvement in workforce diversity; compliance requirements and compliance relief; safety goals;
productivity goals; workforce management and succession planning goals; economic value added (including typical adjustments consistently applied from generally accepted accounting principles required
to determine economic value added performance measures); measures of customer satisfaction, employee satisfaction or staff development; development or marketing collaborations, formations of joint
ventures or partnerships or the completion of other similar transactions intended to enhance the Company's revenue or profitability or enhance its customer base; and/or merger and acquisitions (each,
a "Performance Goal" and collectively the "Performance Goals"). Such Performance Goals may be described in terms of Company-wide objectives or objectives that are related to the performance of the
individual grantee or any subsidiary, division, department or function within the Company and may be measured on an absolute or relative basis. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee may provide, at the time a Performance Goal is established, that adjustments will be made to the applicable Performance Goal to take into account, in the manner specified
by the Committee, the impact of one or more of the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> gain or loss from all or certain claims and/or litigation and insurance recoveries, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the impairment of tangible or intangible assets, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> stock-based compensation expense, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> extraordinary, unusual or infrequently occurring events reported in the Company's public filings, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> restructuring activities reported in the Company's public filings, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> investments, dispositions or acquisitions, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> loss from the disposal of certain assets, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> gain or loss from the early extinguishment, redemption, or repurchase of debt, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> cash or non-cash charges related to site closings, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in accounting principles, or any other item, event or circumstance that would not cause an award to fail to constitute "qualified
performance-based compensation" under Section&nbsp;162(m) of the Code, to the extent such exemption is available. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transferability  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise determined by the Compensation Committee, an award (other than a stock award) shall not be transferable or assignable by a
participant otherwise than by will or by the laws of descent and distribution. However, the applicable award agreement or the Compensation Committee may provide that a nonstatutory stock option,
shares of restricted stock or restricted stock units may be transferred by the participant to a family member, so long as such transfer is without payment of any consideration. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=60,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=809335,FOLIO='57',FILE='DISK109:[18ZAG1.18ZAG13701]DS13701A.;12',USER='CHE109572',CD='20-APR-2018;12:24' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_du13701_1_58"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change in Control  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the applicable provisions of the award agreement, in the event of a change of control of the Company after the effective date of the
2007 Plan, the Compensation Committee generally shall have the discretion to provide for any or all of the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the acceleration, in whole or in part, of any or all outstanding options that are not exercisable in full at the time of the change of control; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the lapse or termination of the risk of forfeiture with respect to outstanding awards of restricted stock and restricted stock units; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the assumption of outstanding options or restricted stock units, or the substitution of outstanding options or restricted stock units with
equivalent options or restricted stock units, as the case may be, by the acquiring or succeeding corporation or entity; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the termination of all options and restricted stock units (other than those assumed or substituted for), which termination may or may not be in
exchange for some payment or other consideration, as determined in the sole discretion of the Compensation Committee. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adjustments  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any change in the outstanding shares by reason of merger, consolidation, sale of all or substantially all of the property of the
Company, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split, or other distribution with respect to such outstanding shares, an appropriate and
proportionate adjustment will be made in (i)&nbsp;the maximum number and kinds of shares that may be issued under the 2007 Plan, (ii)&nbsp;the numbers and kinds of shares or other securities
subject to the then outstanding awards; (iii)&nbsp;the exercise price for each share or other unit of any other securities subject to then outstanding options; and (iv)&nbsp;the repurchase price
of each share of restricted stock then subject to a risk of forfeiture in the form of a Company repurchase right. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Termination of Amendments to the 2007 Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board may at any time terminate or make such amendments or modifications of the 2007 Plan as it shall deem advisable; provided, however,
that no such amendment or modification shall be made without the consent of a participant if such change would:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reduce the number of shares subject to an award, increase the purchase price applicable to shares subject to such award or materially adversely
affect the provisions applicable to such award that relate to the vesting or exercisability of such award or the shares subject thereto; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> result in an incentive stock option no longer being treated as such within the meaning of Section&nbsp;422 of the Code; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> not apply to all other awards outstanding on the date of such amendment or modification. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Federal Income Tax Consequences Relating to Awards Under the 2007 Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The current United States federal income tax treatment of awards under the 2007 Plan is generally described below. This description of tax
consequences is not a complete description. There may be different income tax consequences under certain circumstances, and there may be gift and estate tax consequences. Local, state and other taxing
authorities may also tax awards under the plan. Tax laws are subject to change. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Incentive Stock Options  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There generally are no federal income tax consequences to a participant or to the Company upon the grant of an incentive stock option. A
participant will not recognize income for purposes of the regular federal income tax upon the exercise of an incentive stock option. However, for purposes of the alternative minimum tax, in the year
in which a participant exercises an incentive stock option the amount by which </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=61,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=3231,FOLIO='58',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<A NAME="page_du13701_1_59"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>the
fair market value of the shares acquired upon exercise exceeds the exercise price will be included in a participant's alternative minimum taxable income. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
participant will recognize income when he or she sells stock acquired upon exercise of an incentive stock option. If a participant disposes of the shares acquired upon exercise of an
incentive stock option after two years from the date the option was granted and one year from the date the shares were transferred upon the exercise of the option, a participant will recognize
long-term capital gain or loss in the amount of the difference between the amount realized on the sale and the exercise price. The Company will not be entitled to any corresponding tax deduction. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a participant disposes of shares acquired upon the exercise of an incentive stock option before satisfying both holding period requirements (a "disqualifying disposition"), a
participant's gain recognized on the disposition will be taxed as ordinary income to the extent of the difference between the fair market value of the shares on the date of exercise (or the amount
realized on the disposition, if less) and the exercise price. The Company will generally be entitled to a deduction in that amount. The gain, if any, in excess of the amount recognized as ordinary
income will be long-term or short-term capital gain, depending upon the length of time the participant held the shares before the disposition. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nonqualified Stock Options  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are generally no federal income tax consequences to a participant or to the Company upon the grant of a nonqualified stock option. Upon
the exercise of a nonqualified stock option, a participant will recognize ordinary income in an amount equal to the excess of the fair market value of the shares at the time of exercise over the
aggregate exercise price paid. The Company generally will be entitled to a corresponding federal income tax deduction. The participant will have a tax basis in the shares equal to the exercise price
plus the amount of income recognized at the time of exercise. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
a participant sells shares of stock acquired through the exercise of a nonqualified stock option, the participant will have a capital gain or loss in an amount equal to the
difference between the amount realized on the sale and the tax basis in the shares. The capital gain tax rate will depend on a number of factors, including the length of time the participant held the
shares prior to selling them. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Stock  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A participant will generally not recognize federal taxable income when he or she receives a grant of restricted stock, and the Company will not
be entitled to a deduction, until the stock is transferable by the participant or is otherwise no longer subject to a substantial risk of forfeiture. When the stock is either transferable or is no
longer subject to a substantial risk of forfeiture, a participant will recognize ordinary income in an amount equal to the fair market value of the shares at that time (less any amounts paid for the
shares), and generally, the Company will be entitled to a deduction in the same amount. Any gain or loss recognized by the participant upon a later disposition of the shares will be capital gain or
loss. A participant's holding period for purposes of determining whether that capital gain or loss is long-term or short-term will be counted from the date the stock became transferable or ceased to
be subject to a substantial risk of forfeiture. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
participant may elect to recognize ordinary income in the year when the share award is granted in an amount equal to the fair market value of the shares subject to the award (less any
amounts paid for such shares) at the time of grant, determined without regard to any restrictions. This election is referred to as a Section&nbsp;83(b) election. In that event, the Company will be
entitled to a corresponding deduction in the same year. Any gain or loss recognized by the participant upon a later disposition of the shares will be capital gain or loss. A participant's holding
period for purposes of determining whether that capital gain or loss is long-term or short-term will be counted from the date of the original transfer to the participant. The participant may not claim
a credit for any tax previously paid on stock that is later forfeited. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=62,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1029650,FOLIO='59',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<A NAME="page_du13701_1_60"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Stock Units  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a participant is granted a restricted stock unit, he or she will not be required to recognize any taxable income at the time of grant. Upon
distribution of shares or cash in respect of a restricted stock unit, the fair market value of those shares or the amount of that cash will be taxable to the participant as ordinary income and the
Company will receive a deduction equal to the income recognized by the participant. The subsequent disposition of shares acquired pursuant to a restricted stock unit will result in capital gain or
loss (based on the difference between the price received on disposition and the market value of the shares at the time of their distribution). The capital gain tax
rate will depend on a number of factors, including the length of time the participant held the shares prior to selling them. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Performance Awards  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a Performance Award is settled by the issuance of unrestricted shares of our Common Stock, the participant receiving the shares will
recognize ordinary income equal to the value of the shares at the time of issuance and the Company will be entitled to a congruent deduction. Those shares will then have a tax basis equal to their
fair market value on the date of issuance, and the holding period of those shares will commence on that date for purposes of determining whether a subsequent disposition of the shares will result in
long-term or short-term capital gain or loss. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a Performance Award is settled by the issuance of another type of award under the 2007 Plan, the tax consequences of that other award will be the same as described above with respect
to the relevant type of award. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Section&nbsp;162(m) of the Internal Revenue Code  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;162(m) of the Code limits the federal income tax deductions a publicly held company can claim for compensation in excess of
$1,000,000 paid to certain executive officers (generally, the officers who are "named executive officers" in the summary compensation table in the issuer's proxy statement). With respect to grants
made prior to November&nbsp;2, 2017, "qualified performance-based compensation" was not counted against the $1,000,000 deductibility limit. Under the 2007 Plan, options, granted prior to this date,
with an exercise price at least equal to 100% of the fair market value of the underlying shares at the date of grant may satisfy the requirements for treatment as "qualified performance-based
compensation." In addition, Performance Awards, granted prior to this date, that are conditioned upon achievement of certain Performance Goals may satisfy the requirements for treatment as "qualified
performance-based compensation." Following the enactment of the Tax Cuts and Jobs Act, beginning with the 2018 calendar year, the $1,000,000 annual deduction limitation under Section&nbsp;162(m)
applies to all compensation paid to these executive officers with no exception for qualified performance-based compensation. Accordingly, our ability to actually receive a corresponding deduction for
the equity awards described above, may be limited by this new tax law. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


New Plan Benefits  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the 2007 Plan is approved by stockholders, awards under the 2007 Plan will be determined by the Compensation Committee in its discretion, and
it is, therefore, not possible to predict the number, name or positions of persons who will benefit from the 2007 Plan, if it is approved by stockholders, or the terms of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=3,SEQ=63,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=350278,FOLIO='60',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<A NAME="page_du13701_1_61"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>any
such benefits. However, the following table sets forth information with respect to awards granted under the Existing Plan during the 2017 fiscal year. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Stock<BR>
Units(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>282,485</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>406,504</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84,745</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>121,949</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>103,578</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>149,049</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>101,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,169,010</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>967,537</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Non-executive director group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>113,652</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,698</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-executive officer employee group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,779,524</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>459,761</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Includes
RSUs and PRSUs at target level for TSR and 200% for pipeline goal  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
accordance with SEC rules, the following table lists all options granted to the individuals and groups indicated below since the adoption of the 2007 Plan. The option awards listed
below for the covered executives and directors include the option awards listed in the executive and director compensation tables beginning on page&nbsp;36 and&nbsp;45, respectively, of this proxy
statement and are not additional awards. As of April&nbsp;2, 2018, the closing price of a share of our Common Stock on was $14.16 per share. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Persons or Groups of Persons

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>2,787,151</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman Chief Executive Officer</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>972,745</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>1,192,078</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>615,621</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ellen S. Rosenberg</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>220,621</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 General Counsel and Corporate Secretary</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All current executive officers as a group</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>6,747,831</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 All current directors who are not executive officers as a group</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Each nominee for election as a director</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Each associate of any such director, executive officer or nominees</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Each other person who received or is to receive 5% of such options, warrants or rights</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 All employees, including all current officers who are not executive officers as a group</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>11,337,418</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of a majority of shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter
is required to approve the 2007 Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=64,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=902745,FOLIO='61',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<A NAME="page_du13701_1_62"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Securities Authorized for Issuance under our Equity Compensation Plans  </I></B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="106pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="107pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Plan category


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
to be issued upon<BR>
exercise of outstanding<BR>
options (a) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-average<BR>
exercise price of<BR>
outstanding options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
remaining available for<BR>
future issuance under<BR>
equity compensation<BR>
plans (excluding<BR>
securities reflected in<BR>
column (a))(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans approved by security holders(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,181,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,648,405</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans not approved by security holders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,181,105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,648,405 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Includes
awards granted under the Company's 2002 Plan, the Existing Plan and the 2007 Director Option Plan (the "2007 Director Plan"). As of December&nbsp;31,
2015, no shares were reserved for issuance under the 2002 Plan. The number of shares available for issuance under the 2007 Director Plan is increased annually on January&nbsp;1 of each year by
100,000 shares provided that the Board may waive the annual increase in shares available for issuance.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Of
the total presented there are no shares available for issuance as restricted stock, restricted stock units or stock grants.  </FONT></DD></DL>
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clawback Policy  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As described above, the Board has adopted a Clawback Policy which allows the Board to recoup bonus and equity awards made to executives in the
event of misconduct leading to a restatement and other misconduct. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="du13701_proposal_no._4_#151;independen__pro02256"> </A>
<A NAME="toc_du13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 4&#151;INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit and Compliance Committee has appointed Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, to audit our
financial statements for the fiscal year ending December&nbsp;31, 2018. The Board proposes that the stockholders ratify this appointment. Ernst&nbsp;&amp; Young&nbsp;LLP audited our financial
statements for the fiscal year ended December&nbsp;31, 2017. We expect that representatives of Ernst&nbsp;&amp; Young&nbsp;LLP will be present at the meeting, will be able to make a statement if
they so desire, and will be available to respond to appropriate questions. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>The Board recommends the vote "FOR" to ratify the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent
registered public accounting firm, and proxies solicited by the Board will be voted in favor of such ratification unless a stockholder indicates otherwise on the proxy.</B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fees for Audit Services  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents fees for professional audit services rendered by Ernst&nbsp;&amp; Young&nbsp;LLP for the audit of our annual
financial statements for the years ended December&nbsp;31, 2017 and 2016, and fees billed for other services rendered by Ernst&nbsp;&amp; Young&nbsp;LLP during those periods. All of such fees were
approved by the Audit and Compliance Committee. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,956,979</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,578,983</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,435</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,060,072</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,597,983 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=65,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=27841,FOLIO='62',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<A NAME="page_du13701_1_63"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fees
for audit services included fees associated with the annual financial statement audit, an audit of our internal controls over financial reporting and reviews of the quarterly
reports on Form&nbsp;10-Q for both 2017 and 2016. In 2017, the audit fees also included costs of $80,000 associated with the review of our Prospectus Supplement for an equity financing and statutory
audits. Fees for tax services in 2017 included fees associated with certain permitted compliance and advisory services. In 2016, audit fees also included fees related to related to audit work for the
financing transactions for the "At the Market" equity offering commenced in February 2016 and the convertible debt financing completed in December 2016 and $16,500 related to consents required for SEC
filings. All other fees in 2017 and 2016 included the subscription fees paid for access to the Ernst&nbsp;&amp; Young&nbsp;LLP on line Accounting&nbsp;&amp; Auditing Research Tool and in 2017, fees
related to a compliance assessment project. There were no audit-related fees in 2017 and 2016. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Audit and Compliance Committee Pre-Approval of Audit and Permissible Non-audit Services of
Independent Registered Public Accounting Firm  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with SEC policies regarding auditor independence, the Audit and Compliance Committee has responsibility for appointing, setting
compensation and overseeing the work of the independent registered public accounting firm. In recognition of this responsibility, the Audit and Compliance Committee has established a policy to
pre-approve all audit and permissible non-audit services provided by the independent registered public accounting firm. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to engagement of the independent registered public accounting firm for the next year's audit, management will submit an aggregate estimate of services expected to be rendered
during that year for each of four categories of services to the Audit and Compliance Committee for approval.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Audit</I></FONT><FONT SIZE=2> services include audit work performed in the preparation of financial statements, as well as work that only the
independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial accounting
and/or reporting standards.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Audit-Related</I></FONT><FONT SIZE=2> services are for assurance and related services that are traditionally performed by the independent
registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Tax</I></FONT><FONT SIZE=2> services include all services performed by the independent registered public accounting firm's tax personnel
except those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning, and tax advice.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Other Fees</I></FONT><FONT SIZE=2> are those associated with services not captured in the other categories. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to engagement, the Audit and Compliance Committee pre-approves these services by category of service. The fees are budgeted and the Audit and Compliance Committee requires the
independent registered public accounting firm and management to report actual fees versus the budget periodically throughout the year by category of service. During the year, circumstances may arise
when it may become necessary to engage the independent registered public accounting firm for additional services not contemplated in the original pre-approval. In those instances, the Audit and
Compliance Committee requires specific pre-approval before engaging the independent registered public accounting firm. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit and Compliance Committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational
purposes only, any pre-approval decisions to the Audit and Compliance Committee at its next scheduled meeting. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event the stockholders do not ratify the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm, the Audit and Compliance Committee
will reconsider its appointment. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
affirmative vote of a majority of the shares voted affirmatively or negatively on the matter at the Annual Meeting is required to ratify the appointment of the independent registered
public accounting firm. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=66,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=304612,FOLIO='63',FILE='DISK109:[18ZAG1.18ZAG13701]DU13701A.;12',USER='MKEANE',CD='12-APR-2018;21:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dw13701_1_64"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw13701_report_of_audit_and_compliance_committee"> </A>
<A NAME="toc_dw13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF AUDIT AND COMPLIANCE COMMITTEE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit and Compliance Committee of the Board, which currently consists entirely of directors who meet the independence and experience
requirements of the rules and regulations of NASDAQ and the Exchange Act, has furnished the following report. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit and Compliance Committee assists the Board in overseeing and monitoring the integrity of our financial reporting process, compliance with legal and regulatory requirements and
the quality of internal and external audit processes. This Committee reviews and reassesses our charter annually and recommends any changes to the Board for approval. The Audit and Compliance
Committee is responsible for overseeing our financial reporting process on behalf of the Board, and for the appointment, compensation, retention, and oversight of the work of Ernst&nbsp;&amp;
Young&nbsp;LLP. In fulfilling its responsibilities for the financial statements for fiscal year 2017, the Audit and Compliance Committee took the following
actions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Reviewed and discussed the audited financial statements for the fiscal year ended 2017 with management and Ernst&nbsp;&amp; Young&nbsp;LLP, our
independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Discussed with Ernst&nbsp;&amp; Young&nbsp;LLP the matters required to be discussed by PCAOB Auditing Standard No.16, Communications with Audit
and Compliance Committees; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Received written disclosures and the letter from Ernst&nbsp;&amp; Young&nbsp;LLP regarding its communications with the Audit and Compliance
Committee concerning independence as required by Rule&nbsp;3526 of the PCAOB (Communications with Audit and Compliance Committees Concerning Independence). The Audit and Compliance Committee further
discussed Ernst&nbsp;&amp; Young's independence with Ernst&nbsp;&amp; Young&nbsp;LLP. The Audit and Compliance Committee also considered the status of pending litigation, taxation matters and other
areas of oversight relating to the financial reporting and audit process that the Committee determined appropriate. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the Audit and Compliance Committee's review of the audited financial statements, discussions with management and Ernst&nbsp;&amp; Young&nbsp;LLP and written disclosures and the
letter from Ernst&nbsp;&amp; Young&nbsp;LLP regarding its communications with the Audit and Compliance Committee concerning independence as required by applicable requirements of the Public Company
Accounting Oversight Board, the Audit and Compliance Committee recommended to the Board that the audited financial statements be included in our Annual Report on Form&nbsp;10-K for the fiscal year
ended December&nbsp;31, 2017, as amended, for filing with the SEC. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Members
of the Amicus Therapeutics,&nbsp;Inc.<BR>
Audit and Compliance Committee </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Glenn
P. Sblendorio, Chair<BR>
Robert Essner<BR>
Michael G. Raab </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act or the Exchange Act that might incorporate this proxy
statement or future filings with the SEC, in whole or in part, the above report shall not be deemed to be "soliciting material" or "filed" with the SEC and shall not be deemed to be incorporated by
reference into any such filing.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=67,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=395581,FOLIO='64',FILE='DISK109:[18ZAG1.18ZAG13701]DW13701A.;5',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dw13701_1_65"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw13701_proposal_no._5_#151;ad__dw102143"> </A>
<A NAME="toc_dw13701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 5&#151;ADVISORY VOTE ON EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are providing our stockholders the opportunity to vote to approve, on an advisory, non-binding basis, the compensation of our named executive
officers as disclosed in this proxy statement in accordance with the SEC's rules. This proposal, which is commonly referred to as "say-on-pay," is required by the Dodd-Frank Wall Street Reform and
Consumer Protection Act of 2010, which added Section&nbsp;14A to the Exchange Act. Section&nbsp;14A of the Exchange Act also requires that stockholders have the opportunity to cast an advisory
vote with respect to whether future executive compensation advisory votes will be held every one, two or three years. In accordance with the results of this advisory vote at the 2017 Annual Meeting,
the Company's Board determined that the Company will hold an advisory vote on the compensation of the Company's named executive officers every year. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
executive compensation program for our executive officers is designed to attract, motivate, and retain individuals of superior ability and managerial talent who can successfully
perform and succeed in our environment. Our named executive officers are rewarded for the achievement of our near-term and longer-term financial and strategic goals and for driving corporate
performance. This program contains elements of cash and equity-based compensation designed to align the interests of our executives with those of our stockholders as well as have the appropriate
incentive to achieve key strategic and financial performance measures by linking compensation opportunities and actual compensation earned through our pay-for-performance compensation program to the
achievement of corporate goals. We also make equity grants designed to align our named executive officers' compensation to the long-term performance of Amicus in addition to creating an ownership
culture that helps unify the interests of our executives and stockholders. The Company generally targets aggregate total direct compensation for the named executive officers as a group to
approximately the 50th&nbsp;percentile of our peer group at target performance levels in setting our executive compensation programs. Our Board and the Compensation Committee regularly review the
compensation programs for our named executive officers and undertake a comprehensive annual review to ensure that our compensation policies and programs align with current market practices and the
interests of our stockholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
"Compensation Discussion and Analysis" section of this proxy statement describes in detail our executive compensation program and the decisions made by the Compensation Committee
with respect to the fiscal year ended December&nbsp;31, 2017. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2017, the Company made significant progress towards the goal of becoming a leading orphan and rare disease company with global commercial operations and a diversified product
pipeline. The Company successfully continued its geographic expansion of Galafold (migalastat), exceeding its goal of 300 patients on therapy by end 2017. It also submitted registration packages for
migalastat to US FDA and Japan PDMA. The company also established definitive proof of concept for ATB200/AT2221 for Pompe disease and released a cascade of positive data from the Phase
<SUP>1</SUP>/<SMALL>2</SMALL> clinical trial throughout 2017 and successfully scaled biologics manufacturing from the 250L to 1000L scale, reaching agreement with FDA on comparability between the 250L and 1000L
engineering batches. The company further strengthened the balance sheet with the completion of a $258&nbsp;million follow-on equity offering, while carefully managing expenses. These actions have
provided us with more than 18&nbsp;months of cash runway at the beginning of 2018. We believe that our compensation plan appropriately rewards our executive officers for the exceptional progress
achieved in 2017 and the performance against our corporate goals, and aligns their long term incentives with shareholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board is therefore asking stockholders to approve, on an advisory basis, the following resolution: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>"RESOLVED,
that the compensation paid to the named executive officers of Amicus Therapeutics, as disclosed pursuant to the compensation disclosure rules of the SEC, including the compensation
discussion and analysis, the compensation tables and any related material disclosed in this proxy statement, is hereby approved." </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=68,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=407251,FOLIO='65',FILE='DISK109:[18ZAG1.18ZAG13701]DW13701A.;5',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<A NAME="page_dw13701_1_66"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an advisory vote, this proposal is not binding. The outcome of this advisory vote will not overrule any decision by us or our Board (or any committee thereof), create or imply any
change to our fiduciary duties or those of our Board (or any committee thereof), or create or imply any additional fiduciary duties for us or our Board (or any committee thereof). However, our
Compensation Committee and Board value the opinions expressed by our stockholders in their vote on this proposal and will consider the outcome of the vote when making future compensation decisions for
named executive officers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw13701_other_matters"> </A>
<A NAME="toc_dw13701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board knows of no other business which will be presented to the 2018 Annual Meeting. If any other business is properly brought before the
2018 Annual Meeting, proxies in the enclosed form will be voted in accordance with the judgment of the individuals named as proxies on the proxy card. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw13701_stockholder_proposals_and_nominations_for_director"> </A>
<A NAME="toc_dw13701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you wish to submit a proposal to be considered for inclusion in next year's proxy materials or nominate a director, your proposal must be in
proper form according to SEC Regulation&nbsp;14A, Rule&nbsp;14a-8 and received by the Secretary of the Company no later than December&nbsp;28, 2018. Proposals received after that date will not
be included in the proxy materials we send out in connection with the 2019 Annual Meeting of Stockholders. If a proposal is received before that date, the proxies that management solicits for the
meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. To be timely in accordance with our Restated By-laws,
stockholder notice of any such proposal must be received by us not earlier than November&nbsp;28, 2018 and not later than December&nbsp;28, 2018; provided, however, that in the event that the date
of the 2019 Annual Meeting of Stockholders is more than 30&nbsp;days before or more than 60&nbsp;days after the anniversary date of the 2018 Annual Meeting of Stockholders, notice by the
stockholder to be timely must be delivered not earlier than the close of business on the 90th&nbsp;day prior to such 2019 Annual Meeting of Stockholders and not later than the close of business on
the later of the 60th&nbsp;day prior to such 2019 Annual Meeting of Stockholders or the 10th&nbsp;day following the day on which we make a public announcement of the date of the 2019 Annual
Meeting of Stockholders. All stockholder proposals should be marked for the attention of General Counsel and Corporate Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury,
New&nbsp;Jersey 08512. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2017 (other than the exhibits thereto), filed with the SEC, which provides additional information
about us, is available on the Internet at </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> and is available in paper form to beneficial owners of our Common Stock without charge upon
written request to Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw13701_delivery_of_proxy_materials"> </A>
<A NAME="toc_dw13701_5"> </A>
<BR></FONT><FONT SIZE=2><B>  DELIVERY OF PROXY MATERIALS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some banks, brokers, and other nominee record holders may be participating in the practice of "householding" proxy statements and annual
reports. This means that only one copy of this Proxy Statement, the Notice of 2018 Annual Meeting of Stockholders and our Annual Report to Stockholders may have been sent to multiple stockholders in
your household. Householding is designed to reduce duplicate mailings and save significant printing and postage costs. If you receive a household mailing this year and would like to receive additional
copies of this Proxy Statement, the Notice of 2018 Annual Meeting of Stockholders and our Annual Report to Stockholders, please call us at (609)&nbsp;662-2000 or send a written request to General
Counsel and Corporate Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512. If you want to receive separate copies of our Proxy Statement, Notice of our
Annual Meeting of Stockholders and our Annual Report to Stockholders in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should
contact your bank, broker, or other nominee record holder, or you may contact us at the above address and phone number. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=69,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=958115,FOLIO='66',FILE='DISK109:[18ZAG1.18ZAG13701]DW13701A.;5',USER='JTAYLORA',CD='12-APR-2018;15:44' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_la13701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="la13701_annex_a"> </A>
<A NAME="toc_la13701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Annex A    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="la13701_amended_and_restated_amicus_th__ame02604"> </A>
<A NAME="toc_la13701_2"> </A></FONT> <FONT SIZE=2><B>  AMENDED AND RESTATED<BR>  AMICUS THERAPEUTICS,&nbsp;INC.<BR>  2007 EQUITY INCENTIVE PLAN    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpose  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Plan is intended to encourage ownership of Common Stock by employees, consultants and directors of the Company and its Affiliates and to provide additional
incentive for them to promote the success of the Company's business through the grant of Awards of shares of the Company's Common Stock. The Plan is intended to be an incentive stock option plan
within the meaning of Section&nbsp;422 of the Code but not all Awards granted hereunder are required to be Incentive Options. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Definitions  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As used in the Plan the following terms shall have the respective meanings set out below, unless the context clearly requires otherwise: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Accelerate", "Accelerated",</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>"Acceleration"</I></FONT><FONT SIZE=2> , when used with respect
to an Option, means that as of the time of reference such Option will become exercisable with respect to some or all of the shares of Common Stock for which it was not then otherwise exercisable by
its terms, and, when used with respect to Restricted Stock, Restricted Stock Units or Performance Awards, as the case may be, means that the Risk of Forfeiture and/or Performance Goals otherwise
applicable to such Award, as the case may be, shall expire or be satisfied with respect to some or all of the shares of underlying such Award. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Acquiring Person"</I></FONT><FONT SIZE=2> means, with respect to any Transaction or any acquisition described in clause&nbsp;(ii) of the
definition of Change of Control, the surviving or acquiring person or entity in connection with such Transaction or acquisition, as the case may be, provided that if such surviving or acquiring person
or entity is controlled, directly or indirectly, by any other person or entity (an "Ultimate Parent Entity") that is not itself controlled by any entity or person that is not a natural person, the
term "Acquiring Person" shall mean such Ultimate Parent Entity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Affiliate"</I></FONT><FONT SIZE=2> means, with respect to any person or entity, any other person or entity controlling, controlled by or under
common control with the first person or entity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Applicable Voting Control Percentage"</I></FONT><FONT SIZE=2> means (i)&nbsp;at any time prior to the initial public offering of the Company,
a percentage greater than fifty percent (50%) and (ii)&nbsp;at any time from and after the initial public offering of the Company, twenty percent (20%). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Award"</I></FONT><FONT SIZE=2> means any grant or sale pursuant to the Plan of Options, Restricted Stock, Restricted Stock Units, Stock Grants
or Performance Awards. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Award Agreement"</I></FONT><FONT SIZE=2> means an agreement between the Company and the recipient of an Award, setting forth the terms and
conditions of the Award. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Beneficial Ownership"</I></FONT><FONT SIZE=2> has the meaning ascribed to such term in Rule&nbsp;13d-3, or any successor rule thereto,
promulgated by the Securities and Exchange Commission pursuant to the Exchange Act. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Board"</I></FONT><FONT SIZE=2> means the Company's board of directors. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>"Change of Control"</I></FONT><FONT SIZE=2> means (i)&nbsp;the closing of any Sale of the Company Transaction or (ii)&nbsp;the direct or
indirect acquisition, in a single transaction or a series of related transactions, by any person or Group (other than the Company or a Controlled Affiliate of the Company) of Beneficial Ownership of
previously outstanding shares of capital stock of the Company if (A)&nbsp;immediately after </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=70,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=194590,FOLIO='A-1',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_2"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>such
acquisition, such person or Group, together with their respective Affiliates, shall own or hold shares of capital stock of the Company possessing at least the Applicable Voting Control Percentage
of the total voting power of the outstanding A-1 capital stock of the Company and (B)&nbsp;immediately prior to such acquisition, such person or Group, together with their respective Affiliates, did
not own or hold shares of capital stock of the Company possessing at least the Applicable Voting Control Percentage of the total voting power of the outstanding capital stock of the Company.
Notwithstanding anything expressed or implied in the foregoing provisions of this definition to the contrary, any direct or indirect acquisition referred to in clause&nbsp;(ii) above in this
definition shall not be treated as a Change of Control if, at any time prior to or after such direct or indirect acquisition, a majority of the members of the board of directors of the Company as
constituted immediately prior to such direct or indirect acquisition consent in writing to exclude such direct or indirect acquisition from the scope of this definition. Notwithstanding the foregoing,
with respect to any Award issued under the Plan, which is subject to Section&nbsp;409A of the Code, no event shall set forth above shall be deemed to be a Change of Control, unless such event would
also be considered a "change in ownership or effective control of a corporation or in the ownership of a substantial portion of the assets of a corporation" under Section&nbsp;409A(a)(2)(A)(v) of
the Code and the regulations thereunder. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10&nbsp;</FONT><FONT
SIZE=2><I>"Code"</I></FONT><FONT SIZE=2> means the Internal Revenue Code of 1986, as amended from time to time, or any successor statute thereto, and any
regulations issued from time to time thereunder. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11&nbsp;</FONT><FONT
SIZE=2><I>"Controlled Affiliate"</I></FONT><FONT SIZE=2> means, with respect to any person or entity, any other person or entity that is controlled by
such person or entity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12&nbsp;</FONT><FONT
SIZE=2><I>"Committee"</I></FONT><FONT SIZE=2> means any committee of the Board delegated responsibility by the Board for the administration of the Plan,
as provided in Section&nbsp;5 of the Plan. For any period during which no such committee is in existence, the term "</FONT><FONT SIZE=2><I>Committee</I></FONT><FONT SIZE=2> "shall mean the Board
and all authority and responsibility assigned the Committee under the Plan shall be exercised, if at all, by the Board. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.13&nbsp;</FONT><FONT
SIZE=2><I>"Common Stock"</I></FONT><FONT SIZE=2> means common stock, par value $0.01 per share, of the Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.14&nbsp;</FONT><FONT
SIZE=2><I>"Company"</I></FONT><FONT SIZE=2> means Amicus Therapeutics,&nbsp;Inc., a corporation organized under the laws of the State of Delaware. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.15&nbsp;</FONT><FONT
SIZE=2><I>"Exchange Act"</I></FONT><FONT SIZE=2> means the Securities Exchange Act of 1934, as amended. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.16&nbsp;</FONT><FONT
SIZE=2><I>"Grant Date"</I></FONT><FONT SIZE=2> means the date as of which an Option is granted, as determined under Section&nbsp;7.1(a). </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.17&nbsp;</FONT><FONT
SIZE=2><I>"Group"</I></FONT><FONT SIZE=2> has the meaning ascribed to such term in Section&nbsp;13(d)(3) of the Exchange Act or any successor section
thereto. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.18&nbsp;</FONT><FONT
SIZE=2><I>"Incentive Option"</I></FONT><FONT SIZE=2> means an Option which by its terms is to be treated as an "incentive stock option" within the meaning
of Section&nbsp;422 of the Code. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.19&nbsp;</FONT><FONT
SIZE=2><I>"Market Value"</I></FONT><FONT SIZE=2> means the value of a share of Common Stock on a particular date determined by such methods or procedures
as may be established by the Committee. Unless otherwise determined by the Committee, the Market Value of Common Stock as of any date is the closing price for the Common Stock as reported on the
NASDAQ Global market (or on any other national securities exchange on which the Common Stock is then listed) for that date or, if no closing price is reported for that date, the closing price on the
next preceding date for which a closing price was reported. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.20&nbsp;</FONT><FONT
SIZE=2><I>"Nonstatutory Option"</I></FONT><FONT SIZE=2> means any Option that is not an Incentive Option. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.21&nbsp;</FONT><FONT
SIZE=2><I>"Option"</I></FONT><FONT SIZE=2> means an option granted under the Plan to purchase shares of Common Stock. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=71,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=357616,FOLIO='A-2',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_3"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.22&nbsp;</FONT><FONT
SIZE=2><I>"Optionee"</I></FONT><FONT SIZE=2> means an employee, consultant or director of the Company to whom an Option shall have been initially granted
under the Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.23&nbsp;</FONT><FONT
SIZE=2><I>"Participant"</I></FONT><FONT SIZE=2> means any holder of an outstanding Award under the Plan. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.24&nbsp;"</FONT><FONT
SIZE=2><I>Performance Award</I></FONT><FONT SIZE=2>" means shares of Common Stock or other Awards that, pursuant to Section&nbsp;7.5 are granted,
vested and/or settled upon the achievement of specified performance conditions </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.25&nbsp;"</FONT><FONT
SIZE=2><I>Performance Goals</I></FONT><FONT SIZE=2>" means any goals established by the Committee in its sole discretion, the attainment of which is
substantially uncertain at the time such goals are established. Performance Goals may be described in terms of Company-wide objectives or objectives that are related to the performance of the
individual Participant or any subsidiary, division, department or function within the Company or any subsidiary in which the Participant is employed. Performance Goals may be measured on an absolute
or relative basis. Relative performance may be measured by a group of peer companies or by a financial market index. Performance Goals may be based upon: cash flow; earnings (including gross margin,
earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation, amortization and charges for stock-based compensation, earnings before interest, taxes,
depreciation and amortization, and net earnings); earnings per share; growth in earnings or earnings per share; stock price; return on equity or average stockholder equity; total stockholder return or
growth in total stockholder return either directly or in relation to a comparative group; return on capital; return on assets or net assets; revenue, growth in revenue or return on sales; income or
net income; operating income, net operating income or net operating income after tax; operating profit or net operating profit; operating margin; return on operating revenue or return on operating
profit; regulatory filings; regulatory approvals, litigation and regulatory resolution goals; other operational, regulatory or departmental objectives; budget comparisons; growth in stockholder value
relative to established indexes, or another peer group or peer group index; development and implementation of strategic plans and/or organizational restructuring goals; development and implementation
of risk and crisis management programs; improvement in workforce diversity; compliance requirements and compliance relief; safety goals; productivity goals; workforce management and succession
planning goals; economic value added (including typical adjustments consistently applied from generally accepted accounting principles required to determine economic value added performance measures);
measures of customer satisfaction, employee satisfaction or staff development; development or marketing collaborations, formations of joint ventures or partnerships or the completion of other similar
transactions intended to enhance the Company's revenue or profitability or enhance its customer base; and merger and acquisitions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.26&nbsp;"Performance
Period" means the period selected by the Committee during which the performance of the Company, any subsidiary, any department or division of the Company
or any subsidiary, or any
individual is measured for the purpose of determining the extent to which a Performance Goal has been achieved. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.27&nbsp;</FONT><FONT
SIZE=2><I>"Plan"</I></FONT><FONT SIZE=2> means this 2007 Amended and Restated Equity Incentive Plan of the Company, as amended and in effect from time to
time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.28&nbsp;</FONT><FONT
SIZE=2><I>"Restricted Stock"</I></FONT><FONT SIZE=2> means a grant or sale pursuant to the Plan of shares of Common Stock to a Participant subject to a
Risk of Forfeiture. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.29&nbsp;</FONT><FONT
SIZE=2><I>"Restricted Stock Units"</I></FONT><FONT SIZE=2> means rights granted pursuant to the Plan to receive shares of Common Stock at the close of a
Restriction Period, subject to a Risk of Forfeiture. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.30&nbsp;</FONT><FONT
SIZE=2><I>"Restriction Period"</I></FONT><FONT SIZE=2> means the period of time, established by the Committee in connection with an Award of Restricted
Stock or Restricted Stock Units, during which the shares of Restricted Stock or Restricted Stock Units are subject to a Risk of Forfeiture described in the applicable Award Agreement. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=72,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=580428,FOLIO='A-3',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_4"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.31&nbsp;</FONT><FONT
SIZE=2><I>"Risk of Forfeiture"</I></FONT><FONT SIZE=2> means a limitation on the right of a Participant to retain an Award of Restricted Stock or
Restricted Stock Units, including subjecting such Award to a Performance Goals and/or a right in the Company to reacquire such Restricted Stock at less than its then Market Value and/or the forfeiture
of Restricted Stock Units held by a Participant, arising because of the occurrence or non-occurrence of specified events or conditions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.32&nbsp;</FONT><FONT
SIZE=2><I>"Sale of the Company Transaction"</I></FONT><FONT SIZE=2> means any Transaction in which the stockholders of the Company immediately prior to
such Transaction, together with any and all of such stockholders' Affiliates, do not own or hold, immediately after consummation of such Transaction, shares of capital stock of the Acquiring Person in
connection with such Transaction possessing at least a majority of the total voting power of the outstanding capital stock of such Acquiring Person. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.33&nbsp;</FONT><FONT
SIZE=2><I>"Securities Act"</I></FONT><FONT SIZE=2> means the Securities Act of 1933, as amended. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.34&nbsp;</FONT><FONT
SIZE=2><I>"Stock Grant"</I></FONT><FONT SIZE=2> means the grant pursuant to the Plan of shares of Common Stock not subject to restrictions or other
forfeiture conditions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.35&nbsp;</FONT><FONT
SIZE=2><I>"Ten Percent Owner"</I></FONT><FONT SIZE=2> means a person who owns, or is deemed within the meaning of Section&nbsp;422(b)(6) of the Code to
own, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company (or any parent or subsidiary corporations of the Company, as defined in
Section&nbsp;424(e) and (f), respectively, of the Code). Whether a person is a Ten Percent Owner shall be determined with respect to each Option based on the facts existing immediately prior to the
Grant Date of such Option. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.36&nbsp;</FONT><FONT
SIZE=2><I>"Transaction"</I></FONT><FONT SIZE=2> means any merger or consolidation of the Company with or into another person or entity or the sale or
transfer of all or substantially all of the assets of the Company, in each case in a single transaction or in a series of related transactions. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term of the Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless the Plan shall have been earlier terminated by the Board, Awards may be granted under this Plan at any time in the period commencing on the Effective Date
of approval of the Amended and restated version of the Plan by the Board and ending immediately prior to the tenth anniversary the Effective Date. Awards granted pursuant to the Plan within such
period shall not expire solely by reason of the termination of the Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Subject to the Plan: Limits  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of Section&nbsp;8 of the Plan, at no time shall the number of shares of Common Stock issued pursuant to or subject to outstanding
Awards granted under the Plan (including, without limitation, pursuant to Incentive Options), nor the number of shares of Common Stock issued pursuant to Incentive Options, exceed 20,058,703, with
respect to shares of Common Stock. For purposes of applying the foregoing limitation, if any Option expires, terminates, or is cancelled for any reason without having been exercised in full, or if any
Award of Restricted Stock is forfeited, the shares not purchased by the Participant or forfeited by the Participant shall again be available for Awards thereafter to be granted under the Plan. In the
event the exercise price of an Option or a Participant's withholding obligations is paid through the delivery of shares of Common Stock, the number of shares so tendered shall not again be available
for the grant of Awards under the Plan. Shares of Common Stock issued pursuant to the Plan may be either authorized but unissued shares or shares held by the Company in its treasury. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, not more than 10,058,703 of the total number of shares of Common Stock reserved for issuance under the Plan (as adjusted under Section&nbsp;8) may be granted or sold as
Awards of Restricted Stock, Restricted Stock Units, Stock Grants, and any other similar Awards (including, without limitation, Restricted Stock, Restricted Stock Units, Stock Grants, and any other
similar Awards underlying a Performance Award) ("Full-Value Awards") whose intrinsic value is not solely dependent on appreciation </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=73,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=248434,FOLIO='A-4',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_5"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>in
the price of shares of Common Stock after the date of grant. Options and any other similar Awards shall not be subject to, and shall not count against, the limit described in the preceding
sentence. If a Full-Value Award expires, is forfeited, or otherwise lapses as described in this Section&nbsp;4, the shares of Common Stock that were subject to the Award shall be restored to the
total number of shares of Common Stock available for grant or sale as Full-Value Awards. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
maximum number of shares of Common Stock with respect to which Awards may be granted hereunder to any employee of the Company during any fiscal year of the Company shall be five
million (5,000,000) shares of Common Stock. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administration  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall be administered by the Committee; </FONT><FONT SIZE=2><I>provided, however</I></FONT><FONT SIZE=2> , that at any time and on any one or more
occasions the Board may itself exercise any of the powers and responsibilities assigned the Committee under the Plan and when so acting shall have the benefit of all of the provisions of the Plan
pertaining to the Committee's exercise of its authorities hereunder; </FONT><FONT SIZE=2><I>and provided further</I></FONT><FONT SIZE=2> that the Committee may delegate to an executive officer or
officers the authority to grant Awards hereunder to employees who are not officers, and to consultants, in accordance with such guidelines as the Committee shall set forth at any time or from time to
time. Subject to the provisions of the Plan, the Committee shall have complete authority, in its discretion, to make or to select the manner of making all determinations with respect to each Award to
be granted by the Company under the Plan in addition to any other determination allowed the Committee under the Plan including, without limitation: (a)&nbsp;the employee, consultant or director to
receive the Award; (b)&nbsp;the form of Award; (c)&nbsp;whether an Option (if granted to an employee) will be an Incentive Option or a Nonstatutory Option; (d)&nbsp;the time of granting an
Award; (e)&nbsp;the number of shares subject to an Award; (f)&nbsp;the exercise price of an Option or purchase price, if any, for shares of Restricted Stock or for a Stock Grant and the method of
payment of such exercise price or such purchase price; (g)&nbsp;the term of an Option; (h)&nbsp;the vesting period of shares of Restricted Stock or of Restricted Stock Units and any acceleration
thereof; (i)&nbsp;the exercise date or dates of an Option and any acceleration thereof; (j)&nbsp;the effect of termination of any employment, consulting or Board member relationship with the
Company or any of its Affiliates on the subsequent exercisability of an Option or on the Risk of Forfeiture of Restricted Stock or Restricted Stock Units; (k)&nbsp;whether, and to certify that,
Performance Goals to which an Award is
subject are satisfied; and (l)&nbsp;the terms and conditions of any Award granted under the Plan (including, but not limited to, restrictions as to vesting, transferability or forfeiture,
exercisability or settlement of an Award and waivers or accelerations thereof, and establishment, waivers of or modifications to Performance Goals relating to an Award, based in each case on such
considerations as the Committee shall determine) and all other matters to be determined in connection with an Award. In making such determinations, the Committee may take into account the nature of
the services rendered by the respective employees, consultants and directors, their present and potential contributions to the success of the Company and its Affiliates, and such other factors as the
Committee in its discretion shall deem relevant. Subject to the provisions of the Plan, the Committee shall also have complete authority to interpret the Plan, to prescribe, amend and rescind rules
and regulations relating to it, to determine the terms and provisions of the respective Award Agreements (which need not be identical), and to make all other determinations necessary or advisable for
the administration of the Plan. The Committee's determinations made in good faith on matters referred to in this Plan shall be final, binding and conclusive on all persons having or claiming any
interest under the Plan or an Award made pursuant hereto. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorization and Eligibility  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Committee may grant from time to time and at any time prior to the termination of the Plan one or more Awards, either alone or in combination with any other
Awards, to any employee of or consultant to one or more of the Company and its Affiliates or to any non-employee member of the Board or of any </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=74,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=903068,FOLIO='A-5',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_6"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>board
of directors (or similar governing authority) of any Affiliate. However, only employees of the Company or of any parent or subsidiary corporations of the Company, as defined in
Sections&nbsp;424(e) and (f), respectively, of the Code, shall be eligible for the grant of an Incentive Option. Further, in no event shall the number of shares of Common Stock covered by Options or
other Awards granted to any one person in any one calendar year (or portion of a year) ending after such date exceed fifty percent (50%) of the aggregate number of shares of Common Stock subject to
the Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
grant of an Award shall be subject to all applicable terms and conditions of the Plan (including but not limited to any specific terms and conditions applicable to that type of
Award set out in the following Section), and such other terms and conditions, not inconsistent with the terms of the Plan, as the Committee may prescribe. No prospective Participant shall have any
rights with respect to an Award, unless and until such Participant has executed an agreement evidencing the Award, delivered a fully executed copy thereof to the Company, and otherwise complied with
the applicable terms and conditions of such Award. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specific Terms of Awards  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Date of Grant.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The granting of an Option shall take place at the time specified in the Award Agreement. Only
if expressly so provided in the applicable Award Agreement shall the Grant Date be the date on which the Award Agreement shall have been duly executed and delivered by the Company and the Optionee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercise Price.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The price at which shares of Common Stock may be acquired under each Incentive Option shall
be not less than 100% of the Market Value of Common Stock on the Grant Date, or not less than 110% of the Market Value of Common Stock on the Grant Date if the Optionee is a Ten Percent Owner. The
price at which shares may be acquired under each Nonstatutory Option shall not be so limited solely by reason of this Section. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Option Period.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No Incentive Option or Nonstatutory Option may be exercised on or after the tenth anniversary
of the Grant Date, or on or after the fifth anniversary of the Grant Date if the Optionee is a Ten Percent Owner. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercisability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An Option may be immediately exercisable or become exercisable in such installments,
cumulative or non-cumulative, as the Committee may determine. Any Option may be a Performance Award, subject to Section&nbsp;7.5. In the case of an Option not otherwise immediately exercisable in
full, the Committee may Accelerate such Option in whole or in part at any time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination of Employment, Consulting or Board Member Relationship.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless the Committee shall
provide otherwise with respect to any Option, if the applicable Optionee's association with the Company or any of its Affiliates as an employee, director or consultant ends for any reason or no
reason, regardless of whether the end of such association is effected by the Company, any such Affiliate or such Optionee (whether voluntarily or involuntarily, including because an entity with which
such Optionee has any such association ceases to be an Affiliate of the Company), and immediately following the end of any such association, such Optionee is not associated with the Company or any of
its Affiliates as an employee, director or consultant, or if such Optionee dies, then any outstanding Option initially granted to such Optionee, whether then held by such Optionee or any other
Participant, shall cease to be exercisable in any respect not later than ninety (90)&nbsp;days following the end of such association or such death and, for the period it remains exercisable
following the end of such association or such death, shall be exercisable only to the extent exercisable on the date of the end of
such association or such death. Military or sick leave or other bona fide leave shall not be deemed a termination of employment, provided that it does not exceed </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=75,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=797530,FOLIO='A-6',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_7"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>the
longer of ninety (90)&nbsp;days or the period during which the absent Optionee's reemployment rights, if any, are guaranteed by statute or by contract. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transferability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in this subsection&nbsp;(f), Options shall not be
transferable, and no Option or interest therein may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution
(subject always to the provisions of subsection&nbsp;(e) above). Except as otherwise provided in this subsection&nbsp;(f), all of a Participant's rights in any Option may be exercised during the
life of such Participant only by such Participant or such Participant's legal representative. However, the applicable Award Agreement or the Committee (at or after the grant of a Nonstatutory Option)
may provide that a Nonstatutory Option may be transferred by the applicable Participant to a family member; provided, however, that any such transfer is without payment of any consideration whatsoever
and that no transfer of a Nonstatutory Option shall be valid unless first approved by the Committee, acting in its sole discretion, unless such transfer is permitted under the applicable Award
Agreement. For this purpose, "family member" means any child, stepchild, grandchild, parent, stepparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law,
daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the applicable Participant's household (other than a tenant or employee), a trust in which the
foregoing persons and/or the applicable Participant have more than fifty percent (50%) of the beneficial interests, a foundation in which the foregoing persons and/or the applicable Participant
control the management of assets, and any other entity in which these persons and/or the applicable Participant own more than fifty percent (50%) of the voting interests. The Committee may at any time
or from time to time delegate to one or more officers of the Company the authority to permit transfers of Nonstatutory Options to third parties pursuant to this subsection&nbsp;(f), which
authorization shall be exercised by such officer or officers in accordance with guidelines established by the Committee at any time and from time to time. The restrictions on transferability set forth
in this subsection&nbsp;(f) shall in no way preclude any Participant from effecting "cashless" exercises of an Option pursuant to the terms of the Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Method of Exercise.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An Option may be exercised by a Participant giving written notice, in the manner
provided in Section&nbsp;15, specifying the number of shares of Common Stock with respect to which the Option is then being exercised. The notice shall be accompanied by payment in the form of cash
or check payable to the order of the Company in an amount equal to the exercise price of the shares of Common Stock to be purchased or, subject in each instance to the Committee's approval, acting in
its sole discretion and subject to such conditions, if any, as the Committee may deem necessary to comply with applicable laws, rules and regulations or to avoid adverse accounting effects to the
Company, by
delivery to the Company of shares of Common Stock having a Market Value equal to the exercise price of the shares to be purchased. If the Common Stock is traded on an established market, payment of
any exercise price may also be made through and under the terms and conditions of any formal cashless exercise program authorized by the Company entailing the sale of the Common Stock subject to any
Option in a brokered transaction (other than to the Company). Receipt by the Company of such notice and payment in any authorized or combination of authorized means shall constitute the exercise of
the Option. Within thirty (30)&nbsp;days thereafter but subject to the remaining provisions of the Plan, the Company shall deliver or cause to be delivered to the Participant or his agent a
certificate or certificates for the number of shares then being purchased. Such shares shall be fully paid and nonassessable. Notwithstanding any of the foregoing provisions in this
subsection&nbsp;(g) to the contrary, (A)&nbsp;no Option shall be considered to have been exercised unless and until all of the provisions governing such exercise specified in the Plan and in the
relevant Award Agreement shall have been duly complied with; and (B)&nbsp;the obligation of the Company to issue any shares upon exercise of an Option is subject to the provisions of
Section&nbsp;9.1 hereof and to compliance by the Optionee and the Participant with all of the provisions of the Plan and the relevant Award Agreement. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=76,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=246373,FOLIO='A-7',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<A NAME="page_la13701_1_8"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Limit on Incentive Option Characterization.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An Incentive Option shall be considered to be an Incentive
Option only to the extent that the number of shares of Common Stock for which the Option first becomes exercisable in a calendar year does not have an aggregate Market Value (as of the date of the
grant of the Option) in excess of the "current limit". The current limit for any Optionee for any calendar year shall be $100,000 </FONT><FONT SIZE=2><I>minus</I></FONT><FONT SIZE=2> the aggregate
Market Value at the date of grant of the number of shares of Common Stock available for purchase for the first time in the same year under each other Incentive Option previously granted to the
Optionee under the Plan, and under each other incentive stock option previously granted to the Optionee. Any shares of Common Stock which would cause the foregoing limit to be violated shall be deemed
to have been granted under a separate Nonstatutory Option, otherwise identical in its terms to those of the Incentive Option. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Notification of Disposition.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each person exercising any Incentive Option granted under the Plan shall be
deemed to have covenanted with the Company to report to the Company any disposition of such shares prior to the expiration of the holding periods specified by Section&nbsp;422(a)(1) of the Code and,
if and to the extent that the realization of income in such a disposition imposes upon the Company federal, state, local or other withholding tax requirements, or any such withholding is required to
secure for the Company an otherwise available tax deduction, to remit to the Company an amount in cash sufficient to satisfy those requirements. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights Pending Exercise.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No person holding an Option shall be deemed for any purpose to be a stockholder of
the Company with respect to any of the shares of Common Stock issuable pursuant to such Option, except to the extent that such Option shall have been exercised with respect thereto and, in addition, a
certificate shall have been issued therefor and delivered to such person or his agent. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Purchase Price.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Shares of Restricted Stock shall be issued under the Plan for such consideration, in cash,
other property or services, or any combination thereof, as is determined by the Committee. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to subsection&nbsp;(c) below, each Participant receiving an Award of
Restricted Stock shall be issued a stock certificate in respect of such shares of Restricted Stock. Such certificate shall be registered in the name of such Participant, and, if applicable, shall bear
an appropriate legend referring to the terms, conditions, and restrictions applicable to such Award substantially in the following form: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transferability of this certificate and the shares represented by this certificate are subject to the terms and conditions of the Amicus Therapeutics,&nbsp;Inc. Amended and
Restated 2007 Equity Incentive Plan and an Award Agreement entered into by the registered owner and Amicus Therapeutics,&nbsp;Inc. Copies of such Plan and Agreement are on file in the offices of
Amicus Therapeutics,&nbsp;Inc. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Escrow of Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may require that the stock certificates evidencing shares of Restricted
Stock be held in custody by a designated escrow agent (which may but need not be the Company) until the restrictions thereon shall have lapsed, and that the Participant deliver a stock power, endorsed
in blank, relating to the Common Stock covered by such Award. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Restrictions and Restriction Period.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;During the Restriction Period applicable to shares of Restricted Stock,
such shares shall be subject to limitations on transferability and a Risk of Forfeiture arising on the basis of such conditions related to the performance of services, Company or Affiliate performance
or otherwise as the Committee may determine and provide for in the applicable Award Agreement. Any grant of Restricted Stock may be a Performance Award, subject to Section&nbsp;7.5. Any such Risk of
Forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Committee on such basis as it deems appropriate. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=77,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=980748,FOLIO='A-8',FILE='DISK109:[18ZAG1.18ZAG13701]LA13701A.;10',USER='MKEANE',CD='12-APR-2018;15:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_lc13701_1_9"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights Pending Lapse of Risk of Forfeiture or Forfeiture of Award.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in the Plan
or the applicable Award Agreement, at all times prior to lapse of any Risk of Forfeiture applicable to, or forfeiture of, an Award of Restricted Stock, the Participant shall have all of the rights of
a stockholder of the Company, including the right to vote the shares of Restricted Stock. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination of Employment, Consulting or Board Member Relationship.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise determined by
the Committee at or after grant and subject to the applicable provisions of the Award Agreement, if the applicable original grantee's association with the Company or any of its Affiliates as an
employee, director or consultant ends for any reason or no reason during the Restriction Period, regardless of whether the end of such association is effected by the Company, any such Affiliate or
such original grantee (whether voluntarily or involuntarily, including because an entity with which such original grantee has any such association ceases to be an Affiliate of the Company), and
immediately following the end of any such association, such original grantee is not associated with the Company or any of its Affiliates as an employee, director or consultant, or if such original
grantee dies, then all outstanding shares of Restricted Stock initially granted to such original grantee that are still subject to Risk of Forfeiture, whether then held by such original grantee or any
other Participant, shall be forfeited or otherwise subject to return to or repurchase by the Company if and to the extent so provided by, and subject to and in accordance with, the terms of the
applicable Award Agreement; provided, however, that military or sick leave or other bona fide leave shall not be deemed a termination of employment, if it does not exceed the longer of ninety
(90)&nbsp;days or the period during which the absent original grantee's reemployment rights, if any, are guaranteed by statute or by contract. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Lapse of Restrictions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If and when the Restriction Period expires without a prior forfeiture of the
Restricted Stock, the certificates for such shares shall be delivered to the Participant promptly if not theretofore so delivered. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transferability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in this subsection&nbsp;(h), shares of Restricted Stock
shall not be transferable, and no share of Restricted Stock or interest therein may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws
of descent and distribution (subject always to the provisions of subsection&nbsp;(f) above). The applicable Award Agreement or the Committee (at or after the grant of a share of Restricted Stock)
may provide that such share of Restricted Stock may be transferred by the applicable Participant to a family member; provided, however, that any such transfer is without payment of any consideration
whatsoever and that no transfer of a share of Restricted Stock shall be valid unless first approved by the Committee, acting in its sole discretion, unless such transfer is permitted under the
applicable Award Agreement. For this purpose, "family member" means any child, stepchild, grandchild, parent, stepparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law,
son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the applicable Participant's household (other than a tenant or employee), a trust in
which the foregoing persons and/or the applicable Participant have more than fifty percent (50%) of the beneficial interests, a foundation in which the foregoing persons and/or the applicable
Participant control the management of assets, and any other entity in which these persons and/or the applicable Participant own more than fifty percent (50%) of the voting interests. The Committee may
at any time or from time to time delegate to one or more officers of the Company the authority to permit transfers of shares of Restricted Stock to third parties pursuant to this
subsection&nbsp;(h), which authorization shall be exercised by such officer or officers in accordance with guidelines established by the Committee at any time and from time to time. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=78,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=52485,FOLIO='A-9',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_10"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Units.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Character.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each Restricted Stock Unit shall entitle the recipient to a share of Common Stock at a close of
such Restriction Period as the Committee may establish and subject to a Risk of Forfeiture arising on the basis of such conditions relating to the performance of services, Company or Affiliate
performance or otherwise (including any applicable Performance Goal) as the Committee may determine and provide for in the applicable Award Agreement. Any grant of Restricted Stock Units may be a
Performance Award, subject to Section&nbsp;7.5. Any such Risk of Forfeiture may be waived or terminated, or the Restriction Period shortened, at any time by the Committee on such basis as it deems
appropriate. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise determined by the Committee at or after grant and subject to the
applicable provisions of the Award Agreement, at the close of the Restriction Period applicable
to any Restricted Stock Units (including, without limitation, the close of the applicable Restriction Period as a result of (i)&nbsp;any Acceleration of Restricted Stock Units in accordance with the
terms of this Plan or any applicable Award Agreement, (ii)&nbsp;any waiver, lapse or termination of the Risk of Forfeiture applicable to Restricted Stock Units in accordance with the terms of this
Plan or any applicable Award Agreement or (iii)&nbsp;any shortening of the Restriction Period applicable to any Restricted Stock Units in accordance with the terms of this Plan or any applicable
Award Agreement), the Company shall deliver or cause to be delivered to the Participant that is the holder of such Restricted Stock Units a stock certificate in respect of the shares of Common Stock
subject to such Restricted Stock Units. Such certificate shall be registered in the name of such Participant, and, if applicable, shall bear an appropriate legend referring to the terms, conditions,
and restrictions applicable to such shares of Common Stock substantially in the following form: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transferability of this certificate and the shares represented by this certificate are subject to the terms and conditions of the Amicus Therapeutics,&nbsp;Inc. Amended and
Restated 2007 Equity Incentive Plan and an Award Agreement entered into by the registered owner and Amicus Therapeutics,&nbsp;Inc. Copies of such Plan and Agreement are on file in the offices of
Amicus Therapeutics,&nbsp;Inc. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Dividends.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;At the discretion of the Committee, Participants may be entitled to receive payments equivalent
to any dividends declared with respect to Common Stock referenced in grants of Restricted Stock Units but only following the close of the applicable Restriction Period and then only if the underlying
Common Stock shall have been earned. Unless the Committee shall provide otherwise, any such dividend equivalents shall be paid, if at all, without interest or other earnings. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination of Employment, Consulting or Board Member Relationship.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise determined by
the Committee at or after grant and subject to the applicable provisions of the Award Agreement, if the applicable original grantee's association with the Company or any of its Affiliates as an
employee, director or consultant ends for any reason or no reason during the Restriction Period, regardless of whether the end of such association is effected by the Company, any such Affiliate or
such original grantee (whether voluntarily or involuntarily, including because an entity with which such original grantee has any such association ceases to be an Affiliate of the Company), and
immediately following the end of any such association, such original grantee is not associated with the Company or any of its Affiliates as an employee, director or consultant, or if such original
grantee dies, then all outstanding Restricted Stock Units initially granted to such original grantee that are still subject to Risk of Forfeiture, whether then held by such original grantee or any
other Participant, shall be forfeited or otherwise subject to return to the Company in accordance with the terms of the applicable Award Agreement; provided, however, that military or sick leave or
other bona fide leave shall not be deemed a termination of employment, if it does not exceed the longer of ninety (90)&nbsp;days or the period during which the absent original grantee's reemployment
rights, if any, are guaranteed by statute or by contract. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=79,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=932162,FOLIO='A-10',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_11"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transferability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in this subsection&nbsp;(e), Restricted Stock Units shall
not be transferable, and no Restricted Stock Unit or interest therein may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated. The applicable Award Agreement or the
Committee (at or after the grant of a Restricted Stock Unit) may provide that such Restricted Stock Unit may be transferred by the applicable Participant to a family member; provided, however, that
any such transfer is without payment of any consideration whatsoever and that no transfer of a Restricted Stock Unit shall be valid unless first approved by the Committee, acting in its sole
discretion, unless such transfer is permitted under the applicable Award Agreement. For this purpose, "family member" means any child, stepchild, grandchild, parent, stepparent, spouse, former spouse,
sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the applicable Participant's
household (other than a tenant or employee), a trust in which the foregoing persons and/or the applicable Participant have more than fifty percent (50%) of the beneficial interests, a foundation in
which the foregoing persons and/or the applicable Participant control the management of assets, and any other entity in which these persons and/or the applicable Participant own more than fifty
percent (50%) of the voting interests. The Committee may at any time or from time to time delegate to one or more officers of the Company the authority to permit transfers of Restricted Stock Units to
third parties pursuant to this subsection&nbsp;(e), which authorization shall be exercised by such officer or officers in accordance with guidelines established by the Committee at any time and from
time to time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights Pending Close of Applicable Restriction Period.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No person holding Restricted Stock Units shall be
deemed for any purpose to be a stockholder of the Company with respect to any of the shares of Common Stock subject to such Restricted Stock Units, except to the extent that the Restricted Period with
respect to such Restricted Stock Units shall have closed and, in addition, a certificate shall have been issued for such shares of Common Stock and delivered to such person or his agent. Shares of
Common Stock subject to Restricted Stock Units shall be issued and outstanding only if and to the extent that a stock certificate representing such shares has been issued and delivered in accordance
with the provisions of this Section&nbsp;7.3. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Stock Grants.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;In General.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock Grants shall be issued for such consideration, in cash, other property or services, or any
combination thereof, as is determined by the Committee. Without limiting the generality of the foregoing, Stock Grants may be awarded in such circumstances as the Committee deems appropriate,
including without limitation in recognition of significant contributions to the success of the Company or its Affiliates or in lieu of compensation otherwise already due. Stock Grants shall be made
without forfeiture conditions of any kind. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each Participant receiving a Stock Grant shall be issued a stock certificate in
respect of such Stock Grant. Such certificate shall be registered in the name of such Participant, and, if applicable, shall bear an appropriate legend referring to the terms, conditions, and
restrictions applicable to such Award substantially in the following form: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
transferability of this certificate and the shares represented by this certificate are subject to the terms and conditions of the Amicus Therapeutics,&nbsp;Inc. 2007 Equity
Incentive Plan. A copy of such Plan is on file in the offices of Amicus Therapeutics,&nbsp;Inc. </FONT></P>

</UL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Performance Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Performance Awards Generally.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may grant Performance Awards in accordance with this Section.
Performance Awards may be denominated as a number of shares of Common Stock, or specified number of other Awards (or a combination thereof) which may be earned upon achievement or satisfaction of
Performance Goals, as specified by the Committee. In addition, the Committee may specify that any other Award shall constitute a Performance Award by </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=80,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=612664,FOLIO='A-11',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_12"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>conditioning
the vesting or settlement of the Award upon the achievement or satisfaction of such Performance Goals, which the Committee may use in its discretion from time to time. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Qualified Performance-Based Compensation Under Section&nbsp;162(m).</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Performance Awards intended to
constitute "qualified performance-based compensation" under Section&nbsp;162(m) of the Code may be granted by the Committee and will be subject to the terms of this Section. When a Performance Award
is made, the Committee shall establish in writing (i)&nbsp;the objective performance goals that must be met, (ii)&nbsp;the period during which performance will be measured, (iii)&nbsp;the
maximum amounts that may be paid if the performance goals are met, and (iv)&nbsp;any other conditions that the Committee deems appropriate and consistent with the requirements of
section&nbsp;162(m) of the Code for "qualified performance-based compensation." The grant, vesting and/or settlement of a Performance Award subject to this Section will be contingent upon
achievement of one or more Performance Goals. The Committee shall establish the applicable Performance Goals in writing either before the beginning of the Performance Period or during a Performance
Period ending no later than the earlier of (i)&nbsp;90&nbsp;days after the beginning of the Performance Period or (ii)&nbsp;the date on which 25% of the Performance Period has been completed, or
such other date as may be required or permitted under applicable regulations under section&nbsp;162(m) of the Code. The performance goals shall satisfy the requirements for "qualified
performance-based compensation," including the requirement that the achievement of the goals be substantially uncertain at the time they are established and that the performance goals be established
in such a way that a third party with knowledge of the relevant facts could determine whether and to what extent the performance goals have been met. The Committee shall not have discretion to
increase the amount of compensation that is payable, but may reduce the amount of compensation that is payable, pursuant to Awards identified by the Committee as "qualified performance-based
compensation." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to Performance Goals.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may Performance Goals to take into account, in any objective
manner specified by the Committee, the impact of one or more of the following: (A)&nbsp;gain or loss from all or certain claims and/or litigation and insurance recoveries, (B)&nbsp;the impairment
of tangible or intangible assets, (C)&nbsp;stock-based compensation expense, (D)&nbsp;extraordinary, unusual or infrequently occurring events reported in the Company's public filings,
(E)&nbsp;restructuring activities reported in the Company's public filings, (F)&nbsp;investments, dispositions or acquisitions, (G)&nbsp;loss from the disposal of certain assets, (H)&nbsp;gain
or loss from the early extinguishment, redemption, or repurchase of debt, (I)&nbsp;cash or non-cash charges related to site closing expenses, (J)&nbsp;changes in accounting principles, or
(K)&nbsp;any other item, event or circumstance that would not cause an Award to fail to constitute "qualified performance-based compensation" under Section&nbsp;162(m) of the. Such an adjustment
may relate to the Company or to any subsidiary, division or other operational unit of the Company or its Affiliates, as determined by the Committee at the time the Performance Goals are established.
Any adjustment shall be determined in accordance with generally accepted accounting principles and standards, unless such other objective method of measurement is designated by the Committee at the
time Performance Goals are established. In addition, adjustments will be made as necessary to any Performance Goals related to the Company's stock to reflect changes in corporate capitalization,
including a recapitalization, stock split or combination, stock dividend, spin-off, merger, reorganization or other similar event or transaction affecting the Company's stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Other Terms of Performance Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may specify other terms pertinent to a Performance Award in
the applicable Award Agreement, including terms relating to the treatment of that Award in the event of a Change in Control prior to the end of the Performance Period. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Certification of Results.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee shall certify the results regarding any Performance Goals for the
Performance Period specified in the Award Agreement after the Performance Period ends. The Committee shall determine the amount, if any, to be paid pursuant to each Award based on </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=4,SEQ=81,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=503765,FOLIO='A-12',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_13"> </A>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>the
achievement of the applicable Performance Goals and the satisfaction of all other terms of the Award Agreement. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Awards to Participants Outside the United States.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Committee may modify the terms of any Award under the
Plan granted to a Participant who is, at the time of grant or during the term of the Award, resident or primarily employed outside of the United States in any manner deemed by the Committee to be
necessary or appropriate in order that such Award shall conform to laws, regulations, and customs of the country in which the Participant is then resident or primarily employed, or so that the
value and other benefits of the Award to the Participant, as affected by foreign tax laws and other restrictions applicable as a result of the Participant's residence or employment abroad, shall be
comparable to the value of such an Award to a Participant who is resident or primarily employed in the United States. An Award may be modified under this Section&nbsp;7.4 in a manner that is
inconsistent with the express terms of the Plan, so long as such modifications will not contravene any applicable law or regulation. The Committee may establish supplements to, or amendments,
restatements, or alternative versions of the Plan for the purpose of granting and administrating any such modified Award. No such modification, supplement, amendment, restatement or alternative
version may increase the share limit of Section&nbsp;4. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustment Provisions  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Adjustment for Corporate Actions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the provisions of Section&nbsp;8.2, if subsequent to the
Effective Date, the outstanding shares of Common Stock (or any other securities covered by the Plan by reason of the prior application of this Section) are increased, decreased, or exchanged for a
different number or kind of shares or other securities, or if additional shares or new or different shares or other securities are distributed with respect to such shares of Common Stock or other
securities, through merger, consolidation, sale of all or substantially all the property of the Company, reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock
split, or other distribution with respect to such shares of Common Stock, or other securities, an appropriate and proportionate adjustment will be made in (i)&nbsp;the maximum numbers and kinds of
shares provided in Section&nbsp;4, (ii)&nbsp;the numbers and kinds of shares or other securities subject to the then outstanding Awards, (iii)&nbsp;the exercise price for each share or other
unit of any other securities subject to then outstanding Options (without change in the aggregate purchase price as to which such Options remain exercisable), and (iv)&nbsp;the Performance Goal
applicable to any outstanding Performance Award. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Change of Control.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the applicable provisions of the Award Agreement, in the event of a Change of
Control, the Committee shall have the discretion, exercisable in advance of, at the time of, or (except to the extent otherwise provided below) at any time after, the Change of Control, to provide for
any or all of the following (subject to and upon such terms as the Committee may deem appropriate): (A)&nbsp;the Acceleration, in whole or in part, of any or all outstanding Options (including
Options that are assumed or replaced pursuant to clause&nbsp;(D) below) that are not exercisable in full at the time the Change of Control, such Acceleration to become effective at the time of the
Change of Control, or at such time following the Change of Control that the employment, consulting or Board member relationship of the applicable Optionee or Optionees with the Company and its
Affiliates terminates, or at such other time or times as the Committee shall determine; (B)&nbsp;the lapse or termination of the Risk of Forfeiture (including, without limitation, any or all of the
Company's repurchase rights) with respect to outstanding Awards of Restricted Stock, such lapse or termination to become effective at the time of the Change of Control, or at such time following the
Change of Control that the employment, consulting or Board member relationship with the Company and its Affiliates of the Participant or Participants that hold such Awards of Restricted Stock (or the
person to whom such Awards of Restricted Stock were initially granted) terminates, or at such other time or times as the Committee shall determine; (C)&nbsp;the lapse or termination of the Risk of
Forfeiture with respect to any or all outstanding Awards of Restricted Stock Units (including Restricted Stock Units
that are assumed or replaced pursuant to clause&nbsp;(D) below), such lapse or termination to become effective at the time of the Change of Control, or at such time following the Change of Control </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=82,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=146551,FOLIO='A-13',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_14"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>that
the employment, consulting or Board member relationship with the Company and its Affiliates of the Participant or Participants that hold such Awards of Restricted Stock Units (or the person to
whom such Awards of Restricted Stock Units were initially granted) terminates, or at such other time or times as the Committee shall determine; (D)&nbsp;the assumption of outstanding Options or
Restricted Stock Units, or the substitution of outstanding Options or Restricted Stock Units with equivalent options or equivalent restricted stock units, as the case may be, by the acquiring or
succeeding corporation or entity (or an affiliate thereof); (E)&nbsp;the termination of all Options (other than Options that are assumed or substituted pursuant to clause&nbsp;(D) above) that
remain outstanding at the time of the consummation of the Change of Control, provided that, the Committee shall have made the determination to effect such termination prior to the consummation of the
Change of Control and the Committee shall have given, or caused to be given, to all Participants written notice of such potential termination at least five business days prior to the consummation of
the Change of Control, and provided, further, that, if the Committee shall have determined in its sole and absolute discretion that the Company make payment or provide consideration to the holders of
such terminated Options on account of such termination, which payment or consideration shall be on such terms and conditions as the Committee shall have determined (and which could consist of, in the
Committee's sole and absolute discretion, payment to the applicable Optionee or Optionees of an amount of cash equal to the difference between the Market Value of the shares of Common Stock for which
the Option is then exercisable and the aggregate exercise price for such shares under the Option or cancellation for no payment (or other consideration with respect to Options for which the exercise
price exceeds the Market Value of the shares of Common Stock underlying the Option), then the Company shall be required to make, or cause to be made, such payment or provide, or cause to be provided,
such consideration in accordance with the terms and conditions so determined by the Committee, otherwise the Company shall not be required to make any payment or provide any consideration in
connection with, or as a result of, the termination of Options pursuant to the foregoing provisions of this clause&nbsp;(E); (F)&nbsp;the termination of all Restricted Stock Units (other than
Restricted Stock Units that are assumed or substituted pursuant to clause&nbsp;(D) above) that remain outstanding at the time of the consummation of the Change of Control, provided that, if the
Committee shall have determined in its sole and absolute discretion that the Company make payment or provide consideration to the holders of such terminated Restricted Stock Units on account of such
termination, which payment or consideration shall be on such terms and conditions as the Committee shall have determined (and which could consist of, in the Committee's sole and absolute discretion,
payment to the applicable Participant or Participants of an amount of cash equal to the Market Value of the shares of Common Stock subject to the terminated Restricted Stock Units), then the Company
shall be required to make such payment or provide such consideration in accordance with the terms and conditions so determined by the Committee, otherwise the Company shall not be required to make any
payment or provide any consideration in connection with, or as a result of, the termination of Restricted Stock Units pursuant to the foregoing provisions of this clause&nbsp;(F) and/or
(G)&nbsp;the reduction of any Performance Period applicable to a Performance Award or the satisfaction (or the failure to of such satisfaction) of any applicable Performance Goals with respect to
Performance Awards. The provisions of this Section&nbsp;8.2 shall not be construed as to limit or restrict in any way the Committee's general authority under Sections&nbsp;7.1(d) or 7.2(d) hereof
to Accelerate Options in whole or in part at any time or to waive or terminate at any time any Risk of Forfeiture applicable to shares of Restricted Stock or Restricted Stock Units. Each outstanding
Award that is
assumed in connection with a Change of Control, or is otherwise to continue in effect subsequent to a Change of Control, will be appropriately adjusted, immediately after the Change of Control, as to
the number and class of securities and the price at which it may be exercised in accordance with Section&nbsp;8.1. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Dissolution or Liquidation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon dissolution or liquidation of the Company, each outstanding Option shall
terminate, but the Optionee (if at the time he or she has an employment, consulting or Board member relationship with the Company or any of its Affiliates) shall have the right, immediately prior to
such dissolution or liquidation, to exercise the Option to the extent exercisable on the date of such dissolution or liquidation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=83,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=267584,FOLIO='A-14',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_15"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Related Matters.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any adjustment in Awards made pursuant to this Section&nbsp;8 shall be determined and
made, if at all, by the Committee and shall include any correlative modification of terms, including of Option exercise prices, rates of vesting or exercisability, Risks of Forfeiture, adjustment of
Performance Goals and/or Performance Periods and applicable repurchase prices for Restricted Stock, which the Committee may deem necessary or appropriate so as to ensure that the rights of the
Participants in their respective Awards are not substantially diminished nor enlarged as a result of the adjustment and corporate action other than as expressly contemplated in this Section&nbsp;8.
No fraction of a share shall be purchasable or deliverable upon exercise, but in the event any adjustment hereunder of the number of shares covered by an Award shall cause such number to include a
fraction of a share, such number of shares shall be adjusted to the nearest smaller whole number of shares. No adjustment of an Option exercise price per share pursuant to this Section&nbsp;8 shall
result in an exercise price which is less than the par value of the Common Stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Settlement of Awards  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Violation of Law.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provision of the Plan or the relevant Award Agreement, if, at
any time, in the reasonable opinion of the Company, the issuance of shares of Common Stock covered by an Award may constitute a violation of law, then the Company may delay such issuance and the
delivery of a certificate for such shares until (i)&nbsp;approval shall have been obtained from such governmental agencies, other than the Securities and Exchange Commission, as may be required
under any applicable law, rule, or regulation and (ii)&nbsp;in the case where such issuance would constitute a violation of a law administered by or a regulation of the Securities and Exchange
Commission, one of the following conditions shall have been satisfied: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;the
shares are at the time of the issue of such shares effectively registered under the Securities Act; or </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;the
Company shall have determined, on such basis as it deems appropriate (including an opinion of counsel in form and substance satisfactory to the Company) that the
sale, transfer, assignment, pledge, encumbrance or other disposition of such shares or such beneficial interest, as the case may be, does not require registration under the Securities Act or any
applicable state securities laws. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Corporate Restrictions on Rights in Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any Common Stock to be issued pursuant to Awards granted under
the Plan shall be subject to all restrictions upon the transfer thereof which may be now or hereafter imposed by the Certificate of Incorporation and the By-laws of the Company, each as amended and in
effect from time to time. Whenever Common Stock is to be issued pursuant to an Award, if the Committee so directs at the time of grant (or, if such Award is an Option, at any time prior to the
exercise thereof), the Company shall be under no obligation, notwithstanding any other provision of the Plan or the relevant Award Agreement to the contrary, to issue such shares until such time, if
ever, as the recipient of the Award (and any person who exercises any Option, in whole or in part), shall have become a party to and bound by any agreement that the Committee shall require in its sole
discretion. In addition, any Common Stock to be issued pursuant to Awards granted under the Plan shall be subject to all stop-transfer orders and other restrictions as the Committee may deem advisable
under the rules, regulations and other requirements of any stock exchange upon which the Common Stock is then listed, and any applicable federal or state securities laws, and the Committee may cause a
legend or legends to be put on any such certificates to make appropriate reference to such restrictions. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.3</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Investment Representations.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company shall be under no obligation to issue any shares covered by an Award
unless the shares to be issued pursuant to Awards granted under the Plan have been effectively registered under the Securities Act or the Participant shall have made such written representations to
the Company (upon which the Company believes it may reasonably rely) as the Company may deem necessary or appropriate for purposes of confirming that the issuance of such shares </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=84,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=15351,FOLIO='A-15',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_16"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>will
be exempt from the registration requirements of that Act and any applicable state securities laws and otherwise in compliance with all applicable laws, rules and regulations, including but not
limited to that the Participant is acquiring shares for his or her own account for the purpose of investment and not with a view to, or for sale in connection with, the distribution of any such
shares. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.4</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Registration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If the Company shall deem it necessary or desirable to register under the Securities Act or
other applicable statutes any shares of Common Stock issued or to be issued pursuant to Awards granted under the Plan, or to qualify any such shares of Common Stock for exemption from the Securities
Act or other applicable statutes, then the Company shall take such action at its own expense. The Company may require from each recipient of an Award, or each holder of shares of Common Stock acquired
pursuant to the Plan, such information in writing for use in any registration statement, prospectus, preliminary prospectus or offering circular as is reasonably necessary for such purpose and may
require reasonable indemnity to the Company and its officers and directors from such holder against all losses, claims, damage and liabilities arising from such use of the information so furnished and
caused by any untrue statement of any material fact therein or caused by the omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading
in the light of the circumstances under which they were made. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.5</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Lock-Up.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Without the prior written consent of the Company or the managing underwriter in any public offering
of shares of Common Stock, no Participant shall sell, make any short sale of, loan, grant any option for the purchase of, pledge or otherwise encumber, or otherwise dispose of, any shares of Common
Stock during the one hundred-eighty (180)&nbsp;day period commencing on the effective date of the registration statement relating to any underwritten public offering of securities of the Company.
The foregoing restrictions are intended and shall be construed so as to preclude any Participant from engaging in any hedging or other transaction that is designed to or reasonably could be expected
to lead to or result in, a sale or disposition of any shares of Common Stock during such period even if such shares of Common Stock are or would be disposed of by someone other than such Participant.
Such prohibited hedging or other transactions would include, without limitation, any short sale (whether or not against the box) or any purchase, sale or grant of any right (including without
limitation any put or call option) with respect to any shares of Common Stock or with respect to any security that includes, relates to, or derives any significant part of its value from any shares of
Common Stock. Without limiting the generality of the foregoing provisions of this Section&nbsp;9.5, if, in connection with any underwritten public offering of securities of the Company, the managing
underwriter of such offering requires that the Company's directors and officers enter into a lock-up agreement containing provisions that are more restrictive than the provisions set forth in the
preceding sentence, then (a)&nbsp;each Participant (regardless of whether or not such Participant has complied or complies with the provisions of clause&nbsp;(b) below) shall be bound by, and
shall be deemed to have agreed to, the same lock-up terms as those to which the Company's directors and officers are required to adhere; and (b)&nbsp;at the request of the Company or such managing
underwriter, each Participant shall execute and deliver a lock-up agreement in form and substance equivalent to that which is required to be executed by the Company's directors and officers. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.6</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Placement of Legends; Stop Orders; Etc.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each share of Common Stock to be issued pursuant to Awards granted
under the Plan may bear a reference to the investment representations made in accordance with Section&nbsp;9.3 in addition to any other applicable restrictions under the Plan, the terms of the Award
and, if applicable, under any agreement between the Company and any Optionee and/or Participant, and to the fact that no registration statement has been filed with the Securities and Exchange
Commission in respect to such shares of Common Stock. All certificates for shares of Common Stock or other securities delivered under the Plan shall be subject to such stock transfer orders and other
restrictions as the Committee may deem advisable under the rules, regulations, and other requirements of any stock exchange upon which the Common Stock is then listed, and any applicable federal or
state securities law, and the Committee may cause a legend or legends to be placed on any such certificates to make appropriate reference to such restrictions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=85,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=278473,FOLIO='A-16',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_17"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.7</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Tax Withholding.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Whenever shares of Common Stock are issued or to be issued pursuant to Awards granted under
the Plan, the Company shall have the right to require the recipient to remit to the Company an amount sufficient to satisfy federal, state, local or other withholding tax requirements if, when, and to
the extent required by law (whether so required to secure for the Company an otherwise available tax deduction or otherwise) prior to the delivery of any certificate or certificates for such shares.
The obligations of the Company under the Plan shall be conditional on satisfaction of all such withholding obligations and the Company shall, to the extent permitted by law, have the right to deduct
any such taxes from any payment of any kind otherwise due to the recipient of an Award. However, in such cases Participants may elect, subject to the approval of the Committee, acting in its sole
discretion, to satisfy an applicable withholding requirements, in whole or in part, by having the Company withhold shares to satisfy their tax obligations. Participants may only elect to have shares
of their Common Stock withheld having a Market Value on the date the tax is to be determined equal to the minimum statutory total tax which could be imposed on the transaction. All elections shall be
irrevocable, made in writing, signed by the Participant, and shall be subject to any restrictions or limitation that the Committee deems appropriate. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>10.&nbsp;&nbsp;&nbsp;Reservation of Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company shall at all times during the term of the Plan and any outstanding Options granted hereunder reserve or otherwise keep available such number of shares
of Common Stock as will be sufficient to satisfy the requirements of the Plan (if then in effect) and such Options and shall pay all fees and expenses necessarily incurred by the Company in connection
therewith. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>11.&nbsp;&nbsp;&nbsp;No Special Service Rights  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained in the Plan or in any Award Agreement shall confer upon any recipient of an Award any right with respect to the continuation of his or her
employment, consulting or Board member relationship or other association with the Company (or any Affiliate), or interfere in any way with the right of the Company (or any Affiliate), subject to the
terms of any separate employment, consulting or Board member agreement or provision of law or corporate articles or by-laws to the contrary, at any time to terminate such employment, consulting or
Board member agreement or to increase or decrease, or otherwise adjust, the other terms and conditions of the recipient's employment, consulting or Board member relationship or other association with
the Company and its Affiliates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>12.&nbsp;&nbsp;&nbsp;Nonexclusivity of the Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the adoption of the Plan by the Board nor the submission of the Plan to the stockholders of the Company shall be construed as creating any limitations on
the power of the Board to adopt such other incentive arrangements as it may deem desirable, including without limitation, the granting of stock options, restricted stock and restricted stock units
other than under the Plan, and such arrangements may be either applicable generally or only in specific cases. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>13.&nbsp;&nbsp;&nbsp;Termination and Amendment of the Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board may at any time terminate the Plan or make such amendments or modifications of the Plan as it shall deem advisable. In the event of the termination of
the Plan, the terms of the Plan shall survive any such termination with respect to any Award that is outstanding on the date of such termination, unless the holder of such Award agrees in writing to
terminate such Award or to terminate all or any of the provisions of the Plan that apply to such Award. Unless the Board otherwise expressly provides, any amendment or modification of the Plan shall
affect the terms of any Award outstanding on the date of such amendment or modification as well as the terms of any Award made from and after the date of such amendment or modification; </FONT> <FONT SIZE=2><I>provided, however</I></FONT><FONT
SIZE=2> , that, except to the extent otherwise provided in the last sentence of this paragraph, (i)&nbsp;no amendment or modification of the
Plan shall apply to any Award that is outstanding on the date of such amendment or modification if such amendment or modification would </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=86,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=134619,FOLIO='A-17',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_18"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>reduce
the number of shares subject to such Award, increase the purchase price applicable to shares subject to such Award or materially adversely affect the provisions applicable to such Award that
relate to the vesting or exercisability of such Award or of the shares subject to such Award, (ii)&nbsp;no amendment or modification of the Plan shall apply to any Incentive Option that is
outstanding on the date of such amendment or modification if such amendment or modification would result in such Incentive Option no longer being treated as an "incentive stock option" within the
meaning of Section&nbsp;422 of the Code and (iii)&nbsp;no amendment or modification of the Plan shall apply to any Award that is outstanding on the date of such amendment or modification unless
such amendment or modification of the Plan shall also apply to all other Awards outstanding on the date of such amendment or modification. In the event of any amendment or modification of the Plan
that is described in clause&nbsp;(i), (ii)&nbsp;or (iii)&nbsp;of the foregoing proviso, such amendment or modification of the Plan shall apply to any Award outstanding on the date of such
amendment or modification only if the recipient of such Award consents in writing thereto. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Committee may amend or modify, prospectively or retroactively, the terms of any outstanding Award without amending or modifying the terms of the Plan itself, </FONT> <FONT SIZE=2><I>provided that</I></FONT><FONT SIZE=2> as amended or modified such
Award is consistent with the terms of the Plan as in effect at the time of the amendment or modification of
such Award, but no such amendment or modification of such Award shall, without the written consent of the recipient of such Award, reduce the number of shares subject to such Award, increase the
purchase price applicable to shares subject to such Award, adversely affect the provisions applicable to such Award that relate to the vesting or exercisability of such Award or of the shares subject
to such Award, or otherwise materially adversely affect the terms of such Award (except for amendments or modifications to the terms of such Award or of the stock subject to such Award that are
expressly permitted by the terms of the Plan or that result from any amendment or modification of the Plan in accordance with the provisions of the first paragraph of this Section&nbsp;13), or, if
such Award is an Incentive Option, result in such Incentive Option no longer being treated as an "incentive stock option" within the meaning of Section&nbsp;422 of the Code. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without
the approval of the Company's stockholders, the Committee will not, directly or indirectly, reduce the exercise price of an outstanding Option (other than in accordance with the
adjustment provisions of Section&nbsp;8.1). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>14.&nbsp;&nbsp;&nbsp;Interpretation of the Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any conflict between the provisions of this Plan and the provisions of any applicable Award Agreement, the provisions of this Plan shall control,
except if and to the extent that the conflicting provision in such Award Agreement was authorized and approved by the Committee at the time of the grant of the Award evidenced by such Award Agreement
or is ratified by the Committee at any time subsequent to the grant of such Award, in which case the conflicting provision in such Award Agreement shall control. Without limiting the generality of the
foregoing provisions of this Section&nbsp;14, insofar as possible the provisions of the Plan and such Award Agreement shall be construed so as to give full force and effect to all such provisions.
In the event of any conflict between the provisions of this Plan and the provisions of any other agreement between the Company and the Optionee and/or Participant, the provisions of such agreement
shall control except as required to fulfill the intention that this Plan constitute an incentive stock option plan within the meaning of Section&nbsp;422 of the Code, but insofar as possible the
provisions of the Plan and any such agreement shall be construed so as to give full force and effect to all such provisions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>15.&nbsp;&nbsp;&nbsp;Notices and Other Communications  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any notice, demand, request or other communication hereunder to any party shall be deemed to be sufficient if contained in a written instrument delivered in
person or duly sent by first class registered, certified or overnight mail, postage prepaid, or telecopied with a confirmation copy by regular, certified or overnight mail, addressed or telecopied, as
the case may be, (i)&nbsp;if to the recipient of an Award, at his or her </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=87,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=776786,FOLIO='A-18',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<A NAME="page_lc13701_1_19"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>residence
address last filed with the Company and (ii)&nbsp;if to the Company, at its principal place of business, addressed to the attention of its Chief Executive Officer, or to such other address
or telecopier number, as the case may be, as the addressee may have designated by notice to the addressor. All such notices, requests, demands and other communications shall be deemed to have been
received: (i)&nbsp;in the case of personal delivery, on the date of such delivery; (ii)&nbsp;in the case of mailing, when received by the addressee; and (iii)&nbsp;in the case of facsimile
transmission, when confirmed by facsimile machine report. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>16.&nbsp;&nbsp;&nbsp;Governing Law  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Plan and all Award Agreements and actions taken thereunder shall be governed, interpreted and enforced in accordance with the laws of the State of New Jersey,
without regard to the conflict of laws principles thereof. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>17.&nbsp;&nbsp;&nbsp;Effective Date  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amended and Restated 2007 Equity Incentive Plan was approved by the Board on April&nbsp;11, 2018 (the Effective Date") and approved by the stockholders of
the Company effective June&nbsp;7, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=88,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=175883,FOLIO='A-19',FILE='DISK109:[18ZAG1.18ZAG13701]LC13701A.;8',USER='MKEANE',CD='12-APR-2018;15:49' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">- 1 AMICUS   THERAPEUTICS, INC. 1 Cedar Brook Drive Cranbury, NJ 08512 THIS PROXY IS   SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned stockholder of   Amicus Therapeutics, Inc. hereby appoints Bradley L. Campbell and Ellen   Rosenberg as proxies, each with full power of substitution, to represent and   vote as designated on the reverse side, all the shares of Common Stock of   Amicus Therapeutics, Inc. held of record by the undersigned on April 16,   2018, and which the undersigned would be entitled to vote if personally   present at the Annual Meeting of Stockholders to be held at the offices of   Amicus Therapeutics, Inc., located at 1 Cedar Brook Drive, Cranbury, New   Jersey, 08512 on June 7, 2018, or any adjournment or postponement thereof.   This proxy is revocable and the undersigned may revoke it at any time prior   to the Annual Meeting by giving written notice of such revocation to the   Secretary of Amicus Therapeutics, Inc. prior to the meeting or by filing with   the Secretary of Amicus Therapeutics, Inc. prior to the meeting a later-dated   proxy. Should the undersigned be present and want to vote in person at the   Annual Meeting, or at any postponement or adjournment thereof, the   undersigned may revoke this proxy by giving written notice of such revocation   to the Secretary of Amicus Therapeutics, Inc. on a form provided at the   Annual Meeting. The undersigned hereby acknowledges receipt of a notice of   Annual Meeting of Stockholders of Amicus Therapeutics, Inc. called for June   7, 2018 and the Proxy Statement for the Annual Meeting, each dated April 24,   2018, prior to the signing of this proxy. (Continued and to be signed on the   reverse side) 14475 1.1 COMMENTS: </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1209" src="g28372cgi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=89,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=46722,FOLIO='',FILE="DISK130:[18ZAG2.18ZAG13702]2837-2-CG_ZAG13702.CHC",USER="VRIVERA",CD='Apr 20 22:30 2018' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">ANNUAL MEETING   OF STOCKHOLDERS OF Amicus Therapeutics, Inc. June 7, 2018 GO GREEN e-Consent   makes it easy to go paperless. With e-Consent, you can quickly access your   proxy material, statements and other eligible documents online, while   reducing costs, clutter and paper waste. Enroll today via   www.astfinancial.com to enjoy online access. NOTICE OF INTERNET AVAILABILITY   OF PROXY MATERIAL: The Notice of Meeting, Proxy Statement, Proxy Card are   available at http://www.astproxyportal.com/ast/15417/ Please sign, date and   mail your proxy card in the envelope provided as soon as possible. Please   detach along perforated line and mail in the envelope provided.   20230030303000000000 1 060718 250,000,000 to 500,000,000 changes to the   registered name(s) on the account may not be submitted via Note: Please sign   exactly as your name or names appear on this Proxy. When shares are held   jointly, each holder should sign. When signing as executor, administrator,   attorney, trustee or guardian, please give full title as such. If the signer   is a corporation, please sign full corporate name by duly authorized officer,   giving full title as such. If signer is a partnership, please sign in   partnership name by authorized person. THE BOARD OF DIRECTORS RECOMMENDS A   VOTE &#147;FOR&#148; THE ELECTION OF DIRECTORS, AND &#147;FOR&#148; PROPOSALS 2, 3, 4 AND 5.   PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK   YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x 1. Election of Directors:   NOMINEES: FOR ALL NOMINEESO Donald J. Hayden, Jr. O Craig Wheeler WITHHOLD   AUTHORITY FOR ALL NOMINEES FOR ALL EXCEPT (See instructions below)   INSTRUCTIONS: To withhold authority to vote for any individual nominee(s),   mark &#147;FOR ALL EXCEPT&#148; and fill in the circle next to each nominee you wish to   withhold, as shown here: FOR AGAINST ABSTAIN 2. Proposal to approve an   amendment to our Restated Certificate of Incorporation to increase the number   of shares of common stock, par value $0.01 per share, that we are authorized   to issue from 3. Approval of the Amended and Restated 2007 Equity Incentive   Plan to add 5,000,000 shares to the equity pool 4. Ratify the appointment of   Ernst &amp; Young LLP as the Company&#146;s independent registered public   accounting firm for the fiscal year ending December 31, 2018 5. Approval, on   an advisory basis, the Company&#146;s executive compensation To change the address   on your account, please check the box at right and indicate your new address   in the address space above. Please note that this method. Signature of   Stockholder Date: Signature of StockholderDate: </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1187" src="g28372cii001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=90,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=463853,FOLIO='',FILE="DISK130:[18ZAG2.18ZAG13702]2837-2-CI_ZAG13702.CHC",USER="VRIVERA",CD='Apr 20 22:46 2018' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">ANNUAL MEETING   OF STOCKHOLDERS OF Amicus Therapeutics, Inc. June 7, 2018 INTERNET - Access   &#147;www.voteproxy.com&#148; and follow the on-screen instructions or scan the QR code   with your smartphone. Have your proxy card available when you access the web   page, and use the Company Number and Account Number shown on your proxy card.   TELEPHONE - Call toll-free 1-800-PROXIES (1-800-776-9437) in the United   States or 1-718-921-8500 from foreign countries from any touch-tone telephone   and follow the instructions. Have your proxy card available when you call and   use the Company Number and Account Number shown on your proxy card. Vote   online/phone until 11:59 PM EST the day before the meeting. MAIL - Sign, date   and mail your proxy card in the envelope provided as soon as possible. IN   PERSON - You may vote your shares in person by attending the Annual Meeting.   GO GREEN - e-Consent makes it easy to go paperless. With e-Consent, you can   quickly access your proxy material, statements and other eligible documents   online, while reducing costs, clutter and paper waste. Enroll today via   www.astfinancial.com to enjoy online access. Please detach along perforated   line and mail in the envelope provided IF you are not voting via telephone or   the Internet. 20230030303000000000 1 060718 250,000,000 to 500,000,000   changes to the registered name(s) on the account may not be submitted via   Note: Please sign exactly as your name or names appear on this Proxy. When   shares are held jointly, each holder should sign. When signing as executor,   administrator, attorney, trustee or guardian, please give full title as such.   If the signer is a corporation, please sign full corporate name by duly   authorized officer, giving full title as such. If signer is a partnership,   please sign in partnership name by authorized person. THE BOARD OF DIRECTORS   RECOMMENDS A VOTE &#147;FOR&#148; THE ELECTION OF DIRECTORS, AND &#147;FOR&#148; PROPOSALS 2, 3,   4 AND 5. PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.   PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x 1. Election of   Directors: NOMINEES: FOR ALL NOMINEESO Donald J. Hayden, Jr. O Craig Wheeler   WITHHOLD AUTHORITY FOR ALL NOMINEES FOR ALL EXCEPT (See instructions below)   INSTRUCTIONS: To withhold authority to vote for any individual nominee(s),   mark &#147;FOR ALL EXCEPT&#148; and fill in the circle next to each nominee you wish to   withhold, as shown here: FOR AGAINST ABSTAIN 2. Proposal to approve an   amendment to our Restated Certificate of Incorporation to increase the number   of shares of common stock, par value $0.01 per share, that we are authorized   to issue from 3. Approval of the Amended and Restated 2007 Equity Incentive   Plan to add 5,000,000 shares to the equity pool 4. Ratify the appointment of   Ernst &amp; Young LLP as the Company&#146;s independent registered public accounting   firm for the fiscal year ending December 31, 2018 5. Approval, on an advisory   basis, the Company&#146;s executive compensation To change the address on your   account, please check the box at right and indicate your new address in the   address space above. Please note that this method. Signature of Stockholder   Date: Signature of StockholderDate: NOTICE OF INTERNET AVAILABILITY OF PROXY   MATERIAL: The Notice of meeting, proxy statement and proxy card are available   at http://www.astproxyportal.com/ast/15417/ COMPANY NUMBER ACCOUNT NUMBER   PROXY VOTING INSTRUCTIONS </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1175" src="g28372cki001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=91,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=107073,FOLIO='',FILE="DISK130:[18ZAG2.18ZAG13702]2837-2-CK_ZAG13702.CHC",USER="VRIVERA",CD='Apr 20 22:48 2018' -->

<BR>
<P><br><A NAME="18ZAG13701_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_be13701_1">NOTICE OF 2018 ANNUAL MEETING OF STOCKHOLDERS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc13701_1">IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING TO BE HELD ON JUNE 7, 2018.</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc13701_2">THE PROXY STATEMENT AND FORM OF PROXY FOR OUR 2018 ANNUAL MEETING OF STOCKHOLDERS AND OUR ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2017 ARE AVAILABLE AT: www.sec.gov , through the Investor
Relations section of our web site at www.amicusrx.com or at http://www.astproxyportal.com/ast/15417/</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc13701_3">PROPOSAL NO. 1&#151;ELECTION OF DIRECTORS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de13701_1">AMICUS CORPORATE GOVENANCE</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dg13701_1">COMPENSATION DISCUSSION AND ANALYSIS&#151;2017</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk13701_1">Summary Compensation Table</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq13701_1">COMPENSATION COMMITTEE REPORT</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq13701_2">SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq13701_3">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ds13701_1">POLICIES AND PROCEDURES FOR RELATED PARTY TRANSACTIONS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ds13701_2">PROPOSAL NO. 2&#151;APPROVE AND ADOPT AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ds13701_3">PROPOSAL NO. 3&#151;APPROVE THE AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN</A></FONT><BR>

<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_du13701_1">PROPOSAL NO. 4&#151;INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw13701_1">REPORT OF AUDIT AND COMPLIANCE COMMITTEE</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw13701_2">PROPOSAL NO. 5&#151;ADVISORY VOTE ON EXECUTIVE COMPENSATION</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw13701_3">OTHER MATTERS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw13701_4">STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw13701_5">DELIVERY OF PROXY MATERIALS</A></FONT><BR>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_la13701_1">Annex A</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_la13701_2">AMENDED AND RESTATED AMICUS THERAPEUTICS, INC. 2007 EQUITY INCENTIVE PLAN</A></FONT><BR>

<!-- SEQ=,FILE='QUICKLINK',USER=VRIVERA,SEQ=,EFW="2235408",CP="AMICUS THERAPEUTICS, INC.",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g429299.jpg
<DESCRIPTION>G429299.JPG
<TEXT>
begin 644 g429299.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@!%35),3%]'4D%02$E#4SI;04U)0U53
M7U1(15)!4$555$E#4UU!34E#55-?5$A%4D%0155424-37U!-4U],3T=/+D50
M4__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( &$!(P,!(@ "$0$#$0'_Q  ?  $  @(" P$!
M"0H("P$' @,&!03_Q !'$   !@(! P($ @8&!P8'   ! @,$!08'"  )$1(3
M(0H4%3%!418B(W&!D1<R.4)AL1@9)')WH;<X>+*UMM$S-E)V@I+P_\0 '0$
M 00# 0$               4&!P@" P0) ?_$ #<1  (#  $$ @$#! $" @L
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M,8GT;?LP(LN69B9(_"ER%9*5!Z)=N>WN3V^Q%4:@+L:=@ 9KZLA$.NV?$20
M4Q[+II+R%9$3$",?(<2YC#+5[]2NN-ZKU!-T8)O'_3V:6R.5WB#$P% A6E@L
M;FPD$A2?JE;.TICYI @=O%NY3*( 8!#EYSHA;(2FR?3OPY*V1^:3N.*3S."[
M4^44*HN[6QNHV:59X['P*H+U[C]_47#Q503G<NQ<.3',*H]J375M_M*MS_\
MC9*_^GJWRPE\+)=W+O'>X&-E3&^3K][Q3?&)>Y/$'%RK%FK<F %$_J (EH44
M<1!/TQ[]O/R[D"U?>O'#8[!\6VF!!6\+/XCH"^?RR%:-&GF6E^TS)2#F7:[3
MCS/L==93^1B>JU=HM4LGO;R/'44C4V;7)*<IC\!+*5E^B@_6(]8-857 ,_B(
M%K!C_;QU;"XXXY0GJZ_3CCCAT=.1]=1_J"4GITX0A\NVJHO,B2MGO<-1*K0H
MNPL:U)S;QZTD):8D"2;Z.EDV["O0D6Z?O5/IZX*+*,6/F@=ZFJ6041  $1]@
M .XC^0!RA5\1GM2.:]RHS ]>D!=TO5RL'@GY&ZAE6J^4[TC&6&\N.Z90()H.
M#0I]84 X&%I(L9Q QP%0Y0E3LUP9/<#G6=CWE,9C5E/T]OXS8J9H51@13\JB
M!B_MW&U:DFLP: .-BR@@\Q&W=CF;>#\,OZU-@+U7L3GY'N -C[M@I*6RID$#
M(K5EV+'J8$LB6 ''J?5JKIF]2:D]23&F0;O7:)(8OL&-KPA4[#1Y6R-+6^2C
M96#:3-:LP2K"'A6WR4\(3C!%J#05&SNOOB'65 Q.TE?-?%\/OM$; .^D!CN9
M?E:TC9R#5Q-*$6/XMDKRT47L.+9 0\R=W2TXC)U!N(^8&-<O#P,;P\=@Z ]P
M ??W#O[AV'^(#[@/^'.CO7P*MV^YS;RLU+$XEVK5T\86,:Z0JN"4O1+W&QC"
MKWD6@CY#-GP_ 1E,GYG1VAYJ_G/#:NG?:#=>I8L9^J0 I,'824-4X4J$  75
M7(*?0!#Y8:(Q'K,0XYX'4(F &.8I $Q2 )C 7N8Y@*0H=Q#N8QA I2AW,81
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M'K,_B?Q$^?Q/_E/CY#DRPDPU<N&/)*@QE@QXB?)!$^T1X*/S,>/S'6!_55V
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M3K_5YS'5+DTX)S(*-IV0A9>V)249"O#(Q\K((-V,HNG&K.^]]SK;?V6VWO\
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M6%V!Q&DDW#=U'MI!*\EU46S=STX-TT72"+A,FN&3%RIKID5("[2OK.FJP%4
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M%&,G)E)XG+RDP1^^<*"U$#1D>BFCXI"<TN''CW>YAD<FY#1K<5<Z>)\;PLK
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M-YQO>U8J$O+)79=YXB<@#V$Q0'\A, #_ "[]^1CZ!YUW&G=4\B2>ZF'[+#;
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M&@IK6)7<3LQVZ?P#CKOU.%_KVRY=G2%1"P*JD@0U*$-"9%I(ACF-8!2N7/,
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M^\3_ ,9>0B=)3_M#]7#_ +]LO_Z9'CCB7QW_ ,)]PO\ [9Q__P#I\SI4WO\
MQ/P?_P"MW/\ ]':ZF]XXXXR.GCTXXXX='3CCCAT=....'1TXXXX='3CCCAT=
M....'1TXXXX='3CCCAT=....'1TXXXX='3CCCAT=....'1TXXXX='3CCCAT=
2....'1TXXXX='3CCCAT=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g650180.jpg
<DESCRIPTION>G650180.JPG
<TEXT>
begin 644 g650180.jpg
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M(T%A@3)QH? 8L29RT?_$ !0! 0                    #_Q  4$0$
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M4J"*JQBJG*BFHJ8B*2BZQBID,<2I(I%.JLH8"_*FDF4RBAQ*0A1,8 'V\\3
M(E$ \>?R7S^/F ?)?/CW\>0#SX]_TX%=G GQ2'4CFRQQU3L>5,A:Y3DM(R44
MP'8[&DG1JXJ^BY-2+73<WN!?7"D1)#+$^<59V=BDF8"*,FJQ<I+(IV!:E<*G
M?:W$7*CV>O7*HV%FG(P%IJLU&6*N3D<J8Q4G\/.0[I[%R;)4Q#@F[8NUT#B4
MQ2J"8I@"M?JW6M6,1[B]H?5#N!5L*V'$MZR7-=C&M5,S5$UB=K-HPWL'7G=H
MS[&UMA<6@-TAPKD>DV.>60BR#)P,*J^GHUZ5C7WCR.B6P)D[)FI'0[VM[<ZD
M9"M&JF$LS[GSTYUCU)=Q/6.?J6,GF:J=CY.-QY&V).?79.,KF:62$BTF(2R;
M%>$EK$]?&(1S,<"^YS@1  $1]@ !$1_L'YY4-A?B'^P"$S)I_J#D/ILS=5]D
ML_S5-@%QR!DEK5?VUAH!6!:YER%1JJCC.-:LHB-8'G;(,C.V"/J52;H*&EW[
MMC&/R)6EJ_GC#5ORMDC ]:R=29K,V)8:JSN2\8QMBCW5VI$+>FJ[NH2ECKZ:
MPOXUG/M$?JF"JJ7@R*S0ZOI ^9?4!"I6ZZ7>COAR=<+<U5E\*=0>&Z10<7P[
MP7XP;G<C:6%3OMUR U0<IDCG\KC[#C:#JQ4O07^U2<A#3+1W]44I6M@8?!2^
MP![  %#\!Y_!2A^ #R/@ Y50TG[,=.]?.YOMSU!RIF2H4R<S+L?0LG8TR#;7
MCJL4V7NM:P-2:'E'#,W:+4P@HN!M=.FJR<:R=V\4K=L3^ZQU>G'4F@Q:2N3>
MP/NA_?9,NNN_IKE(S:[>',+=[49G*N-5SV'!NIM+D%@A;9EN\Y28)JT]S+UQ
MBY=A"IQ$K*QE>FRMG<RH^FBP%+M 9;Z[9UMN-VR]G6^$,T92.*,)Q6-.L_ 5
MV2 CY.S%P_(R&3]BY"$EDQ48N()?*5DAFS1W$KKLY1@WC')UA6(HDE8)Y3*H
MNT$[UV[/];_0'U;MX'+%WK.0JA?^PW.TO%-KJ1*'G)0MPSVW>MB.12KM@D:\
M,O:[#+O7B4G1(8V-:!"N75ED'GHW+EG"3=%5==5-%)$AE5E53E3302* G.JL
M8YBE3323 5%3G,4I4R&.8P% 1 /?QR-#J^WLL/85BW/F;E:C7:YB^N[=YSPU
MKU.U]Z\?#DO">*G4!7H7),PJN[>L@E;':/VK*/V58L1]N9QY$$0<)NUUY+^!
M$]VL]F9NOJB8KJF*L23.RFX^T%Q<XXU6UNK9W:3^^V2.38KV:RV%\Q16<1-&
MI#*3CG,\[1])PY<R,>T!U$QGWFQP6A$!U4=EN\D<UNO:5V4Y>QI#69R,I(:5
MZ R+'"N):A!/RI+*X]M>5V9)"V9/33!-)"3<29; 1H[!X6$MLHV.WD!S1W'8
MYN.&<T:(=MM'HT]E2-ZZ+CEA#8'&M60+(6V2UBV#IR%"R5D.F1(HJ*R]EPVH
M1K<CQ#99C]=75)UR\>MV$4X62F>PKFG%>Q&+*/FG"=ZK^2<6Y&@&EDI=TK#O
MZN(G(AV @59+YRIN6;MJN15E*Q$@@UEH63;NHJ69LY%HX;IA&#A7H ZBL(.T
M9F*TKQGDFU^FT&1M^P;BS;$3LN_:*)+!+O"9CF[?!MI-5=$JRBT1!QB1?=NW
M00: 5L66.GT*CX]C"PM#IU5I4.1-!%.*J5=AJU&IHM2&3:I$80C%@U*FV3,9
M- @)?*B0PE3 I1$!^MXX#F,LUXKKV=,.99PG;5GK>JYAQG?,669>-^F"11K^
M0:K*U*958"]0=,P>I1TNX4:B[:N6P.")BN@LD!DS9-XX&M6G.NXZDZLX"UD+
M?IS)[; V+*CBJ-O-DCV43,S\-2XQ.%A%GD;'+NFC+Z.';,8QLW2=.A3:,6X*
MNG*_JKJ:)=\^,WF1.JK;":@3KM+S@FIP6TF.)EF@9=_"7G6:WP.98EZR*1!=
M8AW3.IRD.[.W]!P,9*/DTW;/YQ<I3!<BY[KLNP>$NJ#?NZSSN-:I/-9,FX]B
M"29S A(6S+4(KBVGQ"2::J*SAY+66WQK)F@B;U%'"A/82%/P, ]MMJS3LET4
M["775JM25ZR#GS5O&]DA:U0(-:[3,_CK*[G'TKE)M3(1B65<SCX^)YZXJ1)8
MTSJ1]-/ZJ(7-)HLU@KUZ4=6,[V6L]K,KX2PKD'JZURC<+:C8BTBFK;3!KN4[
MML3I_:4;+7MN+Y2&1HM%]8&*T;,TNPV-H^>/9 MUDOLUIG[!"V-ZXN0Z#8NE
M<(Z-:;X9GE3N)S%&K.O^.9E91L+,ZDM3,4U2!D#F:BJL9L8'C%8#(F5.9(Q1
M*)A$.;; 4"AX#S_N(B(C_N(B(C_D1]O;@5>X73WXHMNHXO4SVLZ=.[3&N7JT
M9APVMT*[Q-9VS,!(P96"W,L.URXPI)_Z9%U*GB6:SR'<2#Q&/DE&Z*)!R0SR
ME\4;66#&)EM9.J'(TDBD)7EH@\L9GK;)T?S[&-$2<[%*-C^ $3 W;G3-Y 0^
M7P(<L>\<#3G1FU;NW+!X3F_V,,)XASPM<K,W2IF!K5,W"GMJ(T,P1J\@_EIB
M5G#%L4FJ66<O&C&7?,THTT0H<&,BM(1C*+OO/8*9AR3U":?BR1E8G/G9KBJZ
MWJ%%4J"\QB_6^LS^3KTT!;[I''(R(R<MG$AZ)%G)TDB$8G2DA8I.K!7->\FZ
MO8<R]FS7#8.]5YY*9/U1F,FSN%9E&=EF#*N267:&MC>[KOX5FY2B[ $A55C-
M6A)ANZ+%NBD?L 1= )Q#8(GCY0$/8#>3_P"3B)Q_/]S#_P#@?CGR&0<=T'+-
M,L..<HTFIY&Q_;6!HJTTB\UZ)ME2L<895)<T?.5V=:/HF59BN@BM].]:+) L
MBDJ4H*)D.7[$ \!X#\![!QP/2W;MVB"+5J@BV;-D4F[=N@F1%!!!$A4D444D
MRE32223(5--,A2D(0I2%*!0  A WIU4W)PUM2CV:]:L'3,IYGE\60F$MH]0\
MC6,M+JNSF,:G)OIBBVBFW==ZRC*?G+&R[]U&P$I85?LTI6'2T;ZI5$'$)9YQ
M>/S^>!7/+\1WA+&BT17=Q-%NR+3Z]*G;(V)ED#6&9MU(B3+G],TE"WBH22CR
MW5P%/G*WE8NH).W@(J"A$";Y"G[>6^)?Z_EU4&.*,:[S["33E4C5"!P[IOE-
MS*&?.1!&/8BG?4Z(C]1)O5&\>R*DHN!W;I I_D3,90MA?Y"^WY#P'@ *8Q2^
M/_J40+_QS@2%'^I_;]%% _\ 1O?_ #P*]NSNKU][CM1LXY!GM)GFE^SS7%&5
M,4:/W_9BSQ,?G6/JV6*RE$9!4RA5<9%M*6'ZY>F!I6B!6)^4R#:(B-F9ZT-X
MBO+OT1EM9-1.GC>#/>1=6;WVO6K!-1U\T.1I9=2.OG5A%\YPFULU B6L/6\@
M9E>3!732R24&$6Q?1L2F_M!Y55=T@YDZU!/+!6+':O   /   !^@!X#]?_?.
M>!#'V7=0[O?++F%=BL1;B9TTAV'PU3+KB]ME7"90=R-AQ?>W9).:JKMNE9*C
M(Q+PLE]6LTFXB>1 [>3?-92-DA3BW$9&?"?#?9VTWM,/G+JU[)<GX3V7LE-F
MJ1L5D#8VEUS.\?GYO/V,MH<6.49RD9(LZQ-QL@BS39HC 6519*/8//OC.9&:
MDYRV9QP*ON"_AB]:;O-Y>SEVL6Y;L,VOSG<8JWV[)2"=OUYJ=;^T0Q(-*)J]
M2Q!<*H@^-(M$&(34M+MVZ+@L5$I1,#"G1D74MWK'X4/K$K<Q8G^.[9N7BN%M
M)D4YRD8[V:EH.JR<<U<.EVD-(BXJLC9).+; \70;(RMAD%FR2AS(N <*N%UK
M,O' IKZ[]?G:/TPYPVIJO6SH'J=M)A+/64)"_P".\Z9!SP6D9=H&-%6S1*JX
M(R XN=N@;%,Q5 =H2,B1>'"5;6E_*K6.1GUI5PG$P4;DSV?]KFS4_P!KW7WL
M#D*(A+K6@R9+9\L>"ZJVBL5:<ZF:MXGR5-[&LL9WER+.SO938:RM:#ABOS=X
M=6IW'+S5BGTF8A*(LV]U;>;LIU%Z]*K#36QN13L[5<53,<:X;HT.\OV;LJ20
MF%(&% QG >K.RB(K!]*XL$@$34XYVHW:R=@9N'39%:K9M.\WMN.JG:MM!K'U
M)8@Z]L2;7Z\Y9NFW68MPLGVJ1VAS=C^"Q/?D+,^IF *B^48X@O,C"RDL=BRL
M2$3"/;7-'M4XTG7KD\L4+"_0]B5/"W4)H'3_ +/]B=R>O53R/*LE8XT6[-+Y
M=6D,HR#E^V5(1P9ZX/;B&66<!ZJI"I&\$3]-,DN/*E&JNHOQ#MDU0U8F\6=L
M6MN-L>+X"P7)8_QZ.G],G3U^A+XJJJE7K,Y9I2G2TG-OHJ$.P8R;TRQCR#Y%
MP\([2(<B)9L>L>$[,J[AK(,+VB7/#-_S#'YCMC?&]QPNPBXIC/8@290Z4 ^L
M,3#5VMPL:^<S!)QS%-4HU.:1@%XY*S>)A-8 "20Y"*$,0Y2G(<HE,4P 8IBF
M 2F*8I@$#%, B!BB E,41*8! 1#D!>4NN;9G1S*MOVDZ=)JEQ41?IUS;=A.M
M[*\N[@M9\RRJIE74I;\#SC1!Q_XVYFE0,HU*>.30QI.NU(PTVPCXN*4B9.?;
MC@1(ZO\ <EJSG+(3?77,Z%OTEW)0!%M+ZI;8QR6,[V_D5!.D4^+[5(G0H69H
M*360=*UF5HDXZD9^*;FEDZ^T;?/Z<M8*$,!1 P>#_P"CS[?.'ZD\^/F 0$!
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=6FPEK)_I ??W$3>_Y#YA$W@?[AY\?XYY<<<#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g245976.jpg
<DESCRIPTION>G245976.JPG
<TEXT>
begin 644 g245976.jpg
M_]C_X  02D9)1@ ! 0$!K@&N  #__@ ^35),3%]'4D%02$E#4SI;04U)0U53
M7U1(15)!4$555$E#4UU%3$Q%3E]23U-%3D)%4D=?2U]324<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ 1P#3 P$B  (1 0,1 ?_$ !X  0 " @,! 0$            )"@<( 08+
M! 4"_\0 -A   00#  (! @4# @0' 0  !0,$!@<! @@ "1$*%!(3%2$Q%E%A
M08$7.7&1(B,S0G=XH;;_Q  4 0$                     _\0 %!$!
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MI^L)(0%CR.87(3;IR8L4B@*"JN]2QX[*VCU(K7(HJ&P=>*'?J1.T@ULR>-'
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M_*OI'U8BZN$^O/D4H@*ZYZL(Q%TA4F0L"#.6@;E7E42IF.#Y$3_1V3(C([2
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M@U!Z_IS:4;2AW8-X6.;3+R&QID-GL:KI)KM")DT#P4.L8E$@(:1M4^$ 6%.
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4A60Y$B,CJ3>.-7CP)F?'CQX'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g677153.jpg
<DESCRIPTION>G677153.JPG
<TEXT>
begin 644 g677153.jpg
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ME$0,H0!#V@)R@(?S 1ZX10/X6^.WT+ZZ^[,?^'CPM\=OH7UU]V8_\/)Z 0,
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M<Z:A3&$1[!#39.QHX2^H;!O3,$UA73!M<;(D4BW4!!4"EDP+W^I2_K" B/=
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M8PB8QC")F$',7WC]D_6U;X)K>;OYA!S%]X_9/UM6^":WA%IYPL]U_4/] ?\
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M6HVM'S<QDW$P=,ZD?;]BM3^75[7Z:L5H5W-O*>@      4I0 I2E  *4H!T
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M[G<$)6!J$P*J(@(>KKGE:X\57;=P13]76.=$$A%(J94_U,N-2$O6;&@Q#O\
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MJWP36\W?S"#F+[Q^R?K:M\$UO"+3SA9[K^H?Z _^(YO+1Y5SA9[K^H?Z _\
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M&0QB)] #T9#&(ET*  4/1E$$^A0  *'=Z%*4I0  * !XQE+))\DGQY/Y>/\
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M*QK/8DFUH]WV9I?C'KAD:0D=K;YV-?-CP]-L_%NGVM9W:;JE9;PSGK'#R4I
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..(Z5ZJF4,7N$$J9"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g144310.jpg
<DESCRIPTION>G144310.JPG
<TEXT>
begin 644 g144310.jpg
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MZ<\X10)X6^.WN7KK[,M_X>/"WQV]R]=?9EO_  \GO&$4">%OCM[EZZ^S+?\
MAX\+?';W+UU]F6_\/)[QA% GA;X[>Y>NOLRW_AX\+?';W+UU]F6_\/)[QA%
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M@KTA<4+LKF8N\08^)U(DR/0-"1&#$(R*[&[(F^K@XD<_FJU;JJF7\YNT/EU
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M)'&$:;8G/8F_0)S:I*G8FMZ*?$K@4$A/"4D[+7E/<U+WU8MY\CH&IY\VQ?\
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M^7LU9K(P!U*D4%X8YXHSEB?EL66=XSM2B7/%7BF/G.,8S.UA2UO[%WVM9O\
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MT,K&#/S1.1.;LSL[DQC&0<PQD+F)NJ&Y#6B>,JL[31R,?JD0E-$XELS3, L
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M8JT89!>7DZ9A[V/92.PJ#97DD =BZ@ <ZP>T49PNX'?<&<4P:\IL(C0)R];
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M)1M&V_1BL'R9"G$3N0T+M0B=W),_(>X($RMO0*5J-.O=A+ -2(]402L=!MY
M53@!M2F&!/<!H$H@*5P499PD:88#U.BBAA'O]>5>L:LU"WDMQ[MB/P].N<XZ
MPWC'Y1+1;,)+0M;O F\J(,KPN"888A;'.2%#)*,1HS3]'Z&:+1FR2@ZQ;%4Z
MMZS-!:M/4$,=E;4,G+$XR6J.-M7:M4RFG@&,;<T UFD%Y)&DE  A,C9QS;.Y
M&[BZ=>S1H^D#/+86E8A8IFDBI9'*U*%NY&$%>P<ITH+)VGC(8XW"(RDFC 7=
MYI1V=6K@5)#D%BP!:3#3-$S Y)-8PI)B9PE!R,)4G.)=1E1XP2Q.>D"%X&BV
M)62<EUK9Y1A8>7$KT*@T)"=:D//$B3N02"5)!IHFY6,PM(X!++,$,2%682<!
M*L#K:90,HT))H]ECUK)KC]QZE#JH9&V;,EN0\B#4/%6)P=)!6L%CX:ULN#VA
M\^V:$5 0:T2-EO2%$%+Y$,]\GC39HG)(UQ$\N7F2A^>DB>QE0,ENUE-H;#FZ
M!G!KIX88F4Z.3FW*W)>PQ1KBLB1L[<X3X4D1M[(]UQI!$F%37Y<&5#FDCF4U
ME;,Y,[26),SYQF]%X6D64BQNI(+=G'0O8CBG*""*U ,8R.\-ES!I)3 )I8H(
MXB-VD@YG:H\61MQWIWB%J'(AAY\OI.S0IY2<*IS5H[=B>I9.P4+-/4:(RCKQ
ME)!'+8DE$ *.RS,5P9L;4O'C&.H=:V(6^@0ZV(0O_P 0AUO8A;_LT'6][_AD
M:J7EL1V2\*V:\6_8QH1ATB01V#-X^[ON#&N//D;SH(_ZNQE@2,.A!UUWK1H>
MO3O9MAE/>"=7G59QL@J%P3;2OLM*46 _%"!H)I2N5[*5MR8[7="/1R&/E,Z,
MT!FN\6:487Z@ZRX6=8.#.G)-+<,]*8N>-XK<F/\ 2=T"%QD"UEY9,D<4HOW:
M2L-D*IMVV>#;9O!<+_*%U?%K?C'KK-UI6FH1Y;T-CI )BBDHX"O#AHIX29FW
MAME1.Z'CVLN^[[IC&,E!0NF,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")
MC&,(F80<Q?:/LGZV+?<F-YN_F$',7VC[)^MBWW)C>$6GG"SV7ZA_D"_[QO>6
MCRKG"SV7ZA_D"_[QO>6CPB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F
M,8PB8QC")E>N2=>CG$ /6MY CGV)C->FX!8>\<J2!*[KNWEZUUV(1Z,&E))8
M=;$-4B3@UKJ/TV%QO7773]_^?\_L_?F)ZZT?BN(&D-0Z,S8.6-U%C+&.G,18
MI:TDC,=6]78O5:UC[807:I%NPV*\1.SLSL]VP.9MZ>S..S=$F:UC;4=F-G=V
M&1@?:6"1V[]*Q"4D$K-W>*0V;Q6%^MZWK6];UO6]:WK>O5O6]==;U_9O7IU_
M9C+#<B*I'7LL&ZMB?88I)SU"MNV ._)-CB,0CU[,,6M=TL 1"&L;0[Z=]&,9
M .]M"9O=><_GIUYHG.\.M6YS1NHZ[U\K@[LE65V$FAMP/M)4R%0B9GDI9"J<
M-RK(^SO#,#&PR,8#T9T_G:&I<-0S>-DZE6_ ,HL[L\D,C>K-6F9NPS5Y6.&4
M6[<X.XNXN+NQC&8BKRF?CG\RW5,2+V@.V38\[:CM,0BQ:"JA<)7:-2+97OT^
M42OTK*\Y:8F+>@'HF;Y5D)6P&'M!@N0E*F2,L;K/I:1YU&X\80G3M&S-D&S*
M4*BQFL\/2&:WH0"5(2AN4D6%=X35&TJP_P!"E4A"91J52=[FDB=Y5(UGGST^
M+!K5R@)822="V$!1"5&G!_1I&Y E*(0-J(K6B42!,F2E:T K77H9Y%W 3TM=
M@XP:LI;XS&6#'0]&S'N-_*UI'CGU$8&VQ5<3,)P8M]GZF6CFMB\18N%[&NW&
MG7WFT1Z.Q$^UBQ&)9VQ&7>&M(+''C!(>[26@<9;G=MJA1P.QC:E:/C^M:UK6
MM:UK6M:UK6M=-:UK736M:_=K6M:UC&]ZUK>][Z:UZ=[WZM:_?O(KDMY4U#H[
M(I=*+1A#+%HC+@0&4R%2^$'M,>FYB=$K#$G96WZ6A2/^DSD@.,;AZ\L0%81I
M1HH8^YKJ(S>QF_R;Y?\ XM7W=F\79OM?92IC(<AO(>AK$,C),&N2MY4IFB][
M:H@B:)6VF.,G<XT=M/(&]B;%!B9R<5C.H"-,N3D)!&%J2STP F'IU!94IM3L
MV/B AU9G!(Z-BH2D*9>A-T>D4[1K%#>IVG/#^H< I:D4IMFE;$2,PD>RC#"^
MZ,7KL[>+.WVL[>_W_8_R=&=G\'9_L??^?%OFI.KB0-#)(#D,I"8;!I@U+X5/
MDY6N\9N*2#112IS3@Z;T)QC"\ENEC0/^L6Y,:;0-Z\H+6ZX32)NL%EDBASWW
M-ND;=UC2J.*U_P"[K=)Q]4CFD%K8@F('A -*[MYH!" :A7)C0"$$>M[E'_S_
M 'ZWZMZ_;K?[];]6\Y1:S<&;UM&+)3!".0P+;35U@Z#K7EEC&(A0*J98=K7Z
MQFPH$KC7[FHWUWY5CC6S1=]8'KK3Y2VAWSNEJ^JZ,//D=*N;W.0=Y)\%:,6L
M[[-S'Z-L].X#/L$-67)2OW?ON1Y&W$IM,:XM:&R5APP^N!C&AU#VBK:GI1F]
M-Q9W80?+U.KCC=F>2Q<BP\+=A[5?QC&:"+JBO&M:UUZ:UKKZ^FM:Z_QQTUZ^
MFNNO1K?3U:_=GG&$3+*<2Z3.OF\(E#E*0\^+H5&I-.3RPCT61%64TH]0E.."
M$6B1/R[:)@(WOH,6W XPOKYN9L-;@ &8,!98####!A+++* (TTPP8M ++**!
MH0S33!B"644#6QF&""6#6Q"UK?95X*<:S*!JSS^3(RR;*G^TCU+ B $1S&B*
M+'\A1()WIWO;2G/-4NF@="QOBY<$.S"DR<S<R<#N'<O$'6U*.Q YZ?P<D&5S
MTI#O#)#%)S5<83OZI'DYX^B4>[$](+LH]X=GUZ\I7BU!PJX=9"2I:&/5>IHK
M.%TQ"!\MB&>:)@O9D69^8(\-6FZX2[.#9&7'0FW+.[M=THL!)8"B@ +++ $!
M998=     Z"   AUH(0 #K00!UK6@AUK6M=-9\\8SJ9X>"XF>/BF,8PB8QC"
M)C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB9A!S%]H^R?K8M]R8WF[^80
M<Q?:/LGZV+?<F-X1:><+/9?J'^0+_O&]Y:/*N<+/9?J'^0+_ +QO>6CPB8QC
M")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(N*S6'LT\C;E&
M7TC9J%P*[NC0=W2E$J+WWTJ]$8+0M%*TAV@FDCWK81=!%&A&2:: 625AP!\K
M>2JHZ]E][8>\H;7$L @I7=M$8(!*Y+O?H#O?31:M-WA#1JM#(,WL/DC#=E\X
M#8M<1RS&$;(_D"T(L0CVQS3Z %P:5NP=S2E&:,(M=!AZ%JDQFA)UA.O)'@WL
M)8R]5O*;\G"AQLP<>5POFN.XA8*L88>_-_15\Q28CF+ Y246=PA*4Y)L?;(3
M>A:DEW;S>U94L<+N)=C0U\JMQI;.G<A*)7:P/S24YW80;(5!=V9Y! 1"Q"SB
MUB(1[]2&';&W/:LK0>]N $1)Z9&4$E2M<'-<9HEN9FEO)&K=7IS/WZ"&YJ1%
MFJU1F_2(( D%:$><2 ?,;'J^45F]?)3VE&>D4F;"SO20DT3>\E]==W2;_M!E
M+M==!/:S1;5EF>DK2A.,I097^])D")M2FHF4X.WQ=M(IM9P(& ?FQJ<PM:UU
MJF.+WO6R68\)+K,]@'L"N0Z1LH]")8CPG<R.#?D[ZJU]Q1L:*U+BLGI['Z3L
M1V->'9A*O9H5!D?HXVO(3%$5[..!1XR>(IH2I^<9>#SJK5=I=I=9<1\3@=+Q
M9K%6ZN1LYB,X\ T1M)%/)RMU+4HML;04.9BLQFP&T_3IR=&67<(IN.R29Z]H
MT# %2D@,2*4MD-0*0:)5JBE!H#'65O!0=]WYP2M226N6A%UVW-Y38QE;T4V[
MV9#^,9VRQF-H8;'4<1BJD%#&8RI7H8^C5!HZ]2G4B""M7A!M^6.&(  &=W?8
M6W=WW=]*+%B>W8GM6II+%FS+)/8GE+FDFFE-Y)99"_*,S(B)_:[NOB/7> ,/
M36]" (.];Z=-Z$'>MZWK?HWK>M]-ZWZ-ZWTWZ,I="Z[LRC:\YD I:O&)AE,H
MNFQ9OQ\B[%\UH]'#]2>MJFC4>D(6]"I;61E;4$N:I%(75J7A;5:\+$NV:C-.
M=D@EMT\=-?NRX"3COX.S[;L_@^SL_=MV]VWV._O7X.V^S]V=F=F=O%MU3B4<
M4HJWM%=,\)4SHE[9=06'N,E12M>E8W(B*/LDF8[AM!HV/1\NG+-(Y'.YA$'3
MR^G'=JSU YO*=W;4 24',.,R>[VZ..[#;\>;8VVQXB)LL&;$;=#FH#:0W,ZE
M#(F"/$0J1R9,ZUG'QI&!#6\KEBINL:2H1NZF9-"=00C..LOC_P#GT[_C^_/7
M,G%Q?9]WWW?N[/\ !_W?9V7C +.SMNVWL;LSMMLV_OV\6^*9SZNG1D2OBEAE
MIHRH/.FE9"9F:#6A;0-#R,D2*1E%[UO0E<.D"9GEJ3>M:,[S.:0 6M*3-"X#
MCIK?76]:WK>MZWK>NNMZWZ-ZWK]NMZ]&]?MUZ,I;-:O=K6*=N&.Q5MP35;5>
M5N:*>O8C**>&0>W-'+$9 8^T2=O:JNG<M8ZY4R%&Q+4O4+->[2M0%R35K=64
M)ZUB$_R)8)HPEC)NXF(NW@HIET6>8/*9##I$0%.^1AW7,CH67OO$#5(3A%;4
MI3/4<A7%>27MYX.H%"%4F/!O8# [WQW+-6\VG32"16U2M^<.\:VV538>];V(
M\S3>@-,J^5*_1WA?*\;1KH<L5#V+9CC#T.S1Z-< !%67.57$+2$^AM7YG3DO
M4*"I9>7&SR>-K%6FZ^/L.6S"9O7,8K#CZH6XK$7C&[-W(X3:_J\3- :=U=!T
M@M7J8P9BK$_JT<Y3VKY6JP.[F$7G0%/4:38SH3U9G[2B[L?Y_=K6M>G>][WZ
M-:UKT[WOT:UZ=YYUKK_X[UK7]HA;T$(=:UZ=B$+>@A#KJ(0MZ"'6Q;UK>N?#
M3L^5S^>T6G?;0:WQXL1#E&:U<2Q%.#Z((M&I7*:HS :$A9-] ')(T;W%[GL.
MA/A:5OWMN7?.A]":BX@YJ+"Z?J%*>X'=O2,0T,95(N4K5Z=A=HP;8FCB%BGL
M&SQP1R'NS?IQ+XGZ2X4Z=GU%JJ^, ;21XW&0D!Y3-70%B&EC:I$)2GNX=:<G
M"M4C)I;4T0.SO[#L\N'1[BK9N0EG-GDVI+L#A5T;7%"":X+0&"T1.71*:#7<
M0)>[Y2))S-=Y8HWJ0#"%.2T#/VTSZRBBR"RR20 *** $LLLL(0 ++ '00
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M@EEC'Z-ZT'>_1G'8E8<.G9:\V)/:=Z+;#4I"X2<E83YN8MT9M.$6EB9-L7E
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MRXH)^F5PUV,M)!*9FI3+F!#5[_5">M3WJ+V7'I,B9IK%)*OU;,)VULKE&R'
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8UJU0'0B$90S/**C>IHC!![@-A+ 1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g28372cgi001.gif
<DESCRIPTION>G28372CGI001.GIF
<TEXT>
begin 644 g28372cgi001.gif
M1TE&.#=AIP.Y!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M=^_]]^"'+_[XY)=O_OGHIZ_^^NRW[_[[\,<O__STUV___?CGK__^_/?O__\
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MFO2D*$VI2E?*TI:Z]*4P=6 ^!%$'0>S# ON@J4UQJM.;"J*#!4"!%&Z:!Q_
M):=(3:I-E;J/G'HP VB  1WB8%2W(* ..:UI4WFJ59PB]1(@+, -XH"#MQ"
MJ39=JEJ1^M,/%@ +%Y#'6Q PTYMNM:D[S6I:P?I!!(Q5#G!!0EK9:M>UXC6L
M6(@#!>::CTO@];%LQ:H@+( $OGH0 2RX  X0\ (&M$6O2,"I8VDJV*0ZU:V)
MI4!JV7)5P[IV'Y>PJ64]F%DY_XRUK&LY:UJ[JE>[LA6$"$AL"S(KU[70=:VE
M_:I29YO! AQA!XZ@PB64H($X )8ML$6J5GNJW;0"]09?X.D^^G&"JJKEN(6%
MK%?36ME)%F"T2%"N;--[VDC2=;2^I2E;XRO:F/KWOP .L( '3. "&_C "$ZP
M@A?,X 8[^,$0CK"$)TSA"EOXPAC.L(8WS.$.>_C#( ZQB$=,XA*;^,0H3K&*
M3S4 38S@Q6\  P$(8H(7VSC&,P9 C6T\@C5L02 #>(&-U^!9@@R@$(IPA",4
M\88MY%@@T7#QBX=09 !$V<94'D@TI)'D)9-!Q@NY,H_'#&,PM!C&DZBRF$>0
MY363>?_*24" E,D\"3 D 2%!YG$Z[DP0-]_8SEJ>\YO9[-DSOYC( S'T"+*
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M+L2]K;YP)?0<:@.H00G2*H@KD%H@]L;K9!]1:+T+XO""$(,/9OSLV.[#$$,
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MY+9YPR=OT>"B]T!J8)N>B;=XJZN#4@J[)>>JJ@L [L"1.AJD(6L0/&N0Z1"
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M\H*#UHB#W+@XBTF2[?J)YAJ-HNPW_ FG "(/,;0X=K&.9%&:JKK*SO1,RT(
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M4+P\.(-)19@"&#+=#\HM10<AL_BWJP4H.TD'>LN5M?B=/_H)\Q@B,H8/*ZB
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M'X_H$1F++\DM6(,%)_B0@2FQV'  E9?$86+_)*#0(4B2,OYAY&""Q:$% BS
M8<4KW:%GPA]0)5< %H)$\4AW.0IB!3YP6I#''!J!TI<56A!0P!-C#&:4%0N4
MA!ZDD4HZ*:656GHIIIEJNBFGG7KZ*:B;%N!)"7&L!D #GL!1%&Y%P=)!JG"(
M >*"VK$:RR-C'=2 $27D]I='[(T*!VZ [7-)+$24)-(^F.@*@$B,Q3CJEV(
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M#L7B%;D#4R]^:,YZZG,-3>2E']44AT>,!E)'B-,5YH0%)"PT3S(01"Q. 2>
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MJ$B%-/^8RZW.Y8B"05%3#*@(^!")PBF AG5<OIW)[XS(0/S>0?D1%A +$Y)
M(1@'KI"%\HP83WQAV6W2$3A!P\1!A>#<5>U#+!B**NQ,') ! T2#&U+.@$$=
M( :B( YBIHQ*^R25"!TB6OD!6U09'1 "3[6("GE$<%T")J2 OO0*6K!=J(G9
M [P95\W$F94);A!&03#%1!3-DR!!*)*3*<@"242*GP%%9=!'/CQ,!67%FP5&
M'0371PR:=-R$]T@)8.&&?V"/& R!&Q81 !2'1_@';D26'Q&17Y'%$5W10<B
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M 0R )R>$*J].+I/%'\]Q4#W?\1#8+=]-$-CM4OD33_3RJR6!!K:R-*P !2#
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M2M0R7YAF/"*_6@U<0 2D@YTY"CQV0B8H0"%0P0*D *Q=@+]G0<?_ (OH/ 3
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M"$U&]#W+9C*9.&107(NQ-%KG 0[*,MH)U SP !$PHJPBI*ZB;BZ* .*A!L2
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MG>+@9P[A#V+!S_!2U-HO QZ" 4R@!JS@_-9""JZ@TI@+0C@A%&;BH+PBG@K
M%># 73*M*VA@%A+P,T$S 3^P:JZF ;QA%A!#B2ZA#OK!0E3+'6*@#@1!"=B&
M &(-3TX3,7*  P1!$%:!#C)A1C@ "02A-17@"Q-(!NA $.H@O"Q#:B(" ^!@
M-C?A>QKCJ,)'B> @'RS@=BQC./MA"38@X8Z%!>A@'YHS>   (7M #O0("2S
M6?A' ^@@'U", ?ZM,C)C&?^P &K .TT  XC3 N+MWQ"#(B]!$/)@ Q"$1NJ3
M<*+N#Y4B0+<S%ORG>LI&30*/4C9 $7@@?-1G,_]29$4JSC) X#RM $$,Y!+Z
M815 84EN4A#R(0_($Q"-1'9&CDD*0 08*P&V3#:U,$)@BT<V(1] )Q+F,(0V
M@ XL@'!^QDS&8!\LH"H130<%P6M&R"**(!;FH$N[Q G&(#ZG3B!,04JM8 +^
M1!HVP -24O!NJ$PHS%.(9 ?&H!\LE$FD(316;NZ*B(>0*$%"($KMYP<80NT
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M:%OW""(7:EQ7=E,V=W5W=WD7T6( (@[R FX- 7&W=XWW>!-P1' N-+E"(3+
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M4@<2^=111Q3J >!.'!0458 ?[RC@#B,50!8-*@2X4\6C #3@!R8,/$ #)@4
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M@!<X81."N(($E$>MSY%4FZFJ0!+$N"%(0?-?? EEM\X5KQM<0 =OJ/,;G%>
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MT+G]0% A!@>6% &F0!8/P+OY8 7%D2I]6 /(BE<M""PS^YX $U *< ,QT .
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M8Z!DD&"03"H#QB>710RAEB%@W&6S>XM9HLE<P >Y2S 'D% !*72YL>".=S(
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MAC?'?>)@2. >E4V:;E<YDAY(") !7=EWAXZU-@N6@R0<P<R!%"2%7B;_':V
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MJI*.,OACLP<V49,$>AAQ;( :3ABB 1DN<&PA=RZ02[#<'J"!$4!(Z!P0Y)0
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M-F@0$Y'U@N$U9 #':\%"+K/T1A"<" !8F$,+&H6&.21M 1]^P1LT$0DBA&0
MJ.@)4MK_=,B1BJ< I/1!D")@E0)HX@VO\8F'NJCC&;3YB(BQ%Q 4L8,9],$$
M:"!"$ATU8X/D8 H12&*?58,"(# .-B+@#UL(S>="&-)14)B1O;2(A@\TFEF9
M:.BT8%3H1K&Y6-&R,@ FZ0%-@*(2% %":!>B"@U4H' K: D]?^ A2@D$UQLQ
MB+'J2:M.!,U^O2Y$$#S@!"@@9M?4(Z76M/F(W6W@(AX*J->.L(5[4N^\,T*
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M>KVA=)#O0#T$L:A*"B($,H+#T$9(R"\;JH4Y"@K:F( ,4!#S@(*KI*WOJD'
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MD6 [,[HE)X0 I+:UIJ\:4L#A2Y$AUK'$K.TF3?.X_VGP2,<E)S$QPQ%.IO:
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M@,G.  $4)<A?DH98@CKTXP1K"-$<(+ :@[$ "">ZI<  T)D@@.)[4/A,B%8
MBDL0QGZE1,W>_V"9A^H92YFQ&.9J4KE*,9 !4)L0A 46.9#5O%).@# 3$RS0
MS>B1DYL1<$00("&%?)P *LF)@26A, 3,W'(2((!"9&P3!" D,I[/DL$*(K%*
M@3;@-LPI &N8 YLB^@X0R<&-O@K!!"50P4!P6D40B ,H)EA2EC9)#TAC(4L
MJ.(/[H,".RF  &G$8 Z)S,Y(0[ ) $+B J]K#T@%(4O[2$$0/E442IG0IX$<
M 0P$" XWKR !B^;#IT]"@"I,L0\Y#>%3Y'D"$\+GCBK4;H\?^H_M!"$&Y*!
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MQ" MJK#C$$!P 2(, 04:4$++G  *8H^.H#J>=L"2\VVE?E,&WU:!$^!@S\E
MP04%4$,,XJ**7?=R_\T:Z%,<?Z-G20]AVO$F&!P^D 6!<\9.-AJR#W:S 01G
M8 KV5+B^GL %':1MKKET!!5^4P@N_$B* ;,/R,$@12BPPMS);,UN+A&!(4P&
MA("J-P-0P(0\S*I;*.#"!Q@@11"&A^?H#DV[K;" -?SLXS]2A5&/J(%$N(;I
M>8,W!-1# 13$X!5SW=I9,P"".,@#I44X]MUD23@-A@)Z58V#:QBUQ#Q>@!4
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M&+; ;LQ!9WV3T6 , .32#W#>*F!, DS!RS -#%2")BJ!W"$ *FQ!(14&H,"
M(CC!"F ,&#H;K06-L:@ (7:+T32<F,3B?P!!!3#:0ME)"X0(EPC$$U#![G"'
MG?S&9$!:&#1?M_QB =R&OPU9(^Y UD!C)_0! AS!&UQA" 2!'(2 'U84* ""
M$XB"!"3 #A!!+7SC+<D=2A6C.PH$HSA+W#S;G2  "VR 1Q5"$"3@/F'2O&T
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M,8EP-<MIEFS;FNL:@%_- GF"U4!U 4HH=$J#<(#^7#)ZS0L-U.S_5P98 V@
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MNX^!E!E-MT4V:W/ #E&K+UD;#;VTJSE!_[\_V[<Q0)6VR1&/G)A,0,*3!75
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M+P%-,%@<&9*#*O!*>"C8A 6NH(DQ6. =+PB%%M HOL0@8322>0 3V*#!?3V
M"U+!GB=$DH\Z'"H?/5 $%XXGP02\80L-X8$-4->[_^3- $S-2X &%E#*W@U@
M$JZ\ET,BT+Y\P1(,L'/0'%9$KP&$( :7C(5:'E:]!O)+1ZVP9(2@, 02JHQ
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M+J&?"42LP#"@0P\R@9)F\]&95,%X/VSPE]W0P=EY20 '2-D0FH/!"']T"US
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M/F (5&$*HB\OH0 ".$2NVH2;7L\'DO]G]T9 $S[$.1S"S/+F";@ $%:P @#
M5( B6]8I Q*3%3CDG<PP#TZ!)T.0;$C+-65$)QY@"C)(#:0 FR:!^&IB.D !
M54S%$/0"#41A#4(@$7H$/:# H\X#\$CC 3C@$<X'*!TA%%Z!(9(K..K "CY+
M7#A@%NY&$8%E0XI@.'># %&@%4Y@"%3@)^\R1$YM"('%5\*%$UI!#'S /2^
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M%R+A6'NXM&"D]DB 7RFY1N*J%FCU $#B"FZ;K9UZ84) 3\XC!'0  D3$R1!
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M</J8LN*ZVJ13D&6CXP-3$5!RO FC)^->G<!G!=^9#O^! R9<^2:'4^ $!80
M$$+ QW]+.AE !D)%X\G79Z(SU#YET,T'"\0@/!+ %-A6G<5%;LG&$PQ]".4
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M%' %A0P#F#K &('2 D&A3H T4;&AH(&,&2V29% $)HE*E#<2_1@P94$*  U
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M-6+0MA4BL1!*'6[K5AJ./19PPPS_:Z!UV ">D#ZX$3'3SL!8IY66R)Q_);F
M4HKOTS@$)SU*!^4Z*(" #'D+$@$52OA09Q%6Z* ""&/,?04KGZ*Q]!)++&#<
M9N!S#@45$>0XYLP'Z!T+\)(P4(UA'Q2# OQF\AH+"$(BV0/!_)80 0E8)P84
M6T4D(*$()\P!0?FQBQ0L@$!!B"$R7ID!G&9BA/!!82(,S)L%,L+  P$@!Y%X
MDTK.U I!"()Q3HO<78P#*ALBQC0CFTD8VF>!$QB$25R@6<1"$ ,+U.&!QAH
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MY4(;^M LC@>YR/ ))S B7F.)U LX\#[%N@(.[Q#*2/) ABS4H$QR9K"]*C
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M$$5H+YAP&/9B>@DP&F?!1T+!D!6  "-A"!  $A*2(&4S"5Q@>@,PD.)H!$K
M"CU"%"M9 (HQ"1R@A0<3#WSD7B.A!(ZP LQG%]:G"IE(4UNP/#*0$?'  _HV
ME$.0 ZHA$ZW6!S#Q ?!C.,61 X$C%$@Y"5*)(.X "B(1 AF7 T! -; V!/])
M0D,#@ $1\!MJ26@),FLF01,1 #\;X2 XU#U),P-D, 5*T $H$9B:-FN.0 6"
M*8-X$8!S8!#>6)F6>9D,<P.;8#44P0;W4P!^$(XI83AB!@"<4 7*= B;T#()
M,Q*B $*N.0FA0%[;40B-"0=U@ D]HT?&YA*NT'4Y( 25,%/&>)NY>0"AXG4
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MBO7>A$0="2X%<7#@K8F()D.KCA#5;'4#TS16M(H&=KI1ZMKFN(5#*>).R9(
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MC4]J.*&%J'HL9 5 F+M!E(\\"2JE#3+1HP916G@HD1\2X"""(0I00X@)5."
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M!T', J3IY*3?.VE!#2[T^U1'U8+8ZZ(5,]' A@.*XJ(-+K0XI(@/I$5C!7D
MR'Y[K!DKQ!1#.D=A@Q8*D4*4-8Z8)A$*<HO!!@94,246+:[*38H3^DB $^*P
M(QUAY0I>N8DJZJ> ]^BO*$*H!!9.\+T!]$X!JA""'%31BA.\#P0##%DH/G"Y
M/\0"-4##0$_BX8E8/")*I@#$(:00!S*\80]5P$$!<F"^(:CB#^^0UA^NH#(G
M,,('X&N%&-:@ ADP0@X*@F(4I3A%*E;Q/Q&J_P1_&*0? DCI$1F@@88N\"4
M' $5_6&0]&17 T-D(!2/" T ;A <BS3 $X;(FRE,8S\ Q(@A#:C!!V(EI0H
MIP)!BL;/%E0$3 0)!4%X"@#L:(A/<,!^@+P6"B[P@_U,LA9>"DT":K&& ;SA
M9X#Z1!% 9D<E2,!(%= $)(/4 ",HP5[W>L,0+)( CJ72!O:*!P]*I0I(.N8!
M'(L5CB( 0!X($@"*LD$MJ)")H>"((OU)@ 8:]LQ99:$&OK"7HCZ@,"KX*4H<
MTT0Y@U0 &4 !@%-0@DUR0 60)9)KUYKGDIX9R$D$+)P86&8.(J&#=<H@ HZ
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M !)ZAH4";/_7!/A>RA\&?_C%/T4&:3A*-(AD/ ;QQ095T\^;$(0A!DD#10/
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M[ .^4/@]20HD>H"\4%"$/T -J'0^YIL-\W@PMT0 (V W&[3!22  3J"#M7R
M34"$[QN_OP3,P$0C^](BPI2=]7,C$<N!)I 8+& #/L.]2A%+2@HCB1D27R,3
M"=B\,BB"*[ Y5C(%R?04&LB$%W@#$1G"3INR3 @2=_"2!RF$%WF]"& "R4R?
M'R@QD6J;V&D ..O'2$H 4_B %U"E3GD]7[B:6=$$4#@DM7J#%( 21 -.[1DT
M@EHC6\H!YE0HCA&WBTC"/@"U;7J]DIPF$7D",E"D7>)";K(!7-DF@HF #A 9
M<^(E'4C_)U@!ON?<M4XQ@1&XI5/+ME*93X6JRF![-F7J Y&Q3DV4PI%IB$\9
M-F@C FGKA(CQ'(IZ&'.*!S08*:J"M66"$OB4ME;,S\[9'$B8 X@J*>/$.T!8
M&0C8G'DDT=5Y PC@*1%(&9R  4L$ONAIB I:DY&#DGO\41 @%'.4G3!@1K."
M 9.0,GECBZP8@C"8@8I0.05HCDC0@FQI)8LX@L<)1]5RETRH!4Q!B1 XR6S)
M*[7C@3(@.J/3N\H*H,("GR)XA8'3Q,J""C05'H!\*IL[ FDX2,]ZJUT"P+<3
MGB> )#Z5R+O+NQ/9 #+H':^ U.DRO=FBGOL"BSF0GL&3( 2*_P9I6 /L2$"'
M$%0\F04"P GU\3SA.;*>+"_K>H+Y"LDJ8*L=@B,%4P)3,#_9*:_O$1+T*HK;
M>X _6 4N@"X,D@/ETTO?HZI$ -8@"TN\L )0F(48R8,+."+E^RM.V( G4I2W
M!!&/!"&+" -.LCVVZKY4%<QV=5? ##$M"B/'4#_V.P4"N($J4(X!,((3D !Y
M[2 "P );W;S8Z:,_P"-('2P.,(04R $FX*-@M0+5C)(%!(XEJ: 3(+)%:DY
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M J7\CVA !?^^BGA(Y0$I@"UH\ ,9@ HGD N7,@17G6C( M71+NKU;PX7D $
M P47D&C8 @<O@"H,D M'  $I@$1R</).3XQ !01@<1,O@(DC<(N($:\-$ 38
M@@*_ERT \01!<!WOCY5IJ $A<B,?D %0\0)9.!0'$ 1(\BOWCQ;O<A6(L1JO
M(RI-XO_0<BA"@".0\GN1ZX]8<2M7\P,Y<]DI<@&9\P I  (7<RNZ<#R=\1N?
MHC1_<_Y1<=7Q<@DW@0K/C>T&$!)/(!J8K9M(=*M(G[64H@)( %2((V_]_RLK
M:H '&8 'B3LD#_!2-_53AY (MZ(\EP$QV7-4A_58!S\3T( )S4?<1?49!QY
MP%-9_^\9]YB9$\P"H%+]]?5C1_:H6.$&0X/\FO(7  '>XY\YNM=L<78IHG8"
MX%<Q*'-D]_9O]_;R>_4"<8=0L("L!O=T5_<#>8+@S@<K !E4'PP+&*=U?U>L
MH8EN#TR>F0%CM_=_;U=^+>7%@%,[QX)+R(-(;RLCJ .6[B ^=[+UB .%!_B*
MM_AOGW#BO?B-MW<$(($<]_5H8( DYW@/<_221_F4'X L&-H"*0!4P/)[40%
MIZ*5I_F4Q_F<U_F=Y_F>]_F?!_J@%_JA)_JB-__ZHT?ZI%?ZI6?ZIG?ZIX?Z
MJ)?ZJ:?ZJK?ZJ\?ZK-?ZK>?ZKO?ZKZ_ZEV=RL+?WD\?Y&2=ULE?[M0_P"R=Y
MMG=Z$V@""Q-E\4.!3:@#(/JP+8KY6$^ %P&46)&B4FIY QF 3ZS/PD\0SR%J
M8#[(#SO\FP<_I+X$)?++95'$ UFH.?#W*J*J,:B#0JZ#?*@#?9@#($A17Q^
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ME0W8JY(G:,';+O"#N"@A'2O<0+A^=04R)* (B1H !E:QAO]IVJN<>5 $&%@
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M60^DUA#@1$87-X(A1&,$8!@(L;#+$ ,7 3?N&&E&&(*^<MK@(_'@P-RB@SX
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M&3LH9;"$R&!G!JPP 1JVC66J$&@%D5%(D3@' L4'MBH)":P6&A"");QE)T'
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MMKD#*#3B(QKB#RC<7.G'6<!,'1@"S.%,011")Y#!9/4A2HP<):H!$)"!$T0
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MXA($&NZ5Q1-L0 MLU-^I0A&<@K0$VD_4C_,=Q+BT3SUA0/MTW\<QQU,^A.B
MY0&XU!4HP!.\F !R0&/@161\"05XB1 <T5W^1 [0 ")XE%<6'!.XWX#LY2EH
M81LD0@<X@2\PP)=$!I[,R9X,QB#@&7O)"0!<F60^@A$(PBH,)22@H )0(P2.
M)E/P2H>Q2A49P?"MH"CP5:4I *] BIZY0'Y@ 2,HP@B\P0A,PALDQ8!@P6HB
MQ^N]"VC "%;4S"6\ VS>!K+=!OR5Y*LQ9]G_#<*J(42H15LOZ< (Y"9O,@"[
M 8(3* <!R( "+H0S]8$:")EO@@U.18 BU$(HL!+![%4YX88K3-A 4,1VE2%F
MZ!I =49R?,1]UB$ 8(%7*0C!D!MW_%LEK=4-K, "Z.9*O$$I(40&H)I5Y("Z
M.0$DH-1*K$02H, *_$ R3D$?WD ,+, (K 1O;L$V6H\GQ $,O.>-3<(4+,!0
MP%(DG V"2(@K*@4L D((1 "!_N8&,.%0<B(!@-5'X)N^<85,L<W9S 'O%$1;
ML=4H>!8 ' ':P($8U")[@8!Q)4 ["L8V]L%B*<&*OL%*F!;0W9P,T,%+M,0S
M2=T<L!\0 $)K0<%V_^JF3%BC382>3:@!#"1(Z)'![]!3*$D#%<!!'CR>7_C.
M!"# U,$>"W2"'(2-2IK$]6@IE2SDU,%817JD0(;&1Y+ U$'G@& > 8AD2&(D
M_?" %A1 1\IDUF' "<#$FE840HC$"CQ$AGCE2Z)3KDY"GXX !DBCL>;FIQ%7
M[JW &NB>K,UD H!EPZ  #1B?05QEPU1KH/F369*E5X"-M8K<2!E!IB6$MVS%
M[Q517K1%"XC?JTUF)<%">#W 9 K@'SJ!(61 *&3"'T21O#(& 7 "ZKU:* BF
M01#L9=+!X]G&+!A!$"WK&TR":)(FQN*$!#H:]16 .^R9HWD"+%S:9PA:%?^4
MD*&5&JME@J0]'E"H!T(8&@40H<A>&FNT9$'D0!,T#!8H(+%P6@YP005T7R5D
M1%Q4P!3]DJ[Y' ^^4J$%F^]1Z+O  !.LFCLL <+\1+;\V@K\TJ\\0@A<P/'
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M(2"'*F 8HX<6CF"_^ $B"0WPPR4$P8:'_ZB""748RP<4< @:P$ *^FA!#<0
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ML JEY"$X 103P),T0/_18U5$0BH#$ $<(D"&)HXL#$'P  GNC%($]#O+M8M
M'WP4!!UL01,*!T,&Z,V*(06!A'<^YB^K4*E7DLA8<%C0$.@*"H/6#J6JT  1
M/H$&*+B GQM%0QN=J,H\E%,ZXJK""7ZZ+!\TU: !C.>08'2D;@5O=HWNM2GP
MNA!2W]>OZLP !A+A W690IL?B6=5I"00*SVI$#?_*=15IXH8M/$01<B#0#)@
MBH^%)>I6DL()%#&"6EP@UVJ(@1:VE"04< &"I(T%/CQKIPPXP;P;-,45()
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MBJ#_ :-N4.+A-=FI"%IF!OED%3*%8EZ&EF;33> D! %L"58A,.F #2C !#B
ME@"@$!*3#AB3Q&S0.!3$$;01!@1S#0K$!KZ,.P' "(B@#[93 9Z@$^;G2V2
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M?,!!1[?_$RSS,B. 6,^F._SFX,XP A@E;?EF_D!@ ;I#%>;@ 6&E:WP-"LC
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M6X.'03P")"3@5D^R(MVA"K0 !::5?F+21_#/>L*@261 #"J22\Z57IU[((X
M7UJB\*QGE5O$NY/2(_"% ")Y9+32<4#U!PJA"? 78-+AO25&&IBF^B#V*1'
M#RC6.?[/"G1@$K) $Y@ %B2@*Q$/ #P+$0B@*Z]H5+;R9 .#P5FA):SO:3V!
MB8Z$(VP/ P2A9L>O16X #JR@4P[B7CXF+38 [^)O7F8RE@<"O3!!@K1 .5RB
M5*!6 5 33B@L+1*!#$P!I5()#A[A^38@4DYD,K_V-5T&RK?K0/XO_R2I[!&D
MDXB(N (.0";@X,+>@PUXA(S_S1,4Z5VX@,IK()ZB09#LSP@6I,S4SQ-H"G6:
M0!44[G2:,9\*01&P:"$X!0<I^@/T" J:1':R3!7\?$:@S&[W;HZZS%58!0Q
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M ;=ZW,"THYH ; $HM'FJJQT7Y>K/*AD[JM+]NM.FL35[C71T*BS]9C3 ICJ
MV W?C7?>>N_-MVXJR"!*'S7W37CAA7-K0]N&I\J"!Q ,KC=+0RU.>>64X\L5
M $]0P9KEGE..@&V3\AV-)I'88/?GJJ^^-P)J7%!G B"<H#'KJAZ2J>VZ[\Y[
M[ZCF,(8%Q/I./.4/=)MZ\8?GBY/RSANNXZ)$8/5\]0TD-GKD(%P2>/7>^^ZH
M_P5AG?#A]UIW^7WZZJ\_&2HI0,Y^_/+/3S_O!1@+=_WZD_KO_O[C/8!/S.1_
M!"R@ 0^(P 0J<($,;* #'PC!"$IP@A2LH 4OB,$,:G"#'.R@!S\(PA"*<(0D
M+*$)3XC"%*IPA2S<8 &:UL(8ZBX'50 $_!J6@#?@[ @ZK%P.D_>0!] @$T#T
M7P[S!Y$C)J (G6M8!C@0AQ\HSH<7(8I9:@"'*UAQ(&.X0O94-8!)X I?AEG?
M %XPM_D-( MIU!\"7C $UM5F!3,+ QW=F ')1"R/&-I ^2PW@!"4(!:/2!@"
M>$B 0DQ)=PC@DINJ=3Y-$>Y\*9+AWAY0A5-,L6\-\/_$.]:#'4^"TG %\(0A
MK'BJL[1@DP?4"A0$!S89^*(/W,+(W5  BI@,\',U(4+S'M* 4<!!#"B)FB?@
M8(BNL*H KIA!"S02AB:,TGN4F4.=Z!<<( Q/?YO;IN4$5*%"* *5\LL #PJ9
MF[X\(CA^5)T). "%(7R-5 G@ ":TQK7=8:J2=S-!),13.!H.RI(JD1C,V%4K
M$!'@ 9L($R2/-:IHI*0 -?#%-(UIB&F>BY5=&UA63-D\!!1181R-6A(\.AZ1
M%71@T9CB1B-:TJR<=*)& $IN&K 5"'"+)"I]TTF+Y0DE:$ ) %7)3(MRU%0=
M;6 UN4DHZ3 27N7 %((P1 ?_WB0PL&4U:C*(P!]7JCB!W3 Z/25KOY8Z418
MH4'\VZ18JR6PML658@,K@!J ,%!GH?2E=-W36R-F+[[J%:7105C4"H'7LY8U
M*XL=&5UKL[-1;35@*D7  *;XU\E&3;-Z75E?M)#0-Z5FG2PH$6$%V]G-XFRK
M!7CB*VKVQ$(60@@$(FQTD,BJN0)V:X^4&,60=C1#;E)JH746PP9  $Q)4H9W
M"HL%/K >3/8"-OU '5\&(8A^P* *VTS 'S AD!M<0@M)T(H6#\$$)&3W S.1
M[B9(\P$2>$*]^B"+6>9K 7U0I)Z720K 2@F+QP&@4!5(0CTOD8\HD*24<,BO
M#SYR_XDZ*)AA#RA"@1_ A3G$P *"L&E1E@@#.H3E$0/DR27\0Q*:%"'$/0!$
M"$0LB!/XH%DFP(!Z_Q-='F@8";'HR(N>B(0Z]".>!0"!% 318E]I14/Z4 05
M(!$#GUP!EK*C0X(!]*(<1$('F@ %$1_"+0V78,BTU+$ID&"!*\216Y-C<U#>
M"8=\I)DV-7"J2C8""5 L #=VA4$,E-"5W8RA'[&8G* )/13*; +)'E"!3;*
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M,$Y9H5:#LAN&2BF:P6OX@8D30 )., .B0AD4DAH2\KR@$ <3 *@=/&!3<!\
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ME\#*MP:W&, &NDP#,[M"9!<%+_H:KT"NH5 !P#0(LZ!];# I#4 -I0DVGO^
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M,R @P!KQICXP$$\V!T0<K9FM5HKPI+P;P:\)AT!,$FH  YP1K<$Z\G2:%6I
M!8 0K1[L"I  N6C@>\H^ D.0;"C<'M9EIWK $=1S! 7-P1ZL,X<2B0ZE$B;
M\SA1AQ70 /7[10,VWE@A':(@![Y6J]*A&,,Z,TZ0C+!M"CI0"W>$KF1OWP>9
MW]:XQ?PMQY0<DM0S #_O]@!P(@I>QG3<6G8L#>W$]P?_4GC<IQMZWZVUY02B
MH#%Y/P2'3SU380.?\ >1=RJC%1SY= A% ,PR$ >/+PUP,1F.E!4W\,F<[_F(
M03OXW24**V/ -/JFC]]-X! O+@&JD"D6JS%R*9CH0ZZBK'TL^QUD\+(:XP[
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M@#!F4/]O/" H*$"-('1@X $T5L"I0_4*M$&! E#PCP 233P"@[["Z.0Z!%@
M18ZPJ( KJX5.>XF!#-"@J8 .*7 N 0R@8*6 0DS)HQ(JJ8!)%5-$$5%'G-0
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M8H&,.*  NK7;<&T5YXB7%QD.1A@H-0O!1] Z=V"$?BD /V"6!!@!$*P"?1D
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M@JD0$PQZQ&!JAB9@"XST,3$!#;4F:WSXQ*4"3JTM9!;P=$4"@4-<(FBX"J"
MD56F=*2@F*"(#;!B?4E@K,24#044472J !$AICT\)KSU% &4#K )>.C(P*/R
M71L20%< ^X#'!PD358&BTUM&##BY ;R>$#EY"L81^A20,0/K(2J9P )X\N:%
M!L@ !GA:4#)B@BD+(@\8%0'"(2 >WDI?4__ 200?"= L ).#R@3/ T LH E_
MG@&0P1M@0&20*D"@MIAT+407P1H)%F3""*A A *#).!7TGUS2)!#)-XUX,0<
M0P!84@-&3"?1?POX)J(.OA7X1DD%L  *)'.X (",GN'8225'F.<; C+,,0(5
MG7T'PBH^L  $3P,X,4.(4S 9I"*.\.C@#')%5$ A4OJ()9!J4.$!A8N-64F)
M,_180 A X'!?!#0>,<(0+H*P IC(5>E" B#<6>$(;X  A6\X K&&=*Q4F&B/
M %@XB2I4B)8!&A]XUH ,HLC10!@K0%J0*APH084<<XVBZ&*J%/$( 9<J1>$
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M)06>5FMT3'>D@%O.' )H)D6\YL\DP4>6Y&+@YFTFR&[JYF56W66ZI6LBP'^
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M/P319!BJ03P%:!5?AX)6I1677TU IGY7%(@88\S9;QT!; P/$( "K!74:&A
M"?3#$HR!(;#F[AQ0QZ !)!1'/RP8^-#5<0G07&B =(70)$S!#*PILNJ>>&'
MGB[!!FP0E538A7G(%(#"!E@ %)E"?(D!47RD!'"+9RT!'4"!?:"!K?+JE'T'
M@JG7> Q*A6VK+Y#B?ZS "HPCF('/#FR"A?&/2L8 )%R"_-3"P;J2BH# !FP
M'" 7=,@26'AG30Y*"8A;'/S%=U21!?3#\]C0=!S)"NC %C@!$%#!I(E!R,I9
MI2K!$(0 *%B-"6C .BW(!)QL'U1+#%C_6++>ZYS%P0K@D+?F0QPLP1*D4@B\
MG[5"1 ;4 !(L;9/M3A@(P:U"03IP#\D2[0#T']AB!:F9&;+^8G1TPAJ$@!#
MP,"FD2H,@B"@&"R1VB94:I$%CA1 ZA6HHISE7QZ\Q\](PP9$0@F,VUN)"1-X
M&5YE@"G0[16 0>%2DRHPP6']#9N<JR 8Y,RQ81U(&82H I0AVZ95'0LL00NP
M"YB(217T@HW=6L0TZ64I!3KQQ!J>V]WF WB!!0I(C$1PE!)PP35RBQ*$PDT=
MPKGV0QY\C\N8PF&)P0_83(*Q@03DS*H@3"](P67%Q!I:F2RL0M%85 [4VO*6
M6SSP0I3!S14B_]$?+)C-P$(ZW,HE3,Q'B($BO(%M;4*Z?L(?7$)!:0*\4<A'
MB!J.5$%(X&$>X*\>S UTR, %E)M/  5<M(M9V(R_<LLEX,- ZFT(0'!OWDPZ
M -(E:,%=BDT1* $"64LF].^" 1VT/64_Q8$';$$(T %?/$61-4 (U([$%8 K
M4(Z,,LEDS+ *\/!U3(;@UO &(/'GG,7GZ,$$C8Z>,4!R2-RH.@(.E4<O<(
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M@9Q)$(#CZ9H3F\1 )5#)' U6K! H>SV.ZH9U@>C)JF\:(J[)NEB,V'" K.1
MLH>)*@C!*5"952P*PO@,(=$ /CQ.OF.,RAS4R00\I8Q 9!1 R9S3A0)OK+!
M(LA#M8A"%M  (N"(PY<H)A2 &EC3Q4\W;P, )[34QU>!MN6 %"!"Q4Q*-9ZV
M08S$IG4\E8EE;$?A2:1$O81,O93%3O3V 4/-C8S_1<()Q+$SABB0=:?)5K,8
MA!$0/0"X MVX _#QC&BPRWG%0Q$ 0@A<PBJ  @R 0O= P$A0O=537B$X A7T
M%2:4,6)&9GN71:P4A<BIU1)  M?3 >6LB5KYF2-H0"QD@B>Y_5UP"B*"-Z>
MJFN,5@.0/1!85G%;\6?:P">0#QC(0!E /HQTC=S3_0F@0=/.?7!,TX<KVVD8
M$(G4@'A(2UZM%A_/A?ATS!202'2QM"E@ON<W[R+_N'E\0@CIC_W<@)X7!0B(
M&' XVM9OP E([W/!!1W$P@EX0*;BQPY(B5.,N"MWB&P]AST-O^(G B" 1H,4
M@ CHP+^"P(HMRW38D]P3_S\$,V>,<, 2K (,O!;SGV1)BGJYM?@6@  ?L%X&
M0#\=7,(5  2%')$F' !P$,  $%\$B:%P<("3&2X %) QPX<J@@8!J *BPTFG
M-2'G+- TI0(!!!+):(@# Q3,"Q,R1++!H"*+3CYJ3B"0$Y0BES!E%BS$Q,(2
M'1!^(DP89B< $S5>Q@0U4\44&PJ<FL!@!09,2!=L')"QPH>,3O(.UBRKBDI*
MIQDPW&RKX:V&1TV='MGAB,ZE.'*<YMS@XR *+J>\^N+X .\D#GL+L%A!!@04
MK@@'&+$"22R=5P?X-N:80(,O!0DF\TTH(U8$1XZXQ'F(X,F&AP .A=)22 B.
M@_^'F&@!\$3(PP+(=T>KY2C&I5BG"J (7CA'\0?%!]1 =&@0H@)&+L$  I..
M:B.Q5IT'E?[3'TP$JE<1SJD*80 /!LWRI/J@!VA Q+4!/+D"IXK^4Z !^5PK
M#,(()9R0P@HMO!##"PNHX9WQV*"H(E?8D."!*O!IZH%0*JC('3;8*L /0S8+
MD(9*DJA(!E%(K&+% EPY@96#?!2%E0)R$$(.(ZZ08#\:M$  BT00 Z"!(BK
M(@Y%1IADA!'6."!*'WZJLH($.?LCC@@4J86.,M(QPA (("S DS@3L!*G!F_"
MX@(=WMCRC3?,K,B("T +:PQ8^DB APGRK&&K.S/!J3O_&U)@U%$ ,%6!*C5K
M8<*02XN8((7"&JCA S"PB( ,'IH@ =5T;EAA@1'>T.2--4*@]=8W)A'4H@CZ
MT)0''3XIME0Z/X  BQE^&!,$)>2L, $T%BA5TRFNK0B$"%A!(8@(_O3UC2U<
MJW8!.=%]P=I2&Q@E@B$*Z020,4?1 8PG0)F##%PU60., :R=%@"_3(%#C#4,
M7, 1>G\J0(09^F@ C3GD'"]>N)2P]=8AP"@$" \,0D $BYU2*%T<,8)K!C)Z
MG21@$!88%BXH^N4XX!U,+D"53CQ((H%N:P&B(*<0D(&.5;34 (H63(A$AQD3
M<F*#7B*)@,D!PI"XHA" :$&5_T835&4*'5Z8HQ='=!C:D3DJH7('($;08)4M
MNWP#C QX* L !*29HP^R[4* !5!T8%H1+FUE*B%-J( C#[DXJR4J$^A._&X(
MJB5":LM/L%63+8<H((1.6I"F$Q!ST.J 0WC0PC7+ =04+P4RT,NU @K9Y(0Y
M1@!AB5,*\[N3W0HIXI0C,)B]6BBRP!VW#5H 8?:#HC'B!$5NW7(-UY3WA<F$
MEC_@" YFB1W-L-";K[H-A#/22>N$ R ')]N?'P7W>68BCSD4V0$.6N"9?9Q2
M@!0AHC.^^ 0-Y'' !A@A#H"XVQM&!T$/A,Y60^C.?'B3'R/103\">H0G8+&9
M!VP"$?^%H1,LPK="!6R0(QF2X0QI6$,;FLH/F&" .^+ BC'YX1T,2)&- E2%
MMP$@2D&B4Q"=DB+842F'"A"07-QQ 0K\L(14^D,$BG.C*1) #1=HP4]RH*(;
M7$ .#Y.&H,XX1OI9Z4%A^DF*'D&".BG@0>,)U0.X4($;G6HK^:M710I!AD'E
MH B/B.$--@"(#(S*(-WY@*C*1"5441(GB'S$KL@PQR)@0HIB*TRE%) #(% !
M"A3H#A$DX Y0B.P@A7@#"X(PJ8,\X0U)& \4@L0H'>B-5)9,UR$Z84O6+,M"
MOL16 K3EKAH0 0(YH$+1>/8&;"&$F7S@RE06D(4:;.N!$8#_P"&FB9,$?+.4
M5(A:6_"&+C 4; 1@^ D*7DD";6GB(UQI'BO0Q:0&B$!8.:A=13* -[>8<V G
M \$,F 0QB0UD*^P,V"CF0)'5+6 S!86 0H15D6:YD0546,(<V.*40PPT:*OP
M@0FTTE 9S&$-$8- (4#AJ)4P5&44.()6N%( -03!D1I8@A):@ )3Q&$.6;L(
M9I00OB.,8 C,9&5"1- )5K!TJO]<@2*<T-2#/%6#_[K1[2**D*-955.9"9\)
MH*H0*#24!4# #!1 = 1-# $!N]+5"G8#%]CYE0!\28 3WGJ0L-F  ( M#08*
M2[H-",\I#;",<A1S"K>&SW6/V ,/_RC#@@VL(4<460X7 .$$48!H #L8PBAE
M<(+P/5*1MWL%7WSJ/K-B#S',&4X1,I$_Y1RB" +4+0)N8!\$8 ]$[J"#<>2'
M'1K@ P!A!()C,F _+)Q@2@T(PQJ@A%TA;5</#@( )ZZ# @+N)SQ8R .(."$%
M A40"Q\Z2 +^X)@&<?"&^=7O?F^XH7<<X %%B!/IJF"<$AF'1J?098O8<JKJ
M[:<*<? !X2X@/ $!XD8FX, 5(%"9"V#X(.ZX!!NF-,4D-,@7?1B #"ZAA>Z<
M *]/",4C3LP!**C8"7!XQ*  <$8,)X \F$C'@0QI*NRMX9&5'(!\&#  #)R
MN]8I:TX2T?])A 38$)/@+*4@):I,52H%W1&%*G.L@UU-2B%T"-6=@AE95'78
M$R7 !!@ 26<CB.('"% %%S[P)E&T0,]<L$&'E]KD8F6A6.]4%@0>N H/L&L,
M[Y!3(:#ZH/DV$R+(HE*W&&U:0"#@D;X@F) \L8I*K'@#'\@"&HC@KFY-S F0
MR+-GEV61%0"" 6&# J._R22!IHMT,P $NM*1H\0Y80Q74+',+A8Q'U@$$AY@
MP.V4,#HG .'3+(C!!X;%&6:K[-DA ,6D]!8!'S2 TUVKZ;0U(+'., )?&IDJ
M_31@A2G?I=8AB(%#*E-+/0-A 6#8VK)GT *M<:T 80 "!1JP*VG_9V *PBJ
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MF98C!GH $(Z@45Z@4;CB5%)&(<:@'V!@VP@M$;HG0IAI 6XD6\#)$XB@EXP
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MXEGZ)@3*,18**Z\V80"78(P2#BU"H H"0Q"\ZPDM8-X@@@4V(1\NT@S_ :N
M] X61PH4Z,^L)JLB4( &A(=P[O$BQTCF$!$"U$ W= <F$Y&0RE$0\F#P(*0=
M/3(?#_+S]N)A5"$49BOL-BP%,F\W#L%)W*'R@,LX&@ +X  282 ('B('3*$.
M+" .>D'KJN,Z3*H(4J@S\B!(,B 44@@ 4.#[YD](5 $I]L$*4N*!+@%(\(,P
M^))&4N@0., N>P&%\@@NZR ?XN GEVPTM,\Q'U/[$@ 5+,V&#FP MD -)V0
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M##K)%1EX!<RM,)[@^Q20!'8@!B!!"O+A! :)>#<A&W%:A:0A""2GX6XM!(0
M$BY!6E[R(Y/[";NN(W@  NUBN?E*A=:.\31T"UY@$!P0?%9L#%HV#A[MPQ55
M A  !1P1)%4BP6&@LK,' [+Q%Q&@$$S! D1;88!C#DJ@#O*@7H K%%&Q.J3
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M"USGI(433I7_0R0.<I6 $Z*T0,":$S19"!<5=*90(4"01AT&="RQ1)R 185
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M:< H%,&:J,!N!A;A5*&.-0 L%>DJ"0#!ER9R([F 8 X2F,@<ZM4 5\R@#52
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M<WKXZ]P88!'"R G5'8F04UW'<QS RBDJNVE.8AF@32?$0!!7:"M5HD.XC)B
M?QQ:BCH70-8WO&$228@.;/J#@0M$0!&UR$D*'@ /,<X@$AO@[ @F\=DD#&!
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M]=$ ,,@*S$(>D54 ZL09@Y4F3A)T&O$ 3& (G\ %S6%8/!9LA-4;+W4%?5
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M1'$@6R.P!M<12+W!>5V6$9RG;F(V<TF0 U.P1E&Q1=2" &K !&+ 8BX&8R$
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M1:09?G LH^Y &K"/!#30(06":H )A:4@@0$4.DY $*0&C*##@BN:4""!*70
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M<O_5I!8ZE'BC5*L*N&$#]#QUWKX'.,!;//((<&>)2EZKESVKI),1,B4F,25
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M<0(X@)E/<()-<*\#.#=B)8,=&(,H:,RADX%+6 (RR(!: %?TZ,%PW:I!@$U
M>-3[4X!QA0)Z],#:NR%];="!9=! @H/74<)]:(XV"R0&'!+PX9)'((&BM(*
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MN!T]*!232[@"H'A=%!+/T163O>I'!" !AGC=3 * >  !S<V_!%#61O7#LP.
M TT]@5S7WG2*<_-<,'"".NB7D]#<PJ G@278[47"AGV$BW@ EX$%W$RH&'C9
M/3&..GB'=  1-J" CXB-]"* ^ 7:'/T!)]31YVA2I[%?)&/1&XW:5>@%VEC
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MP7"%JI?I%!/P05_X!$^ S3:>K)1L"",03O+EWE:V/>FXA,X['NV</"XL2'<
M!:G<$UC^ /9=RH^ P!_@E:STR:7$2N5#,BQ8PDHXYN[8%Y2%6@[520L0!*[_
M-(2QB04]Z>%-R-DGH8/-ZBPZ\-D671 UX&9 R "L[1;>X^;KNU2[E"Q!^ !R
MPH ON +R'8"F[$F*6.,K4 27Q:V=W =+J&&9"($%3#?>M-)?Y:8C6&,EV*(G
M:%Q%W01".!+R2]07<.&=O&1+X..ZU2'RNYM;>NA6$Y/ !0HU8((XJ( C9LR[
M'+'.\V*&$.*D<F@!W<G-R@,3=HK0S8/22S\!33=JW@?^*PHIR(->>,&D,@'7
M2^ATXRPY$$\H= QU,H7YK(,XT $5T "H%LI]6 +9T99"&-%T\T[5.S?\%$AE
M]=VMXH#[^P0,P.F YDW9H:=^L!=7UNM7GBQ,H!+D_T/6/<GGQT(.XT""")4(
M3CC4,@ #&4B^!:%? G"^^B5GY$-F 'B"_9U@0JA@O&2#"E:%&(B%1[BRAC6$
MAZTM([6)K80( '"^@0D!"K:/R>;J2U IFS)$$"1K?1B8%8;CEA4$0Y ?5=/.
MEIX<E_V $<!:;>Z*B32%$"$/'T8NLW$*YU/4)0R_::+!3UCC#\@_T<QB7.V!
M*@:MX*5N$AY.\5Y5,)XN#1IC]FLQ*V@,S*I.]%!C\_QND A/I%;0!WA6*,AO
MR8J% 5^":;EB00!P 2D$_OX7!/@\,Q3.2<  !)^WK8 V6<30V#U03@Z!$IB3
MH CE+)CP>[Z*:# "_-[K%/]_N^,I@=>A",):% A0 8NJ Q)O  PH@0^\+SC0
M0*S\V&1./GFJK3@0YHNURI%J4?Z 0'DZV3\U#J>5E,FZ AYV!SI8 D @ 0R
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MC37:>"...>JX(X_CN4*'#3WU."211;96@ @E6*#$$!F  (<89#AH))55&CD
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M02AS5GXY9;,H'0H2.0DDR"DY;'()+/^:/1 *&^E@4()@ EE!ABF7Q $#'8+
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M1ET(1E\!O !2+$U9.0('J)U(#4(<*,)$Q,':95U3V< 3 9%>U$$L( +;/:!
M4(8@(($CGF'X@8E9..#=62 #ZED.7((6%, ]/!%KM)\6(, +* !HQ:')-8 [
ME,T-$"#EN<U(]!7P*-3_&<5)-$%1]7!) @S"(JG&%V:.[$T@)C;=Z^6@[+7$
MZKD=:+4A"L#A3#0 "( "3YQ&!S[C(*JBS,UA"]P $TK0)ZB "C@!(QQ? 6Q!
M%HBC$UR"Z67>]:F&0FV/:M @#YYA)JJ>0%3BEU1@&MZ@Z0"AGFF@ U5 A>"/
M!?3 9YF&$9["0"*A-JJ<_<F!]:T@%#%A?K2B&P)@82# ?O0?#?SBZ=WC["T@
M[968#X+A/;X&*6(D332 '^P%*Z1'![K#!;CA0ZZ<">R '@J"$G" 1?*6"IY&
M"!I??H@@3>2 %%A +S@"4TJ!Z,QC#8YD)$8BZN7C#FJB!2Y@!29<DC6 3@Z'
MP"$,!Q&JAE<Z@@;PY'!H@4/>),G1E9(T71ZTXTRXPPH\C34F@EW2Q!OEY7$4
M0A& C2#T@QB$5&J@WMW)20(^X#%:0 +:H&&2Y#ZHB3N,P4B8(=D-$2=(09SD
M1!6RI6?>"#UF#C_2GMOIH/A]WS"NGB/VW&>V9J=H8NU48.DD(!FZIFW>)F[F
MIF[N)F_VIF_^)G &IW .)W$6IW$>)W(FIW(N)W,VIW,^)W1&IW1.)W56IW5>
/)W9FIW9N)W=VIV\&!  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g28372cii001.gif
<DESCRIPTION>G28372CII001.GIF
<TEXT>
begin 644 g28372cii001.gif
M1TE&.#=AIP.C!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M88\;L,J0M-$"U4 "!E (NT 7.'-!;L]8SZR0)S-@@$$6.]=0]M077 T!!A!
M8 _.3@"@ -=OYXUS"XO,_Z"WWAG, @<&ELR,M-),.PWU0!=L <$4N$P1#RE&
M)*0 !4],,444+F01=-6#_TUXY05=T,7C'TR10"8S.T &W+#G'00=L'KB>.13
MV'/&SE6?#KD]02P. -AGB%T#UQB<P<#K670PD">/V)/)K0O80,+C4:@NO <5
MV,-(QWC#;H\(2P^$P]RB9[!!&'[#+3<&"13O;RJHVZ.[V <=<<GCFN"\^T!M
M<$'LWD<'FCVF!F((0 #DX#S&#2(&;U@#K!8@"C%4P0P+Z$,, E"&SR%P"5E;
M@"&HH(\B\$P,;Z $[\(@AGV\ 04;((@GGA #%. /(3(0@CQBT @P"$0&?%!@
M#__;H(8-*C &&UQ"'(;WP  848%O( (9J*! )U8Q!I18A! "D $)9'"#':R:
M&$!XJS (@8H;W* ^LA!#@UP #E2T8@#F(06JS?")1D3!RX8'1SD&0!]>4T 3
MCUA%?9 # $1T(AK_F 6Q>8($B]Q@([P& $]8(0!K6-7=J(@"$"P@%O(H1 ,1
MZ040BLT0FR!D .2A#RC,S!!\>$,G.C;(*L[C:1/4(!X5R$ 9I/**"FPEK;80
M1R-J(FL'(6(,J(!$!6JBBP*!)1XWN$0#,D:$<2P%):LV" 66P@P_%,,W = '
M!9(1 +!(1R6( "L<D-"$59M$ /ZP,Q%6,0G" T 8'DC_B!LF<XL!J,0289&*
M(,ZC$47PP"6)P  %.,"AMF*B/,J A(8RX*(.6 "R:@"' .#3 8=@0 V:$0 ;
MDM.<R$SG$F1QK1JP@0IOL,00%)"(;E8"F00A*$P+ 0,%F(X/,>C&M3S131@J
M@%LE:!A!/""$F!Y" 8IX0@!&$;2',B"18S "MP;@TAAHP1(55<1+94D 6'0!
MIC+EA!**6(6@S3  1/"B.SF(!  L( 4!T($/!=(&;ZRS=EO4Q!DVH "F>M0-
M"P#B/&99$%ATLPR1N, .?H!"'1@M@P' A!,LBJQ=R4 -F'SH!,@ VBI4K@U2
M)8*KCB#545"-("/U:EH5\8P _[R!'+!"Q29NBRR'.L"?UCR, M@0@$: -@ND
MJ^0@Q^!%6%8!!E]4H Z65@-OZ&,/JW('%1!Z0BV@K6K-D$<C<!%%_%FRI M+
M"%/EP<@(U*";5-1!$=K05,:"K*C)%8BP' "'>>@ G *YP!91$('HYI6Z8\0N
M  QA6]SR;!)3D!]!CK#%K [$K%YX0Q$(<%Z&KLP08J@$U B@ -)*X7,"H; \
M4$"]N79B 0\.@#U\D,, $")6.%!##PD0AM0R0 D9]IS \"I* )82#5XLISZJ
M*1 6OM (L'P#D_T%2A@*3 E46,(>8!6+O#IO7C7^WI"S;$(/H) +KUK "38A
M!1B<R_^=9#UA  KA0UB6<"#S"BYB?#D/<GPC!M/E63>O8-LE5K 41?BB/CAI
MA)&^@:4BU,(2X#F\2<A#A3^\0BLU:%F!78"XA,CO05 !6@@$0 H=F.$2*A"
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MUP*4178$OZ1EJZ*B+[1\CA4#129#-*1PS]--[.9S<&61R)<* T=IOA0"00H
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MA?(Q4-K\]O.?PV!&U+I/B$!55#@-[@&Q"-7*QVL.8 , []2XSO4880'=M-W
MED Q4 IG(*#^4+Q5Q)?&\D9>8$3%NT$R2>\'05">9T@<=D;2Y0-Y1F%(I \)
M8(I.C0G$Y$<*-%%=2-D;9-FQTO&E&]U.;:KA6?GO*]\L[W( ]$M_R8*0;5LX
M)1&8]=B(CA"B[7G!Z'D*=/HN]_2FV+H*- ;9.1!'D/=_5)"U&T8VX_NS;TL!
ML _[QDUQI /36[N:WTE?TT<RCU+)M:Q0M.>?E/<Q, I[_Y6H4&WW6D_8^.,
MBG!&&W3Z<Y3[NZ]/"<1,^K""I6OY%_'?'C7NE9T H-7SEAO&.5^ZI3N+ $$
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M"<#;VS&G:I-8"0%7:1;_)% .(8I#7IF24M$'2Q#&"P@2NY"#O& G,3*#]R$
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M*0T+F-E".M?<HTD( :%KJBO0 0KX$VA,CT'HSP);CRMXSNR*A;[@QH.@&I9
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MJEL L!H&F@6%&P "H<((16"!7M" _?&?"^  J)77@PB#IST%(% HRCN% V@
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MZ&D7.(P\M<-9R[)]?X)%,],3J(#<;?C_!A"!%G#;'A!X$9 7&F%54I 9:JV
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M#"V8E@6P 5(  4-HA# )@R?H!AF8[0!4#E0 "$WD'#@8 $ &E249&+!!(0$
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MB3TW:*!&(V:<H$8ADFS!V6P0P9*"/J"P\,P;Y!BB"1T+]+#)'^IE,4(3*W2
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M;2)6L ,*H$"A0&@;N8H@R7?!XA<;Z (Y""!)[0X#.H8@! /@*U^E24D#4"
MX8P0WAV080PV2*T"3I$)#Z1%CJ1( $U+.(LM<&,$S:4 #:1[" \D0+S'FH@H
M6O]P A3D]PRG<(,G:+ #=V'7#0^[J9@0BX MD'@"=SB$(<8@6D/ IP8:R$2[
MP+  "HC3! A807XSW ,I@$$&M@7%"GXAL(F$(0U#J)<2$J.A!&3KQ;$2FA$6
MH @D+ (!LX #"GHP-#!#Y (_*,)2D*I4IJ) PC^@J2>VD(0*[&$ 1Z !"/Y\
MY4R<TA,KN ,%RK !FQ+@+SJPH2+(F07F.A>Z*Q@;*FAPW@^'@0:#SG*8D=EE
MFRK OW8Z008BD.(>5.$%%QB&$\0D!5=3,Q.*2$,D1(&&=UVVU[[VC2$*<0,6
ML  (B:BD$TKX+@LT@01E,ID;C/:"!+O!!G)%PPY(( +_29RB!3V 3QBR ,Y?
MO*L&:>B  DA0! 7<(A-N9L$IC%O1"F1A%MKN!0M:(($+:. 'H/B"01R@ 31@
M-U\2'4&W)>"!8;  #F/80+]! 83&4B"^$/E<)."0E/1"Y @-0%L]_D!0Z)@;
M;0[H 4USN_ F;,' \&%W)I2@ Q;@FP6DB#7$[$T#;K=@%AHXP &<0"]0-(#0
M<_*$"4C !4[28!A@"$,0=O"+:0>]IO!AJK5ZH> [:.#$RK[X".# 4@?8,Q'N
M<D#%;7"#']1;V\2^@7>&Y@EN+.+<%.%E"V"MA*4Z0!2/H '*4 'CAQ&A=)SH
MP;!)D.:E'D&7L'OS05"0U/^V_P$%-J#$A*.T .F(()JH1?<6\D[9EAZ !30>
MPC?*M!3'.^ "]\ZWYTYA@G_3JP$2+\HT\^Z$O9_'[X G@.!+G8D!3.P$>VCT
M)4X1,4\T0&"YK6LCG%!72W3!Q;^^/O9OTP8:@(%>F6   TK @!W1P8)D*"]\
M+'#S-E#"<\, A22&<($GN($"4'" !S)06U6;(!*YA5T6=%\*.$4J $&6#<%'
M'1<-F ,<9, 6[ $#"$T$G( 93$ 7G %;T L$7D*L 4 -_  $RL#W= $4,$"6
M48 ;E$ /F  (A($:!,'HU< C1 (9+%6*45;VN$%=$0(LV-]^+4VI04%IR,%[
ME> )E/_!@>W2G<E 8)3:#8 "RB@!YOW &3B T)P"'7P1&O0 %]@1*8!!G,#/
M%D0? "B"$.A2BJW8+MU"A/W!;!R!"#A!WT73WWC.(YC'R=$ &<B&R62"Y)0,
M%L"?_+%!_15>(I",D_%?E G9(6",$OR5$3!A\9 !*=" #O:!BT0.H)U<"]P2
M V!B#Q"!!(0;"%S<B<79R8EBCJ&"%&P !9B'!SS!*.Q T)F=D#UB%BS-8BA5
M=2@:C_G/((Q")   &2@(!#8> _2 $R3)&9P %W""*(#"NSB $GR +DDB)U7B
M)?:5!NQ!@PA)1Z48%IA0#@) &Z26QAQ 9\C !P!:]KTC/.;_A0*005>HD)V@
MTB/T"/?5  ET!1I( &I%0(*UP!8DP!,0P08XDPO8PQZ(H*J! AC PB24@6)(
M$@CD%&]QH =@0!ZY#-09@2+,P#"X0 )@P!X("0:X0!! ![]8%W;9 ]JX4AHL
M9!S,8U?,@ XLPA,D@ O0%"P, B',"QL$P0K,0 (PB;]XP"-@P#(10$@>9>A,
MDR8D  W0 2S08P+,P!CT@!;X8\E0$U4BP,W5E G9@$69I Q 0%<LXTZZ0 OD
M5^@H12K(0462 #E$3A"8PR34VU@RVF+T  940)A(A ?PB!HH$KET109T0(H5
M#P58PA:X@ M0Y!%4@ M@ #D,@ ?(_YT(1 (;) C)2,018("+30E 90$2*$&7
M_('MT*,+9($C%&16IED&$$#CO4LS/4(""$%0>H :$ DA7-X+V(!DVL,//!4H
M], 8B0EIQHP26)16@E,_6@L% %1@V(!1,B0!#(E*FL$1 $@"#%]$A,$=2DDJ
MG&9JKJ;PQ<H  ))7<,$Y1@ JD224?-$9\-(>U, 3H%0\]J=_RL6I2$#*/ 7=
M6,P"R0?Q0<3^;(##$-#;* RZ1 W"^ OG ,"I%(3O6(P%E0#R))'X381!R(SM
ME,"#$@ GD$U\_ W9\,L 4D3 B5]\)-$=D(Y?X@JS]!<:#$&)<D()%$08I%8C
M*L6R2$20>/\H ]FH4DS ! T S(@HO[#GDRX&UDC$L@RHKE#, OR0Q>1("10H
M 76HPL3HMEB */":?&T!99DH@Z++B9:-[;R/<5 1DR9H@XZH# 0E 4F IU!,
M'89IA,8*08V>PLP*D_++B;+%J<@'\.1-$HV*N'"HG9QIFIZHPZAI02@,P@B)
M'SUH@A)0H2:HIW#<?XXJJ>:%U>"'G>39T)PJP?1  PQ#&K!DJP+!JLB'T;"J
MFIP*PGA  QP?3<C 4HD$K_HJ3;1! A K1>"JKN$J1>19;98JM$9KU\#"'?!:
MJ21"_F!$ ?@*12S ^PR*!2#!D<B$ U 72+P*S,1$N*9KJ3!J1]3_@+A*J[S.
M*[W6*[O6*[[FJZ3@ZK;F20-QZT?<JTAT*DFTD$9D$4D<:!A.1(\ZP+?^ZT94
M#K.B1)V&!"=03PD(K$<8!\)L:^5H;,X ;+>6P,2.1,GFR"'<Z,PHZ$JD[,GJ
M*\SBJP+4T$7,+,I(A 6PP!<P:]\A0<V(0BF>A /0;$EP @N  :MZ0A.40!.0
MD4@(#0-P *TB"P<X00V$)@#DK--B1!CLFDPPV[AZ1*D!P06T@+6.A 6T  AD
MH-1Z@N.)!"HA:T6$06V^;$?,;-!VA-;^+#C= D2EA )@P=;&+.%*ZZSTBE*4
M0,9BU\WV2M0<0@$4 $3HJB>0 DU51)SR_TOU$1^/6A ''@XGN*O##@"NQ(J)
MBFZ!FA:_."K!D*A2?*R0)@*LU<R'MA0I3  I  'KPLV17.R<].C#/(^ :BF_
M.(#DZ.@ 6$ :7.Z!MBZ;59&[ZFI%?)":1DT)',D'18XR*$;HIFL5D6S,7&].
M[0$ !.GH1D3HOBPG3%*!BE *!6WZ$DR0-J^%'@(9R,* ?N@ ,"KB+L;U6D2?
MFHJ[BHJ<M!?:_(W(4BGR*._EV@X'6H"[P$W9<.Q$X(KH!NEB<,($#$,#%ZX'
MCZHG+.0CV(-!-2$<V ,&B, IJ $E& %!84 0P.<4J$$6L$ F))4]J.0*,,'4
M3H0GZ*8+G($-(/^"'"!!/V( #:QP"Q.4/;B,(F  %-- !4! 8E!&$]L:%%,E
M"!B"CRR"&G#9S2J%65YF',A 86" D?26/3R!#N3+8CRQ"TB!T)% (]S #'R
M"\P!G(5D=Y+'%&2"F.X(5*)"-R3C%G8%!A"! K" &[A@#M,  C"!]*7"89E2
MQLP D8R"$5A /S() Z0"68@,%%I=#TP!!I P"F^2!TBF"BD !4Q! DS!&<"!
M%J#!#Z2D0R +*%/E)E= 2@;!%SR@VRZ"*6- !A0/#H3RV:+26RI!:GD "^Q
M/BXD)=E::O'2%1^)R:B!#GP!-=E#CI)!2D[!&EQMX/T!#V!RMA@- V#_92,,
M5#]&YSV*0CTJ1Q.[P2A^<48!$PTLPBDK4D5P3RCO !/\ %V6&BXA0CQ@0"WO
MP S$L?2=0&$TL"L]]!1H13%#P5=. 1LWU =_='^VBP^D6TURX!$00>HT@"1<
M @PL  [HD@?00 \XE_!-P WLTA: PE[-B0@.P02L '!U[0LP7R9<PA>X-$S+
MM'.%P0PLTB_   Y0P@8H@@CTPAQTP >6M!/@P$+LP,ZN2P]\@0+@ "$XE1'
MX1:[(?.%\30='VH901LHPQ!< A<LQ1]\(!HLVAA(H;5RDA_%]!9(-3*)  P
M0!_TE8(%V0(H%(3)@',1%+'" @FFAR[A0&FI_](8& $L;(HDIP=M1D JP(<(
M[D #G($)4D(R$D$$R  *.((R.,+)0(6ULK9F#]P%I('T0=<![,&J.9<G'$ 1
MH((.R-\#PHQD>;,6%(&NF9NVI$(&_)@BJ%!4M]%R)M$68" JC,$0_'8#E$$'
M/,@:>,)>R< 85%QZ<$$),8 &$,$ D#<%K(%M0I)$>,*_+<45P+=XPP"/,8 3
M<<(EF %7\[?/4D0;'#1G_T 5."8YP,+)?,XL_( E3 51J%E?+P(0F" *F/5M
M(<%]J5H%=#!(A_CU=1I67T)&^L#AF5XA (&).T *8$(#'$ :C&/Q_-C0LL M
M9T #E-^J\%("W, 7^/^WT&$!"SR2))#"%[@X)@!=&BB?$?QV1+)T'V""">B4
M!LC!"5% ')!+),T #=S @"=IURV3",H78+D#2[V:&Q-4E)@;"'@ *<P"<#\,
M"DS (!2"(]& !J0:LO2C(ZE2:J7"%!PS  3?+7!!N!G! (A"$##443C23"7H
M-#$"4V7!!O3!LUT"9!V.>*,,CPT< ># ?WF ,BR"45Z%I8,Z:T>W$9R "X!"
M)CQHVM1FW]TN*:#-^1T D,ETQ+S:%QB"#C3 #X2GF%[<+9Q"&FP!$;R9^OD
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M4S)@0(8@%LMD@DM $^V 3!CXH8,-.QP&E!&8D&0&4 [8$19 %Z&PEPNW((*
M /,22($N1$AM#!M2\@04,#Q1Z =[Z.@TJE=AC57666FMU=9;<<U5UYX<N&.
M!29P  !.#G%@D1$0F&4(3Y#X*)$15MA  20$*N&0!79 ]HY9[I  EBYL VF!
M9Z,%X(([AK!AA!V0*&&";H'M 0AI?2  V $<*$$"!R:0_U?:.P!8P%ISD6#
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M2+_H2I6NE*4M#:(%H', -,P.CS\0 0QLT( &L 0 -9@3B$Q5_P%.!DP47W"
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ME #@"$YA& ;) 3A@!#(!E")CM"X$"!Q,1F[ "?]@012&81AZ8;Z6I%Z:PVL
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MP E\-72P@)+BCH4YV'G)U@/$0!Z((&1(H!3(CT34@ H"( ;>H!$F$8S%( !
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MQ)HJ_S<A .:Z#Q%:H1FY:QW $!XY"89$ 09!F2,$K+,  19A"_@@F#EK A"
M#*C E1]&!0;!"];  2B "E[PL?F@%))*I"D- 79@!^[  8_, X1@F@'Q!_A
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MIN"W,T81Q*#9[:4/WB #8!D'^  3-B$)#'J@]2$.8-O5SY71],$>^& 45(8
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M/@&T4'E#911HD#@K3::<D\[@& %HSY.5\*:8)#Y@I:""8M";##V$>%58@T2
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MTE'^2/ &2Y3  4L1SE,>=$+D8:"R&! !%@A8! :HMPWSBL.OY#%;"&A!'WO
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M]*> /9A^I6:!!!B )3B +_B#$+B#")@D! A^,UA^M9$D5J*!>O:#W_> 3-B
M]X> #E> 3<A]\C> -7A^0LB%VJ&# 7 'V:>&:\B&;3A7#) V<0@N1_,M%0 N
M4F6'<:A/<<B'=WB'?3B'?5@!>TB'>8B'A:A/@6B'#1"(A\B'A)B'D?B'@UB(
M= B)?&B(E%B)1P.)DY@V?TB(BOB)HHB)F_B)F7B*I2C_AXB8B:0XAZ0HB9HH
MBZKHAYX(B['(B7EXB:JXBJF8BW58B'Z8B\$XB\!XBGL(B]\RB8JXC(Q8B8ZX
MBG/8B4/@AM5HC=>(C=FHC=O(C=WHC=\(CN$HCN-(CN5HCN>(CNFHCNO(CNWH
MCN\(C_$HCU^F "5 ?=RX )PP!/<8CO4H1/,(D $ID.=8.^PQ$5< 8E_0#,\#
M%WC4'4*2 F- ?0O #OS"!@_!%S.""WV545*@0HRD4?QX1!6I5]9S%XF#D%?@
M)&WV%R*A-RII"1:Q !-P!]2G /W ;RW)#O\(%D?0/%< E,B67'RQ (E  D!Y
M!?0F%X9 (,%C'7'0(V"$%GUB_Y+UA@%^)!<+X #L0(T#Z95?V8T7P $C@ 5"
M8 ^2T 1 4"2 $Q=JU)1X]E9F(0-SPS\=Q!<7\ Q6Y@ 5PD,])C8DP%5P,9=T
MHP&%1A?6H0.2, (C< HI]"F&H 7<@ 0[H &; $L6, -$D).!M&*A,IAJP0.3
M( **B05;@ N:^2D^&6\3D A/8 ]F())@P90DUSNE5 2E- 8G=19]@I$K- 58
M*1>#&9M@29S%J7*BL6]"LI 3\'D>$A*<@ !#QS%X= 51@)K600D$0$P3P X(
MH)LST@B98 070!\.X'E5I! ., $U=PA0Q)W>>3VB@ %HL(\9=5\7P5Z.AF_<
MN0.Z^?\2[^DAX"F>BI<U^J@ W;D!K=6=0\ )_AD:L9"=2:4)S54"$[ #U)B/
MT5F?%U"?"U "0S !A]!:]7D1OB$%]-$C^^8!DR!1RL()K8<$[6E-51 ))\*<
M-B<VNM><ZBF=(<&=2-"5]5@"K;>/]!.>/'D1BO (F 61A= !G%"A"* 4/]J5
M'FJ/__FA#I ;-; !['1=9=!FGC #O?1 ,(JA4)H(562>0X<#C:!E/MJ=2+
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M/NL))# %FA#C7.#9A[3&1D"O4R#D]XMPGZV<?S"I1;#'5U!!X^U;)SW_6!^
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M!?I  :[/0FOC$1J&F0$7 F6P)R&J8D%N-=-2 B Z>VZHC@80/,#@#++4(&(
MO?BXC+4CGFA$A!MFF(*("!1(P9Y,=F"CC!5Z>#&#"'#0PH05YFMA0_Y*/!$
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M+RB!;Y ""RP#L5J)'E(.3LB(O5..@P "I9"(C*B4VNL!?P,:,>"2(6BVE7(
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M)5"!L!4$F\ 98B6W28M4:$&#)%V(@15>B6PAA!;S,$M#B#5 .46PPQ*;0 *
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MZHY8@XD%ZU1I11G5AXS=T)* 0!'S5HS"%WBM/- 3)]=$$B-./.D'F8;&$,:
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M.PS!!B2C YS>F[./"OX:M8\A"?ZZ17&"?NL;>6?<LPO( *P?KDV[@%2[197
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M*0@M+6T#G$-P-%N&=,>;#CG!CR)XA.,4U1-"L!#-DB!+J"CNG_'Y*438(%<
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MAS-H#PR<>:WSR!2VNSU7+]BW/K8ZMQ"&4BXA:.*"E5)<(0+\D/0N058.<4D
M&'F!<Y'9->/5-A3S!N1I#K0&4C):O2'V% M,;-]%GH3L,&8M$_,P':5(L:YY
MWG.?_[RA-2 !A\CL@)V\878-<2N.2QJ 1'XM  $ [@[# *)HPR(5FZB$:LO'
M!]-2#4+4ZM%M3JBX"FU177_"<G&\E0%J"9U#>V;)= *PA#,8*B)-4MH"LAA@
MHLDC Q+R!+:W?%4A:X2SI6V(2_^0;BBC$\B^GM-'X+$E8H,AZ#8W@4AU.:3H
ME1#@4V\H W%>T[T X!@6FZ*19T"C5:^L+]N]\IN)2DDUCBNL1WPH15&-@W3!
MVQO(41%X"\^S<Z ?'_G)5[[)!K^AP>(B "U]:11).N6G*_<-*(B@=(1PA0!@
M@B8%@D*.K<T0&Q!("_; K Y [I%ES ,3+YD"!"I9ALXEZ TB,>(;["'WE7SD
M/#" #V!B$ZKC#,:H.^!AOGKJ)/B/_MZ%):+H#3+.8?3#Q#I("_2!)JA ! 9!
M'WPM3_)/_2JI_^9D,P)@L*[@#;AA$D#'0PB$(L3I"FB  G8E6#S!WMZ@$<)/
M'[( 5\#_P@.6XOMX<#LT3@A($ *DB/WZ9KS^2/T"0!_H30'8@*<<9J&,;_FR
M4 NWD OC A9Z8 ;L8?X2P F>210>@0AV*!6>0) <I@OL(1/ +"(P8 KJ4 3:
MKYDP0&0:HD<@8 KLP1X2IF\D90T280O4X \S(8+490O\< HPP*7&8CH6XP3H
M$ /Z8E82@0VRP+V*K!&G0 WLH046D2$N8 8PT70P8.<<!!$QP!($I 0M[A,?
M,1+[Q@-FP ^#P TTA1._R1 1,13+L :V( A^: []$ )HX-/&@A/(@ Y!41F=
MK2$XH0O\,!0%D24\X1#_4!3))Q54L6_8(!:[D!S+T1S/T2M@_X0!#F'3Z,(!
M%* $?K LU'&RN":%:(,=P>(=\Y$LVF9_:J<$KB@MWM&)ZF)TQ(HE'( 3&  A
M<Z4 & 0M:$-+VM$C."$@%^ L1B0>VW$?*1(@"Q(=0U(D1Y(DX0C,RN?.[B*#
M3(XM/)*.7+(A8+(D9Y(F:](F;>UA;FXNI ,A^.8F?Q(H@U(HAU*B4#*-[ *$
M6)(HEY(IF](IGS)-[%'6[&(E*PXJKQ(KLU(KMW)-Z$8FN1(LPU(LQY(LR](L
MSQ(MTU(MUY(MV](MWQ(NXU(NYY(NZ](N[Q(O\U(OL7(!)H =IL\O%[!O)N .
M!',O#Q,Q$U,Q<R(5<$'6-,,QV[':_/]O,2O3,B^S+0/(M(SM^EAB"F$(,T-3
M-$>3+ ?@ @HS4DX*+&+LN4C3-5\3-HFR*#AS-5\("V,3-W-3-]>B+]D!"VZ@
M"9# 1?J&$WRS"58@2\0"..Z@,29@$?0*"1R@*QQC$9I*.*>*.JUS.!\B.X-S
M.UU#B&3I:3BC+SG@.(> *Q; -E>B.Z]S-]\3/M\S,!X!L_1A"H)@;IY")V;@
ML=Y $UQQ-**C!S# "43A": O"NSA#"*H1PZTDJ: !O*3#QT,%QXT ?H%3!JT
M0M_@#Y6FE]2@#75C#;C'^>P!0')C&8;IJKH  S;A02/T*^-31F?4+E4$%Y+
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MOH&C!!Z<>3B9 0(@ 0"  >[ P2V\91L %$XA!K@4 ^X Q%OF#ER !0(  W:
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M^\[O"@KA1U-=#?IY]!:E!S)@ DC!"8Z@$5S @/IE]C0!]XM"[J_@@(YQ1D
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ML Q"C@<BR+V&W1IS+,4B4NS0@!M8X3 & UU@!( A.LQ02 O5=O,"29X$X00
M-?Q 2@5G) C'325+,<L,='@ "@C_ PZQ!3DX];&&M*A;"\;(."GQT+TDW0 J
M!D.\:OWUV&>O_?;<=^^]J0XD$ ,5(W!5 R*,,,  21'M\(P](C30P!Y )]"
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M[(T@&PN DEJ@";&.5VSZZ['NRODU"=4NZYV!%*D [/H;[5B!DK*NPD:9%'R
M"[&>'EAQ!$+P[!]P!6ZJ'[$.PII@LO:D#[).!2"C4UK@[OJK";B!+3*APKC
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M!0@64!!/)( +?4"!XO_& *^X?> ,!,">#F!0Q=7)0 N=<$ /).&(-+QQ(*C
MQ<&2.=$O#O&,A##"0@GBR(,!(%'MHY] ]OB'A0X H_A4*!F"8(8O?E0@]B,$
M#S:Q/KR5@@Z&"( ^W!!!GAZ5!*4#@"*$8,HG>-,@]?C8 CP@!!2T863?2&A1
MUT#%\@D$%CAXYB@Q0 X"[%1-P"PC+ 9APBZDM8%KA8,<0%"#&60A DQ$[$D<
M<*^1Y"NQCQ6) [[!2P#(#P4(Z,$3%+8)>! H$[OBHCY:L(@M-$)E7ASE$N*
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M+QI)A4;X 8;AF"F4 '7RL,Z;$1F8!^U\'HL1/:12$QRP*,&Y':B40EN*H"0
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M-Q$ GBRX ST\@2NP!\X9+S4Y@;2CD18QA"D0L_C&\IT0Y0K-\BZO"132 GN
M@"G0!"L;A2%0 H1>+=J>13+XHX,H-.-[2)=D@'7; 3UD(%Q8'X1P)-;[MTHR
MA ^(T1J8A-LL 5%0 R((@Y2ZVSY3'1^'@A.0*@;P2'( LBC0-ER0 T7@_X-&
M[92BC-%$@$.868"P<<E>?F!G9@&C@4-<U!)%8 -#="9XP1XFQX!-($=MC8 ^
MJ&ND.N N*)U,280F& )1F(),&(+E]O)E;PF.3C929O9H-XF&S8(A4 #"#((&
MP 269 ,U0Z,$<($I<.X!GX$QX"V!\ #KH\'PCC0JF@(ZZ%L@*](G#Z7_\DA[
MJ  1AP$$*U(Q40(U\#M*XK,GF(($@(!"^(*%9( )>-(;H +XJH L2$+XHL$K
M?Y 4>'@,H $LP"J=HL$$*!T+F 'R5H#W/0%3FZ4IV(, M $A,'B;Z;,*A$=]
M:  (P( 1#4,UH $92TQ/E?:?5ZSK_8CL!?JB)_^)"_@RI;6!$5@$)TA!3]BS
M!=@! F$!"#V(!; !@U-93]" 80BV=;&!7@( I#]>@U@ #6!D6%@$L;^ /1M9
M&SB%89"$8E$ +'!5$X'[8?#KA?($%O!Z)/& >]Z1$4  +" 0#0 "==6  P@V
MX\-ZJL\$:E+K1#B%8%O'+B"'8:N!$9CH"^B'$'$ 40#))&N=%8@I&SC\+RA:
M&_!Z$#@_1C9ZZO7[!N"*8:#]!K#] S"!!BB!F6CO@H3VV!=^H##MD<C:A6A;
MD96(XD\()L3HH#V_2&"(OIT(ZA_^Z)T"PL^,[<^,19 N#$ "CGV)+1<)W;W^
M\R_Z 2@ Y+=^]"]Z"(C_VX-H  28"6>WV.!W__S7__V7=@@X?OD'""0 !A(L
M:/ @PH0*#SJ(LO A1(*23D6L:/%B10<:-1( H'$ P8T;07IT0'*@1@8.2HH\
M65(ER 4F4190B7*F1Y<W1Q;\R%(D4)T^;Y(T"=0@ : =!Z3\N%&E2*(.H,Y,
MZJ#CT)]7FYHD:=5FR0$#K&X5279J2P!6.ZZ5>A6 3*]/TUIE";6CVJ  F(;$
MB[8O0XX$!\ <R)2GS*P#SZ[,.1CGWI6'!;\U^-&O4;R3*R>,BM+@@LDG(;/$
MS#-DX[J&&Z,\C#<I:K:"2V)%VS'NS:14\<(57/<K2+)4N?)..@"WZKQF:<?N
M_PV2*^>7;V7N[HFV\FS4)Q,SP'Q[=MS$>6/.3%P\N\>[UE5^7_D[)?FQXL]^
MWXZ3(_>/U"_G)SUPRDH+U)14";PU@ !&"5ZTP!0*8J0!"PY*.&%"-6@P#"C#
M9+*! AID$L% "G#P R@F-/ A  KT<(,/ RUP@085) #$$#:8:"**+GIR0 *@
M?#$ )Z?0 0",%3"!!@@+>( &$@186,1!1]QXPX\NVC#,%P[T4&(#)J QRP%=
M=@D";PY<^056-MQ 9@TL?'%EB6N>9,$I7+;09 W#'(#A#3#8<( )@)JP PMT
M)&5#)K-<F&&? ]1P2B82+) ($-UYI B7?7J288:9&/_A42(:)'#B!F9J*.F6
ME6Z)XP83:- EAD LTL(&</700@< >'(*$!TIL$@F$T J:2*9,!"B!B1B^.6:
M +1)QZ3*@M+"IRGV<*,)0*B(JZXL).G!,$R8 ,, *D8:D@T_)"#"%\<6*0(0
M$JAHPHVJTOO#AKQY@B&?(.S;JP.B2'*K!-:ZD<@P_)("P@6GN%&0B@TD,*ZC
M=0Z3+0./FGCQ%PIY\H.)-P QP 7#.$'0HX""#,- CU([4"+J@N*$HRSP:P*:
M QTQ;0<+B#(,&B#Z3.6E*F<KJ2B>*GF#$P4OW>(%/;C!0,0),$G !2R887#)
M@K8P!%XP5KEOEC'W6*FKL(+_(BN_TQ;<<J&>X#P +%(3-&^7?:IXQML*(/JI
M)RRJV':\=VNPA=5-6K!GAK22Y#>G5);;PQF6AGAEBZ">TN./OQH[@)I?O&T!
MTXGT24"'9IBIM <BO^VL!C?D"I?9,Q. E]\R7BTW",ZR\/"[M';8:R*GG.&H
M!D!@02N138!!T 4LIHB%&P-LJB>]1NS([X8[F@"R";T;A,&Q"G21Q1 G!&$$
M7DRP0R'\!0W@4/P+]1)A_?EC5,,3233P""Z@,(%!C*):"H"#/A)P %"@R!.3
M", ?.@*++DRA 17X !JVD, &'  -K^,?)@Z  7N8(0Q\6,,%X* &$51@$W+8
M !D"_X""#=1@$FM B@RN$(\*J$$'0TH1"4(P!B.<@(<))(4-^*"#!C2 %.1"
MV2"T,(:"3? -*#A$#<2PAE0DD(<Z>-Y PK"))39@$S,TH0X6" HDB.('0M!'
M/$BQ"#40 @ 3Q,0(U. _'LK!7YLH!;1248C,+0 '"62"$$9! 2H4H@$SN (1
M".")04R!A1_(  -BJ ,?9#$ E)@%":(@@AG@(@L[Z,(SJ* #4#1A"TF $@ ,
M\0$H,* //@P1',:PB$TLH0@+$"08%4"&"N!"'R) @Q+TP0A=">$/A=1'$#A(
MBKX]0Q,BX& F2D"")1!A &WX !T\,,(&J,$>1:C!,PKHHO\CE-.1C8""^2 P
M2ER00P&AO.8!@D4":[I #2@0'P".0 5[,'%A;=!"(XH BQ2,H0N]U-434- &
M/H00% > @0DCB)(>X((&(K2'$\* BT:(\ -[\,08.>@CG1#D" ' !#EU8 :!
MK@$O8B0C*7)FB! TXF$U&$0(1T@'3PC!?PNDV4!D$((DN$$!;*!"%7)5 S:$
M@!"2XN*HGJ&%.)A/!TA0Q"3Z2!"BHH !)\  +<F@!1HTX F%P"@5.@'$,201
MIJ2<X4 NP(8R?,H02Z ##QY1P0L*D (SH(+_,D&!-RBP@]5B)B%0$8(O.I40
M>$'G'M50B"^08!2ULB,<1M&[(^C_@ZLD:(0"&8@['%R!K6Z%P1&T -,+9L"
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M1BI08@-=*,3L'$"&-*=""PUH!'O)3(!1NT$F./AK%V*P!#=,^ U9F,4@",$
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M-U1+>Z% KCA ^KE!#YP@&G2  @R"!V)  IC6$.F*&-R<FS4",+JA0#7"%+3
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M8 ARU* 'C>T/+"[Q@R)X0@-&6$ )+C"#&X#A"$+0Q![8"M<)E*@-<5#I$XA
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M%Q:0B@R$.=;M=O><N/_[;GD_U*A:R@%*.%&".S35 1=@1UVC9*$26,@!)6"
MP37#[GDOG.$J$G'#(1[Q=A+@2!>B'9:.5&_^#*!*1@+=GRZ^(\V(?$$:ESAF
MS7QRE:]\4P[P1%[Z0](&F'08)V6 *'@"J!?5]0(MT$N(/)'EK6C&!C,?Q@$R
M$9(+-$$H"E+ '5+*<NV^6NI5?],0V'$'=NS@#@BX ]?!CH2L>SU 6/\Z$G;
M=02H7>UB1\(= G0'M,N=ZW,7^[[O/@N#+B 1<"@%3F*,@4S$A\H,4/>'2*Z9
MDYP@+X=-4>()4.\=]28!7RC27%(1!" @  N/6+<"F'Y%>CX$23OZ#. 5WQ[_
M%BT@\E:_:+Q='_LI-:8"(FA !7 O@MSC'O<-N$* [*+["C0@ <2_O?%YGY8
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MX0KD  8N@ WT01.RP*MP8%<UX0PN( A@X$K%X W60 '(8%<+@3T6 "8<4P?
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MJW3 !R0,!60@:CG8"+"0"W"*PSYCM-)W 61 #DXA 4"@!E+@#TZB!DZ!.<)
M#8J )E& V2:!$4:""3;X!.[4$]2@.\E@<?<U#A08!I82!=I _Q/BH P#T#I)
MN O*8!$VH1.TU1Y@P **>(K#8MU.F Y@H0]0H$:U*D*U58!38 UV>'P)( QF
M@'P)L#E(X Q(H QD<2^Z( @4[0<2  TZP )FX P<P"-O@ D4@RL)P!!(818N
M02YD@#Q@(06 -PC,8"F?0P8(M0;@8 Q8--P8M8LN(@.,H :>@!PFM0R^H$9A
MH3/QEQ$V(P,F8 :X   4X1) H;%,M1-B Q1>&1'H0#5H $\!0(']\3EJX(+]
M(P'@3DD!Q 62U$"<]#^N8!0?0DH/ZK \@_X$Y#-  ?I(80/8@3F"#@,:@#DN
MP@5H  :L;$TGX"A 2L=RUL20@JTTY/\"*  ROH#O5H!Y1>$2CF_-?(+I+(##
M ( 3*$#'3NPK.903N@ -0, 3!$L$OD !;LTAP@(RS"(5DE)^^:DE1R(0M<\J
MV* 17, >XOG*=+(V?OG3JH"^.F*&C0 .B, A!G4$,( ('7 ![H #-& +XF$%
M@F#H4$(Q": /=%@@FEIM;6 $-. )UL !<$ A44$*%D$*=IH&.H"4C0 UM@((
M&8 S2B %+ $.9F(8GF$45.T"^N'-,( 1>#(S:-*(46("D'H+"@$,3@TG3F!8
M86$9R*$/&J&C9D '%N$ZGWE8W8$0FL(01""R*?@Y('0/^D ':FX0U,H0Y* C
MYA06)N%!V<#_+#KS(5"A"B+ (2+5.#&2#>7")L[@!\Y U?ZO*0] #<H@)&2
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MC1%=X) $8. #43.B$XW8'/7@XHE/=($]) :^+&IQBUP$E[D\EX(_H"((+OA
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MNJ$&,Q"!&B2S!5P(E #$T82'"' $#%1 F*ZSUQ%F$(5&2((-QC3#!6*JB;D
M0*2:.,,)*!$!#]"@HN:I'YS_#I$@!C#H$%KM*H/4LR &<'6K71VK6+L*5JZJ
M]:QK'6L)%-#%N,IUKG2=3]CF XMEK$$&^G #09G9AB# H"D-H"=+$N"#,*B!
M"#O8 D1JD )9 /&3-2 !$62PA#,,P1-,< -B$F"&5,Q/!D$P EZ,X DVK($,
M<E0 &SIA)='2-"P$?=>)NH &'N""",1+ #+/,  ;I $))- !$DZ  2<HX+1A
M*,I=LM #'1CA MFLP2-(:H,$9&4Y#&S*&$!0@TEPH0<TV, "R>%1-:#  3;
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M2Y"@#$WH!0FZ$4TZTF$A6\A$&BZCE#@T&PT+J $BP""_FX!A(0UH@&20C8%
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M* 4I*Y"%#8@D 2)XAH%M\ ,K.D&-]F!" I@ A+'X7 $'X BT+3&(1B2@ 0E
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M [.'D5Q0&%P@?J;1D1X21'3A=_Z3"AC !9M'>SU%4(I7% "0B6;0 [-7>[,
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MLSV;,7PA D^0 )M !)9%*$=P!5S@D&TQ!IX'!V5@ Q!@ HHQ!>\J>[5G=E%
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MZEN>70.#,)8IP TGH 5$@-,$D6#>30%9@+DHX)^X!2<EH @NT )= ,(,%JI
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MZO-B;XBG %[8&@LH$19 =-8QY]%Q ,FW\E- E!HA<B*B""1@])D0&V0A7PN
MZ%/@ D*P!IQ)%X:@!2VO!H5@!I+>#(S0DI!1/HG ]$1$" %O':ET S>P!=P
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MQ8EA,- !<(3)CR!F "B(Z"D-_T*8GH P4+#%7H(]#U-T\C3C3(0:;-:$) !
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M[)RN@ONX3*6,K.@28TS/C!->1_TBM$$$*8MW$_O]%DCA#\-GG_M\]-&?PDT
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ML$ ;-*!8A&G ZM 023C80R0RJ,)9+N 2 @1Q$)4 0C/( 0<H$. \3WB#'"A
M!110  5DD$<9ND"*1=C3CBVQ! *00(9&0!!\;P))(2H)EJ: %#\U2$%L)^)-
M3%FB!+ #@2?4D(4[P.X+6T##'3R  2<(_R>?9Y@%'#"Q)0;A 'HC%$,A0-&
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M'7*; )4[4+"6MHSO(:*8J!.NPC'$@  5CMZ*(IZ_9X1XA2)M()Q8(M6%/8@
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M*LF""CD7D"#.!>B#=0J"K#B!=*0=C(N0MT@92Y!,QD/.XMC)P=Q.[NS..4$
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MB#%>,@WQA"K6P6QA! >X*5!P@JJH'3#V8Q@D8PJD84,^9$3^)8(Z@PQS !S
M/B4A 8.]KA'8 5J"P->1XLA=@0'@!"9I 2P@.*M@3HLZ *QH#&X@/=63G9VP
M7E#X@A,1!<Z5CKZ-#^LU@;+D@/]A. "X2N05V]4XD9#Z=,^AC&'A^1[QB ZO
MRZOO<;,1R3"L8I 6A@E#&).6W1 [ 1'L0:CF2;$-(BQ?#F=Q'F<X8=JJ<K-P
MZA>P. ^:$(]<V3D GLB5(0M*T%106 $*F )P@1RV.0)00 "V:0H@((%":($>
MP( BZ!%YACCR$."*+(OC!06''A822#R@(V?(@MGT@3KR%-T1.P38Y1*APVB2
M+FF3+A!'E@.PG*XO32VPV-->[B8U$+0%*"0'\ 2I<,[M29RF>+4-48D3Z)8^
M6(,V2 ,DH+.6&@M:Z94R(UCPFH44&(.^W0$F.(,2V $2D(4:J(!)/FG'RD^O
M#FNQ'FO_LO8/&1@J-Y.! TNL^A!-A[H#^QL33R"!*[ '/E@#G2:<L("#?78H
M[3@ 1CXR"B""HF 6$NB$,* M7+B"NGX"?6!L*J $#0!&(: "QKX"(J@!4MB\
ML@8F&^YLT YMT0[GPZ,!02:L[N5:L/"^+/B*\4B#81B:/:(SM'F+D+ !A?*$
M9_#IRD2$>)@+3T $"&B^S28 MR"'AA3D1$ "\O(V)&A:J@:*1-B TRKDT88;
M8+YN[=YN[LY5!=".13*C.[ !#2A:T6V*+%@!#;A=^V.-95J!11"#->A;;[GG
M?.[K66&#,9"(9M&!-+R$I( %$F"J'I#H1:A?VY&$ X<"YU1'_Q%8 ?VE _GP
MR.Z&&XVN< S/< V'203Z@1MP%%!@2O\PI0I(XP9J@C:.*)_I 3J 0P>8 ":Y
M <X "P40A4648Y#J$?X6A2=:XMOQ)!]F J_U!-I8$M*3#@7HA_+=\#<!:R9_
M<BB/\F*SD9!>V;^B"PT04]QFX"EIYH/R,"FGD_4,<S(O<S-WPAXAE=X-Z3-_
MK.QN<SB/<SD7MBWLM!F><Z>Z<#S?<S[O<S]_52?_<T$?=$(O]"7\;$-/=$5?
M=$8?L3=O=$A7]!((2DJO=$N_M$C/]/W0<TWO]#X? 0P RD0:]5$7=: 4]2C8
M$ 6HD+/#D LI@1)@@*[8H+/["KP[D?\) .D:$1X%B/6K\HI(JA"OX 18=_4(
MZ;J6\O4)B748*8%>+_87F1#T]'0M#71JOW8Y'Z89&UTW6#XN^+9>$ $2<(&)
M8H$LZ(!L^0(-< //D/ N@ #3/H)RV8DNL >..A3/*!<J<8A4D(1+(/=&(85,
M<L:(FH*=4NOVLX'1PP"AJH ,, \AQG8M172)K_@RA\)D:\4UD $MR((>*+UQ
MT@ ,^ *P'9;;% ZQB(-TP6<:H  I>($#TMY%P ""\X0GJ((TO-O&@(()^%TG
M: ,:* +?<(,_(5%W&H,-YK)QDKTOH X@.!<VM_@F?'2IKWHF1X ?V/:*&(-O
MT 1[X!5WRZ;_-#"/\\4"-<B$+:"!$5 #*'B+07-35B4P-Q +G#FU!)B$3F@,
M61 ?*$@(YOP74(ZR+>""FH@V.2!12W@G"?A6D- +^++Z\>1TR)]\[AX!$Y#5
MFF@$". &-N"H=TK7(.B (U"#*\"%1@ ".+B"*= "2[A4 J"5"N#%)%.5H7:H
M+@"%;QB#0[A;MX"" 3"W#O"NTH^"5"X6RVR  +B"0O \0H#!C>BF25B#J*?\
MO[-VZK]^T<Y>K:^!9BB%_BP%.C $?56$7PC^-  #L0 "E$\!+E!.(RAJC3&"
M 2BQ,W"7?6X*39@"33"#32V!&5@)@/ 0I$.8-&!@L9%T"0H#5#K@_Z!8E,:)
MH3$1VOSJ   A.0 >/X(,*7(DR9(F3Z),J7(ERY8N7\*,*7.FR2@.:.+,J7,G
MSYX^?P(-*G0HT:)&AZXXX!(7R 5LI(#XI@.&(10,/- P<H2&CQJ3W&S9P[$-
MA@8)LO1H9&(8BQD)*@0QXE$&C16SV!#I8:_"1  8C7@*4@16+49*[#7  $4)
M)15;LE @1,!&&KD(&1W-K'DSY\X^IRSP+'HTZ=*F3Z-.K5HH@A\NKX1,!(3
MA7X2/'VA?4<"IQ42%H@:<N?0@D0@%G@XU6)##2PL6'Q9=(.%#P( BB/Y[<F)
M E'#G$@ 4",[IR\,@!OI?BH3X-P75MAP O^@]@"/HD"LSJ]__^HH]?D#&*"
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MFA:[Z,4OIN15W@,C&?7UN#*B,8TB7$0)62(P-<+15->+(QWKV#@$)& '.T#
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M\$0%6D "%+3S!$$XCKN44*L+', -GG"QS6FP",J&Y @8\+ '$C 8-GR\M&P
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M1F/Y28!7S"8B');5J %_ IN\]< 9] !O!AU>,L+$X&,-W%OID?^@8/4<"XQ
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M"\0@ #H!+15!"*Y !U8@1M] A+:31O%2(CQ!#2#@"C0! XA4!T# $YZA2*$
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M#U']D&MY,> ,#J$$\/2=]S)-,X ,=,![DHIVX^ Z7J!8&H)=[<&=[^8[)+G
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MCXW" ^QA&#! @YZE9/H 0RGA=A?9(7A"J,='#2S! X"# #Q@XV !!PX( ]!
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M#R*F.OA*<+7!T A-$QRP(%:G@JX=FO8THV5#DKD+FG90XI!P@@O8Q*'(.CB
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MG2J)@ )C& AJ)@D 0T@E6$HP"K :0:43T$ "J"P(+-8!A8MD8'VR H$OF[*
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M7^68P'$W61 4PYC!&&SPZO8$_/G0C[[TIX^9+^H$%O)1 !(&<H$AS+$'0$#
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M7X"%2C@+-'=__I<L];< Q6%-&E"';55^[=>!'Y@(?58";&<=:< H<\0!+&"
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M$*) "C+A":?P%FZ0CR99E59YE5B9E3BAC8TA-0TR02<G@Z4QE@C1!H@@"3O
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M1\E4 5S  (9 !%@;GCYD!!_?+ G  AA@!A;$F5V0-B<0!,S;!4"@:A+!:B7
M!HS@ % 6;D501AD0.IER/B$Z$8S^TLA-SA@PC9H@W13!"?9@Z3K='O%!&O2#
M$+BJ"2V !3-0X\CD"6YQ:6UUJ@)R$7[)\[SA!,/C2.PP GGT9_Y:$;@Z!EH1
M)C<P!<\6@;^8"!R@ 5L0#V!0V%"[[!#=!!KP _;@ TT'+!50!&--!+"H]A5
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M!>B%&^ &.2N#PO $$:" -7  /+0!X]B"*Z, <@@#>JD'%+"!+[ !R^TW +"
M&S"#(T !.#A:#4!)%%@ .+#47N@!2U""!\*"!A"!+U""0JB %G"-(9"!BJ.
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M+7 #11"!7D!(J[B!(]V".$!:(%#,!?B&.% $W-7=3H"%WN6&(5 $$_@!-[@
M%M@ Q70 &TZ%,UC-3C FQ82%+6"$-N@%KYB ']#BJG!J,I"ZBE <(N@@5/B
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M:;R"#PC^VE]"XJ?]WA]^W_="%IB)>^P)1:AEL>D08CXIL9D^0Y!? F@#PKQ
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MU@(]@,'7M0?0L%@1-0"Q@4 3]%."!C!XDLDB3O1P0!8@&(()$RT8\5*N+!S
M1*0"7= $)_GNNT@O,TP1A0@)^,"JHFZ4FXD-EABAP!8-!$&'2@[8D*8;GC !
MJ4F>S #*#15T3( G6XC00A-(>,(I B.<$BZ1-B=0!%Y;D *$(A70, ++/T>0
MT!T8S"/EU5)*.84DK6D419!FBCTVV66;?3;::=?8@Q,>6$(&(1.<LJ8)0_2Q
M!@$XB_##&NDJQQP 2EA" 3D>9''PJ6>T(0(,2F0PMR)H'.P &6NVT,,:9*#
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MPQA@$ ;9P<$'"KC%"!(0A$78 PT7$-E/\V:=G:+ 4'1%@A+64(,#G#@Z/1F
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M)'#]]>_['G#\)C $1S#.I$$+GN_\I@(*3$T"H^__,K "8[ %I %R-+!)H"\
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M":CQP3RS'L_R!K1!,T] ]%[7+\  )[2*%X\,.Z@Q\_9.'3=!)HSS(M#SW@U
M7=6O--LR$AA"$!AS[R" !@#!'91 (O2QV_T #7CQ$*0"K?V(#>BR:JT )3O
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M"VR!JPF$Z*#,$4B!.?S 6G3YHV_*!MO+(L !"CB"H@]$&&S2I"5 &1S,A#N
MN6DV"MB ,K2@ O3#(G0V8[6Y(H%"@"\ \DSQ%S)L@X^) J2"H?>!>5R8X/7.
M%JP%>*!",UO #11!&.P2%A@;*)2*D3> 7LA KV?!MS3!VJ4+C0=!![ [.2P.
MEH^ 7#1'P6"!88MY,PG7PJ. ZD@ 2F>"1LO%!>#2?BN X:4!$!3*%HC%.6UZ
M!D2 )P3,29G %G!#"I@'+-Q")GC )CG *;3 P1.$!7!U:X_!,/ [)WP#A8L'
M#A#!U(A"$!"*_PPXDP;LP0"HN"+ 5XZD$@'4  JGMB+,@"3<Q IH %%3  H8
M <E5P";H@"0LP@ILO*JWAP/P  U\!1D0 0]40 O<Q BD4WXX0!O,P3!D0(6$
M 0T8 2>00ET80J]GP @L0A,@M@#!\"]$PA;HQ3EMUP<8^D H0&,7]1A<@-C'
M1S,[0"K80]PO0#/5P"U419+; "DPG ?TM=O[@/JZ^0]4 #=H.]ZX>U/4;+Q#
MQ;2<RZ#C/(OQAP9%@"%8 CI+@ 68@!/D%L[/P(B; 0'DS^VY :ZDT0<? 2DT
MW9[Q "5T .5T0F,YP3([OD"HN#F1 "@</"RD@&[] /FG D 0$I4A@O\G)F86
M*,DR:Y@/!8.X=.'B(-49"0!@=8%"H T-(P,EA!$! D!)6%NT<)$Q1H*%+4 \
M23'B:48+4DX(E 1P!)0/6'U04(#"0 81&90D>!K6JQ (!SAH'-BSH \A!SW0
M<$1QX9<1  X.E5S0(XL$&1YQ4)IU@,L"&3K@3#0D9P,.<@Y."-'A8T$J(A%*
MHJ(T\]2*-#  X%AS@:U;.12(+/!@J8V465NXY 3@J6N- SA1!;44X<C@DIRV
M3$5%2$7J!95GS;@!BHYF!5O<+,"!PE%7G:4C*-#00 0,!2G6*#CE!H ,0C9(
M>2W99XU;&C!*OZAQ8Q@-OH/6:-8YGGQY\@/_<J('H)Y]>O?F 41Q )]^??OW
M\>?7OY]_?___ 0Q0P $)+-#  Q%,4,$%&82/HDP(@"65*>QQXZ*2+KA$C3)\
M $X!%LR@*8$$1+CAAB^:BTR1)Z: X(_6U+!G#_%$>024+#:XJBT/,,! #C!T
M\N01&C 0P0T;7.BQDP42F0$#"#*P(8.<>/31*1R>)&A%>\H@"4,2[ G"# !$
MR<H3-*0#8 %#/.K+'AD'Z.N**0J1Y 8?Q+LM 7L:R& ", OQJ0L(*ES3'A>R
M8, #-3[ 0!98.)CQB Q4>":+(;K(9("O<- $ PX=4$+%1S"PQX<32JT QS">
M"-,,5#&@H0.==*-P_X\S23J!G 44(76O&IPLQ(DP*"% D0,ZR G8+":X!08"
M#)%E%A)*I4,GX7J48U9/ (4AE5U%N6'6KU!-H *U!LE"NC#*&BL3&]1H! (B
M/L1)!B@2>0*-"]M08\3KB U. S-DZ!$#<L0#<(HKKOB 88<;?ECB*W )8 3X
MIEB@P8TY[MCCCT$.6>2122[99 ,=V)2\!1A0N;P%2DA8)P<608(!Q7)R@ ']
M%@AK90;$6^!"L>9[V>>2'"CZ*P=D_JII\CCI(9,+F1ZO:O@62-EJ\;1&>NBL
M[6/RBYQ[(*)E\P[1+&GR%-"LYZ9UIF^! L2C^[]#7)ZY )?!MF_M^S@98?\(
M!;I ^#Z6ZW-@Z &GZ(^%B\V+(N^3*:_<\LLQSUSSS3GO? %1#ACF "\[!U !
M44P@O;RGZR,@8=;SXV1G-45Q _;62Z?O]OT4Z(&[Z#2?0NG\AH&\O"EVSUWY
MY9EOWOGGH4=09]C!BOL_!S@98O;+679Y^O\XR3'FL/$.T'HUT];/@1Q&WAM!
MF"<H88CYP&+0@0F&2%ZG ?[6G4#Y^,,"#< '@-$SX $1F$ %+I!R#A"%$R8W
M'E20PP80JD\-FK XY7&B"7@B5QP$5 ,T86T"_;A "\;U'QD8;B<;R9T"FH"B
M WDB#2(X0 52UX8L &9C"[A#/V"'P4., "?P@:'_!O^3,?[<P'CD42(#H1A%
M*4Z1BE4L@ 1R K.AR<X0A&  %@&@@/PAK00["X,RO.* $D2P/ X8 AM+4CZK
MI2^,X[L/]NBX $XD8ABU44 )R!">KZ2-  I('\Q\IC,[DG%3;LR; ]$P@<.4
M8&AJ;-H?AV9(G('%.1?I&?WL&#Z5J3&"?\S3!C23/9<9<I1K+(\8Y\.)'P#A
M$%0[Q/9>24?XA*$17YC !;9PAJ.\ 'VST^,&6GDT4[;1E:<IP5?*=!%+DJ<&
MOQB"!C*A/5J5$0#53%. A,>?4S2!@'"LXCG1F4YUKI-CI\O$!1J  1<$ 0R?
M2Y(:4,"!K)S 'C.@BP=F_^""*9R!!)HX@PTJX (I $DL)X#" (3CAA.XP 6%
M0 )6"# I": " U.844ED,(52H>%F]DA HJ2F&W5YH G2X58\,  %"< B!?:
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M8%,S'CA#!#P@ B08X@\%:< PRM !6,"A$S6X!!<&(!@';P$%&[C "FQ@ B?
M,$TUH$$/YC"3S]"J3#1$2"HZ81 W.*"+/!2A$6Y#COX.-@5E^$%;<.#%$ZCK
M"#0P@P(H4 A0K)8#0TC%4-B!!)7YE,P;.,I,2(&%'5[_X =QF+)Y)7$ OQIB
M##RT0 M H(#SWN8,!)"!%,J!X# $P0<R4%<J6F #KUZ@<*SC90NP\ ,:.*$-
M53 "&59*@T68S1,##@T#2K@#)BQ9OSST!*,70.$CB$"Q"M$ &A0A)K 203S5
M',(6-M)%!H@""!(P! IFX9L!%5 _PR!GY(;W76E/F]K51F#OT$N#P0:2!Z @
M26BP8@-02,<!%]# *9Y!"$708 ?/2$ #*D #8B(M!5Q0 A1R3)(PS*$"4" -
M"LQ2K/$<A0">, $<&B$">*/A G$.PA8L<8HBZ.0"'#C%#"+LCC4 X +#J  1
M)&!>*-3@)@3H0SMNF( F@,D$_U]P !E(! 27]7<1?>[XQ,52ID1HV[QK6!&)
M9E"6DBC !BS8PL':P(U9*:$,#9AX: 9P@BD53.&JPD*1,L$ '@RI!:A$FBBP
M;A9>NQ@(BSC%%NRA$K.5)!&#*$0#F" KI"5" S^8UX<F'@9$V".S+BZ"BU<P
M#">@HA$-:$ "I@:?(WR@1$ 8@ENDP  PP3L(7^@!"RH@+ 6 Z40_A[>Z2M+?
M#KR<'*@@@E?:D 86H(&?"D_ OOC[BQ>< D(R0 $!)M"#BX^"!T'XIL)<MY_'
M84QCUC;^\9&?_ 9BI09IJ/4:>& "OG2Q;#P0 9 \L *(7W0,]MV!GAF0B$SP
M$*3VJ/] $4H]\38$X0=_<;01/+##\;2!$MH!Q1;*,(0)L ,&?9G!&DY@"H"G
M)'"@#)# !FA@"$BLX$"A'-3ELF2!Y,R  -P!!4I@ D9@!?1/ ]+@"^Y@%FP
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M [<SC.[ 9RZ@/ET.?RZI'\C1.0G  1*!/4TT0A$@19F$/5-S$4@TD^X@3B:
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M; B MC"-!8! $<8-L_^@)#Q!!Q,#!7K !%C &0F@;'2CT$IC!V8 '4^A!;J
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M8 5--6D#O@H:JE8F 5==50E<@-;,3,"K<>6,6B<S# Z4M6A0K6MG[CH9#$R
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M+I*2%"KH"3]P!RTP8W@RC$Q  7\0!L,  DEA!G"PC [0!BY@#]"H ?=R"4_
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MH2(Y (&FP]GGBI[ HGT)<B.PF CP82$S D!P:*( ! *$$1<P B-@/YIMV0J
MV9:=+)[P81N@)A,@3Q\F<)S  >M9!@9X!G<0>H!X 8N =?_R,MJ F @;@&(@
MX D,M &>  *PP$3]4$ /YF'D,GD8>P&8W028C02)D-G)HMT@AF)-@+$#L0(M
MQF(C8 3:+0D(P %(0=LK, 2<T \M5LAZ-S+E;=P,] 5IDMD74-O^^6$I82L5
MS0#:W018C1'S(@*?F G&G=V;#2RG0!Y<XV$KP ZC?=YLAP!W0-S*/1<]P B*
M0 )$, 2I8 9C6>!SUF*-;=W$LP 5OI8H -Y6)ML+X %8QP[@/> .'MH<\-L6
MP$!W(&0@(&9=P U8UVU8)]I#4.%;<#>,!@.5K8\*X)\K@ 5?8 .@L 50P X<
M,0$6S-\>IQHXKF8K8 0Z@W43\C'_,>[B1M #/J#=7? '!, )HI )&R#:(_-@
M[* !7X S>SXF%?X%)5!C%^ #"BW:79 !-H%R(T/HE;T"=X  #*3#<7$$.9<*
M(A ''M "J% &9R@!_,UZ *#=*1[:P8T$]LUB'A= 'G;:M1WJX;$(.%[A2L+=
MLOW:2(#B^:UFW;>2$P "1R "7W#C7Q R6#<62Z;:HDT!&; #P@,$D6[G,##.
M+:8"0S#FV3T,+3 "+"!X6.<\"='?)1#K7Y8F##0+/X" (@#NI W;3; (*X#C
MVLW9[,  G# +%6(!PV "(W#=*WD'':  "3@"/P %.<[H0C8$M0'J4_[<:2(\
M,# !'S<$_Q* *1^&ETC #I+@A+,P!#N ? S ZH#8PZZ^ 3T \4)F!+0] EB-
MG%@WYEH39"/@!%'X!;I=W=B-*S-3>!NP1)=V H-\0PI  L.Z!76, QB0 &I
M!6] !!3@C-)S ",6%SB@ Y)  =S0 ^0 "V20!:=@ HO0 ARP!5?1 C=P""=
M QI@ G9L"%G0"Z?P;?M. G'@"0VP+TT^GK@&!6UP(QPW G"@G_>G 4\P!AMP
M I+0"S!P M<S9QAG"0S0]AU7&GQ),"MP"AB'!CU0!!?0"[V0F )1 S]@ ET
M!8K0 C;B VW0<R1@"1H H_M"#A?!?Y*@% 3SA^LX!AIPV)+  ?]P  5<3R^2
M, ,^0 8BH/84( *2D)< X.,K$#>A?_J6H 1&> KHQ );0 XVT (:P TGH -X
MWCJ(C0;1@P4F0#P*\ .@4 $M0/I : (L8#X'(0(L0 %$0 :Y/PRT#P7>UG$>
M< 8E !!=B@ @6- #&@XL2.U(8Z1+%@TF%B5H<H!.F 22NL0A>&38C1L4QF Q
ML4+#"#AQ./W(TD-$KRTM?MQ@ 8*  QM--' S(D/'B!\F?J") $#!PQZ63M#
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MEB/HHPA4A-#ARPR*\J )"3SI%PLS"C*D$P5Z 4)@Q*AL0Q(&4G&"VP17..6
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MQIE'R, 72\:^YYQA$0V0Q'.W,) %R* D'YO%#- P!!QP P%8V&F=GI$8*EF
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MG 8_2 !YMFZ&Y'FAUXH#"U@F3$F41M& "IB!H?N[,^ O&XD2D6LPR2D^)*"
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M",AI00T7I!L7I)8!"$BX4@ C<( %<( 28("F*P$7+$@'( !/^ (&H!( @"L
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M2$>=&%&<2-C$#5HMTUDQF 18'$/%%5@%2+[P2&KZIPF95AAH5%$-5W'5)P=
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M Q2L=0(+&1=R0T("(E20R707]/#B814 $4$;:U# (3=P)-!  YE<T()! "B
M!1 ]S$"#$0# TMP,*$SG"0L=#+! 'T4L(,HE.J(2QX@8M!!!#90P0$$1-6S!
MQ PFML#-%HFU0<H$O8 A0X\R'<$% 6T$02D."510@25NFHAB"XO,T&4&TRF
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M 5!!CDF-0&$*H, 7/)&)-7E" S-+B@\\,0S2>> +R7*"_\-DP(U47 T+Y=L
MC\X8!DH8X03D8 T1'-"#.-2 &R!A@ W(=00G<&(+*^C%,%HPA(OU@$,M* <4
M#E'*](VI*99 P 92,:Q PH!'TZ&=#X[0 E\*S@0L1,4?RB2"%FS@""'" AU$
MT00CN&,-Q?$*%!P@"BBHX 8@L%07%T,$6V5 1M7:0!M,\(-!]@ &%_A!+TCF
M"30HY@*\3 4PUM"%(AR!&[9: ZY.B +^A2$I7)#!L!8#351 X9^>, $%_M"4
M"]U@"^1PP GV< &!IH(.$VB>)"+A+@?80&Z66@ %0,&"(>" )9T8V09PX(8C
M78 #8W(7)UA0!$.H82P$.,(-C/]PL:8P(J!8X(("4D #IOC2D'3($0.RN8@;
M:(R@AO)A+RS:/!94*81<N, BM@ %!FCE<RV0@ RRL @TO(1'%!"9)"AP5@^T
MH!<<_)D@:52T&I @"QW@D=2:UH 6H'5J%J"@U"Z@$4F<8"QDPL+,UD C+-Q
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@N\)KO,KKO-)KO=KKO>)KONKKOO)KO_KKOP(LC@8$ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g28372cki001.gif
<DESCRIPTION>G28372CKI001.GIF
<TEXT>
begin 644 g28372cki001.gif
M1TE&.#=AIP.7!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MYAP7+%,<\!'\$\@,HF@[BM6"%6J(8 O8Z(2OU6()\WC$N+ZPNM9I, UQE!T
M3/&&ZCE""P11W0!0,;,VF6)YBZ!8"VK'.@?,H00ZT((T!H4GX1$O$Z2  CZD
M(8 X6, !FQP"$080B"ALT@(SF ;K -!"0^XL?5Y@7XT\0(]Y@%( 0Z"@[G2U
MR\@]PI7!K*  6T (VPF E% 0@*EJ1$A.1"$.+B@%YJQ!@"U)8PB7; 0>2-D!
M"93B#9A0!-:LL 8J8(*1S?(##OLA@ O\8 "/^-H(!]#_.A5T(0=JR"$S!W ^
M#<9@'HW8V08!:@.LZ6$-Y>.F(AE9D%KX4!&DD,$3A'D[B%U4"P)P@2BOU+L<
M@)"4/A## %IQON$- )38C$$);D$'@T0@!L4;03^D884"GH$.!.B='VZ!A%E)
M0Z3$)&.#:F&) 9R!'I@00J52P48UM#0& XC@/F\(S]-]3H1]]!81_!'!S1$!
M$QF *A=YULQ%-/))9JQ>([J5"B]\,0N22-X %!&X&D4/DV\[".=R$ CZ%8"/
M64!>!%;)O$4@ )>.:)P*#EI8;\7 #_DLR&+]$8@K>&L';\@"'[3E"BJ\4"'1
MPR?]:C&(,QA!D 0H!6$]6R,"_[(RL(M50R.VT(*F!N)KU/P!)S2WS[Q>X UJ
MZ&C_,'':&G5.ET5HYF_!1H0<S&^$.7!K#Q$(W%J40@TWP ,YDE<"&_2U=R68
MWT"*$+GG#0\33GA;".C1"G$5)):ZD]T*0D"(+"00 %[$Q!B56J%1G(&HJYRN
M0!;H5 1NX8UQI  4&_R(*]PQCWMD8$W_&&$U0M4.6 U$8%677=X]\JDW0$)L
M2_"+!Q#4HGOM01(4\(DKT:@ MO"O' XUHTJM *>!B,- \&L' H2 ?&<HGR'(
MH3Y=+C"Q;RU($;R "2/HRG*+U%8S@_<)"8B"1BPR107M,0L&C*$ <%I""1S!
M/UQB0O_%!/% !>T0RQML6$N?*JYL<0A<$6YY3@IH 19OL#/UD<Z15+B%'2;,
MPS;-@0HVZ+,)(B>)&D3 %>D<U)FNM()!^B,35Y" J+] Y?!%+P>8L,$L(H60
M6JP"O .FIC^&6P /O.$6?/"R!,8090(?B'-J>$0#R#"-% _$<IA@ SVR8(1/
M^/ 2$B;$+=P0.?-Z59\D]"/$B "[<;EZ?0V()2:8L"("1%=WO>[= #C!@>0Z
M^P8L*"#R?(C6-A@M RRXI39O<>^QV2"-PR.L8?DX@/ M%A,:@ ,KRP"$:;"O
M #/P0GA9A:M92;,@J7C##<)'$ +F(':UO 7;4C!- -2"""G_S$(6VC""."BI
M -KD!&W3AU Y* G+9CCNH1$RPA)DP@M4['/(,P"'POEA'I%MUAOFJJ0B5% (
MXVCKKRQ: D4$MH5J6 3TZ)V!7]@;#C9H@+IOP8(%8( -4DBOS0%0A +&+POV
MR$,3IHY371)D%.#-:X#;P+9N^=I!$P[?0+4+@#7>X I+4(,U40YM]KZY%%1H
MQ"RPJ$< +'"6?\Q!6?F;7 *TH("+J!55LXQ:,^H "],(1"R\<(M9%- .5+_%
M&3) >WK8H'$XON'L:^]$L &YS>)N70NS$ 9B5_FX#S?TUDPP"'K,_A>Q!@ @
MYF%-)87 MYYO9O66:(8^=QP+<*B@__P,8:3A4:&SF].F(_R^7GHD]P*Z9;]!
M1OB[$F1@ (TPA)K.S>_:JP'_8K<$ Q!9&"=/0A +D4-1CC8 84<U_J-UEX8Y
MM/<#M!=VO?,[2X0Y+' N5%,S5/!_".1R!!$!:Y #]>!] ) *.7 #3$ .8G9
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MMTL07T"YK@0&!_"?!8 .COLD+M %+Y"^BSL0A,L%K8L!E)NWY  ( 'P K7L
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MS]7_PT.+-3T57SZC-5C5<\N)Y#\P6,_=[.40%_*S!P?T8,_YY^]M$M3SS.(
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M":XHBMQFD!F3^,,]=3@0(&>S0M78)%X%<8 5_B?#&1(P*5IKWLW:(L7\:($
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M51R5JF5[G5P.4N-;*# B&.W)T[DJ/BH\PF.V<P_HSC*?PK?)=OX@:U"J7$<
ML\<].KI6!-9PH%U$+LQIPCEB"E"7M#(A*2 ZT"(&M((QU0$3CZB8UK=:_Y 6
MQ):D=QY .C*U K+M60>_ N?CN#;WV :B!\3*018(_FVZ#**M75R!"S8@@@U
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MS\@!-1 NB[*Y*<I&V: $(I@/AZL-Z'(#,6A+@#S"UTL#/P*-PJ@HLS IKWS
M*'!,[#B(^RB!9G(,G<@Q@[@,*=#,Q1R 1Z ^LIF?B9JA(/$3(+B-&UA$=1NY
M_P19JUC4)J.;&(,DFU(XQG;R"1-TC02#BQL81:*4SNFDSGHA0#6)3ENAD-^(
MB20<.]]Y"Q(SH[G,CUR$#@%:.H3(OID2*[,L W+XJ1:@P^74"^'I%1-*@@O8
MK\T< #?0"P*Q!7EZ.B3[$<?C$=L9HJ@B&S14*4@IPVC:O"LSBR_8+Y>T ;T
M@D+DA*^XQT;  Q78@;\:@ L%L(]I@0M01="X!3?H ?@\B!6P@J$9HA7U! F
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M3T4<9HPY0.G<IN$//H<MS)*)8@[6*8"W'O,,48A%3V^1@HS0=:91.',(#<@
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M&*X2$(57,RG2$(#!BHW-:<B8">W&#L0<%F+"V'!)<#43'@5'3X14)L !%=Q
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MCQ]!AA0YDF1)DR=1IE2YDF5+ER]AQI0YDV;-E2JF/6I08-6; 8ZVA' 5B".
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MX +'FP$.O#B-3!Q!!??P(40<$(/\D<,#/TA!%._@B05ID0QW6!*.5C )BV6
M'C_(P"'_$9G(#)PA VP T$,40(D'<$ :$5' !C)@2'ID4I&=W"0;#B" P(V2
ME*4TY2E1>2,=\8@G/T "^'Y!#R,=14E,>H,B)L$ 78ZA '/ A!O$L#T\&(0K
M(X@%XN#0"$,4P"Q&T*4NR>,67L2I(U^(4J4B4@!Z&0$&J_B%GU:P"FG50@"?
MV(&T(J#$-=A@$D^XP"_HH((UV&,6#(!"#4C%@GI"04(>F<$/N- %/PS #!=H
M!1Y4@!0]3&, @="#%Q;A@!VT@A26&$ C9D$$(QFD%DNX@2'(< HA$$!69D!
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M_, ,',3"" H<V13$A51M6  ;V+" );D "S3XQ0C.90(,>!C$(VE<+!4Q#7O
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M'N 74@ CZL@>/*;$4NT2PM'T,J -D  C!G%V.!*"*"*E5B]Y@E(J7 A1'@<
MDD ,#F4$.((@[Z 'N H'EFD0,?!D4NYC1.  >B0:; T(KM($UN !-( #_V20
MK59JI/XL Q!R6J)@L1RB%A02)T,RZFI($J@IFSK-"2@ ';C@=B+@$+R(# [%
M'JA*;VZ/! !@]C* "F@.-'] !(Z1!UPQ [0C0!Y) CY! (9O ,! -Y@MN=1
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M EQ3#1Z  ;A#/_M"8;$M"0! !)*1<2VU;#)U.+'V=%$W=6%B!:R@"D(B(V@
M%&-N#E#A-W@ 1@-7U2S ! 8!;R5"07XA#P1@"%P("31F"73@:DSK ?Y/)8J@
M=_-O"*J@%J0 LF) "$[6E# '%20"B"",^E8K]RA73=1D P0@9'W %5\T0'2)
M%ML2%<%@$D3 !ZK'!:R-"IZ@+X:@+<EW QC@-LP5755W@ DX^EA7!"8!XJ2"
M'X8 #&8A#A(N"8CK=BG""HJK(&I!'QC@@6N@!8A+"_\:HP!<P($AK@#T00!\
M0 1 ..'T0<OX@0%(>%$L6 1Z@ %!P%PBX E\H)Y\ ((O9:O^100>V 4LX1%(
MP05.[D,M^($7Y0GZ(85!6(0G>$(/6(4;(X=W. X>Z4 O( \4N  \6(638X2%
M^':R"H5%@((?0@7F0 J_  6B((:Y,H6CH' /0@72H,@HPA3\J)>XEZ/F '94
MR((3>$"4 ('+8&TD& S   3B1WI$H(X3S@<XP@$H62ID  ID( Y"QPP8 /;H
M>$.CPP?,V.3&^(,Q0A\@> 7P 7.M  :>00OJDW4_V##X00\<N /^  RBX 4A
M>19 . +X88=/RUB06 ^$&"/_+H 1Y'<6O/9?/EAC].&)T[A-@IB#_P9Q ^03
MB(,X .1/Z^ !%& %H"!*\H:;!8 -%HD><(#:%+8V8Y&;N[DT#((!G,]T"SB?
M]5F[4 H'N& -1N N4N$46  +2$ J#T(F,4 #\L "@$ #%H #W* )!L<>&"$\
M(!H#7@ /Z(@&+DP#Y "T[$%;LP@Z^&JEEJ;#0$P)-  #Q !D8B #>&9P=. %
M9F$-XJR#C" !(5H,6& #Z"<*%J0:<8 -%IJ-O( %2#JDT6 !1FS)E.YWC%H#
M%"4$O, ><&8]6)H+7MKB_H #C)H#P@.L,0 -[B2R[H"K<8#2#J(%B,"-O< &
MV( #_W2@ U0 "S0 "SC@>Q]B!KKH(;[@Y;:WK0<!ZQZ")UB #0[!(^=QKL&R
M'35 T'H(L@\@Y.I3@N)L!B2C!@);"P2K26S LT%@ 3HL!183C#F@L5"*9P9Q
MJJ- GG@EG(Q  $"!9** /%B7$=C@I:]@!DZ!$C# +IV:!B8L/B*; ]#(!*Y:
M YHP$(1Z:;05PL)K86C@J\@ HCE@H_%XI-G@Y9J%!KC:+K(W1LAAM4I4(N)"
M M*WM9S"-55AV6)T^)1K !C@,K[U#,!@43U"%J56@/?YOP$\<(K D6M GB["
M!%!+ DP !-XH%4#@"E; !7C@B9!  D)@ [2 7H1@#![C(O\49-Q,K0: B 6D
M(0T:[#':E*/20!(RPI$EP,&O /82! QZ(+"U)0*\0!+&0().S:Z&P#T,(WZ)
MH"G."'F4IP;B: 1<\DY:P-0<[P@DX ^T8/E"X,AK",080L?)0Z) + + P.)V
MI@,,@ QZP0=ZV0 T(H)BX&$8L,24@B<0Q 241P*2QQ ZJP<D +3<D*PH\8[3
MH,YBX!;&T2!9 !2U"04,@<XWH =,X!>N(,]94B.V8 7^Z0@ @4'R?! ,[R \
MX!%_9!&D; 04X'J1Q'HA:'=^YK!W9@S*P@XB2P@2I%&TP$[\96=<P,0M #X?
M8@ ;0!2LH =FX $RTA0XX0B"QW;_(L M+1P-\$#./\\!:'<%/ #UG"BT@& L
M)4#2(^LB"!,'^B$-YB/).<]XN1QW:^3V'H '=$G=&4#=]>"9>.  ;J$$Q)D<
M7%,#7&!$!.!J#F <X?8)JB:Y<D #GN"9VOW=>4 ]=6E:-37 '?[A<62E'F]:
M'K'1EZ30D&"&M: %S,(&>CD5^GP%# #''>*)[($-7H &.&$#'J"HV0 .'B$?
M$FM;Q*E )(@)5HI!YN44>IL>9 CB!G%)0,LA(NL]\M *_,@@5D#FS&"$(&@&
M'N_K6" 60FM;2'T:?L -2$&4,V(C<(=!GG>_OHX>?L$(7'>QV-I"1A@+Z&$C
M7MU?"%?I_W1WP(F>KH:,N3E@&M;K(4S!4QZB!=" "61.$7@ #.# =B+"\=Q,
M @Q@T:QY%19!CC!N$.2@5?#>#_ZXJFA "[J  QZA#&+ #A Q]!#17P#!U?B+
M05)A(TQ@'0VB!6@@"B;M0X7GUK<V(\A^!+8JZ/D\3G[G7I+ "C8 ".E@P+?
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MK"$)7F0P0HI=!,PZPB>@4"BS$J3@M<0E>M" F"DH <!C TXC9H+"U<HT(#E
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M8,K"_2P.A2N  @0 2E"2DI2B#&4GAR  !2B@<*LKIC&/B<QD*A-UJ(S !0[
MA3AT)0+\Z$HMT)$;A+E@ UB8!13HX@,V1), $7A"NR(@ RP<( I=68$5#G"
MH]7""F01317:DY 5#.$R26# -*W0 0GX )I'BX 51-"!<IXSG+-@  /(.5 N
MW),U4<"'/\$)32T4_\6<*AE"' SPA<-%H5/7T@,&N*!1F7"4(=@B*-T*\(?#
M'8TU!YA%/P * !G$024MN.A"DN"#BE:3+E9 #$WST"Z9)0$,6.#")'RP "W
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M1 BP HL<][N(;("%*X3>\E+8OW"2@#"%Z0)A2@/%PZSP)TZL@!2+( -U&(
M2&OB81)%F,0TL0L*E^-:JE(!HJ#P=8^,Y"0K><E,;K*3GZR1"'3A!Y)0L.I
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MO\ &-/ [C407._ +.' T"#,#O9 2BG$9,R $1> %1H &.,!.FB4&#'B#?W
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M!JO0"F[ !4. !D:0#V+0"EPG_STCP !D\ MX  A*Q!DPD 9&  ,7\ M(
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M><  5B"$2M!VC\HC%# *C1 %H.0#8Z@2^DL$J/ %:("NVGHL$^+_-*002F!
M"IJA @C$$'W,!1K0 ![P--\1"+;Z%B$I%PHADE8) Q4Y _40$P@'!1'C'3(0
M YQ "II,"N2@<4.@%N4J $, !FC@!'-KK5K3=D5P"J2P!G=)L4\@5U$; R1
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M5ZM2IHH0TA>/??\'DX &CT(;S9+6"J" -N ":" )<%9)3T)Q![<*X+D2F7W
M"ST(V(,#-P@$2%TZQ-3!== &_<:Q(N!O&;9*( [B.#MN&\"Q*+X!*(X% S$
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M E<Q)-'?_A"!@IL*^",/X\[<C)P#,!%L %)+-974_\!*>$ "<OCRJS 7"%!
M@\GJH +#MT!:H081<CAC PL4. $\56;T]%ADDU6VJA8P."*"0>AHJ8 05,'A
M@ W0T"$VW0JPI!%#  ASB44HW>T.;C.;X0Z@0BH@E7D42;>I&;@0]*,(IGFD
MW5J(L,;<DCQ@8=Z95A#XWF6;VN",#+!U>(.''=9@L%\^84Z/#2 682L)]!"!
M#7K4T  ,!DCT2%8&3L!6!#!.X&" $C20)F&::[9Y1_W(*K C"9*00 +4)%
M:)$*F &%*R*PA ZA"<A3 E&P*XN($3 %(((TA%A(/U$"_!EJQ!P0A:ROH?/(
M+>B +K#G&O#RNE&/E%;CDO_8:ID#E;A0TR^NG[5<3$L""O" D2V@GDJ_,?H#
MX&O%/^)::OV:$V4M_9(@@Q&".\+:!C0@%;=GHA?W6>^?Q]A:\9\!B-SP%2[
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MHBMX^((7C  %,OR@36<#Q!VB\ DK"-,!JP !'ERP"DSBJPL4K 52'- %L[H
M"RSH1QKLH+HT4D %7M@OHSQ#@ ]I($P*8, 3JIP/?I0L<$\ J?T6)P >^"#,
M/-"#DYC_\P0-4*$.:F"##QA@ ;E$^<MLX( &V( !#/E4SWOF<TT@*JU:1$.K
M,WC  J+ @#%X  1AT,,3+%&ND)B !A\>Q)'76;M1G"$,3_!!&A:1O53L*R0M
M8 0=%M("TX#W:FN0A \9NPH68$H%1BX /F*D!%4X01I9$U<G%7!&((S EMZR
M@P1VP%=@WP8 ,B3%L7UCBDM0( +D,@ @" > 6J3!"#O0P20X+87P[E6$<:N"
M &2P WKPP0.P 8 *3G&$$'" 3X++,;XL888A^  %6@UU;&IM8:NY0 & >(35
M3&&#(0@3VVE 0@'(P&X5@$ . LO<U9;&Q=K-P0CIQ4T1[@'?_S'&1=S$'JBX
M6-$'%:R!!5'(QP5^$848F(%2@@NE%MXLN($M>Q!16$,*E#)K.Z2<"3*T1PJ^
M@*Y4W&&5@R!* )=@!M]$=A&35>.R%0Z2RS6A-E<H B/X!("E\EP('7'HGT6S
M,!( P %/".<9&,:P$[R%!Q5YP- 4<( ?9. '#/N!!JH@)G(, 4H#. ,-\BP"
MB8CI9PIPP!@^D;H^1U[RDR=)"(9RM87Z4 D<H $.Y(H)-V" "U&AE'9_>WD[
M4= 4MW #%NALA$1U-UP>^0(/PB*'C@2'"1 E2A+6@*<(2,&]NVPWK>U)B0.@
M@05]!70G+3"*.VBA"RD0R6*/O-0PW/_-3B/8B@ROX'P E *YD44%:5@0]3F8
M@0B<X (;W"\'US!T)T_4 !<PX 4^D*'J$#4$JG$/@!FXM@ "A!^P!S;0 'JP
M@088A8+SB%"SFHXPA4!0"CT)!*\""J5II233.=1BMY#@/:-! 21P!2&8+]_X
M@E_XK36PAJO! MBKA9/S@%[ E )P!6OX+ .$D 7@ 58;B402@PS"@^7!#:":
M!0Z(@H5P@%Z:+#,  B?8@ 78,0LPO7:[/'R) :T2ER5 KJS E*0;JXX(@8""
M-@J0M/\+CC P,G$)M@X(OA7SC +X$%4   7H%2+QAPV0 (\Z@XM@%0VA@@_
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MD "8DC!=E)B<JW!<E(":DU@!4;B)%1@#P4T))QJ$,/W< $H"U>V, JB!A>$
M.K1#RO 'P2R )ZB(#[A<)CD#-7 [*E"#R%"##_^  3J$*3@X 0%P@$-T ;D<
MGZ$)7KT]7_1-WY5 1I9@U8CM7/5-WQ78/$^B$;0C  <X@3T=@*W-APP8@*_5
M#A+(6LHX@R<HH/XY@Q,@$?TYF0:.7PB.8 DNFA:( _@MB0@X!W"=X/@M "L0
M@<F]CS@\ PU8'!DX  VHLSIC@R&("[8,D9_Y0QI(80Z I"/)  X @R=X@@V@
M!#80@4;+!QYX B'F-!Z(%0Y.8B5>XL!EXOA-CAJI6BE;' 40.&FHXJ'I"!Z@
M!P!V  .0A@_  1^XXBKF 3@0C U@ #:  PUX A=@6R'*@ >88QV**;5U8CS.
MXV0!J!#68S\^$[<H7C'_60B-T@NZB(L__0 XTQ!54 BYJ $ZM16$T !5R0=(
M5BG_H0PJP (2R=T__F10KA$!/=I0+N4?61@X$  !P <!@(*$6&5IP(<X$("%
MJ8,,N%PP_H"-@ (7$(!\.&,U<&,1^ !*<.-^$ %5",1(@@@U>  -.  &@ *?
M,65J#N45P <%D $&H),(4.4JP X7T.8.4),W4SL9J:&M40"_78$D*(AQY@EM
MQDG58649L*$DT&8KJ+=JWN<<J8$#4+.#DN,H&F@=TB'PJ)]%_@!?&6A3A0@J
M.(SJ& (N0%3O50!ID(8#$ P.D 8!F 0-^( #8%-^'FDF#CX6J#/UNB$O",0H
M_["".M, ]=(N)B"'"V"$'I! 3!%#SP$ %Q"#.-$ 4K "GR8!XEA)4, !21T"
MG]8 -/ MDG[J&EF8P<B! ? '?YCJJI[JR,@ A>"+5+GJ$D"/6]D/%V"# ?B!
M!=Z:)X@(#/B9YK7:PX1JN4Y?V8$Z2N*W?8L#SQ0""=#)V@&".]@ #D 4&3H"
MG$L7UR"E)-B!/+B %!B#&4NK1UOE=80":M+GN<[L^"@ <G@"$F!H@F;H.GZ
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M>;!V!A("D ]%1=,$P@4/Y+/LT!<OO O 'U%\U:U#,9@!A14T&#*#>K4LP0Q
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M0@O68 0&^$ #40 $; Y2P0LHXH0!E, 7U-L# PR6!LO*$PT@MT]KD8,J=)"
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MD(K.6R(9%2 5K4#O*LP0BZI$SE\FN >^XFP0U1'.7 Z0BHUF@(.'L0+A$RD
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M)S$>@0DP?,/H6))S?,=O:6C4->'0M@?@P G @1'X  _XP"1PI *-;F"%AE.
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M-R?_?@ E&/+ JOW^5@6,$ $:<( $"2A,KWF ITAG\ N$*C"F28A!!CY@! 4
MP0A)?$84"! "_EJH663 Z@HXW!W^XD%Q:R!91&I@@D.PP:4; <,&:BLBA1V
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M 2(@!3[,X =NX &SM^ =@</:$*NP!TF\<(<\Z"$-D@A,:UZ2;4;CX 33,(,
M6D,!]]R;D4C ];UY+1)20%SB,YK!(-SPA">  ;MX@(D9^J$$-$AB!LU&%@<B
MLP:0CX1X!G"J0XH2!9AH^TH%(=F="0!P''"A#,!;P1):D8(A; @*:VA%R_5
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MC41A@HC' =(W5WI7(R3 "0E/ O27>&/W=BV EFJ   J@>(%G<>* ?^. '!P
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M0%4 I$@54HZT@&-O0<L%/&+_""'0DU$#F3$+F+BC98<1"Z,>/2WPA4:407P
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M@((^!(#SVD)E!2YP>Y56('>FE\GA#.A1!+PNK!:9">QQJ %;DQYVNG=L\PP
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M=X #>6 %>7@ 1.%[X9=8(;>(GL8  Y=RCB@S+/< W#>)'>(_=E!1?8(HG-$
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M;L,%/S@(FG!":1D3._(TM\&;8H$&LQ"%H@<2(2D671 &I7 )G[ &Q$$?0N
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M@6B)FN[S%OH)!"C@!@XK/D:H"2*@L5!@H5$1 H-@!$\@!FX@#1T:'4*@ G/
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MUBG%S?B>!)8P#WX>$ZF0AS="VQ,/U6I@VBU " . "25P"7I$! .'YGTQ"C^
M":]1F&IP"V]R.&J0"1[O-#&A B1/9'=S+%[@"+71 FG0Z66P!&B^V,6"W0/0
M"-_2W$Q #M"=YC%!W3? !(69 T;FZ 60"L1-!9K=EMV]VU%1"O/@Z?0Q (KP
M--E1"@-@V_\Q(3+DG2&E>\RRC-*!_*]7OS)K?S35$Q_1J2$J< I7@'05EP18
M0(=F6Q@UTQ,:T  K( ,*H%>_AP5^0$#DC 73P.QFVP4L, E/\ 04, ,?$ 4"
M\)44<$<1P UFT \"H ?YV ! L/-E()4Q, _&7>NLH A:( ,P  -5<)Y$, *H
M/S]VX  NP !D< 9A  ,1'5'\ A2X1"'W\M05@JNZ2LBN8 10X,EKQ6FX>N\[
MM 2],U3"UU(NC>\"Z-QW!,<]4=TP*A,ST-IV4 0>#VIS\W2-( ;*O06'D0-E
M/A/=O4 2,0T D85/*36-M   D,35@ QJ,#$A9^J-(PH("P#Q@TG_ [U;1@@@
M! F@@*D<MWX,,-.A!;<;> @4L)5%40.0,]XTPA-QP!DXF(206S+ 'IPLD@@H
M'* C"@,]%^"H$6*AUIP22AE<9="O!D);5;4H4.#BPDV7(<V>!<F H02T;=V^
MA1M7[ERZ=>W>-0O%WP<!>/W^!1Q8<,@(:5!]+. A4$6Q&/)T<!#CS(@.*WQ@
M6*!E:\@55C <B&(!0*US/"XLB")!Q2 Y0WA(?<9@PP)2HB. 8<,ESD<3![:0
M9H"%MFI01F:'3@@& Y<>6UN >7(@\\<6&QQW,!OA&<T5%[8\CSY=A60CG[8#
M88$=I(,=; @=9L]FT**/ $SDH:!B#1()_Q]K77"BHEH&L0.D B(@Q"B$BFCE
M"@_H^:%  (I0Y0<C-A-I#E[J TD%4"0$P(,HZBOB!SK.BD"R$8HXQ3C:1$LN
MMP8P!$ ",A8080W*$KJ C>'(P(,MTK8 J3 C=D#-@H]N8^. 'LA9A9Y'0OL#
M S:0J^69)S (S84NKE2RR!U^&"$60HPX#3DF%^B!K2+!, TU 7K$0[05O 3S
MI2K!+((03E(@Q[4DGC#M2NRZRPT,4MP<#+ /2CC K@(*L*DE#D.Z:)Y&##&K
M"'I0<H&0++B0XA8^R)@FD MR>&2+ @#YU 8VV"#!CP$4H:"6&-1PI $3I/!)
M-!6(*,$-(@9XY/\*,KSH%21=J1@@*2+/&FD 3K#(2!(5IKDAA8](:A6D5+QH
M"0!3D.7@C44^L>26$= 8 )4:IHHV@Q_.H**$< N88P JS@ 88!NF#>J6-CX@
M 8X?2G"B"0/NZN<,>A1HM&*++\:8+@48ZBMCCS\&V2)3[J@HA#28 *"%-=P0
M00P6RM@A R$^N0 '$;#00 X.5R #!RXVX""%&E200@<NL, !CR(&,02($<:(
MP N?L;ACT1@T$ $#%EQ5HA<+(D#C#DTN8 2/%J:YXP"D\="5!;5QZ"'$4UC8
M0(P[&FA!#);%&*$B<5$X H (0*%C!B]8:/GNR'Y)X0NFG58/H17B^&3_CL-6
M@.*3)0X3R8,1+/CUEP^27F&'ST>SQ!H.5>!&PL3.V,(#',0P@X 5E%B#!DE"
MFDH1*,!2P((#8V@C# 9J6 %#3_DX:SS&7?#"'BZZJ/JH&!#O(L B5]'A9GJ,
M^'H-Q#' X0I3M$_ECFD%M^21HS6(8MXE6'B_!R!0L &&"S3@8O\4O@9%!MPP
M"R7P3P0<R ., ." 563 ""Z0PB/>A@<&(@YG6\!081YQ,SB,[Q='H!0'>B$"
M521P!@8,VA LH0-2K  ] @"%V+! @RA\8A46_!Z-0O:6#PQ@ W?AV1LLA98(
ME&( CCA(2%+QJ1%(XQ4W0((E,&&$+LQC$8"H_T,FB&0*6T7+BX'H 0%:0(@<
MU$X_MZ*)0HKRA6F48 1=F(C?1)**:5B+4V@920YTT \BJ"$0L2"72PJPA!)D
M@B8(L0E.(I(#>YQ@&HX )"?"0 0J&,4!"]G%+YX2K8Y(A2JWR, ''@"'-KB!
M)C#)0K1*, !]A:$#EZ*+6C+ J!W6TI:W1(@"<O  BN'2E[]\2RU00 <"F( 1
M( 2"#AIP(#1(P@HTZ$$(?F$(<A0@!N #20C0X"V>,:('$9#"3R*P!B.HX!1-
M2P_1[$".<0HA%1\47 S,4(!5%"@"EC"#!,AQ 19 T"CC-,(,0' % J2H=@(U
MA!A18 A^+G,U)\HFX/]&\Z%4@  )Y&C!()C7LR:L!IV'Q-02Z&,1D=9G!6R9
M 0K" (-5<.(*@+B#' !@$\XAI!81G!4:?B $!'B !6!07P%VD(<U" %#*P@*
MP'Y !3-41 4[H,<90& $.3*(>6<A R.VH$X#U**H-9@!W-B9!CO4)P0+9><:
M4A*!#2RS,'9HP4(+4 HSP*@ M4B#&1!0 'YV( 0#C2<JAF4'%ZS!*&"%I@HL
M(:\0= %\E*+!%4(R QIL%11"*.@UO_ +G:7("(PJ3%WU\SD/T2$".\!F*FA
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M5D"Z_#(%?]">.7R# 6@$&PR!.CH#%N  $GB#6U@[_:( _BJ!1CB"8BP!U8F
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MD?A#BR!%0 PUJJ?B4(FT"#+X "X0 WJH*Q-X $I8 "R0 E08C9;2&0/!JSM
M4 T@!4'<4 3% 3FHA0TL "50!3?X3Z&!4(1 !PZ@A -  _P(_PF5P0$].#0
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M3&F!Z0NW#@#+)*B"CW"!JHW9KZW:XS&+6DA:3$D" 7".OP6 I340=+@*/6
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MSYBN[OB,[ 4'"6G(@9!EZ7Y;XE80@A:0@D8(AM,>%QW(!T*X 3G03['NMT:
M*,&8BKIB"Q(F@!G0JI0A@C/X!1(@OT$@E>)L@D"V#S0X QQ(5@N8 3@ F!&
M@GUM!"; M.*<$3R:5"D8<@MP'#:(*O!Q(7K@!%6HM;88)S9 @UMPPCY<._:
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MK.>SGD$-.)TSH,DJ:#H3.M"%'K2A$XWH11^ZT8IV-*,?+6FAZC0#-^("%K@
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M(X-#CM*+*P)@X(+(N6-\RD@G AB(@N?_B9_9 K2 ']%7ETV_)?WM2W\(UW$
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M/R"-'9HA(IJ3(9ZAS4!( &TB6T@B14S(S#2,*3) ' !'"XQ!C#"!%S8,E0%
M)*YB%M[BU]T?+CZA .3')^PBMXG>  *C=JB %VC J6G CIB %^! ZY !#VF
MW9A"(#P$DB&!,?9*%_!0EFAC-.)!#0QA"7$ ')232WS!(? 0#:2  I !#:B"
M!KB!R!6 "7# "=$ 0K0 %D2CC[6 &$0C](G('7" !N" FU5$"VRC"8F%Y!"D
M-"8?16D 06Y%CT1C@ZP [Y20ABF!/?(0(;E)"S0C#[% '+2 DE#?/__RD!S
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M=NH.?( ;&Z0*)T$7P$$&_^1'&XP \[F *MR1473! XQ #?BC5I"29=# )2
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M7?\M")5":D6PIC$[<U'\+4N_-$RK*/I"QYUB\P T0I5FF1I@0AA0P!!*P0
MM&6\03KY]!<0@AHT@MGLP#P,@!]?V [X 1@IAHRU,RWE0$P4 2'P1SK?Z1L$
M@K,0P!X!@D(#1AZ]!%[= D&U #?< **8 A5P D-[ 2;@TDO0E0X4R1<M2'NJ
M@"M@@LH" #GPK!H$@E_,00E4,W#HA6(D]"-X@F*X0"D,P WH&W0(<TQ;!!24
M'P9FMF=_=DU>,'1,20[<03  ]F#,,Q@I\@R44 _H\P $@LC-@"K@@+9H-<F0
M4E?L=%2PLSLG!!', R]0@%9C=*C>Z0\X LJ-@D)+[0C_"C1:M0Q$&'24K(,:
MR'6G.C0E5:Q-:\SEO,%[#  JU !6)#8IK8 I_#-((78U*TI"8[=J30,FF*-S
M# '?@C9XC!Y^[S=_.Z$9/P>"^,'$7+-AX\0,T#5\*9S+?8%#(\'+$#!%N%$]
MV\PHT$,[$T J2$$]7[4\OT(6G!4G',82J(%R6P1S<U&)I?=0#4"H-O09P!=<
M<X('-C0F1(E UU$]1^4 F#8FM&<$_+4B\$ 5" 0<J$&S7'0G#\$ "4 XIC<;
M,8\" ((79 %!!?.Y\+<+E, 'K&%_=[F7BR T/P>*%/:%R#='GXQ;G_6!U_6;
M+<4\X#2IT -@(X!R6;5JS8%P_R. V& "%["S(I3!$B2W;H=)<WO72Y3 +W"
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M)$ZUAC@C@T].S+3$MM[2U-.Z(M@ACPX*4 *#ZPI(XH(\8'0H C P>($--O*
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M.>,2"F2\(8Q/7$ $TUB@%MP84U0@@@JS_WAF$)Q!C:2:UH++G2@"@S!$8$+
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MU&S0AOH8S8I,<@SDB( 4A$# &"BB1^3HYB<]24KG%!,(C$@;[]:GR3%.\X[
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M<"X=K,5?3.'KL$. C( "4N$--,\$I* 1MN +3A(/!BD&A(P""D@'*, !!&@
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MB(S#H@H@!H##8*9!#09 /I_BXKS #!*D?_" 0')D/A>A,RY@&A+"-B"H%J2
M3%*A"6_R+"0Q.&K!$LP "CB*WVK3"%S ;CP(*P#!%%-A[);2GF9 -QT@?%"A
M!FIA"6X@!:"D>TJA%82 (9P1S*R@TSB(1VHJ0F6-ZQY"#9P 1O C0K]@#=*I
M%@;!0B_ #RC-%+/"^U+  JP@&2N($V=Q!CA!"^*''CAC_[RLI1:( $>MS *Z
M4 X^H12\*T90X J.,[&N$V-6@1-4;0><  K K0?*3+2(U#4;K0R20$C)815P
M@$Z[0+2<<26TQ@BDD= >@4[7(!<O8C.LL,T,X1.4X-4L8 X6H0S84@MN) 44
MP,L.[AV1,])VS GBX O20 <44!)*A1&LI38-8;QF(1;6X!:PLR\Z;CQQ52N0
MQZ!R-5.<)P-4KU?W@H-8H$;JR0?M"QZ-:!7FTB$2[0.@]0-HK@&>5+(B *Z,
M  &VK;+ZJE5J00FTZP$HH=XL,B0+@EFS!"VR+=X ( 36( /N( 7TR .NR@BZ
M@ )-X  VP@2*U?;R "97X:LN8_]0EI+8PN(+;M-'E L/R,%8<. Z5NNKE-5@
MI"!#V_5=!66,O.P7W* +#*$(7@ W"\(#3,P>KL-RHD*$HJ#O^&I@\ZH7B,5=
M,R ##'7YGLL&*+ FMD )\B!!LDW.0N47,)%QF@7OMHLO'<4$WI5F8<0!=N #
MCFLCT"PJ#M _SF\'#@ %,N!?CZ3@YO 6@> !.'8#6*7@FK0(5"$Z_D"YT&0%
M>!9&LNVIL("O:*7,+DAU>@1E2X4&[D 0-LY!7$A8A=4[!9=$V@(.@K5P[T(&
M&, '9,9Q\T%F9"9R)5=F&*!=;*9R>< '\J%S,==Q*]=R)_<"1*!H'I<'G@!A
M3%=F^&'_<R67'RAWH>+" 8!I!3KP+!P@= K 6/H5+5))JB;K=AV@%)6OEQS"
M>,FB ,;@=[(">;4B GY' G82+;1F!,8@">SM4)_#>6EW14YGD=Y19!O"D:2*
M>!K"?.&%>;4B=Y/W#_"J -"A 1]D(!475PMJ!.L70Q@R?^GB ^J ;?S$;'+@
M4 YE /YW@ UE@,TF@-WD3Q#X3QJX31@X(:;0'R@8@MD&@1&%(#_%736@5O4B
M5&C@ZDSN-:?70BRGK3QE57V1!DAH?L>%?[F3<&780J @!Q*RAN.B *J  ?2
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M%(Z _4#:#$SA15J@%\!@KU> J);L#[+,<CB3=_M!G;%C%EU@&M)I3Q&$JZ^
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M.7!?!_)AKUF\)&K3TK/0U%A@ US#$, -P,4@ XY@VP:]3,8JK_J9 IPH*OZ
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MEG+:6Z:?ZBCJIJ1Z:FJGFE:JZJBMIAHJJO,QZIZD/(*9Y8S$+9=CEK1&2:9
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M4!H\, 9 _W<A/B  SG=FJF$%(G!^:,$/^?=\&"@"/$ !+L@/3_ $L8 "A@
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M9L?'$C.(%CM C!RP(29P"L2H"D[@%TK  6R  32P!4G0!>V8!Q; )W? !FQ
M WD0"QF7 D#7<R" CRC@!EC  32 !"K0!1K !AR  Q_B 8S0 $J@ 7C@ CM@
MD1RP:$VG 0O  4,'$Q&P!D8 !&]@ ]-G?V1PDN[8 ]A7D1>9D2; "*J0CWBP
M!#8 7B9P![C8$BJP!AE@! JP"NUX7C#A CFI"C]P!"ZP!I2  1KPCS$1 8.
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MK>+F=T^C*QRA3<7%;G_34TSTASM#'<2"//_C6[W%3?CVG#-ABEQ5!-/P"%N
M7VCP /,P @I !+/(8"& >5-Z(3N@!@G)DG#@!XX  Y9P"TAP 1'W>GNV"-7B
M !9 <:QP!G00?Q(@"@20EBP@ &F@!@\0<P_G 6W&"=_Y$C/P !:) 7!0F>;'
M S*P!O;U$J80"%)1 $+[!??P(9<7HD! #W? !7% <YRP /A(#]90"SL@!%*A
MI)[@JXEZ 2S :$ZP%KZ:J3YP 5.99S&K!L>W C' "5C) =. "L#Z _:0!W$0
M(N#YLQ$@!73P<*-@7AC !G"@" 2H?FCP W;_8 +T\ LC<!9@9J55AX-AUP!"
M2[2F(+8OX0 _BUZU, A1( 8RM[E ^Q(J('5Z1H\JP  ;,)5"$'6OMP2+X !+
MP EN$)?T8 1.UQI%@ *@^PN4<)$90 =@]@,:D(6-6K=1P'TUT0*,P(W'EPH:
MH 66P <%L HC\ FLT =A!UZO:R!SE#\V$DBS&4]U-4V0=$D'LSFB$TCF,F(]
MXWC/89QF$GBCN6TM]G;AZB)A(G@AE)OL 7@#A4GG.C% !F3D\G;S^T"HDZ\W
MX0(E #*B)5^^MQ(&, IJ(+NKL+9$ZP'3X AC]Q*UIPACUP)IT C3>PM78+U=
M=ITBQYE\,@!+5XO3_R"V'3H !(J#HT!I]@"%+S$*#@F$&Q %9+##I+ #$+H2
M8:H%JW ))%=PC^"$LJ8"H."W<7$!#W &1A #F0"$0'BBCJJU=Q 'OCJGX;6K
MK>$!@4 !M>"KXR %C\ %8# (D@  '@ "6/ +2$ .I< )7;P!M+@4%X "9V!U
M+P&Y4^RW,/$%/\ %00Q_(2 %3@L&4I!G6X&XBT .3G<"&1D38=<!IO!Q*Y'&
MADF"58I>BHH$:Y"0DC$'6;N2H+"Q-@ #@_ +O> #:%"I2"L9H-RHC[ !7<R&
MQ4:&L[ &]B "LW !=SL5L8 !!T<*Y# $.Z"-Y=A92\ %7"I\+X %D%EP;O\
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MY@NK3QF\7%$#I,6-!D2N (O1JTNQ7T>>S=B59-J.*\+"O2CA[ H775)8,&F
M0,<"2KAT*.#AT9:+*PRPY:B"$)\"90&XO:ABT)'(&U?\_=B5+@ )G.LR#OG9
MHVF9)DD,8%.E7T/8#@\*."@;H< AKA<*[+>P=Q49OU\[3$@[-\+A#%W#+NZ0
MP>OE!P4ZC*T\N</>R&D+X(Z]>/*%P7,+;\Z=_.ODMY.+EP@;MG !Q7W#GDW]
MH(SXM[?_9OAZ]L%;,E @-0(+-/! EQ08( ,!$'3P00@Y^L"? 0;((0<+,=0P
M!PHMK/_0PPM#U/!#$#$<H$,22<RAA I-7-%"%E6LD,(<GHCP1AQSE"D5%)Q
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MDHN4HP9F88%:/(,!6$"E1EC)!BX\X0D46,$%$$,.=)"B%N?8P@I:L %@4@
MJQA!!R 8A0MH;@8I^$L$P%!'C,!2D*<3YRPC8(47+( 4E/S#*=<YF;P(DC#Q
MS$,9V.+,3/X%'5$HY2GY"0!53J:52;B " Y BKNXP)# ;$(!7/",#?2B 01E
M0R]ZP"HE3))V"SB '+KY#-D]\!GYP,(">M""6&J! '$L2B93(07_3C!AI2[
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MP,8B$(,1<F8"&AS) 3L8+PUF01/T#D*]1$Z"%^Y "81BA Q>,&X7G% &(/Q
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M))YC 0Q0!2-X.Q; WA$(*8QH7I+S7:+ @>HUA4<80A08 8O$3P P $"@,C9
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MD &"=ARAG9@D8("50C@/BH!CF8PX\(K2M !G[F@!0( (8  >F"D]$ $M$ 4
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M18(J!AUA6&"5&0L7^50,*3(DB0%L! P1T&](E7XJ!3!0.01&2YE58*)\&5-
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M\.N4\((%L $%1JA!=<8DN1B,  'G@2!$8G>\)9A!=C:@0(.7*8DE<$(#;."
M*HQ #C*XKCDSP 0+V, &&AAA'(.0@TQ-<0D)!\\.O)3##E*@$/0@H1:26\(9
M1,P&$MBAA 2!780=*@4^[).N#HT>#8I3$)3*L@!*8 3N^AF!+OB8:I(PW M<
M3 /UI%0A=O4$A@F@@AT@EQ+N@<@:A%#".9CA C<"0/_09'H10QCS0RT8Q"14
M\0LVE%D#<VX(:";Q@A/$<PV&$/+D5F!,%X#"=PT0E)%WAZ?C@1 D5[-'F3G
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M]$"#_QV%+4P@T>@,ZN&^6EA!"VT%W6< MP8D*(0'T(!Y'(0);-WQ_($8 !L
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M"V":W]S!%I33;Y3=8UV9)63/8K% $YR&!O1#_L @$8")1'7$#,!!4YE3#;1
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MMFKKMBX&.F" !BR %CPJMZ;2N%:K?G# "T2!M0D,K9+KN\)KO,KKO-*K7!:
M!)AKO>IK99#JOOKKOP)LP KLP!)LP1KLP2)LPBKLPMIJ.<F@K1: IQ;&::
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M:4'8X0 66X$8X  -L  ID$.H;1G/UH84W$(*$) ;XT!IM$ 7\/ :;/_-%W"
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ML6I_ OCP['D4S%9[_Z,T6 (]K@WQ>8$A7( &Q($%D$$\>3)R"]1$\W=_^S?
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M54XZD"OB!8F,*C5JQ;B$  B+!@7F")&PRHB%$(,&UDICQ]2=F2VDT)EQIPF
M"(/X1.B2$\"7%V)8=!CU: N $&@DM>!9,!56I8?D ''2 $!+,T>S7J50@,Q9
M @4)UK)D)TD7(36THJ%#E^#6%.0*),GG A02@JL<JA@4Y>E#%3\+E*)4%'!F
MS9LY=_;\&71HT:-)ES9]&G5JU:M9MW;]&G9LV;-?IP*!9\@%>D(LF!B4-8(E
M.O]%:.09$N,,G\P%+K1*,62'$VE=1O2S@N:7EABM\%@1D[,E"RW74Q =J#G"
M&H$1Y@22 _$7*0$[Z%DK .0.C^.H7* QHB &\:Q((R>1\)B+KEHN^(&+ S8X
M@(LJ5) "#Z5V,,(\ U98!0=28EG#" HFQ$,)1M "K)95=&# "AJ>VT&'!LB@
M@109B.!DBZWR$, '-&*$:  S'MILG5MRBN"G""[H\+@,E -L0S60(&")6Y@@
M2(5I'FG !"D">4@D*:D\X\H9\K"@%!VTD $Y.BY@@107B!"" $!<_(0(:VK9
M880:BO@J E#L\. .4J#[@0X/3 1 A5,&(H,10]<8 0O_AT;Y)8K<=BL"A"U,
MX*(#)(T08,DM',NCGPM^.6(41K)*I9ZW8NI@N3D68> "&H=8@P4*,HM@%3BM
MF%2:G])B3"<ICI@QTRYP0,L$>ASQE;9JK;T6VVRUW9;;;KW]%MQL"_" !AK"
MN""*&I)X!JU:GI&C !,XT("+0[*BJX#[/M#@ YD(,$$,'#1X8H-^G%4%ASQH
M52I7#12.X)GSEIN!B[>L !4 <E;Y (=9T"5 21(^&*&,^WHAQ8&&%0;@OA00
MI L=,32@1 -57L##@6@&6D$?4B*PER#FT$B85HBW:&'ES%H T8(9.*"!A:P*
M4 +A#9YIHH _./C #3!FH75"_R9>_A6#G2_00BLL2&!A$BPDIJL%+I(JHI<3
M 5@E"@24/)#EN),R80&TE,@# 15VH$&#*"XPQ'"11_ U91;* ,*06GJN(80#
MVKW@"A5*V7>6'?!P082B=\AJ!:II,&*,/Z*P@#G$\T W"<U;8!> %KI86PX"
M"FA!#*A)(:"%TK7JQ=<_9J$6L!D8>5V)K>O>C#D25N] P2L(0B<*"1HU9.JM
MW;C7)U3&#A?]]-5?G_WVW7\??FTED "T%20XWZ W+7#@9?L1C" &-KD?8.97
MD *$YH!TF=_Y"E@0 Q3$ ?2KU@KX@B_1V ]*%2P(!H,F@:/8;32%P=^U!JA
M"9J& /\2J,$(H71"$WI&A/B2P -/4X 5$*2!G>'@9HJ @O/L< 5?8(3VXE=$
M(QX1B4E4XA*9:*U9=:8 ,8!*$YD8 2R@0&Q4U.(19["&0"R,+BL@ PH<LD4S
MGA&-:53C&ME(ER2,@85!>V,;X1<!&6A!@W34H[5:\ 0PXLL%/!C2'@E92$,>
M$I&)5"03;[A(1\:&AH^4Y"0I64E+@F8&--@"DOYR24]^$I2A%.4H25E*;+%E
M!5;H@2E9V4I7OA*6L91E':T@@B?$82X.\($ O!8' &1R)OIH0!+X(8->SB4)
M/A"!(#.33%O&H8+.%&1AE,F#CU!SF0]Q@!6\5H5<UG(6N)S_Y3C)64YSGA.=
MZV,.O3C @MX5X10LP  '8L06)-DA%5*0IRK.XH =:&">(4K0/^>I@QX4I@L
M79T+L !0$HP  4EH:$#'4"(VL($&1U@!$#2 !0ZX*ITA%>E(25I2D\;K 7CP
MGA0MD HOV$$")D !'IS7A$ A80:G0$)OF *I+4C *X:@2^:V4(,6&"LF/3"
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M)16_F(4(L+";W(G!#2?XCC36L  1B,$A*N;"";J@@SA<@!&W)0$2_*D!CVD
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M+G;@(-%*,T,E(D'P"[Y&P^9A$:!  7Z4ZV;32A!$+(/D$]+R^.9GPM+"$JC
M#LA@&JA #78Q!%[!)EEF!^KP)G6Q#'Y4[-)B&N32=VCB!HS@2-4 (!T"%'F!
M'+R3%+Q4 8@4$'+ !O] "&ZF(1/V*A#>P@//42M>P1%\A@ANP0T(H1%Z)Q@5
MX31O 2_Q916HP 9<X0;PTBZ,Q (^(0E@\R_8$!62X!4X0;?R4BUW"PVRH)-8
MIA$#X0"FX0Z.8&SL A..D65,(0N<@ +TDA<^P0)RR("N<RY"@!XPP1  ,1!X
M,P0(02XC($RG)&AJL8R*(%@S8$9S!S8UH0\E86Q*$Q.F% &@- - <BY$ E(M
MM%$+ ! &(/\ 0#>CTTLE[#9';R<C] E/!/PR00QXTO/N@T,!(UCL%.O:+BB#
M,$7>(!.D(#Q%</%",P<-XB[G H &@ -+<Q$H(!7F(1/:CR!6( ;FX0P^@ 3_
M1&8J"<*E%I(N/" '8F0)YN$6-(!E!2I!W!() )$3K% (7( 0#)$@'A9;ZT(O
M;Z$-/G9D*, O;\$>%H -[O7R;K-@(S$Q%Y,42^!G/]8-B$BT!J! -\,4X#,6
MX. &A.HXU8!.X+).4T%+/"$K)8$O2G,8LU(VX88(NG8&U("_["(+?H%EX2 Y
M668.!*L%GK#]!C8_ X,@AS,M7 $3SJ 1+A,PHH5D"^)<=: ,TG)E6=8B7]9J
M80 ,8H *&F$+2/$66( -,$ 5WL &FB 5WL U@R8TZW16YV$ G.#ZX,+Q@N2/
MS-,+W$$*ZJ$'D(,$J&#TBN!MKP (UE,GL[9 Y^(D_S#A%X!6 ^1@.CG!:,4@
M&,"6)C=SU!A4")R09$5+,<_G"[[,)ZGNL]B 'X(0'A=A>#-A YX0 587C%H"
M$\P@;4LA2-(V%Q6A U)A $P,,&CB"N?O S(@9 $@%2RO_49!#2!W"0!R '+
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MB5,*ZE LOQ( _F :/G)%&Y,W,\,#_-A?B_0,J*#O ))._Z*(8^=!^Q)R"L_
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M^.GSZY>_73MZ\R3@U]]\W<TG('?EO:<*!P2>1Y][]_'7('?_T6=@=APLN)^
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M2,9( M21"4R;9"-=)LC<A*:0;RO(&D/SR((P\B.G-&5:*.F053QBBH%D9 &
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M>U/$1.&H/%+0"-^3"L^7!+P80&A% _#(!2E1 !](1D.P 6*@ <$P1+-42Z:
M"3B CV<P?A<@186%!G20=F+T"6)P!B\2#-BV!'$64&M@! C0@^GT!QO ("FY
M!:;  AL&D:D@B)FW3&U!!*C@$#&@"-( "E@H@$3D0DS7/6]@!AM6"CBT"E2&
M%4(43HYX ;]#=/-C ^\ED 11 *,P1/R#E$H9"&4 !$,( *;0"O:P'6@0DS)W
M&":I 80 3DF0!DRP?%7H %: !1Q  WHU!FJ'B!,!!K]# VJ !!'01$H%"GU
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M\/_8"'$:2FT%B88SR "'DE0HC9RRSR9YW (D4+A)]TJY(\!20( LJA &E*H
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MQ0,>\:YW/>1A_WK:S][VK:]][F^_>]W+WO&*Y_V+5?'[WO-^]KZ__>49?_S
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M7!V'V A@O#=A!( 7:;"YC#83H(0&2X(#_QBO,3 <<MB*N*Q*?NLV">@(ERP
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MH(!5Z#\SD(!2"%4;X &S*995R(,ON*"0^($VH <[L!1DA8\6(((4;==7@B(
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M@!,0 S.0!AD0\$'V $[8 !'8 "Y8PQ9@@T5I'2Y0!8\6@0/0@@N $7/F A'
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M5UQ@L45EA ,I6CRZ< E! 5.H:@$9,= 4$Y6C=+@%HN%(D3L4",R@E(_&D0)
M=*0L&.%9'@(J!KE=E<<4SUJK;,2"U>""M1H%-8]PP4B.: Y'5!:8T:N!B8\F
MW5S>6H1+![P.(>Z(LB-%C0)S[!18]<",A9"&5=-Q /H+YMX:GC TV>L$#4,
M6FRX6W#%JA$=:A$1<D&(;+8-5I"QT:$%(7>H%]QK(UB@@EED&$87$P[L,%8(
MT]BA4BW_K)Q%D04J:5B "8.PL%4J3C2A&0L4Z*?"&F94995Z@'PP2TL$D'@8
M$RL60<-=+&T1G%LS:*#%&G1H"( *4MB#!P!L]?AC&G04<$$>+N"X$AN3,(('
M.4"TL1MO%UQGP9/6D!%4;Q]P:=4613"BWCAQM>4!#C:1D4*6;:F&"B!_%;"$
M)%F.,(9&9B@()I^ X$!!EA.J9$)X/C[1UI"U6"+4(7C4$ $1#:60W0YG E#$
M(+-4"A41?-2RA!VCM-5;&!)XX 0"(8"UGFXW&L=%/S%,&$$<L@T)@ 8#?/ K
ML<4:>RRRR2J[++/-.OLLM-%*.RVUU0[)QAGY$$2L 4"4B%<T_W0"\4 &OT 7
M@A2_M$&"(C 0D4$&3C1&[B]19*A2"VB4FP$27ZQ!;DXSP&&&"U)D\ &[#42P
M PJ_.$$&3[VAA-<. *MBQ"%1A(1"!G>0LE+$0!CQR05PM &'(D49M :\OXSE
M+\!0',*$;"V LL4*2M";@FU;S< Q#F@L0H )A-A  1 <FRL!&2BT00]G%#-A
M0E\8!::B"C&0>\<5>+'\@ 8:R!'97:FX48;.\-KCGD'/U3!:8URXT/"Z-NCQ
M2 .%W0M 8;;MUL(:72]*B!E60)H*)6C#46X>>Z_W;P8L]/-,"H!-1P"HDLB6
MA-8=C_B<!..6BT<+'!^<@@0ST "O$?]C='E&!C_()W*&!>SPPR_VX%9 #$XD
M5P1/+<10[C1]M-!%!O1 &@++']"C*  %6$)=6LD16\L<9I3$.PH/Z(#;06?8
M(_2*0\'+ @EA5"J;"EUL+3@ (01%90^:/?"#/5&0LP2_&R[A1$HT S3]\8\)
M%S"""^YQEQ:\H <S0,,#[/&8(65.-JM 8.?"II[H)<$2-HB#!Q;WBR@QX@H+
M2YZ -'.&7WBO 1ZX!)A,L8CXL2QR+H3AGE#A(+5MA3>B^P7IIK2A-&0B"ADC
M 'WZ!;F<: A42#AB+=; ![[]0!*KH,?H"# *&,JJ:RT0PQ70(L(P6.0'=.A*
M#XCU!"ILP%K_;GPC'.,HQSG2L8YPE, 3/J  9!E@2"LJ0 04L+<5""!#52F
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M9$7I1*6,%+HW<H(3GCRM2C4UI( S",".?OTK8 ,KV,'.$08;*"EA$SLM%:!
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MLO8T'+%OBR,K!/2(.]B##O:NDD'M)'B\36K!<\IO,.0D4 -&-A0!--P"#FI
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MRJ&G5.-*#.(R74 >.@!#_M3_HGK +0)=+JZ(YUWD!60DT.T@JI[@#,8 :Q9
M"*"!&<@&21Y2==*F%'#B#P9A+MI@:!8B#E[!(2U!*C[K"59I<?9D&>R@G[;
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MQ"-H 5:1E*.B@!!@U2?$P,])WB7TK3ZMB#6Z@#[%0AJ807)XH1%(@SX];"V
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MJX'FF 0;YW$G/_"' 2K=%JH$OS+_WEKI$&R 8]FR"/0 5%F!"-BR+>LRT/E
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MY;F@^TH29/FC;\@0F!=S/5($=+E)6<'_$_! AHCZ@BM FQNX<Z$42D5 H#.
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MEMPZ(V1IQ0@['MDB@CD"@6*'KP@H @X;* # J* B0&,1<@#HKR(/[CB!$5+
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M4I=JN0V8=Z("%0;"R9BC03]GR ".:T$$_7 "#Q)PQ26L8ID?7($,]NC)4'3
M ;13X0ZDP A@!F(/4A  $&3)B K0@'9PQR$$9K3-8Y## E6@?2!580L]SD#W
MR%2W(N-52 :895[.%& 5()!#712RX5WI1&CRY!O6!C*0%* '[3K0KYG0< 8J
M7,X @,"!%B8#A33040Q&T(T18H$")!3A!VW_ 1O,F""B#(WSG$@! 3Z7>SST
MQQ1WB/^O:"2QJP)$J![O7,%V]<,EPF5@1FO@_!GR"5TSWB=[ Y&/R"X.*C"(
M(U"$,W*K]F3-8E" \WX@T] %=LZ.(#RA% ;B!R2B%*B@[>Z@ 6IANW0O,DS
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MN"C# <0@'0K266W2.)C#[=ZF'Y;@ML#/%%H!"]2@IQY@:0VL)HW#(EQS ,Z
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M=QP2RIQ[7(C11@B1CCOZ8<J1(MQYG@$[#C1:(MDZ'*V1M#,BE_?E"0BM!:)
MH'X D]TGF4UEF3_J_3[@P]N "22 #%C _<C@%V2U#5A@7/Z#4!C:"MJR)06@
M"SX<#NPA!0;'-WEK2JZB)Z62MX+R.&@@T_Y#B3"B"&05Q:V5+6B "3XGQ1\
M:1X@Q7$ :W,B#4H<GAJ"]81@'&@@Q9\PYK  #EP(!U) Q%1ARE-\S8\O"4@
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M" ]#]!,>7(#\$*<"-4A02B:32($*.7%=E,H;M^C0#Q%F3&O@&6]%D(8B%A1
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MH/A-.X!7;, !R],D9A '7S (&H "Z= /"D"+FW$MG( '+A #'8,P,) AI*
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M?H[I6'[C;E[C+H[DG_[C?X[B-R[I"^[A?D[G4A[J<4[H_ZWFK@[K *[H.;X
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M0\"VAU  ., :;H,)KLD)!:()&7B!!Q*F9Z"U%L  &RHD-,"O#_@%AGL&.2"
M/T"#!V"!'B  $T #&>P J:LX?8@" L +.+BK]/"-%A#_@79JL!UX@%\@PC\0
M 9B*%?RJN+(@&#W(HXUH@XXHPDW3P>FB@=JZ@%]H R-  '1( 9>HA0N @P_P
MF55( 9NKPY^8D=]P@5:[#XBX(FO)@ \P @'H@A0@AP+8 2'@D52PI_>8+D6
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M",?X^A-?"8Q#J200T(0GP (<>*Z1_*/0J2< %,!Z*H-#(,(&<X%,? )70 4
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M$R>.X#$!&A]0&*1R 0: @D^0@+-L8WS@DA4PXC4N@S(")3V(8!1MN"<NXK(
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M+'@PX<*&#R-.K'@QX\:.'T..+'DRY<J6+V/.K'DSY\Z:%6AH7*  $!96'C4
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M0<S8 #-)K:PE8!CI2$BV$B$&D$ -5E"#&ZW@.[QD0 =D%DXV56%<#EBE!1Q
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M7 T?_T4>'OUQ>Z"8"2N0-\L1(LO(P-DF*ZBN9'<]D1!DBS S%TP+7D"*9\!
M!!U8EN&4P(8OM6<A9*%#KE# B;L01I<FK'D!O-Q3U52MNC'_*&!J+AB(&6)R
MYWPS+H'0BX0>QNMDG[J4K2YSMR.D+?^&>,8>ORN!9DJYDDO5N=V5=C,56,ND
M@UG!-<F<=\3L/*3,[H'#)"MU$_IHZRTG[X09\XF!(]FF!>#J)[RN=X2L?")2
M/^XB;4*.&HQ>SCYR]N21#!K'0.\!9_"._Q1K Q8NW S)3%=MC@(&N>[5 C@W
M1"J<P)UT68 ,]#B#$^#]L#6$(1H-<%@1S&/)0Q@"EV22U"(< (9\,$(L@2G"
M#S[P WO(X6!2^($.M%"$!V0 _3<S ?"9D(I6D. ,=\BU"G;P X;W0&)E@ W8
M"@J< <I972TLP0"<@1K\ AR<0<G<A%S]@!GX@!2HP2*,"VFT#. A 3F$BQ*L
MGP[T@$^U!P3_BIC_+%S^+%\=!09IT(-AJ8>\C$@$S4$.-& ;R)[QX<P/_$ 8
M* !?9( 0S, EP  1S)4:V(,6Q$ &!-^4K<$/9 (<V(%-1(@:D&!<&5:V_4BX
M6, %.*$.Q $9R!ZO1 !OW--'0.$9_ *[/8PE,. 9/, /V '>+%^T <$#1N %
M&):-M-YX5=YB!.(?$F(A6H:2-<9&$&"$Y,_5 )X=E$+[)1337 &*C, !B(4)
MH, 1X-P1>$MMF((1? $(1,<% )N4H44&A$$9$, H.$%JD(7X&8LU',0H!,)!
MG)%@E!K3I4LL@( <@. (6,$/2(*1<9:X?($1D(%?'!H!S("Z> 01_YX!'HQ!
M"Z  'DB $L368(#=#NA  T0 (=!!!(!!V+0 (2 !&9R="<T "W0 (*B!$"3!
M&HC +X*@.P(&NW %$9$"&B3(!2Q$,P(&TT"%5\Q*#7; BGCCT(GC1NR1"J!!
MQ"F"%E@ (#@!;-@&$ER .VZ0'3@D I ?2)P-*-!/&C!!<OR%E*6+0@#CL;%!
M?P !]TA7TLS!#;&,!=#?X"P;(\" *IB!-/A'M"V+$"SC$12!%*#"/8J;(9K6
MY36&4S)E5$HE8PRB8E2$1 ! **X2&(#!*]C!*HC+"ZZ"-1#$J?D 2<#!.&;+
M#!@?!Y;"(QS !JB"]0$&673)%MA+:H0 !O\8!%Y$! (4@ =<PG=(A_@-Y+<4
M 0YT 2=PP0:XQ 70)6"@Q0(\00<\D >8@06L@ SX !@0P2*P96JDPB^XP0%@
MP2\8)F#('5CNBP)9TEF>  H@@0?T@IC5#"DL@0Z\0#YPP6(VIAC<P7  !B09
MR >0PAH@ 0 L 5P>P!H$@K@5P$@(B:RP!XFLIA$ I@)!2DJ: @M@R8V,PB74
M1@MT@21\0@SH0%RFP2*X !O\A86(Y,- 1RKD"$7X3!=F41=0 A?T@P+\QTR,
MDK,D"1' %1JP0%RB@!!@),[PP!HH2PSTI2TFFP7(77OTPI=,I6B]'E5J5ZQE
M#A0T$NMEZ(@*AC3_8%8B"FA67L():, !B( 4V($>>5E[.$$^L  4[,"!;@ <
M\ '.R8&[F((9E$(C<,$!'$ >2)L*1-(J: %*5!]#O,W@'*/,F,(B($0N!L94
MU 1.L %C&FD>A,A2UMD&:( 3D,&WA"("^,X", <JL"6M_$!C'@ 7D)5@1$C8
M644"V0$Y_*> V %M)M1.: ('I9@FE(*7SBF& D ([,<!" (.3,(+ ",!:8)I
MG@E>% $'+, !<( -A*DSUM&==I;,:"<;#,XJ&(>W":8%J  6D)AJV4!<OF02
M<$"N>41\!HZU0%MJ2$ ,T**478 U)($ "(D&Y &Q<DD>!*&*U&0+Z)"1_^(:
M8"@$VXC%1D3H'6R =T!,U\S "\ :B4X65 HBYB'9"K@ %N"8"&P !@@/W#E4
M/O # V#98R1!/VR.0WUKF_%48$0 *X&>"R@JX@'L9KF \X%K8FPH8P@+L:B6
M$8B!1(0 (>2/@MII&FS/OP0,"JCE$6!'6\6 &0 "#<[ + !4"TQ'-'@"SSQ<
M<L[ 4(19 :!#;!E+%5)$^'U7$107 )#!"! -0WS!+'SBF_E V-P*%H@G:9C!
M>)A!L<P!:+;EG Q'"XA &;@ K+5%%-!==L+5;9!#"$A!.M9FEF: $T@0)R!!
M'[W/CP&&">  5Z!%%$P'C=8$&5QJ8+('R<3"(/\<02V03$*" M;VAIY2B 0L
M2QZDJ"LVF+(Q";'P"Q[@3<H, LWB15MP(L"X#<],Q JDRQ!P00-P%FGVP J$
M; -$@[B$ #W8Y(/X1ZX%Q1IH05@DB2E2:'7([K*(B>\$[,&>%:TU1B#F!;Y!
M@5*9DF8J@#0T4DZI$Z;\E)%)@ .,05Y8@ $\4C!E#O&.@?,Z+SE@RB-A4CWM
M6R9) #YXU654A 9$029EC@OH 0>$Y=>E 0ML !L8T6,$IG><31?HI DAGV H
MQ'F0&ZZ.6PP L&CXJHCJ+F!D%^QUP0_@  @U&!S CHO)J+I-"OW$P >T 0N@
M 1+XZ+(\  Z@@1G@#1S_M($]&([^0F &9,D)T< ']P=/C,4$/<!@7FEZZ.+Y
M?4#XD,,JP $<M.$7O,1WH<4'_((R\F":S@ *M($&-,>;-@00I% ;Y,%Y2F[<
ML<+"Y>D<0$+]P X5)K$0)%3$)B40X,H%D/ '2()/A4 7_ +L:, ) $X2=$$/
MVT/##*02[XX-E,$$Y3$%U,(5_P"S0H(!_ $:  _ZH,R-L*4>K!_PL, D7# <
M?&,!D-$OT #JII8EV$ />  -0' 8 %1W!&$;VPX,$3$3D,,0:S#3S8 A@Y"B
M,AL/Y!S.M#$+E,'.CI+>CDC8'O!D525BB*O'S-4C]$ I*-8(# 'P\2!%I$%F
M_X8 KAU$3"[H3A#+$G@D$IJM*=#A%Q""$93"IQE?"_W57*7 'P3#7+'  @.6
M 3-&+:S"-@I&"+B7G8*"'2C5SDB"WC&4X^522?4S>(IG0[#J&IB;"9$&;0@&
M.M# >50,S4IO]"Y2U8G3(DE 0Y-4)1D 13.4852,=<3&1O?RO)TH8S#)L8XO
M/9'3.3F;X;59/\14;#P,/@0O.22) OCK"\[C%6Q.!,A !Y!4ENWK1^F:B?2
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MP3B@@"0\1P:T00I\\]EC02\ 1*E%9%"I0&/$ Z8V./#,^/'K XLN#U"8(0
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M/XF&DF6/G;;8!<TN,X!'SN:P@PQ&9GFB P>Z8.*B)5"!LH!1+@EO%#<N.!N
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M1_!<!P%IMSA@Q) 4\-)5+'>!+Y5O$5 *P1U&DH1#&,($'#2="'#@E!:\X%L
M,, ZX8F 5;Q.;&S17.ZF9TN'/A2BP5, %4Q348M>U*)"C.AF5N ",?^P0 0B
MV  '%M"#)*+,!QN81=T@$X$J$(DC)3DG !P@@PY<I*8,N&EE%@.%C?X4,M+0
M:&7ZQ8@HF$@!R;+ K"3!2PI S $R4P$(]+4#(RSK"(.ZJK$*,"R>X&.IB+&
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MWL &\H$0' $* H7,M D(C&M8/."9R( 2+H#IG$,#=$#_#I"1+?1&$BXI!JB
M"NJA!Q#C$R++ !R& E+A#BC@"[R@$>2 '(# ":2!#68!MSZA"[PSA3"BO SO
M/('J-%.41>MP137BE%I "D9@" AA$2)(4**!"63S2U8A!5H( 5YR"-!@!"X
M!T1  [A@$G@@)#8 !WJC +Y  V;!"M @!2[ "3;@#HZ@ #P &B8T@U)A$#[
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M2<7@ RHB>A^XA\H6B9=XM,KV;&FJ:(PD"L8 R9#1!5(B":! ,5;-!01 !N)
M!1A  /*-,T+MEU*B!7Q "YH,"A2@C=G8 <Z+:))@C/N!BH=@"/HA#I) #W@@
M3IF8@?L.D ?9QB*X02:8D'WPB1.9D4GKAX*HD7\05R.9DAWJ$QY@"&"  329
MDS>9 1B@'S99!OKA"1"YD@-0B4\9_^ DX)-;V95?N96YC"-AF99=^;4>@Y5K
MN99E&><D@ U^>0%^F0V"^9<QH)B%F0V>0)4)4!H$>9D#3Q3. )FGF9I_X)8=
M0P-(@)JW^9<_X  @@P%^@)NW60V>V9P+9)'/&>@*P ),^3%H0!H@@PT$H#(8
MX)L?0P#8H#)^0)W[^3^$:B,ZR@>F&#*@QP>\%D'P+5BYPDBX $5O!-\4V"-J
MBJ4(!'KZ@9>'YD( !'HV6M$6=?6>8$@HXUH[XLB"M:/MK:; 0![]Q@7 P %=
MNH!KP 'T(*1Y0(MI9@A"^@EXH*(?0P70,1@?HZ.JX(@!)$?PX:<M(PG<&9NO
MN2->@)XIX_\)[MDQ&$"?*2,#_)FK;TF0H4<,0,,&4)0D5N$'Z$"B!\0#$J^@
ME8 #\L#P>L(0@""W+$/;",$,R#I _F !&D"T3( -MB"M#<Y6-*(6WI8+-@ +
M4D^O2:*K-M,C7$ $,G<C )LK_X0F1. D*.!3-%L2>&(&CK0Z6@ +ON<#?F%
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M$4<"O'!2!D/E).:89)9IYIEHIJGFFFR.*0T-"ZW@0A4$%%#76P]%< $-!VR
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MM4P[V8OL'*"=DT1@*G1-2 3>E817+B2O%.'+&.X)$L".I  <<< 83)(OD!1
M 80-[&(7 EF%K&"R&.GK8<=P1I(\5F:*[>QE.RN[RBH2LR5Y+&/VIP#2HN2Q
M7[#_:0<E!Q$#K$ "*W*M8SFKR +PEB-G--YG02(!*9E$ RZPTD5,DH^R0F2.
M=R/'6Z=+W>I:][I]?%-,(G  .1 V!(= *4L0B]WRIM9OIN1"[C"B)QK\=+QC
M4H :C_M5BL3-)%JBF]U*D@'S^O>_  ZP@'4"R)>L((1[J8)?!\Q@MR;!<2.)
MP!.TH%O 28!M):$!%*R$)9-H!"30Y>\*&BP3!;#AQ"\X,1M2C&(5LY@-(B"Q
MC&=,XY&XH, V(6^-=\SCO*W-JR"Y;TF>X-R'G/5N/5Y)$AY0A2$T^<E.CC*4
MJ_ $."7$ 0K !Q0D0(X'ZT4"#U; *S4+9E'UE;!8UK($_Q2P6"S7H 7]J$&7
MM:P "3A S304@)@KG.0^^QD <4U) ?!1L"?P( XK&,)Z2W+;QJJD<9A-]'I7
M$(LG6#H.>_D#&+1PSP)8819Q>%(!_C"+.#\D"3[(CB)1K6J?I'K!"XD  U9;
M$QB-Y+8%D$'L:.(3!A#@MI&%R0IDL&@:7QC('&&##. (8B^9!$Q_-DF@3S+M
M4>3R$:0@ SW4,((.M$ 5N11E!]-0NA!TMTX72$&85F"*7'*"%$ P@S2ZD +/
MG,$(+A##M1NPBES: PU4^&:PHTWP)$/!RBC1TQVX@ 4._"(/&!"I20I !E6O
MY)WBQ7@@VZ !#?!A?R3:  <F9?\G)VQ  X,"@@XV("B9O9,+7;@<;3@ <UG)
M"^8RQT@(IE43 XGWA5TXPEWA=1.*Y^4"2)#N3!#U7AEWE;Y!7FY)]%#DA=3M
M)'@K.$A^C!*N4R@0AFP!#?#@ 'ZY[ H""1&%Z)&C$/2"*@!(&JOB;8%\U<(2
M+-# ^0P!G"A@  E<+L !70 P 5U4ZXC?\8U5XD,WZ$5%#[A#%'Z=Y3$HKP"B
M^ 0-";N")73[15FV@/+BE(00*@_,"HC%O% F#1=P0.T),0$&S+B7^Y'O"^4I
MPCVV<$@W#&$0.GI!(U]$EMYQ9P7.(P *)8:  K3P(0YP09U9M@476#XA*\CR
MEA^K "C_U& %=]XR , \0^-1T!!/NO/U%5*$@=P/"=)_O 2D'^P"K%G,5^Y^
M7E<@?PD8H 8.X'EC %@.T&D2( %JAGV0-GJ-4UGWTTD\1@[D-($K58$KE0%G
M4%\0<0"#-$@6^(&#%&,< 06@U($F> :@A()G0 ]UE'A<Q1,Z 8//P0E<< )%
M8R[Q%@N,X 98<!]/X09$@ 3 \2@^)!2*M HT. M$I09"8 6)1  AL 8XP 4-
MPRA@,""I$#0NN(4T!@4X9A(1('<== $H$%)E]P%PT ;%,PJMH $?T 8BY6FH
M9 ?Y\0$?P *D$&L_A(:6008H8(?V< 5*0 ,?0 )M(%Z>A@)<_R "G*800X5/
M<@ (@< 8[H$%Q!$O[:17]$879O )3#$42V #6% \=K(X"M$":/"&1F %*."&
M;9 "O1,#=O@!*6 "/] &+- #?\ !=A@&4' !=H@#AF!,2_ &-M #,Y"*'V 9
M"5$+K' &N)(&.&"'])&,TQ@&8R:+=]@ Z/(!.  'B^!#LE( <R )9$ TJ"0)
M_ (I:V '"1&%OV"'2N-IRD@R2H &TT@R]_-S7-B/:N5U)N%UYT$)(L N*0(8
M+I"*]& '0P%#E( &9C $;R<[JV -M&8*G, &>> <0' &0@ (*_18*6,/;( $
MM; #9_ !V,@RA^>/+EE>TW823V$/(O^@'#3',"' !0W@ .RR-$T%/K)RA*O"
M'T7$.ZWR#"=D!31P HD" /$S"1R !Y[V ;"W A'$<!^ ! KA1.:2.7CP%8PA
M+VS@"&\1 B] "D.Q C& 1'4A#6LP>3"C QI BG5!:U]1!OCP!%;P W900N42
M 3H9,2P0"S^ ! J0.7F@ "Z0!IJ  =CX!W#9C* @=*0$A979C&E F9=3!*H0
M!8= ,J@X*8I$!CC0 X5A!N=( ;7@.L<SCK]#!K)"*SBS0B83,C!D&3"$!"8S
M%R_W I.7.5'P@"\YG'L4DR51;;-1!#@0!4"!;XR@!4L@<ZGP 1H0&OG@FPKP
M"4$%!9QE)V;_, ;:$0*$T'&S@#Y?< @\@ %,( J6=T 4,!0FP @M29STV5;:
ME1)A^ LLL !<P !%@@<28 6100/V,E0C8@:K]11Y0 Z_,Q0G0B"FM $8P 'V
ML %&0P#?=@")5 0<\'-85B=UF1"C<%4M "!7Q!A%H $8<(DN0W0.H!]TL0@*
M$'%U$HH<H!7>26N9HP$+0 K4I#4IH@022J"Q4 _O600TT :40 (/8 1@H H:
MH%ZQ-IDFP ((42C'DA JD!DJ\'HHLP::0 CV4)V:M&YSP F4H &$$ ABP)""
M(0DCXIKFZ$I+H&Y1.!;,V$&?6!FQ4"X=U 4?8 ,(X0"&X@(G4Y^(__HW %D2
M LD+C!$QP<B-+V _*)!T0. &4- "1& $JI !-' )@M *]@!$!" C;8 #I+ $
ME1(#1H %O_  (^"6&? !Q+$*1D@;/)>HNII6A,-X[)([=X4$)S(+/!!4%( A
MM)2G_!,S.'.)L@,<>: '8* !%HH0[Z0)&K %#10<EN4"F%8 J;%: F*M&-!1
M6;,])S AVX-2_E,6I?BBZ@8 <]"J*=!\#:HO56 %"],M")$*(#.L,B (;F %
MYQJE#,  3\  ^" #>A!#N7-217 :%"D$JQ4!F;E7<Z$"1("M_8FP=*)(,8 @
M#)!JZ^B=!' XS3<'?< [2W LHM-R>K4&3O_R%$+P!58J.X!ZC"]R0$G0E+OZ
MLVS2JP36*I'F EK0/Z)0)YJE6%<&9E# 9A'0?8,%  [PM I #G15  X@"@?F
M..!GM8S#>:( M&2;1XN'GU#!*G>%!Z80")?1!>+"-$1E!*ME5$'"E4^1<\_Q
M1$#0!J S(FT0!3(K 3/P"XA80!W0.M;0.)=Q?!*3N*# !Q)00(O90Q)# 2%4
M -+3 .<7IQU 05? &2(D0(H4*Q00A1CP",[!&@W@ 7=  ?MB!@3[GC"D;N\4
M!N?F1$=S=T>@ H>@;D6 !A*7++W[+OBQ!M5AN_ 4)J)31*L@"8#@!(EK":A
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ML78 $A?1(FT3C3P2TU8$>3"Y=) $_% #+B "D_^ L&#022T0!U8@ HSX'1M
M"JR*!;, !@V0!$_@ R(0!1+ JCR@ $0=!>@,:BU0DSIR ") "A(@ T5M :LP
M"T7M OS0 630 _@@ ,\P?"-=UA@!!?UKUM55 "TPGQ#1 D^P: ?FR6I=URHQ
MSASA=1Y !W+"<GC@&+. !7#@!F"0,3A#"J4@"3[P#%0'!HC-!1@0!1> =J#@
M!CSP!!1@"ERP = R!%V0 4AP#E% %C[02%7$ (<  S[=!3Q@"O9 "DH0!5T
M Z#@I#T !(ELUVHMM+K=V[Y-G+PM;8!D)PB-#PI@'V5 !"R !O30!BMF+NA
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MG#\I),S0D(<"0HH 5E@A!6!&'H,5/7X$&1)A"$83*ZYPP:.CR) KDCQ9^;'
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M F,PXI,8A'!AAV)3L"""#:*HH988D-A! S@T-:B%->BQ@8,K*/KBCILJ'A
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M )*<WB1F$8- %' (5;""&,Q@!1"PIP4O. &*(,0&.0#A$I1L@?\&1/ ("([
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MD+'W?  )QD&.*5"!- UH  <%ODH1:*"!%ZA"$7KX0=O-. Y0M;T@M>@"#CA
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M !*82+*.EO@+]2MPF%:EAQP]B"(X!7MP.X+!C5_0 &:?'1SX@/D34^T= S)
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M !P>H@'L(H0- GC($_B;$ :\X"$9,#"&L9+9%3A _QH*6 O^1E(\XNK$  [
MJ%@HRI_B_?0B29! BP_RXA@?1$"6HG%"SM+<,9!X*$D8 XYU(B 3PY@B$FB#
M@EV@$ Y4X2$\D#!"_/L0>O0XPU9&2E<+(B1*L($-G1*,!S1P1:"<*PI!ILIS
MD!"<+_P2)@X  RE"C) WVV1S?^B!"68S$0G\ 0MLP, "W&04!_B@-$E9@16V
M$ $?Q)DBGYBO0ZY[WP<[1 ]0/@B%'_*#*W-Z*>\]BQC"P  &]*T@$5C# XZ6
M(.*N@,3^0<^K<WR3%:BR;@DI,D&J;! )L+H_"UD!.<YC@'ZAPB!)X(=S<"T0
M7A<DU@N)P"&BH&Q8!XA *__ QUT.H^L S4<(J7@=<0F@((28@ -Y@(("+J"!
M*PR(H[X6D$?A39!6K_@@*U!"%,2W[8&(6\[]$5"U0UP 2QS! /C8*$(4>FM(
M-X0$##X(?IU\:8-4X;\.N7"G,VZ4S_:& SQ(3(YMJ(=[9"@"Q<$!"TCA@*EI
M(.4UB  &6D.*/VH@WTG8P&L<5*(= +)0(Z#Q6;I @YYF< $DH$&^$UXQ#5#"
M)B'0P %HX(8>2,5OZJ;!(S/(=$)(0@4X]](J$&B!&?".EDG8 0G$]7(L<"!D
MAA W$-2LH2[@0 ,U1T 2L!"RV<BD[ U8P1/DL((+A.RE.?: %$#P $ZP0>I-
MZ*C_$E1! \,;Q$'#$D@$&)"6%DC>#7%( FZD_@0,D, (!%#":DF@Y[-K  >S
M&4UJ)S^$K_OP""WHP!-IX'I;C^0/:U#-'F= Q)MK@?,TZ$G/R$X#+G2@!;T
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M8:Q';_0"%)B"&9#!)>2@&Y""!4A "U!"IW2;"HR)!3)"#]@0[WF*]K'(AZF
M'@R":(@02KZ<Z'S!+X1!'$Q;C2V!MY'*<[2(*=2+#.R (O!>DB1000 "U@"
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M?AD9H(%?)@2TH0H<N@$'-(>JT@&A#?^,M9;!IWR!F<E1"B@ 7A)$!R4E2'A
M_XDD$'T!#P@<!G:H;=! (IK/%VBEC0)!+XQ! 9B-L*2%OWR"QM2 "OCC':7
ML!&!:!!>B@I$"^1;"-!@O2:.3[0 2M;"#F@ &^2!;_A$$A0&8Y99+&W!X*UI
MFU)1HVB $"0'#F2("O #>@+6GBJ$PYU?^C&$I8F7:BX$:QZJTV:$5P% &OW9
M"PB."7"!?H!B^@B$%CX!#7P.&_3"$*"!/7"!<72 2G5E#OZ9F G$##P SA >
M%QP >PJ+!0 !$^@:M4 =H,' (>"!=JY!KAH$R%#"!JB"#JB04A)-T X$$'S
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M ,%FD!O P 1*P"KL[C!^ N3H 1R8 10$3#UWMX5?^%7HM"-G:\_(D37PZ-J
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MB<F=HWI=)4$<:--&V<44$L:VZ_&H?5X5C!H_:?^[N!V<EQ &%!0 /HS:7BB
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MH22Z.'AA/E0P HHY./G!!C0D(6<&#CC(@XP,<*#DX#!BX"."#;8H8)6ZR-"
M@Q1F,T&$!CQH0P,V>BD#B%_8V+D7_6I9PP8>=J!DV1TXB0*\&6A@PPTR2J9!
MDPT:&$4B %K0!&!*-""E710\,^( "CR0! A)R& #C4L08$[4?*+68)(P&-*3
M!1*,^((1-A9H(A4<5/G%#1I2  05?CD8(98UW'A!"X/?)<<'/+X >00+3)B%
MU"3$T. 7L'L1(&(TF(A!9S.LZ(6A DQ@ 0P68(!<"QGF^!  0*J-P89B04#7
M!$8X_P!ABSF- &\%WTGU*)-91.AAA0O44.2O)9Q@*(D9SC "C"@DH%8+*U#
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M:-,#0HW[ (.8HF>8BFL!C(#24&%0I=6,HHF2H( ,6*!R34">1*4,5H$4!.\
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M@P<DU0U( 89<I- X  DDX MZH1!_PP&LH M&H!_(8(S7A0<D5)61]Z&#J >
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ME6 !#B /(N7_<$^*UF!?-L?[_W9@ =P&%7;IDG?G U1A >9;.H1E$3X!%)!
MB6.!!.!@C3U!:W9I%F8) \) L4(  S8 #H3 ![0 H=U@M+1@!LXJ#_XBGU@
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M2QW'4@ "2"6/R"E #=IRQZU(\"J!Q,H@[4@5/I:ED()Y8!M54P E'  #"SA
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M:"S  XVE"1L0!FA)"F!P?F* !(#@F$80"XPP"UW 9JD ;RW !9X "G@@ 4/
M /KD =EV 490 Y7V"1O !0P@!FZ !6'  '.P"%!0"GF0#VN !2RPF#UX5F3
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M%]"34*&R6D$05)%.!6!54.4246$ HW2R>Q2S4]$"6-"F"%4#/)L5-:NR,XN
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M%3V+4(6H1RL@E$>15+XK4N);4B(P33<1MG,5!29 ;:KDO3<K_Q4UP(;35 /
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M"6E@!X(%U0M@6O2E=?H4 6$M HR ![T%U6L0!J2(T9H@ C4=%1GF!#Y ?V#
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MP@V#F8,=^.*\HS*"**D@V!?<H#O5<.%67TP;9'CU53"'6?_,8R;S: JP!#L
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M2$2 @0\P02H'L<9*BK#C6CPVSPW_4<(!H &H%>&A "JXAR=>S08.[+@O%_C
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M9W*"&$N!3_"^E8@ S_,!%)"#!^L-,R #(R  G6L )=B],"" 8Y.&0XB"#0(
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MA;ERZDV8$@KS#)?Q=FYR["'S]E:C!Q_1:]D 8S6V*Z!2>V& D/$<B-"""[P
M./\_2CVWC"*@E0A@@#]E"A/ D_%Z @95\-B>;)X)L>\Z&A5@2\MH\^2![PL0
M 6,M"T3WF.W,[Q X ,FQ%S* 0VRU\\L( 7'M"RNH5*8(]*;B&Q\E@0G/;#@0
MA0(@R /XKAP?+Q[P42D_GF!WPA7 MCCX \9-@GYS 2@8 W+0&P&P@&<? BA
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MP %/8!,N6(!\:$0Q@# :$(*S_U^X#6@C0\A\&%F)&>C[/(""51#6E0!'E74
M(+@#2"/^7L@LXN>"$PB#(3B$?M@!'1"#.WH!3;X25'!##+@#/'BV#6"#$^
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MRLJ@%I+0 W*XH!_]L$ $JO )'U"P!B'P1!)2^ 0:*H&!THB#0C3@O?PA,8D
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M"+ !#W#!QY2!.LZ F"E$$1A!"_0/#SS#%B0E%HQ ZDP)*8C!5'J:";"!D&"
M#=A++ #E%I@ #BS !O0D&4@)H$G: H@ 2*J"!IQ +RICMF2"7>(E!D3!).@!
M&X@ '.B:K\S ..8!&:""!*S"7&C"!33D+)0%Y25$_Q$P@F*20D)*P@STP@',
M@A5D@JT84BKHP &P 3!&)A[X "G@HR7T0=XL@$)J)%N. @M@02]\"E42'J[\
MXX^<@ B0@A6,XP=@XW1N0 K$0AAP#!;8PPEHP"L"VT*XI=9X9S1<3F8N0#X<
M@JT8@ABP@!@X2>!AP :P@""DP 8< !HDQPZXR3]*PA+,A1% (PY$6DPN !@D
MY@C8AI5P0#Z2 @E-34_&P@N(I!MLBB0X@(*RP4<B02G< 5NB"!F HP5,)P9H
M !C,"QJXP0NT"BH 068: 1E(0DL>0*NP !$$ KU\9(,>8"()(XLFW%^102^(
M@2:L@AE01@I\@8C>YU"B!/]QDD(7O.(PJHV+J@L;J (G)&:)6@ S8H JV, 5
ME*8OXN4U!IX&B,!]<@ .2(QSKL$B  $?1(!T%(&(L@%.4B=U5N-7L, &%*I4
MKL&B$80'Z, &<,' @(6<8H (7&,++*7R, (&<,'  8$;B $FHL8%J$V>*N:<
M39X.D,(GID*0(H'WA:*$C"(;H$ &7$(LT( A%,$/G($9D$%!S@$J(,![+=,,
M_ (.:$ 8Q(*8+8$16&@4,  #Q( D>! /0$&T6BBVN(X978 1Q$!=G, 5< H!
M^$C!U,P!X $@_ (>? $_D($10 $0',87S((GC (? $(*,!#CN  /D($;-, H
M[-W_$4K:" Q!'EC!+%A $2Q,/X8!&8@?[DB"!(B,TZT"*B &'Z1"&)"#)9Q!
MR31(>.C(8W3 5> .QY(!H/*#M5H*G-+C&GQIR=B !TU"$Z1("_" $I#HK%C'
M LQ"!Q0!#G# 6;H!#_" %;#!+&A"AK9 ST0 "UR '<2)(<T '80 %U# *&"K
MYE!01?'B!VA 'DC#"7C"GUI'"B@K$A2 'LP" RW3NH%!B22C!5R%"FR 23P!
M%KB!)FQ*Q0* ";R2#VP 'X1 &,@ /UC! AQ!K%K '$BK48C )-A<$O"#'F !
M'[0 ZW K%X!'MM"!WO*MWTX"%N !.:CL:0P(4H@ %DA"_RVTK#]:P: 9P@(]
M [[XF1OT;1[   .LPJLXQAC, ,OJ&G4L"26\),2>P 8X[ S800N( <E6;4%\
M 1=X#.#&J@J@ZF-< '=NP"3PR9(@V@Q@;QR((9_4@@>Q3I(X1%*H!?\().4Y
M */R;A>,P D$;D%$K0CP0[A>  6 VI+XZL3VP>QJPKO4@@]@(\_Z[ D\$3\P
MSN0E#19@*1RD #E(KLWXQ^ >P$Q* CD @AN(@ 6$ -5"@N2YP/^ZQ!*X[@GD
M3&.L)>8D2:#"L%4^016TP*#1BA%>@"1\@1V8@,.>\.%*G@PPP \GR0(?0>85
MP RP@'3$ZOIJV23L@!GH01AHT/\UJ8 !=X1AA@'>5F[M.@"W4H)4]BU&^EF:
M*4$O/"U!D,4N2H('(*X(\-#28D 8G$ 9-,;ZPG LX+$(L YU*(0'_,CP(,$&
M+P"URD ,C.X&S!(:2*OC H!3;D$7=ZTD^$ 4[ ".]FVR 0"G$)YARNHGUJIN
M&$ (, (GJX$3,  -X($)K.+"/( &T( 1D(/\E5/!F5((1$$9KRNCGH!_?H$U
M:L$<N($354DL/8$8J(*[ "KR% $JD(-^+*,-/,$!D,)U(,$%)*8;I*5>K WA
M:.T:](+$^-DW-T"52:3/J(S,S  1#^CC_JBGQ2H"B$PB"<(B1 H?Q+,%V,(M
M2"M3 @#_]S9 "(",^X;RQ?H(IXK M9;K#(#L$DS"]#Y'+)S (3@L 'A 8K)!
MB0:M]M"F*AA!(O4-&+"!)H3!P)&%[K% /EBMG!#$#"!!XG: JUP $E@!%H0%
M0;CEJ,1)#P !'JPM-U,2Z,2;Y*V"!AQ!"ZR!2R0)Z5)"\XJ _G+*Q_G I6@
M'_BC-Y/E%8BA!@]T/O1M+]@&.C2M?Q2!)D!!*20SKX!$5._MWI#0Z49!I(QF
M(1"'<N",!?B(/XH$&<B!%=B+ANWN"?0//L; (NS %AB?@%1SI%&'"J"TPYH
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M %"@(*77%4 )%I! 8(4+!ATD#.GGHH-D!A(*X)M<@Z #&0P4=&C!0\^!(Q&
M)BD,H#.#. X0)Y$AHU\9SIZA* AL8068** +[.V'<L40!F,2SQ""H$"2?E5J
M.+ <>"#!"% (./B$KY^ ,@7]6B"71('R[  BN*A26 4%@K6@1*<0N5\_*!+\
M#DQ"8"_" GS-MO L2,6,R5K@8I9^@!O- NN.@\*"Q H:@KHDQBA  =#8B^.3
M,22(@ (5+) ,I<84D*"Q3VJ(;38%. 0.##Q6Z/"K)#H 38$*2>20'!010"R"
MNV"#40$*"H!"PCC_+*BE P,<<(&?#J:<+*4(+!.@@P(^V>VDQ$@$X$L4^2/
M!1D$D ^ 5.RH:S('ZG.-G!6'$,"O/.*(( \$&K/-21?"LU* .+MTX#769DR"
M 0<=.(\! >[2<CE$NTJ.@=ZJ&ZB6*BIUS\E/.AO"2>U&HPR*TZQ@0PL%R&%-
M0[$BJ"*E6!7]Q )&^Y' Q3$)BDRV3Z"P H924(G.+PH<H" ))15P@8=8L+C"
M5/V^P_)/!JJ@C0#7,.U@!=X4B'0@!P1PC[!F5W@B#H(8%8 [_,J0LUO@QG#
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M$CMW[:@%6@B*8^04E@*P+3I& LL*O*<B%A&0<AJ;WEF*9*&NN- LVX$A6 J
MH0JZ!G0D5$P)%1>KL830*\A*BV-Z]$,<GC L+IB>8PAP&G[$H8AXBX#JZ (%
M'C9F"!J\(>0>:(&?6? L'R1+"*CH05KM!0I?X= 58?,8Q>R'AFR,HUHB,![8
M1+$LK &='LDB0=K-T"L28)N.M%-&V34+ &Y4RPH 9$BP;">&*2K+"I 8/#@(
M3H&9S%\)GH!"3QZO;P/_H(+_1DF%')3 E*(4I>%D5X3'62$*3]A %%)"21=*
MP(VX5(PBVYA(%HT"%>2H9 0ND((6O" %['E"#YQC@1/J\E*"+( >J(5+ A@
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MS"T&),'_+B ,R( %G@ +Y* (6& X\$(3+L -\H$?"B,)9O]!!L0@HKZ@%P0
M#!Z0!XJI%,S !S2 %+KF J( QLA $>+@Q'C@!,D )#8@#QC@ O"@!=Q@$G9
M=[IB%,S "F9B$L@@(E2CPAB@"\) !$6@ X @(KB@<U;@(&9A%5 P#'Q (]R
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M9@$<=P#_6(#T&& 'HN Y.V 51D />N$ES6*^1BF!3$G]^D>_S,\_]<: !NS
M!%3 _F;  DS!1D<%),'^)&$23@ ):H$(W  +6  Y9@ #NJT,-6 &=Y$&H@ ?
M"FL,=R J)""O#$+>5 H(4B )<@X :L$'+()!+4\5W*#;_ 1DUO]@!*# \D3@
M0#R1#U G!FP "R@!#[X@#!)%$V" '1\' $)@ PZ !'2G (! MAP '6;! E3
M"4X@2/.I"%# )2-@'/M@W@Z "% A%L)@ \2 % !@"'K!!32! O+*0AQJ!90
M Y @!G3@ %Z "Z-4%23!"L3 #<I@#AB"!7J ($!Q ;"@$&+@"&H!#$X@23V
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MOF 0SI([H<!<H44!_,]G:V$-MH!VR91\U.*_TH^^ L>^$G2"ZQLLWEN5 (Q
M!13 Z%MQ(B -[*#32N$'6ML$5$$#?,>?V%$5N)$#-,!)4X$1(/PJ[TT28F$-
ME+!CN2X*N(!1\S0%5" /EOH"6*"L]9:L.( &\  VDD<#'(P,EI &Z %(4?]'
M&KI  T9 ;9.4( 8V'SB  Z2G%-F  TB %"-@FHV 1S6 $7H "/@@!&C 'IAG
M!E3<$ +Y2;N $D@ 8'] $7I@FG6\!4S8392 64<A Q(<!DC!!7"</DT R$D
M!5_<$UI ##2 "UZ##%Y<#*18%3X@$RS5 G;YJ(T@%FB !,S@)191.\*< BZ
M QCA")X\!$C 'AAA"ZH<K#@V)[0<#5!A!F@ +3G@#B*J!9*T6G=  Q+] B !
MF1L "-Q6%6A P6VQ#7"@H\)SUKI %5A@-<2 !.1<#]3V#JBH!3"@R*UAHFG@
M R0A%>@A$QJ;0=$ATJ-@!DZ6#%0!!1[@#.A@!F;_/<0SG!(H4@4X0!6V,QV%
MX!,\3-59H&A5 0>0H&/-/)31 -_RP73BMVXC<F!A8 <^X '", 34.M03G0SH
MX)1[' WL(,9WX ?L8!PR7,B=EP4:7"(X0 A>PP2@)P4^ 0M48>&MX,%)P4U
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'E%>N5D  .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
